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 Abstract 
Background: Interleukin-37 is a newly discovered member of the IL-1 superfamily, 
consisting of 5 isoforms (IL-37a-e) due to different RNA splicing. Current studies 
are only focused on IL-37b isoform and demonstrate that IL-37b is an important 
immunosuppressive cytokine in TLR response in inflammatory diseases. However, 
the function and importance of other isoforms is still unknown. Here we 
investigate the function of IL-37 isoform a (IL-37a) which has a unique nuclear 
localisation sequence (NLS) and elastase cleavage sites in the protein N-terminal, 
while also containing the same receptor binding domain as IL-37b in the C-
terminal. 
Hypothesis: As IL-37a carries the same receptor-binding domain as IL-37b, the 
two isoforms may share the same receptor and signalling via similar pathway in 
the regulation of TLR function. However, the unique N-terminal domains may 
confer IL-37a additional function in nuclear translocation and gene regulation.   
Aims:  
1. To produce IL-37a and IL-37b recombinant proteins and transgenic mice. 
(Chapter 3). 
2. To investigate the regulatory effect of IL-37a on TLR response in vitro and in a 
disease model (Chapter 4).  
3. To explore the underlying molecular mechanism by which IL-37a and IL-37b 
differently affect TLR4 response in immune cells using transcriptomic analysis 
(Chapter 5). 
Results:  
My results demonstrated that: 
1. The recombinant IL-37a and IL-37b monomer and dimer proteins have been 
successfully produced in E. coli and purified by chromatographs, respectively. The 
IL-37a protein is bioactive and able to suppress TLR-induced inflammatory 
ii 
 
cytokine production in immune cells. The monomer IL-37 is more suppressive than 
the dimers. More importantly, IL-37a is more effect than IL-37b in the regulation 
of TLR function in vitro. The IL-37a transgenic mice that express human IL-37a 
under CAG promoter, were also generated successfully. The strain produces IL-
37a in immune cells and in blood. The transgenic IL-37a is also bioactive and 
regulates TLR functions in vitro and in vivo. 
2. IL-37a is highly induced among the 5 IL-37 isoforms in human macrophages by 
different TLR stimulations. IL-37a is able to suppress TLR-induced 
proinflammatory cytokine production in vitro. In addition, IL-37a is more effective 
than IL-37b in the suppressive effect indicating that IL-37a may be a crucial IL-37 
isoform in the regulation of TLR response. TLR4/LPS signals play a critical role in 
salmonella infection; we found that IL-37a can suppress LPS induced inflammatory 
cytokine and NO production in macrophages. We further investigated its role in 
the regulation of TLR response in salmonella infection in vitro and in vivo. In vitro, 
IL-37 enhanced bacteria survival in infected macrophages, while reduced 
proinflammatory cytokine and nitric oxide (NO) production. The same effect was 
also found in vivo using recombinant IL-37 protein or transgenic mice. Using IL-37 
receptor (IL-1R8) deficient mice, we demonstrated that IL-37a signals via the 
receptor IL-1R8 as IL-37b. Thus, IL-37 may be a double-edged sword in salmonella 
infection; reducing inflammation but enhancing bacteria survival. 
3. Transcriptomic analysis results revealed that IL-37a has a broad regulatory 
effect on global gene expression induced by TLR4 signalling in macrophages, by 
enhancing or reducing the expression of many genes. Furthermore, IL-37a differs 
from IL-37b in gene regulation, while they co-regulated some genes. This confirms 
that IL-37a is independent of IL-37b and explains their functional similarity and 
difference between the two isoforms. The key signalling pathways regulated by 
IL-37a are also identified, including Mitogen-activated protein kinase (MAPKs), 
phosphatidylinositol 3-kinase (PI3K), Nuclear factor kappa-light-chain (NF-κB) and 
JAK-STAT pathways. Thus, IL-37a is a novel immunoregualtory cytokine in TLR 
response. 
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1. Introduction 
1.1 The immune system 
The immune system is a complex and powerful defence mechanism that has 
evolved to protect the body from microbial infections. Cells of the immune system 
recognize and induce appropriate inflammatory responses to microbial antigens 
which limits and resolves infection and maintains tissue homeostasis (Murphy and 
Weaver, 2016). 
The immune system has the following main functions： 
1. Immune defence; to prevent and eliminate infectious microbes, such as 
bacteria, viruses, fungi and parasites as well as their toxic products.  
2. Immune surveillance; to recognise self-antigens and thereby to distinguish non-
self-antigens and to eliminate them. An important example is the screening, 
recognition and elimination of apoptotic cells and of potential tumour cells caused 
by gene mutation or epigenetic changes associated with ageing or environment 
e.g. exposure to smoke. 
3. Maintenance of immune homeostasis; this is an important function which 
maintains the stability of tissue homeostasis by mechanisms of immune tolerance 
and immune regulation (Abbas et al., 2011). 
The mechanisms of these functions can be summarised into two general 
categories: 
1. Rapid responses which are encoded by the germ-line genes of host. These 
recognize the molecular structures of microbes and their toxins that are essential 
to their survival and which are different to those of the mammalian host. 
2. Specific responses which are encoded by genes which might require gene- 
rearrangement and the synthesis and assembly of specific antigen-binding. This 
process requires more time and complements the rapid response described above 
(Murphy and Weaver, 2016). 
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These two categories of response represent the innate (non-specific) and 
adaptive (antigen-specific) immune responses. These act synergistically for 
optimum efficiency.  
1.1.1 Innate immunity 
Innate immunity is the body`s ‘first line of defence’ against pathogens. The innate 
immune cells can rapidly engage with microbes immediately after infection, but 
they do not have antigen-specific recognition and immune memory that are 
associated with the adaptive immune system. Innate immunity is mediated by 
various innate immune cells such as myeloid cells (monocytes, macrophages and 
dendritic cells), granulocytes (neutrophils, mast cells, eosinophils), natural killer 
(NK) cells and innate lymphoid cells (ILC). These immune cells lack antigen 
recognition receptors but express pattern recognition receptors (PRR), which can 
recognise pathogen associated molecule pattern (PAMP) (Murphy and Weaver, 
2016). 
A subset or PRR are the toll like receptors (TLR) and these play an essential role 
in recognizing microbial antigens. For instance, TLR4 expressed on macrophages 
and dendritic cells has the ability to recognize and bind to bacterial 
lipopolysaccharide (LPS) on gram-negative bacterial surface membrane. Binding 
then triggers an anti-microbial inflammatory response which is an example of the 
innate immune response (Akira et al., 2006). Additional key components of the 
innate immune system include tissue barriers, innate immune cells and innate 
effector immune molecules (Murphy and Weaver, 2016). 
  
4 
 
1.1.1.1 Tissue barriers 
Physical barrier: the skin epithelium and mucosal membranes on digestive, 
respiratory and reproductive tracts comprise the physical barrier to restrict 
pathogen entrance. 
Chemical barriers: the anti-microbial substances secrete from skin and mucosal 
tissue such as unsaturated short-chain fatty acids, lactic acid, lysozyme and 
antibiotic peptides (e.g. defensins) in saliva and in gastric, respiratory and 
reproductive tract secretions (Murphy and Weaver, 2016). 
Placental barrier: Placental barrier is the defence system which prevent toxic 
microbes or molecules from entering the foetal circulation; this barrier includes 
cytotrophoblast, syncytiotrophoblast, villus mesenchyma and the foetal capillary 
walls.  
Haemato-encephalic barrier: Also referred to as the blood-brain barrier, consists 
of several tissues such as choroid plexus capillary walls, pia mater and astrocytes 
together separate the circulating blood from the extracellular fluid of the brain; 
together restricting pathogen access. 
The normal microbiota in the digestive and reproductive tracts function as 
microbiological barrier by limiting the ability of novel microbes to establish 
infection (Akira et al., 2006). 
1.1.1.2 Innate immune cells 
Innate immune cells include white blood cells which mainly develop from stem 
cell precursors in bone marrow and develop and mature in peripheral tissues 
where they mediate their innate immune functions. The key innate immune cells 
include macrophages, dendritic cells and neutrophils (Murphy and Weaver, 2016). 
However, certain tissue-resident macrophages develop in specific tissue sites from 
embryonic precursors. In contrast, innate lymphoid cells (ILCs) do not develop in 
bone marrow but in peripheral tissues from lymphoid progenitor T and B cells that 
lack antigen receptors (Abbas et al., 2012). 
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Macrophages: Macrophages are generated in peripheral tissues from blood 
monocyte precursors which can migrate into tissues in response to locally-derived 
chemotactic factors. Once in the tissue the monocytes respond to signalling 
molecules from the local tissue stromal cells and differentiate into tissue-specific 
macrophages. For instance, microglial cells, osteoclasts, Kupffer cells, histiocytes 
and alveolar macrophages differentiate from monocytes dependent on their 
specific tissue environments. Macrophages play a crucial role in innate immunity. 
As part of the first defence in innate immunity, macrophages can engulf, digest 
and remove invading microbes. In addition, macrophages contribute to immune 
regulation, wound healing and homeostasis; for instance, macrophages can 
recognise and clear apoptotic cells and cell debris (Aderem and Underhill, 1999). 
Furthermore, macrophages can function as antigen-presenting cells (APC), which 
can trigger T-cell mediates adaptive immune response. Therefore, macrophages 
form a crucial link between innate and adaptive immunity (Yurasov et al., 2005). 
Tissue macrophages can differentiate into different phenotypes depending on the 
local conditions of activation. There are several emerging phenotypes, but the 
initial classification was of two subtypes which depended on the stimulation of 
activation. These are: M1 (classically activated) or M2 (alternatively activated) 
macrophages.  
M1 macrophages differentiated in response to cytokines of a type I adaptive 
immune response i.e. IL-12, IFN-γ and microbial LPS, produced for example during 
inflammation and infection. This is called ‘Classical activation’ (Abbas et al., 
2012). Classically-activated M1 macrophages can produce pro-inflammation 
cytokines (IL-6 and TNF). They also express inducible Nitric Oxide Synthetase 
(iNOs) which catalyses nitric oxide (NO) production. NO is the main intracellular 
cytotoxin for phagocytosed microbes (Mungrue et al., 2004). M1 macrophage are 
also tumoricidal, and dysregulation of M1 macrophages may perpetuate infection 
and contribute to inflammatory disease (Parisi et al., 2018).  
M2 macrophages differentiate in response to cytokines of a type 2 adaptive 
immune response i.e. IL-4 and IL-13, and this occurs during a parasite infection or 
an allergic response. These ‘Alternative-activated’ M2 macrophages produce 
arginase I and transforming growth factor beta (TGF-β), which are involved in 
wound healing and tissue repair. Aberrant activation of M2 macrophage may lead 
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to pathogenic tissue remodelling and fibrosis (Levings and Schrader, 1999; Alber 
et al., 2012). 
Neutrophils: Neutrophils are generated in the bone marrow from stem cell 
precursors and are the most abundant leucocyte. They are very rapid responders 
to infection. are very efficient at removing microbes by phagocytosis. For 
example, microbes that infect a wound can cause the local innate cells (e.g. 
macrophages) to release chemokines which attracts neutrophils to traverse blood 
vessel wall and enter the infected tissue (Godaly et al., 2001). There, the 
neutrophils phagocytose microbes and also release enzymes and other toxic 
granule components to attenuate the infection. In addition, neutrophils can 
synthesise several pro-inflammatory cytokines and molecular mediators which 
drive inflammation and resolution (Abbas et al., 2012).  
Dendritic cells：Dendritic cells (DC) are a type of antigen-presenting cell (APC), 
mainly present in tissues which have close contact with the external environment 
such as the skin and the inner lining tissues of e.g. gut and lung. DCs can be divided 
into three types: (i) conventional dendritic cells, (ii) myeloid dendritic cells which 
act as APCs, and (iii) plasmacytoid DCs (Spears et al., 2011). The main function of 
dendritic cells is to process and present antigen fragments to T cells to induce an 
adaptive response. This process includes activation and maturation of the DC by 
contact with presentable antigen, the DCs process these antigens in the context 
of the surface major histocompatibility complex (MHC-I and II) molecules and then 
present them to T cells to initiate an adaptive immune response. In support of this 
presentation, DCs provide additional co-stimulation via CD80/86 and cytokine 
signals (Abbas et al., 2012). Furthermore, DCs can produce many anti-microbial 
factors to kill the intracellular pathogens such as NO and anti-microbial proteins. 
Therefore, dendritic cells act as a bridge between the innate and the adaptive 
immune systems (Plantinga et al., 2010).  
Natural Killer Cells: Natural killer (NK) cells are derived from the same common 
lymphoid progenitors for B and T lymphocytes. However, unlike B and T cells, they 
do not have antigen-binding receptors. The main function of natural killer cells is 
to recognize and recognise, attach and kill cancer cells or cells with intracellular 
microbes. Following attachment, NK cells produce cytotoxic enzymes and 
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molecules to destroy the membranes of these cells and induce apoptosis. Natural 
killer cells are important in the initial defence against viral infections and tumour 
cells (Abbas et al., 2011). 
Eosinophils and basophils: Eosinophils and basophils are granulocytes which 
target large or multicellular parasites. The granules contain preformed mediators 
(either eosinophil major basic proteins, or basophil type II cytokines) which are 
released following contact with parasites and assist eliminate the microbes. 
Aberrant activation of eosinophils or basophils can cause allergic-type responses 
and chronic disease and tissue damage (Abbas et al., 2011). 
Mast cells: Mast cells are primarily resident in mucosal membranes and connective 
tissues. They play a crucial role in wound healing and tissue defence system in the 
inflammatory response. After activation by pathogens, mast cells can produce pro-
inflammatory cytokines and granules which contain chemical molecules, these 
together create an inflammatory cascade. They also release mediators, like 
histamine which can dilate blood vessels, accelerate blood flow and recruit other 
immune cells to the infection area (Menzies et al., 2011). In general, the mast 
cells are mainly involved in inflammation and defence system against pathogen 
infection (Abbas et al., 2011). 
Innate lymphoid cells: Innate lymphoid cells (ILCs) are a group of lymphocyte, 
derived from the common lymphoid progenitor (CLP) and not the myeloid 
progenitor. Due to the lack of the recombination activating gene (RAG), ILCs do 
not express antigen specific receptors as in T and B cells. However, they have cell 
surface markers which indicate distinct innate immune cell lineages (Spits et al., 
2012). These cells have varying physiological functions; some works as helper T 
cells to assist the activity of other cells by cytokine expression; others can express 
MHC class II and serve as APCs. Based on their cytokine profiles and transcription 
factors, ILCs can be further classified into three subgroups, (Moro et al., 2010). 
ILC1s are the major population of ILC and have anti-tumorigenic potential. 
Following IL-12 and IL-18 stimulation, ILC1 express the transcription factor T-bet 
and produce Th1 cytokines, for instance, Interferon gamma (IFN-γ) and TNF. ILC1s 
are analogous to Th1 cells and share the common transcription factor T-bet. They 
are crucial in protection against intracellular infection and have anti-tumorigenic 
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potential. However, ILC1 over-activation may contribute to inflammatory 
disorders e.g. inflammatory bowel disease (Gordon et al., 2012). 
ILC2s are derived from precursors in bone marrow that have high expression of 
GATA3 (Walker et al., 2013). They play a key role secreting type 2 cytokines in 
response to helminth infection. In response to IL-25 and IL-33 activation, ILC2s 
produce Th2 cytokines, for example, IL-5, IL-9 and IL-13. Therefore, ILC2s are 
similar to Th2 cell function and respond to parasite infection. ILC2 dysregulation 
leads to overexpression of type II cytokines, aberrant inflammation and 
remodelling (Spits et al., 2013). 
ILC3s are the innate counterpart of Th17 cells and share the common transcription 
factor RORγt. Following IL-23 and IL-1β activation, they produce the Th17 
cytokines IL-17A and IL-22. Unlike NK cells, ILC3s do not have cytotoxic function 
and do not express IFN-γ or TNF, but dependent on transcription factor RORγt, 
ILC3 are crucial in defence against extracellular pathogens. Aberrant activation of 
ILC3 may cause autoimmune disorders e.g. psoriasis (Spits et al., 2013). 
1.1.2 Adaptive immunity 
The innate immune system plays a key role of rapid detection and elimination of 
pathogens. However, this mechanism is not antigen-specific. In support of the 
innate immune system, mammals have evolved an adaptive immune system which 
provides a more flexible and finely-tuned repertoire recognising self- and nonself-
antigens (Murphy and Weaver, 2016). The adaptive immune response is mediated 
by T and B lymphocytes which express antigen receptors. B cells mediate antibody 
production (called humoral immunity), and T cells produce regulatory and 
inflammatory cytokines (called cell-mediated immunity) (Sattler et al., 2013). T 
and B lymphocytes cells differentiate in primary lymphoid tissues (bone marrow 
and thymus) and mature in secondary lymphoid tissues (spleen and lymph node) 
which promote antigen-specific immune effector pathways, generation of immune 
memory, and regulation of host immune homeostasis (Murphy and Weaver, 2016).  
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The adaptive immune response can be divided into four phases: 
1. Initiation (priming) phase: In this phase, T lymphocytes and B lymphocytes 
recognise antigens via specific antigen receptors called the T-cell receptor (TCR) 
and B-cell receptor (BCR) respectively. 
2. Activation and differentiation phase: In this phase, lymphocytes receive 
antigen co-stimulation and cytokine signals from antigen-presenting cells (APCs). 
These signals initiate the activation, proliferation and differentiation of antigen 
specific T and B lymphocytes into their respective effector cells. 
3. Effector phase: T and B effector cells produce effector molecules (e.g. 
cytokines) to eliminate microbes.  
4. Recovery phase: in this phase following resolution of infection, the stimulation 
of most effector cells is reduced. Without this stimulation most effector cells 
become apoptotic and are pagocytosed by macrophages. Some effector cells are 
retained in lymph node niches and develop into memory cells. 
In summary, the adaptive immune response comprises a cellular immune response 
of T and B lymphocytes activation, and a humoral immune response with antibody 
production (Murphy and Weaver, 2016). 
1.1.2.1 T cell mediated immunity 
T lymphocytes originate from a bone-marrow common lymphoid progenitor and 
mature in the thymus and express the T cell receptor (TCR). After receiving the 
antigen detection signal from APCs, the mature antigen-naive T cells differentiate 
into effector cells in the peripheral lymph organs. On their surface membrane, T 
cells express either CD8 or CD4 glycoproteins. The CD8 positive T cells are called 
CD8+ cytotoxic T cells, and the CD4 positive T cells are called CD4+ helper T cells. 
These effector T cells can mediate the adaptive cellular immune response via 
antigen-dependent ligation of their surface receptors and secretion of effector 
molecules; mainly cytokines and chemokines, which play a key role in defence 
against pathogens, particularly intracellular microbial infections (Delves et al., 
2017).  
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The cellular immune response is initiated by activation of naive T cells which 
receive T cell receptor (TCR) signals by interacting with antigen-presenting cells 
(APCs). In order to induce optimal activation and differentiation of naive T cells 
into effector T cells, the naïve T cells need three signals from APCs. The first 
signal involves T cell receptor recognition of processed peptide antigens presented 
by APCs via their MHC molecules. The second signal results from the interaction 
of ligand/receptor pairs of co-stimulatory molecules on both APC and T cells. 
These include CD80 on APC binding to CD28 on T cells and forming a bridge 
between these cells. These two signals are sufficient to activate and proliferate 
T cells, the differentiation from native T cells into effector T cells requires a third 
signal. This is provided by APC-derived cytokines. With these three activation 
signals, naive CD8+ T cells can differentiate into effectors CD8+ T cells which have 
effector function. These include cytotoxic clearance of virally-infected cells and 
tumour cells. These three activation signals can differentiate native CD4+ T cells 
into several T helper cell subsets, dependent on the regulatory cytokine signals 
they receive and the effector cytokines they produce in response. 
1.1.2.2 T cell subsets 
CD4+ T cells 
The precursor CD4+ (Th0) lymphocytes can differentiate into several distinct 
subsets dependent on their specific cytokine activation environment. The subsets 
are morphologically indistinguishable but are distinguished by their profile of 
functional cytokine production. CD4+ T helper (Th) cells are subdivided into 
different subsets including Th1, Th2, Th9, Th17, Th22, Treg (regulatory T cells) 
and Tfh (follicular helper T cells). These subsets are characterized by their distinct 
profiles of cytokine production. These Th cells are crucial in the immune and 
effector response functions (Raphael et al., 2015).  
Th1 cells, when activated by IL-12 and IFN-γ, release IFN-γ and TNF which are 
crucial in the response to infections with intracellular pathogens, and when 
aberrant may cause inflammatory disease (O'Shea and Paul, 2010).  
Th2 cells differentiate in response to IL-4 and produce cytokines IL-4, IL-5 and IL-
13. This response is associated with protection against parasite infection. When 
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this response is aberrant Th2 activation may cause asthma and allergy 
(Golubovskaya and Wu, 2016).  
Th17 cells are characterised by production of IL-17 and IL-22 when activated by 
IL-1 and IL-6. IL-17 is an important cytokine in host defence against extracellular 
bacterial and fungal infection. Dysregulation of Th17 response is associated with 
inflammatory and autoimmune diseases (Weaver et al., 2013).  
Treg cells are a crucial Th cell subset. They are specialized T cells which act to 
suppress immune response and maintain immune balance and immune tolerance 
(O'Shea and Paul, 2010). Recent study confirmed that several signals (ie. TGFβ 
and IL-2) are important in differentiating Tregs from naïve CD4+ cells and are 
essential in maintaining Treg homeostasis (Chen, 2011). 
Th9 cells are a recently described effector T cells subsets. They differentiate from 
naive T cells by TGFβ and IL-4 signalling and can express cytokine IL-9 (Kaplan, 
2013). Tfh (Follicular B helper T cells) are antigen-experienced CD4+ T cells which 
exist in B cell follicles, mainly identified by the expression of IL-21 and the 
presence of B cell follicle homing receptor CXCR5. These cells are important in 
affinity maturation, germinal centre formation, and the development of memory 
B cells (Crotty, 2014). 
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Figure 1.1 CD4+ T cell subsets 
(Modified from Golubovskaya V, Wu L. Different subsets of T cells, memory, 
effector functions, and CAR-T immunotherapy. Cancers. 2016 Mar;8(3):36.) 
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CD8+ T cells 
Naive CD8+ T cells can differentiate into subsets with distinct function. These 
include effector T cells, effector memory T cells, central memory T cells and stem 
cell memory T cells. These functions are associated with different CD markers 
during the differentiation process.  
CD8+ T effector cells are directly cytotoxic to virally infected cells and tumour 
cells. Their cytotoxic function involves increased synthesis of perforins and 
granzymes. They insert the perforins into the cell membrane of target cells and 
activate their caspase enzymes which cause DNA fragmentation and cell apoptosis. 
The cytotoxic T cells have Fas ligand on their membranes which can bind to the 
Fas molecules on the target cell surface and further activate apoptosis.  
CD8+ effector T cells have a short half-life, however some of them differentiate 
into long-lived memory cells and can rapidly expand upon cognate antigen re-
exposure. These memory CD8+ T cells are essential in the defence against 
pathogen reinfection. 
1.1.2.3 B lymphocyte-mediated humoral immunity 
In adaptive immunity, the humoral immunity driven by B cells and their antibody 
and cytokine products play a key protective role in the defence against 
extracellular pathogens. B cells produce antibodies which can neutralise toxins, 
prevent pathogens adhering to tissue surfaces, activate complement, opsonise 
bacteria for phagocytosis, and sensitise tumour or infected cells for later removal 
by antibody-dependent cellular cytotoxicity by killer cells. 
B cells differentiate in the bone marrow from multipotent hematopoietic stem 
cells. B cells function primarily in secondary lymphoid structures e.g. lymph nodes 
where they are stimulated by cytokines released from T helper cells following 
APC-antigen presentation. Following B cell activation, they differentiate into 
plasma cells which produce antibodies. B cell activation can be either T cell 
dependent or independent. In the T cell dependent response, the activation of B 
cells requires signals from T cells in two steps:  
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1. Antigen recognition and activation: Initially, B cells recognise antigen by their 
B cell receptors (BCRs), followed by interaction with cognate T cells in the 
lymphoid follicles. After antigen recognition, co-stimulation of surface CD40 on B 
cells by binding with surface CD40L on T cells drives B cell activation.  
2. B cell differentiation: Thereafter, with the assistance of T cell cytokines e.g. 
IL-4, activated B cells can differentiate into plasma cells with clonal expansion of 
those recognising antigen. This is a rapid process which can produce a substantial 
number of B effector cells in a short time. These B effector cells are mainly plasma 
cells with short half-life, which produce antibodies, express immunomodulatory 
cytokines and work as antigen-specific APCs in the peripheral circulation. In 
addition, some B cells can differentiate into memory B cells which do not produce 
antibodies but have immune memory functions. These reside in the germinal 
centre niches and can be rapidly activated to produce large amounts of antibody, 
and this is recognised as a secondary antibody response (Liu et al., 1991; Hardy 
and Hayakawa, 2001). 
1.1.2.4 B cell development 
B cells are differentiating along the lymphoid lineage and are derived from 
common lymphoid progenitors. B cells develop in the yolk sac and foetal liver 
before birth and are restricted to the bone marrow after birth in humans. In the 
bone marrow, signals from stromal cells activate the differentiation of the 
common lymphoid progenitors into pro-B cells. These signals are derived from 
direct contact with stromal cells and from locally secreted differentiated factors 
e.g. IL-7 which is an early stage B-lineage growth factor (Namen et al.,1988). 
These pro-B cells further develop into pre-B cells with gene segments encoding 
the κ and λ chains rearrangement, then the IgM isotype will be product on their 
surface after combination with μ H-chain and become immature B cells. These 
three stages (pro-B, pre-B and mature B cell stage) encompass the development 
of B cells. 
1. Pro-B cell stage: At the pro-B cell stage, the gene for the heavy chain (H-chain) 
of the B-cell receptor starts to rearrange, then the genes for the short DH 
(diversity) and JH (joining) regions are recombined dependent on the 
recombination-activating gene enzymes (RAG1 and 2). Successful gene 
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rearrangements terminate the production of intact μ H-chain whereas the abortive 
H-chain production leads to the elimination of pro-B cells. These associate with 
the production of Igα and Igβ heterodimers and the development of pre-B cells. 
2. Pre-B cell stage: At the pre-B cell stage, the newly rearranged heavy chains are 
reacted with germline-encoded λ5 and Vpre-B chains (surrogate light chains). 
After the successful reaction between the heavy chain and the surrogate light 
chains, pre-B cells can express pre-B cell receptors on their cell surface 
membranes associated with Igα and Igβ proteins which become the functional pre-
B cell receptor which can transduce signals to trigger further pre-B cell 
proliferation (Schlissel and Baltimore, 1989; Meffre and Wardemann, 2008). 
Stimulation of the pre-B cell receptors assists the development of pre-B cells into 
immature B cells, followed by rearrangement of the Ig light chain sites, leading to 
random antigen specificity and increasing B cell repertoire diversity (Schlissel and 
Baltimore, 1989; Nishimoto et al., 1991; Lassoued, 1993). Therefore, the 
recombination and BCR expression on immature B cell surfaces enable them to 
recognize specific antigens which is the main function of B cells.  
3. Mature B stage: The heterogeneous immature B cell populations are refined by 
negative selection to remove auto-reactive B cell clones and the risk of 
autoimmune disease. In this process, the immature B cells are exposed to self-
antigen on the neonatal thymus epithelium and in that environment the auto-
reactive B cells can be eliminated by receptor editing or clonal deletion. This way, 
the B cells which do not recognize self-antigen will survive to become mature B 
cells. These then migrate into the peripheral tissues. These mature B cells are 
quiescent non-dividing cells with a short half-life after which most will become 
apoptotic unless they come into contact with antigen. Following antigen contact 
in lymph nodes or spleen, which provides the environment with APCs and T-helper 
cells and cytokines, the B cells survive, become activated and differentiated into 
immune B cell subsets (effector, plasma and memory B cells) (Liu et al., 1991). 
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1.1.2.5 B cell subsets 
Mature B cells can be categorised into two major subsets: B1 cells and B2 cells. 
B1 cells (CD19+CD5+) are found mainly in the peritoneal and mucosal cavities. 
They comprise ~5% of the total B cell population and function primarily in innate 
immunity because they do not possess RAG genes and produce abundant natural 
IgM and low levels of IgD. They express several surface markers, such as CD11, 
CD54. B1 cells have low expression level of BCR on their surface and the natural 
IgM has typical low affinity and broad specificity for microbial antigens. These 
have a powerful protective function in the innate immune response to infectious 
disease such as streptococcus infection.  
B2 cells (CD19+CD5-) are the major functional B cells. They produce high affinity 
antigen-specific antibodies against antigens in secondary lymphoid organs (lymph 
nodes and spleen). They express high level of antibodies (mainly IgG and IgE), 
which can execute somatic hyper-mutation (SHM) and class switch recombination 
(CSR) for affinity maturation. B2 cells have three main functions: cytokines 
secretion (e.g. IL-4 and IL-6), serving as APC and producing antibody (e.g. IgM, IgG 
and IgA).  
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Figure 1.2 B cell development and B cell subsets 
 
(Modified from Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte 
development, differentiation and activation. Nat Rev Immunol. 2003; 3: 317-30) 
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1.2 Cytokines 
Cytokines are small glycoproteins (8-40kDa) which have regulatory function in the 
immune system. They are produced by various nucleated cells either 
constitutively or more often following activation, e.g. in response to microbial 
infection (Thomson and Lotze, 2003). Currently, more than 200 molecules are 
identified as cytokines, including 38 interleukins. Cytokines are key mediators that 
regulate immune and inflammatory responses. Some can amplify and coordinate 
appropriate response patterns of immunity to prevent the host against threats 
from different pathogens and virulence factors (Holdsworth and Gan, 2015). 
Cytokines are molecules that mediate communication between cells. They are 
released by cells in response to infection or tissue damage and can bind to 
cytokine-specific receptors (or co-receptors) on responder cells which then 
perform pleiotropic functions depending on the stimulus and tissue 
microenvironments. Cytokines seldom work function in isolate, instead they work 
as an evolving cytokine network that influence the production of other cytokines 
to regulate the response to, and then resolution of inflammation (Marshall, 1992). 
However, when the host is exposed to chronic infection e.g. tuberculosis, or 
chronic stimulation e.g. autoimmunity, cytokine production may be overexpressed 
and lead to tissue damage. 
Cytokines can be divided into different subtypes based on their cellular source, 
functions and structure. 
According to their cellular sources, cytokines can be classified into three groups: 
1. Monokines: cytokines produced by monocytes or macrophages 
2. Lymphokines: cytokines produced by lymphocytes 
3. Interleukins (ILs): cytokines mainly produced by leukocytes  
According to their function, cytokines can be classified into four groups: 
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1. Pro-inflammatory cytokines: expressed during inflammation and in response to 
acute inflammation, e.g. IL-1 and IL-6. 
2. Anti-inflammatory cytokines: inhibiting inflammation and supporting tissue 
healing, e.g. IL-10. 
3. Growth factors: key signals for cell growth and survival, e.g. Granulocyte-
colony stimulating factor (G-CSF) and Granulocyte-macrophage colony stimulating 
factor (GM-CSF). 
4. Chemokines: participating in basal leukocyte migration and attracting immune 
cells into tissue sites of inflammation by chemotaxis, e.g. C-X-C motif chemokine 
10 (CXCL10).  
According to their structure, they can be classified into 9 cytokine families: 
1. The haematopoietin family (IL-2, IL-4, IL-5,IL-7, IL-13, IL-15 and IL-21). 
2. The Interferon family (IFNα, β and γ). 
3. The tumour necrosis factor (TNF) family (TNFα, LTα and β, RANKL, APRIL). 
4. The IL-1 family (IL-1α, IL-1β, IL-1Ra, IL-18, IL-33, IL-36α, IL-36β, IL-36γ, 
    IL-36Ra, IL-37, IL-38). 
5. The IL-17 family (IL-17 and IL-25). 
6. The IL-10 family (IL-10 and IL-22). 
7. The IL-12 family (IL-12, IL-23, IL-35, IL-27). 
8. The TGF family (TGF-α and β). 
9. The chemokine family (CCL1- 28, CXCL1-17, XCL1 and 2, CX3CL1).  
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Table 1.1 Functional classification of cytokines and receptors 
a does not include soluble cytokine receptors such as sTNFRp55, sTNFRp75, sIL-1R 
type II, IL-18 binding protein, osteoprotegerin.  
b the chemokine family includes CC and CXC chemokines with over 30 members. 
c BMP, bone morphogenic protein; BNDF, brain-derived neurotrophic factor; 
CNTF, ciliary neurotrophic factor; CT-1, cardiotrophin-1; LIF, leukaemia 
inhibitory factor; NGF, nerve growth factor; RANKL, receptor activator of NF-κB 
ligand; VEGF, vascular endothelial growth factor. 
(Adapted from Dinarello, C. A. 2007. Historical insights into cytokines. Eur J 
Immunol, 37 Suppl 1, S34-45). 
 
 
21 
 
1.2.1 IL-1 family and receptors 
The IL-1 superfamily is a group of cytokines that have similar protein structures 
and have essential roles in regulating the innate immune response (Figure 1.3). 
Currently there are 11 molecules in this superfamily, and the majority are pro-
inflammatory cytokines (Nold et al., 2010). All IL-1 superfamily members have the 
IL-1-like domain structure (Garlanda et al., 2013). However, due to the lack of a 
signal peptide, these cytokines cannot be secreted via the endoplasmic reticulum 
and Golgi apparatus, instead, they are released by a less conventional protein 
secretory pathway, via exosomes, secretory lysosomes or exocytosis vesicles 
(Carruth et al., 1991).  
Several cytokines in the IL-1 family have dual functions; following transcription 
they can function as a nuclear transcription factor e.g. cytokine IL-33; or following 
secretion they can function as cytokines e.g. IL-33 and IL-37 (Boraschi et al., 2011; 
Roussel et al., 2013). The IL-1 family members can be subclassified into three 
groups, according to the size of the N-terminal pro-pieces that remains after 
cleavage of the complete ligands. These are the IL-1 subfamily, the IL-18 
subfamily and the IL-36 subfamily (Garlanda et al., 2013, van de Veerdonk and 
Netea, 2013).  
The IL-1 subfamily contains three group of cytokines: IL-1𝛼, IL-1𝛽, and IL-33 have 
the longest pro-pieces containing around 270 amino acids. In the IL-1 subfamily, 
IL-1𝛼 and IL-1𝛽 transmit signals via their common receptor IL-1R, which is a 
heterodimer of the IL-1 receptor accessory protein (IL-1RacP) and the IL-1R1. IL-
33 signalling is mediated via IL-1LR4 (ST2) and IL-1RAcP (Schmitz et al., 2015).  
The IL-18 subfamily includes IL-18 and IL-37, which have long pro-pieces of 
approximately 190 amino acids length. The cytokine receptor of the IL-18 
subfamily consists of IL-18R𝛼 and its accessory chain IL-18R𝛽 which together 
mediate pro-inflammatory signalling and TIR8 (SIGIRR) required after IL-37- IL-
18R𝛼 binding and regulate the inflammation of the host, which will be described 
later in detail.  
The IL-36 subfamily, IL-36𝛼, IL-36𝛽, IL-36𝛾, and IL-38 have smaller pro-piece 
lengths of approximately 150 amino acids. All the members of IL-36 subfamily bind 
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to the IL-36R, except IL-38. The IL-36/IL-36R binding also recruits co-receptor IL-
1RAcP for signalling (Dinarello, 2009). IL-38, also known as IL-1HY2, which shares 
similar structure as IL-1 receptor antagonist (IL-1Ra) and IL-36Ra. IL-38 is a 
candidate in inflammation, and functions mainly to inhibit IL-17 and IL-22 
expression in Th1 responses. Moreover, IL-38 also suppress the production of IL-8, 
to inhibit inflammatory responses. The putative receptors of IL-38 are IL-36R and 
IL-1RAPL1 (Figure 1.3). 
In summary, the IL-1 family is an important component of the first-line immune 
defence system against pathogenic micro-organisms and tissue damage (Veerdonk 
and Netea, 2013). 
 
Figure 1.3 IL1 family members and their receptors  
(Taken from Dinarello, C.A., 2019. The IL-1 family of cytokines and receptors in 
rheumatic diseases. Nature Reviews Rheumatology, 15(10), pp.612-632.) 
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Table 1.2 IL-1 family members 
(Adapted from Carta, S., Lavieri, R. and Rubartelli, A. (2013). Different Members 
of the IL-1 Family Come Out in Different Ways: DAMPs vs. Cytokines? Frontiers in 
Immunology, 4.) 
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1.2.2 IL-37 Introduction  
1.2.2.1 IL-37 
Interleukin-37 is a novel member of the IL-1 superfamily, previously termed IL-1 
family member 7, IL-1F7, IL-1H, IL-1H4, or IL-1RP1. It was originally identified in 
2000 (Busfield et al., 2000; Kumar et al., 2002). The Interleukin-1 (IL-1) 
superfamily includes 11 cytokines which share a β-barrel structure and are closely 
located on human chromosome 2, except for IL-18 (chromosome 11) and IL-33 
(chromosome 9) (Boraschi et al., 2011). Functionally, most of IL-1 family 
cytokines, for instance, IL-1α, IL-1β and IL-33 have pro-inflammatory functions 
and are produced in response to infection by pathogens, tissue damage and a 
variety of stimulatory molecules including other cytokines (Krumm et al., 2014).  
Several biological features of IL-37 are different from other IL-1 superfamily 
members. To be more specific, the majority of members of the IL-1 family are 
pro-inflammatory such as IL-1α and IL-18 (Nold et al., 2013). In contrast, the most 
significant characteristic of IL-37 is suppressing the production and function of 
pro-inflammatory cytokines (Nold-Petry et al., 2015). During the inflammatory 
process, the synthesis of IL-37 is induced and activated similar to other IL-1 
superfamily cytokines, but may mediate the production of other cytokines e.g. IL-
6 and suppress the inflammation process. According to several reports, IL-37 acts 
as a key factor in regulating inflammation and has become an important inhibitor 
of innate immunity and inflammation in various diseases; for instance, colitis, LPS-
induced septic shock and obesity-induced insulin resistance (McNamee et al, 2011; 
Nold et al., 2010). This important regulatory characteristic of IL-37 is of particular 
interest. 
 
  
25 
 
 
1.2.2.1 The IL-37 gene 
 
The locus of the IL-1 cytokine genes is on human chromosome 2. Nine of the 11 IL-
1 family member genes, including IL-37, map to 2q13 (Taylor et al., 2002). 
However, IL-18 and IL-33 maps to 11 q22.2–q22.3 and 9 p24.1 respectively 
(Schmitz et al., 2005). The location of the human IL-37 (IL1F7 gene) is between 
IL1B and IL1F9 genes. The size of IL1F7 is 3.617kb long, from the initiating 
methionine codon to the stop codon (Taylor et al., 2002; Nicklin et al., 2002).  
IL-37 is the only member of the IL-1 superfamily for which there is as yet no 
identified mouse homolog. The explanation is that there is no known IL-37 gene 
in the mouse (Nold-Petry et al., 2015). It is possible that the was an ancient IL-37 
gene in the mouse which was lost through their evolution. There is evidence for 
the first exon of IL-37 gene in the mouse but without any open reading frame. 
Investigations for other IL-37 exons in the mouse have been unproductive. To 
explain this, it is possible that an ancient IL-37 in the mouse was disrupted by an 
insertion of endogenous retroviruses (Dinarello et al., 2016). The expression of IL-
37 protein is a major difference in immune potential between human and mouse, 
and this may provide an opportunity to investigate its function.  
There are five splices of the human IL37 gene (IL-1F7). In these splice variants, 
three of contain the β-trefoil unit, encoded by exon 4, 5 and 6, and are called IL-
37 a, b and d (Dinarello et al., 2010). In these variant transcripts, a consensus 
sequence of the IL-1 family has been detected in IL-37a, located at exon 4. 
Moreover, lysine 27, which contains the putative N-terminus, is situated 9 amino 
acids before this consensus sequence; and this putative N-terminus is essential for 
the activity of recombinant IL-37a. Although the activity of IL-37b with a N-
terminus at lysine 53 has yet to be found, the bioactivity of IL-37b with N-terminus 
at valine 46 has been detected and confirmed; the recombinant form of IL-37b 
shows a high bioactivity (Li et al., 2015). Another form of recombinant IL-37b 
which has a N-terminus at D20, binds weakly to IL-18Rα which is one of the two 
IL-37 receptors (Kumar et al., 2002). There is currently no research finding 
describing the activity of recombinant IL-37c, d, and e. 
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Apart from the 12 putative β-strands peptides encoded by IL-F7 which can form 
the β-trefoil structure, IL-37 (IL-37b) also forms a homodimer under experimental 
conditions. Several studies reveal the existence of two single nucleotide 
polymorphisms in IL-37b; Glycine 31 to Valine and Threonine 42 to Alanine. In 
addition, the second methionine of exon 1 forms the IL-37b protein initiation 
expression site. This suggests that the sequence between Me 1 and Me 2 is 
essential for IL-37 (IL-37b) expression (Pan et al., 2001). IL-37 cytokine is initially 
expressed in an immature form, or pro-protein, then the pro-protein actives 
externally to promote the development from an immature to mature IL-37 protein 
(Nold-Petry et al., 2015). This activation is done by caspase activity. A Caspase-1 
cleavage site has been detected in four of the IL-37 isoforms (isoform b-e), on 
exon 1 between D20 and E21 (A00492). Moreover, a second caspase-1 cleavage 
site exists on exon 2 between F45 and V46. In CHO cells, after the over-expression 
of IL-37 proteins, mature IL-37 protein (translated from V46) are detected 
(Boraschi et al., 2011). Although IL-37a lacks exon 1, it has a unique exon 3, which 
has another putative elastase cleavage site between L21 and R22. Furthermore, 
there is a nuclear localisation signal site (NLS) on exon 3 at the N-terminus, 
upstream of the β-trefoil structure, which assists the translocation of IL-37a into 
the cell nucleus and carry out their transcription factor functions (Nold-Petry et 
al., 2015). 
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Figure 1.4 Alignment of the predicted amino acids sequences of the five IL-37 
isoforms  
Sequences of five IL-37 isoforms are detected by the free-ware system: ‘ClustalW’ 
(www.ebi.ac.uk/clustalw/). According to the arrangement of the six exons in the 
gene, all the exon positions are shown in the diagram above (Figure 1.4). 
Underlined amino acid alignment shows the position of β-strands predicted by 
PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred/). The black arrows mark the pro-
peptide cleavage sites in this gene, with the grey shaded area on exon 1 between 
D20 and E21 being the predicted caspase-1 cleavage sites (exist in IL-37 b-e). As 
the authors indicate, there is another cleavage site which has been experimentally 
detected between F45 and V46 on exon 2 (marked by blue; present in isoforms b 
and c). Moreover, the black arrow with a question mark shows the location of the 
unique elastase cleavage site in exon 3, located between L21 and R22, and is only 
present in IL-37a. Apart from this unique cleavage site, IL-37a also contains a 
putative, bipartite nuclear localisation signal (NLS) detected by ProSite 
(http://www.expasy.ch/prosite/), spanning residues R5 to R22 (highlighted in 
yellow).  
(Adapted from Boraschi, D., Lucchesi, D., Hainzl, S., Leitner, M., Maier, E., 
Mangelberger, D., Oostingh, G., Pfaller, T., Pixner, C., Posselt, G., Italiani, P., 
Nold, M., Nold-Petry, C., Bufler, P., Dinarello, C. (2011). IL-37: a new anti-
inflammatory cytokine of the IL-1 family. Eur Cytokine Netw, 22(3), pp. 127-47).  
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Figure 1.5 Genomic location of IL-37 gene in human and mouse 
 
A) The IL-1 family gene locus on human chromosome 2. B) The IL-1 family gene 
locus on mouse chromosome 2. The IL-37 (IL-1F7) gene location between IL-1β 
and IL-1F9 in human which is absent in mice.  
 (Adapted from Boraschi, D., Lucchesi, D., Hainzl, S., Leitner, M., Maier, E., 
Mangelberger, D., Oostingh, G., Pfaller, T., Pixner, C., Posselt, G., Italiani, P., 
Nold, M., Nold-Petry, C., Bufler, P., Dinarello, C. (2011). IL-37: a new anti-
inflammatory cytokine of the IL-1 family. Eur Cytokine Netw, 22(3), pp. 127-47). 
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1.2.2.2 IL-37 isoforms 
Previous research has found out several fundamental structures of IL-37 which are 
called the rudimentary domain structures. These unique protein structures divide 
IL-37 into 5 parts known as the five isoforms of IL-37 (IL-37a-e) (Boraschi et al., 
2011). These isoforms have unique structures that may result in different functions 
in the inflammatory cascade. Although existing studies do not yet clearly explain 
the mechanisms and functions of IL-37, and the difference between its five 
isoforms, the majority of cohort studies focus on the largest splice variant, the IL-
37b (isoform 1, 218 amino acids). Isoform IL-37b is the most prevalent variant of 
IL-37, and is the most studied and best characterized of the isoforms (Ye et al., 
2014). The most complete exon of IL-37b’s sits with a putative caspase-1 cleavage 
site and a second cleavage site which can best characterize the structure and 
function of IL-37. IL-37a lacks exon 1 which is a common structure in the other 4 
isoforms of IL-37, but has a unique N-terminus, encoded by exon 3, which is not 
expressed in the other isoforms (Charles and Philip, 2013).These structural 
features may endow a differential bioactivity and immune function to IL-37a. 
Furthermore, other short isoforms IL-37c, d and e lack exons 4, 2 or both (Boraschi 
et al., 2011). 
IL-37 isoforms have a similar maturation step as the other members of the IL-1 
superfamily. They are produced as precursor molecules. These pro-IL-37 
molecules contain an enzyme cleavage site at their N-terminus. These are cleaved 
to become mature proteins (Taylor et al., 2002). The expression of caspase-1 is 
required to produce IL-37 isoforms (except IL-37a) (Kumar et al., 2002). However, 
research has shown that caspase-1 expression may not generate the complete 
production of IL-37b and IL-37c because of the other cleavage site (secondary 
cleavage site) which is encoded by exon 2 of the same gene (Taylor et al., 2002). 
One possible implication of this is that the inhibition process of caspase-1 only 
partially influence IL-37b production, which indicates that there may be other 
cleavage sites apart from caspase-1 (Sharma et al., 2008). The in vitro result of 
IL-37b maturation by Granzyme B and caspases 1 to 10 showed that only caspase-
1 and 4 have the capacity to assist protein maturation. Moreover, caspase-1 
cleavage was the most efficient of all the enzymes tested, with significantly lower 
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protein maturation rates observed using caspase-4, and no activity with other 
enzymes (Kumar et al., 2002). 
IL-37a has unique N-terminus encoded by exon 3, and a stop codon directly 
upstream of the starting methionine. The base sequence of the IL-37a gene is 
unlike a classic signalling peptide, but may act as a pro-domain which assists the 
maturation of the protein (Taylor et al., 2002). Exon 3 is not present in other IL-
37 isoforms, therefore the protein translation begins from exon 1. Moreover, IL-
37a contains the same β-trefoil structure (12 putative β-strands, encoded by exon 
4-6) as other members in IL-1 family. This suggests that IL-37a may be a cytokine 
with a biological function in the immune system (Boraschi et al., 2011). 
Furthermore, there is a putative elastase cleavage site found between site L21 
and R22. This unique feature not only reduces the requirement of caspase-1, a 
pre-requisite for IL-37a protein processing, but enables the pro-protein of IL-37a 
cleavage by elastase (Taylor et al., 2002). Using an amino acid sequence alignment 
test, the length of the IL-37a protein is 172 amino acids (Taylor et al., 2002).  
IL-37c is an isoform of IL-37 which has a similar structure as IL-37b, but lacks exon 
4. Both IL-37c and IL-37e lack the full sequence of 12-putative β-strands encoded 
by exons 4-6. Due to the essential role of the complete sequence in protein folding 
and protein function, the lack of exon 4 in mRNA may cause aberrant protein-
folding. Therefore, owing to the lack of this β-trefoil unit, IL-37c and IL-37e may 
not have cytokine function. This means that both isoforms are unlikely fold into 
proteins which have the IL-1 superfamily 3D structure and may not bind to the IL-
18 receptor (Boraschi et al., 2011). Furthermore, although IL-37c and e are non-
functional, they may act as regulatory factors for IL-37 protein production by 
competitively binding to the cleavage enzymes. Due to these enzymes being 
essential for pro-protein activation and following maturation, IL-37c and e may 
affect the expression of other isoforms (Boraschi et al., 2011).  
A variety of haematopoietic and non-haematopoietic cells can express IL-37, such 
as macrophages, monocytes, and neoplastic cells (Huang et al., 2015). However, 
in several tissues, only one of the 5 isoforms of IL-37 is expressed: for instance, in 
the brain, only IL-37a has been detected, and IL-37b is the only isoform y 
expressed in the kidney, and IL-37c is the only isoform found in the heart (Boraschi 
et al., 2011). According to the research of Dr Boraschi et al. (2011), the 
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constitutive expression level of IL-37 is low in the human body, and increased 
production requires stimulation. The reason for low expression levels is an 
instability component encoded by IL1F7 gene exon 5 that leads to strict regulation 
of IL-37 mRNA and subsequent reduced translation rates of IL-37 protein. In 
contrast, following LPS stimulation there is up-regulation of transcription of IL-37 
with greater mRNA stability, and increased protein production (Borachi et al., 
2011). IL-37 mRNA stability is controlled by instability elements present in exon 
5, the deletion of exon 5 can significantly increase mRNA stability of both IL-37b 
and IL-37c. Since all IL-37 isoforms contain exon 5, this instability element exists 
in all isoforms, to ensure an increase in mRNA stability only in inflammatory 
conditions. A similar mechanism can be observed for IL-18 (Bufler et al., 2004). 
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Figure 1.6 Alternative splice variants showing the exon-intron interactions 
within the human IL37 gene, and the exon arrangements of the 5 isoforms of 
IL-37 
 (Adapted from Boraschi, D., Lucchesi, D., Hainzl, S., Leitner, M., Maier, E., 
Mangelberger, D., Oostingh, G., Pfaller, T., Pixner, C., Posselt, G., Italiani, P., 
Nold, M., Nold-Petry, C., Bufler, P., Dinarello, C. (2011). IL-37: a new anti-
inflammatory cytokine of the IL-1 family. Eur Cytokine Netw, 22(3), pp. 127-47). 
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1.2.2.3 IL-37 protein 
With the help of immunohistochemistry, IL-37 protein can be detected in several 
human tissues and cells. This protein is expressed by plasma cells, blood 
monocytes, tonsillar B cells, neoplastic cells, epithelial cells and peripheral blood 
mononuclear cells (PBMCs) in many tissues. The expression of IL-37 has been 
demonstrated in a variety of cells including macrophages, monocytes, and 
neoplastic cells (Huang et al., 2015). According to Boraschi et al. (2011), the level 
of IL-37 expression is low without stimulation. The reason is that an instability 
component encoded by IL1F7 gene exon 5 leads to strict regulation of IL-37 mRNA 
and this causes the low expression rates of IL-37 protein production. In contrast, 
stimulation by LPS can cause up-regulation of IL-37 protein production and higher 
mRNA stability.  
As with other IL-1 family members, the precursor form of IL-37 protein does not 
contain any classical signal peptides. Pre-IL-37 can be detected by Western 
blotting technique in human blood monocytes stimulated by LPS. The constitutive 
concentration of IL-37 in serum is low (typically less than 100pg/ml) in healthy 
individuals. This concentration is increased during several diseases, for example, 
pre-eclampsia, lupus and rheumatoid arthritis (Southcombe et al., 2015; Ye et al., 
2014; Zhao et al., 2014). In human blood monocytes stimulated by LPS, additional 
exogenous ATP cause a modest release of processed IL-37; but the majority of IL-
37 proteins are still in the precursor form (Bulau et al., 2014). This illustrated that 
the additional ATP can active caspase-1 via NLRP3. This enhances the secretion of 
the IL-37 precursor, but it cannot significantly enhance the secretion of the 
processed IL-37 (Bulau et al., 2014). Moreover, as with other IL-1 family members, 
such as IL-1α and IL-33, both precursor and processed IL-37 protein are biologically 
active (Kumar et al., 2002; Li et al., 2015). The mechanism by which the precursor 
IL-37 is processed to the mature form by proteases in the extracellular condition 
remains unclear. 
According to the research of Ellisdon (2017), the IL-37b protein crystal stucture 
indicated that IL-37b can form a homodimer, which is a unique configuration in 
cytokines of the IL-1 superfamily. They confirmed that both the proIL-37(1-218) 
and the mature-IL-37(21-218), or IL-37(46-218) proteins can form homodimers 
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under certain conditions. There are several amino acids involved in the formation 
of dimers. The main amino acid which causes IL-37b monomers to form dimers 
involves the formation of hydrogen bonds between Tyr85 and Arg87. Moreover, 
this interaction is sealed with an ionic gate provided by another two amino acids 
Lys83 and Asp73 (Ellisdon et al., 2017). Due to the lack of strands β1 to β3, the 
Isoforms IL-37c and e do not have the amino acids for dimerization (Ellisdon et 
al., 2017).  
The formation of homodimers may be enhanced when IL-37 is in high 
concentration, for example >1.35uM (Ellisdon et al., 2017). Other factors e.g. pH 
and buffer composition have additional minor effects. Several research groups 
confirmed that the homodimerization of IL-37 can significantly reduce its immune 
suppressive function both in vitro and in vivo. The monomer of IL-37 is the active 
form for immune suppression (Eisenmesser et al., 2019, Ellisdon et al., 2017) 
although the detailed mechanism behind this is not fully understood, but it might 
represent a novel self-regulation of IL-37 function. This phenomenon along with 
the instability element of IL-37 RNA, suggest that the expression and activity of 
IL-37 can be highly self-regulated. 
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Figure 1.7 IL-37 protein induction (TLR) and maturation 
 
 (a) LPS activate immune cells which express IL-37. (b) IL-37 expression enhances 
and releases into the cytoplasm as pro-IL-37 after stimulation. (c) Caspase-1 
enzyme catalyses pro-IL-37 into mature IL-37. (d) Mature and pro-IL-37 can 
secret into the extracellular space. (e) pro-IL-37 can be catalysed by 
extracellular protease into mature IL-37. (f) Both mature and pro-IL-37 can bind 
to IL-37 receptor complex and trigger signalling. 
(Modified from Dinarello, A., Nold-Petry, C., Nold, M., Fujita, M., Li, S., Kim, S., 
Bufler, P. (2016). Suppression of innate inflammation and immunity by interleukin-
37. Eur J Immunol, 46(5), pp.1067-81) 
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1.2.3 IL-37 signalling 
IL-37 is thought to be a dual functional cytokine which can signal via receptor 
dependent and independent mechanisms (Dinarello et al., 2016). 
1.2.3.1 IL-37 receptors 
IL-37 has two receptors, IL-18Ra and IL-1R8. 
 
1.2.3.1.1 IL-18Ra 
There are two receptors of IL-18; IL-18Rα and IL-18Rβ. This is similar to IL-1α 
binding to its receptor IL-1RI and then recruiting IL-1RAcP to transfer the signal to 
activate the immune response. Initially, IL-18 binds to the receptor IL-18Rα then 
recruits another accessory protein IL-18Rβ as co-receptor to activate immune cells 
(Huang et al., 2015). Moreover, this accessory protein is essential to stabilize the 
interaction and forms a high-affinity (0.4nM) complex with biological function 
(Bufler et al., 2004, Huang et al., 2015). Due to the similar amino acid structure 
between IL-37 and IL-18, e.g. the Glu and Lys sites are the same, IL-37 can bind 
to the IL-18Ra (Bufler et al., 2002; Sharma et al., 2008). However, this binding of 
IL-37 to IL-18Ra is not sufficient to activate intracellular signal transduction; 
another receptor SIGIRR (IL-1R8) is recruited to form the tripartite complex and 
produce signal transduction of IL-37 (Bufler et al., 2002; Garlanda et al., 2009; 
Quirk et al., 2014; Nold-Petry et al., 2015). 
1.2.3.2 IL-1R8 (Single Ig IL-1-related receptor; SIGIRR) 
IL-1R8 is an orphan receptor of the IL-1R family (Garlanda et al., 2009). It is widely 
expressed in many human and mouse tissues, including liver, lung, kidney and 
intestine (Lech et al., 2007). Moreover, it can be detected in B cells, 
macrophages, monocytes, dendritic cells (DCs) and natural killer cells (Lech et 
al., 2007). IL-1R8 lacks the Ser447 and Tyr536 on the TIR domain, which is 
important for IL-1R1 signalling in other IL-1R family members. This feature of IL-
1R8 structure means it can act as a decoy receptor which can down-regulate 
inflammation (Garlanda et al., 2009).  
37 
 
IL-1R8 was believed to be a key negative regulator of IL-1 signalling, which 
orchestrated the differentiation and function of innate and adaptive lymphoid 
cells. Within the IL-1R8-deficient T cells, the IL-1 signal pathway was 
demonstrated to be enhanced compared to the wild type cells (Garlanda et al., 
2013). However, such inhibitory mechanism remained unclear. Following the 
engagement of IL-1 and the formation of hetero-dimer IL-1R1/IL-1RAcP, the 
recruitment of TIR domain-containing adapter proteins, such as MyD88 and MAL, 
was known to be essential in activating the IL-1 signalling. Striking, IL-1R8 was 
shown to be able to directly interact with some of these TIR domain-containing 
proteins, such as MAL, TRAM and TRIF (Qin et al., 2005). Such interaction could 
further prevent the protein dimerization and signalosome formation, further 
dampening the downstream signalling. IL-1R8 exerts its regulatory activity by 
inhibiting NFκB and JNK activation induced by TIR-containing ILRs or TLRs upon 
ligand binding (Wald et al., 2003). Because the TIR domain of IL-1R8 is altered 
(also named as TIRb), MyD88 binds to this TIRb domain resulting in a reduced signal 
to the nucleus (Garlanda et al., 2013). Therefore, IL1R8 can modulate IL-1 
signalling (Xu et al.,2015). The immune regulation function of IL-1R8 also 
associated with IL-37 function. 
1.2.3.3 IL-37 receptor-dependent signalling 
A recent study identified a co-receptor system for IL-37b, involving IL1R8 and IL-
18Ra (Nold et al., 2013). Due to sharing similar critical amino acid residues with 
IL-18, IL-37 can bind to the IL-18 receptor IL-18Ra. However, compared with IL-
18, the binding of IL-37 to IL-18Ra has low affinity and cannot become a 
competitive inhibitor (Boraschi et al., 2011). The co-receptor system-IL-
18Ra/SIGIRR may work as the anti-inflammatory signalling accessory chain, which 
assists the signalling process of anti-inflammatory proteins after binding to IL-37. 
The increased level of IL-37 in activated macrophages is associated with 
downregulation of inflammatory stimulation and a decreased response to the 
production of pro-inflammatory cytokines (Ballak et al., 2014). 
Both IL18Rα and IL-1R8 (SIGIRR) is essential in IL-37 protein function. In IL-37-
transfected macrophages, there is an 83% reduction in IL-1β level compare with 
un-transfected control macrophages. However, after silencing endogenous IL-1R8, 
only 34% of the reduction of IL-1β production is observed. Silencing IL-18Rα also 
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causes an attenuation of the IL-37 effect (Nold-Petry et al., 2015). Overall, these 
results indicate that IL-37 function is associated with IL-18Ra and IL-1R8; IL-1R8 is 
a co-receptor for IL-18Rα, and both receptors on the cell surface can bind to IL-
37 and initiate an anti-inflammatory response following IL-1β or LPS stimulation 
(Nold-Petry et al., 2015). This interaction is essential for restraining inflammatory 
pathways in intracellular environment, for example, IL-37 and its co-receptors not 
only inhibit NF-κB and MAPKs, but also reveal pseudo-starvational effects on the 
mTOR pathway, inhibit TAK1 and Fyn and decrease the activation of the anti-
inflammatory Mer, STAT3 and PTEN (Dinarello et al., 2016). If one of the receptor 
complexes is missing, the effect of IL-37 will be attenuated. 
 
 
 
Figure 1.8 IL-37 receptor-dependent signalling pathway 
 
Figure 1.8 shows the IL-37 receptor-dependent signal.  
a) The classical pathway of IL-18 receptors. 
b) IL-37 receptor dependent pathway. IL-37 protein binds to IL-18Ra first, recruit 
IL-1R8 and triggers anti-inflammatory signalling. 
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1.2.3.4 IL-37 receptor-independent signalling 
Another key characteristic of IL-37 is its regulation of inflammatory gene 
expression by a receptor-independent signalling pathway. Two isoforms of IL-37 
(IL-37b and d) can suppress pro-inflammatory gene expression in immune cells 
that lack IL-37 receptors (Luo et al., 2017; Zhao et al., 2018). The mechanisms 
for nuclear translocation by this method remain unclear. The most-studied isoform 
IL-37b can translocate into the nucleus dependent on activation by capase-1, 
samd3 and the mature form of IL-37b (Zhao et al., 2018). This can be confirmed 
by the following evidence: 1. Caspase-1 inhibition prevents IL-37 maturation, 
nuclear translocation, and reducing IL-37 function. 2. Mutation in the caspase-1 
cleavage site (D20) inhibits IL-37b translocation into the nucleus (Bulau et al., 
2014). 3. Smad3-inhibitor inhibits IL-37 nuclear translocation, which can decrease 
inflammation in vitro and in vivo (Grimsby et al., 2004; Bulau et al., 2014; 
Dinarello et al., 2016).  
Therefore, IL-1 or TLR signals may elevate the IL-37 precursor synthesis in the 
cytoplasm. Furthermore, IL-1 or TLR can also induce the expression of caspase-1, 
which can catalyse pro-IL-37 into mature IL-37. The mature form of IL-37 can bind 
to phosphorylated-smad3 and form the IL-37-smad3 complex which can 
translocate into the nucleus. Although the detailed mechanism by which the 
smad3-IL-37 complex regulates gene expression in the nucleus remains unknown, 
due to the involvement of samd3 in TGFβ-mediated immunosuppression, IL-37 may 
also engage the TGF-β-smad3 signalling pathway to down-regulate inflammation 
(Grimsby et al., 2004). 
The pro-IL-37 protein (IL-37a with unique exon 3) can also translocate into the cell 
nucleus by its nuclear location site (NLS) on exon 3 (unpublished result). This 
observation provides a potential translocation function for IL-37a that is different 
from other isoforms. However, the effect of this translocation on inflammation is 
still unknown and needs further investigation. 
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Figure 1.9 IL-37 receptor independent pathway signalling 
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1.2.3.5 IL-37 function in the immune system and disease 
Previous studies that have noted the immune suppressive role of endogenous IL-
37. For example, in human and mouse macrophages transfected with IL-37, the 
signalling kinases and production of IL-1β-induced or LPS-induced cytokines are 
significantly reduced (Nold et al., 2010). Moreover, in primary human blood 
monocytes, a knockdown of IL-37 causes the increased production of pro-
inflammatory cytokines, such as, IL-1α, TNF-α, IL-1β, IL-6, G-CSF, and GM-CSF 
(Nold et al., 2010; Nold-Petry et al., 2015). Furthermore, in human blood 
monocytes stimulated with LPS, a neutralizing antibody to IL-37 increases the 
production of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) (Li et al., 2015). 
These observations support the concept that IL-37 can down-regulate the 
production of pro-inflammatory cytokines in primary human cells. 
IL-37 can suppress the production of LPS-induced cytokines, transcription factors, 
and signalling kinases. The mouse macrophage cell line (RAW cells) was 
transformed with human IL-37b (the most studied and the longest isoform with 5 
exons of IL-37). These transfected cells, which now constitutively expressed IL-
37b, were stimulated with LPS and the production of pro-inflammatory cytokines 
and chemokines (including IL-1α, IL-1β, IL-6, IL-23, TNF-α, GM-CSF and soluble 
ICAM-1) were significantly reduced (Nold et al., 2010; Nold-Petry et al., 2015, 
Sharma et al., 2008). There were similar reductions in cytokine production by 
bone marrow cells of IL-37b transgenic mice. Various signalling phosphokinases 
were reduced in these cells, including mammalian target for rapamycin (mTOR), 
FAK, p53, STAT1, STAT3, Syk, p38, paxillin, and SHP-2. In contrast, the anti-
inflammatory pathways were elevated in the IL-37Tg mouse. For example, the 
kinase and the induction of the phosphatase PTEN was enhanced in comparison 
with wild-type mouse cells (Nold-Petry et al., 2015, Sharma et al., 2008). PTEN 
plays a crucial role in regulating by inhibiting pro-inflammatory pathways such as 
mTOR, FADK and MAPK (Dinarello et al., 2015).  
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1.2.3.5.1 IL-37 and Inflammatory Diseases 
 
IL-37 and Inflammatory Bowel Disease 
 
Gene expression of IL-37b is significantly increased in inflammatory bowel disease 
(IBD) patients compared with healthy control groups. The IL-37b is mainly 
produced in circulating B cells, activated NK cells and monocytes, and correlates 
with the severity of inflammation (Nold-Petry et al., 2015). This indicates that IL-
37 may precipitate in homeostati attempts to control the reduction of 
inflammation in IBD patients (Imaeda et al., 2013; Fonseca-Camarillo et al., 2015; 
Li et al., 2014). Furthermore, the IL-37Tg mice have lower clinical and histological 
scores compare with wild type mice in colitis models (McNamee et al., 2011).  
IL-37 and Inflammatory Respiratory Diseases 
 
IL-37 levels in serum of asthma patients were lower than in healthy control 
subjects, and the levels correlated negatively with asthma severity (Charrad et 
al., 2016). The IL-37 may act as an anti-inflammatory cytokine which can suppress 
the inflammation in allergic asthma by suppressing inflammatory cytokine (mainly 
Th2 cytokine) production. Moreover, in an asthmatic mouse model, IL37b can 
significantly reduce the allergic airway inflammation, the airway 
hyperresponsiveness, decreases the inflammatory cell infiltration into the lung 
tissue, and dampens Th2 cell function. Therefore, IL-37b participates in the 
pathogenesis of asthma (Lunding et al., 2015). However, recombinant IL-37 does 
not seem to have immune suppressive function in receptor-knockout mice in an 
allergic asthma model, which indicate that the anti-inflammation function of IL-
37 is dependent on the receptor IL-18Rα and SIGIRR/IL-1R8 (Lunding et al., 2015). 
Furthermore, the IL-37 level and the inflammasome inhibitory molecules NALP7 
are increased in the bronchial mucosa of stable chronic obstructive pulmonary 
disease (COPD) patients compared with control smokers (Di et al., 2014).  
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IL-37 and Atherosclerosis 
 
Serum IL-37 levels are elevated in atherosclerosis patients. The IL-37 cytokine 
produced by macrophage can reduce the production of pro-inflammatory 
cytokines (IL-1B, IL-6, and IL-12) in vitro, and reduces the development of 
atherosclerosis of patients (McCurdy et al., 2017). Moreover, IL-37 is highly 
expressed in human atherosclerotic plaques, and ameliorates atherosclerosis 
formation by inducing Treg response (Ji et al., 2017). Therefore, IL-37 may act as 
a potential therapeutic approach to prevent atherosclerosis formation and to treat 
disease. 
1.2.3.5.2 IL-37 and Autoimmune Diseases 
IL-37 and Graves’ Disease 
 
IL-37 expression in patients with GD are significantly higher than healthy controls. 
In GD patients, IL-37 acts as an anti-inflammatory cytokine which protects against 
the inflammatory effect in GD by reducing the pro-inflammatory cytokines 
production, such as IL-6, IL-17 and TNF-α (Li et al., 2014). 
IL-37 and Rheumatic Disease 
 
The expression of IL-37 is significantly augmented in rheumatoid arthritis (RA) 
patients compared with healthy controls. In murine arthritis models, injected 
recombinant IL-37b ameliorates the clinical symptoms and delayed disease 
development. The regulatory function of IL-37 in RA relates to the inhibition of 
Th17 cell proliferation, and the decreased pro-inflammatory cytokine production 
in synovial cells (such as IL-1b and IL-6) (Ye et al., 2014). Moreover, IL-37 also 
affects the monosodium urate crystal-induced inflammation in a Mer receptor 
tyrosine kinase (Mertk)-dependent fashion (Liu et al., 2016). 
IL-37 and Systemic Lupus Erythematosus 
 
Plasma IL-37 concentration in systemic lupus erythematosus (SLE) patients is 
higher than in healthy controls (Song et al., 2013). The increased expression of IL-
37 is associated with anti-RNP, anti-Sm and C3 levels in patients, and correlates 
with disease severity and renal damage (Tawfik et al., 2017). Moreover, IL-37 can 
control the pathogenesis of SLE by reducing pro-inflammatory cytokine production 
(IL-1b, IL-6 and TNF-α) (Ye et al., 2014). 
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IL-37 and Psoriasis 
 
IL-37 is highly expressed in psoriatic skin biopsies and is mainly expressed by 
macrophages and effector memory T cells in human psoriatic plaques. Moreover, 
in human keratinocytes from psoriasis patients, the human beta-defensin-3 was 
shown to enhance IL-37 expression (Keermann et al., 2015; Smithrithee et al., 
2015).  
IL-37 and Behcet's Disease 
 
In Behcet's disease (BD), IL-37 expression level was decreased and correlated with 
high inflammatory responses, for example, low IL-37 level is associated with the 
activation of Th1 and Th17 cells, and increases the production of inflammatory 
cytokines and reactive oxygen species (Bouali et al., 2015). Corticosteroid 
treatment augmented IL-37 mRNA expression and this results in a reduction of 
inflammatory cytokines (Ye et al., 2014).  
1.5.3.2.3 IL-37 and cancer 
IL-37 gene expression is increased in several cancers, and this may become a 
potential therapeutic target in cancer pathogenesis. The main role of IL-37 in 
cancer is a protective function. IL-37 has a therapeutic role in cancer 
development. Until now, there are no results that show that IL-37 can be a pro-
tumour cytokine (Ding et al., 2016). To be specific, IL-37b downregulates the 
STAT3 pathway in cervical cancer (CC) by inhibiting essential tumorigenic factor 
STAT3 expression and phosphorylation which may become a novel treatment 
strategy of CC (Wang et al., 2015). IL-37 can also downregulate the STAT3 pathway 
in renal cancer (RC) and suppresses IL-6, HIF-α and Bcl2 expression. Moreover, IL-
37 can suppress fibrosarcoma and non-small cell lung cancer but the mechanism 
remains unknown (Haabeth et al., 2014). Therefore, IL-37 might be a novel 
therapeutic regulator in cancer. 
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1.2.3.2.4 IL-37 function in infectious disease 
Endotoxemia is a severe disease induce by LPS from gram-negative bacterial 
infection. It may cause endotoxin shock and is life threatening by causing multiple 
organ failure (Li et al., 2015). The mechanism of septic shock is the over-
activation of TLR4 signal which aberrantly elevates inflammatory cytokine 
production, such as IL-1, IL-6, TNF-a, and oxygen free radicals (Wang et al., 2018). 
The down-regulatory function of IL-37, especially the isoform IL-37b in the mouse 
model of LPS-induced endotoxemia has been confirmed (Li et al., 2015).  
Endotoxemia is the best studied IL-37-regulated disease (Li et al., 2015). The 
transgenic human IL-37b mouse has reduced tissue inflammation and inflammatory 
cytokine production in the LPS shock model, compare with wild-type mice (Bulau 
et al., 2014). This regulatory function may be mediated by both the receptor-
dependent and independent pathways. To confirm this, one RNA-seq assay was 
performed on IL-37b transgene mice cells with or without IL-1R8 in vitro. The 
results demonstrated: 
i) Several genes of anti-inflammatory and metabolic mediators were activated by 
IL-37 in IL-1R8 dependent pathways, such as FOXO-1, PTEN and STAT3, and inhibit 
the metabolic checkpoint mTOR which downregulate some genes of inflammatory 
mediators like c-jun, IKβ and TBK1; the IL-37 can also suppress the NF-kβ pathway 
which is essential for inflammatory signalling. 
ii) Apart from the receptor dependent pathway, IL-37 can regulate the LPS-
induced transcription factors activity by receptor independent pathway, which 
can significantly suppress the inflammatory genes production, such as STAT5, SHP-
2and IGF-1R. Therefore, the dual regulatory functions of IL-37 in receptor 
dependent and independent pathways of LPS-induced endotoxemia have been 
confirmed (Nold-Petry et al., 2015). 
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IL-37 also participate in other infectious diseases: 
Infectious diseases 
Despite the successes of antibiotics and vaccination, pathogenic infection is still 
a big health problem. This is mainly due to the increasing antibiotic resistant 
bacteria and the emerging mutant or new strains of pathogens. Some pathogens 
can also evolutionarily develop the ability to help them to survive and colonise in 
the human environment by silencing host protective immune mechanisms, for 
instance the vIL-10 produced by EBV (Kanai et al., 2007).  
Immune system plays an essential part in protection against infection. As 
described in Chapter 1, during the early infection, innate immune cells, including 
macrophages, DC and neutrophils can be rapidly activated to control pathogen 
spread and colonisation in the host. Later, the adaptive immune cells, T and B 
cells will also be specifically activated, and can eliminate the pathogens by 
cytotoxicity (CD8 T cells), helping other cells (CD4+ T cells) and producing 
antibody (B cells). While a rapid and strong inflammatory response helps in 
pathogen clearance, host tissue destruction secondary to immunopathology can 
be a deleterious side effect. An appropriate anti-pathogenic response is therefore 
necessary for minimising tissue damage while still allowing clearance of the 
invading pathogen.  
Regulatory cells and related cytokines are critically needed for this purpose to 
maintain host homeostasis and immune tolerance (Abbas et al., 2012). The 
importance of IL-37 in infection has just emerged and available reports suggest 
that IL-37 plays a regulatory role in bacterial, virus, parasitic and fungus infections. 
However, its role in infection is variable depending on the pathogen. 
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Viral infection 
It has been shown that IL-37 can influence the infection and pathogenesis of HIV, 
coxsackie virus B3 and influenza infection (Hojen et al., 2015; An et al. 2017; Zhou 
et al., 2018).  
Viral myocarditis  
Viral myocarditis is an inflammatory heart disease which is caused by many viruses, 
including Influenza, hepatitis A & C viruses, HIV and coxsackie virus B3 (CVB3) 
(Zhao et al., 2018). CVB3 causes myocarditis in both human and in animal 
(Spartalis et al., 2017). CVB3 infection elicits TLR4 signals in APCs that 
subsequently activates innate and virus-specific TH17 cells to enhance pro-
inflammatory cytokine production and myocarditis (Fairweather et al., 2005). It 
has been reported that IL-37 treatment impaired inflammation, pathology and 
reduced mortality in mouse model of myocarditis. This was accompanied by 
reduced effector function of Th17 cells but enhanced immunomodulatory Treg cell 
numbers in the spleen of myocarditis mice. Furthermore, IL-37 not only inhibits 
IL-6 and IL-17A, also promote IL-10 levels in the heart. These results suggest that 
IL-37 is potentially therapeutic. More clinical experiments using human 
cells/tissue are needed to confirm the hypothesis (An et al., 2017).  
Influenza A virus (IAV) infection  
The expression and function of IL-37 in influenza A virus (IAV) infection was also 
studied (Zhou et al., 2018). The levels of IL-37 mRNA and protein levels in the 
PBMC and serum samples from patients with influenza A virus (IAV) infection were 
enhanced compared to the healthy subjects. To understand the effect of IL-37 on 
IAV replication in epithelia cells, A549 cell line was infected with IAV first and 
then treated with rIL-37. The authors found that the level of IAV RNA was 
significantly reduced in IL-37 treated cells. The result suggested that IL-37 may 
be able to inhibit the replication of IAV RNA in infected cells. However, the 
mechanism underlying the IL-37-reduced virus replication has not been explored. 
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Bacterial infection 
The role of IL-37 in mycobacterium tuberculosis (Mtb), Strongyloides stercoralis 
and pneumococcal pneumonia infection has been reported (Paterson and Orihuela, 
2010; Liu et al., 2017; Schauer et al., 2017).  
Tuberculosis (TB) is caused by Mycobacterium tuberculosis and affects one quarter 
of the world's population. M1 and Th1 cells that produce IFN-γ may play a 
protective effect on TB (Berry et al., 2013) and M2 cells that produce 
immunoregulatory cytokines are thought to be pathogenic (Huang et al., 2015). 
Recent reports suggest that IL-37 may play a critical role in TB, however, the 
results are controversial in human and in mice (Huang et al., 2015; Luo et al., 
2016). Zhang et al. reported that IL-37 level is increased in TB patients. The 
elevated IL-37 production in TB was positively associated with the 
prolonged/complicated TB and also the TB burden, while it is negatively 
correlated with the level of pro-inflammatory cytokines such as IL-1β, IL-6 and 
TNF-α in the patients (Zhang et al., 2016). The result suggests that il-37 may be 
pathogenic in TB by inhibiting protective inflammatory response thereby 
promoting infection. 
In agreement with Zhang, Liu and colleagues further found that IL-37 single 
nucleotide polymorphism (SNP) is closely associated with TB susceptibility. The 
levels of IL-37 protein in TB patients were elevated compared to levels in healthy 
controls. Furthermore, Mtb infection enhanced IL-37 but reduced proinflammatory 
cytokines including IL-6 and TNF-α production in macrophages. However, they 
demonstrated that IL-37 may be protective against mycobacterial infection in 
mouse model in vivo (Liu et al., 2017); BCG-infected IL-37Tg mice have less 
mycobacterial burden and tissue damage in the lung, compared to the infected 
WT control mice. This suggests that IL-37 can protect against Mtb infection in mice. 
Moreover, the immune mechanism study demonstrated that the protective effect 
of IL-37 was associated with an enhanced level of Th1 cells and reduced regulatory 
T cells in the spleen (Liu et al., 2017). Thus, IL-37 may protect by promoting anti-
bacterial Th1 response and downregulating disease-promoting T-reg response in 
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Mtb infection. Unfortunately, how IL-37 promotes Th1 and inhibits Treg response 
in Mtb infection is still unclear.  
Streptococcus pneumonia (SP) infections can cause several human diseases, 
including pneumonia, bacteraemia, and meningitis by enhancing inflammatory 
pathological response (Paterson and Orihuela, 2010).  
Given the effect of IL-37 as a suppressor of innate and acquired immunity, its 
impact on SP infection has been studied (Schauer et al., 2017). In vitro, the 
overexpression of IL-37 in the macrophages infected with pneumococci decreased 
the levels of proinflammatory cytokines IL-6, TNF-α, and IL-1β, but increased the 
intracellular pneumococcal infection. Consistently, in vivo, compared to the WT 
control mice, infection with S. pneumonia in IL-37b transgenic mice also 
decreased the expression of inflammatory cytokines IL-6, TNF-α, and IL-1β in lung 
tissue at early infection. However, at later stage, IL-37Tg mice enhanced the 
pneumococcal burden, lung tissue inflammation, damage and mortality. Thus, this 
is consistent with our result in salmonella infection and suggests that IL-37 is a 
therapeutic target in SP-induced pneumonia and in salmonella infection.  
Helminth infection 
The role of IL-37 in parasite infection is less studied. Only two reports from same 
research group so far show that IL-37 can modulate T cell immune response and 
cytokine balance in Strongyloides stercoralis infection (Anuradha et al., 2015). 
Strongyloidiasis is a common parasitic disease which affects about 100 million 
people worldwide (Anuradha et al., 2015; Anuradha et al., 2017; Patton et al., 
2018). The protective immune mechanism in strongyloidiasis in human is largely 
unknown. The Th1 or Th17 response can be protective or pathogenic depending 
on the degree of T cell responses. Th2 cell-mediated immune response is thought 
to play a protective role in the strongyloidiasis by counter-regulation of Th1/Th17-
mediated pro-inflammatory response (Anuradha et al., 2015; Anuradha et al., 
2017; Patton et al., 2018). It has been shown that the patients with 
strongyloidiasis infection contain significantly higher levels of serum 
proinflammatory cytokines IFN-γ, TNF-α, and IL-1β and significantly lower levels 
of anti-inflammatory cytokines IL-4, IL-10, IL-13, IL-27, IL-37, and TGF-β, 
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compared to healthy controls (Anuradha et al., 2015). However, after treatment, 
the cytokine profiles can be reversed with negative enhanced levels of 
inflammatory cytokines and IL-1β but reduced anti-inflammatory cytokines 
including IL-37 (Anuradha et al., 2015). To assess the role of IL-37 in the regulation 
of CD4+ and CD8+ T cell responses in strongyloidiasis, the authors measured the 
changes of parasite specific Th1/Tc1, Th2/Tc2, Th9/Tc9, Th17/Tc17, and 
Th22/Tc22 cell response in the PBMC from the patients with strongyloidiasis and 
healthy controls following the anti-IL-37 neutralizing antibody treatment in vitro. 
They found that IL-37 neutralization markedly increased the level of parasite-
specific Th1/Tc1, Th2/Tc2, Th17/Tc17, Th9, and Th22 cells by FACS and related 
cytokines IFN-γ, IL-5, IL-9, IL-17, and IL-22 by ELISA in the cultures. Thus, while 
the reports demonstrate that IL-37 can modulate S. Stercoralis-specific T cell 
response, the precise role of IL-37 in the protective immunity against 
strongyloidiasis is still unclear (Anuradha et al., 2017). 
Fungal infection 
There are only two detailed reports in PubMed so far that studied the potential 
role of IL-37 in fungal infection in vitro and in vivo, the candida and aspergillosis 
(Moretti S et al., 2014; Veerdonk et al., 2015).  
Candidiasis is a disease of fungal infection. While the protective immunity against 
candida infection is still not fully understood, the innate immune cells, in 
particular the neutrophils in the mucosal tissue, play an important role in anti-
candida infection (Anuradha et al., 2017). Given its effect on the suppression of 
neutrophil migration and function, the authors proposed that IL-37 may promote 
infection by affecting neutrophils function (Van de Veerdonk et al., 2015). They 
demonstrated the hypothesis in a murine model of disseminated candidiasis using 
IL-37b transgenic mice. Compared to the WT control mice, IL-37-tg mice were 
susceptible to candida infection, enhanced fungal growth in the organ and 
mortality. The mice also failed to effectively produce inflammatory cytokines and 
recruit neutrophils to the site of infection. Thus, IL-37 may be pathogenic in 
candidiasis by interfering with host innate protective inflammatory immune 
response. However, its effect in human candidiasis has not been explored. 
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Aspergillosis 
Aspergillosis is caused by the aspergillus which is the most common fungus in the 
environment (Moretti et al., 2014). Aspergillus infection can cause clinical 
conditions including opportunistic infection and allergy, depending on host 
immune state. (Kosmidis and Denning, 2015). 
Activation of inflammasome during Aspergillus infection is pathogenic for 
promoting the secretion of IL- 1b and can result in pathological sequelae (Sun, 
2018). In murine model of Aspergillus fumigatus, IL-37 plays an anti-inflammatory 
role to suppress IL-1 production via control of NLRP3 inflammasome activity. 
Furthermore, treatment of A. fumigatus infected mice with recombinant IL-37 also 
reduced lung inflammation and increased IL-10 production in lung tissue. Thus, IL-
37 display therapeutic potential in decreasing the Aspergillus-induced pulmonary 
pathogenesis (Moretti et al., 2014).  
 
1.3 TLRs introduction 
Toll-like receptors (TLRs) are a family of cell receptors that recognize conserved 
surface structures on pathogens (pattern recognition receptors PRRs). Currently, 
11 and 13 types of TLRs have been identified in humans and mice, respectively. 
These TLRs widely exist on the cell membrane and intracellularly in many cell 
types, for example, macrophages, dendritic cells (DCs), neutrophils, and mucosal 
epithelial cells (Zhang et al., 2015). Examples of microbial recognition include 
Gram negative endotoxin which is recognized by TLRs (particularly TLR4) and 
binding can promote neutrophil activation to enhance phagocytosis of the bacteria 
and their intracellular killing, and the production of anti-bacterial substance e.g. 
alpha-defensins. Microbial recognition by TLRs can also enhance the cytotoxicity 
of NK cells and maturation of DCs which is a link to adaptive immunity, antibody 
production, and costimulatory and T cell activation (Casals et al., 2007). The 
persistence of infection, microbial recognition and binding to TLRs are one of the 
mechanisms by which the innate immune system in turn activates and maintains 
the adaptive immune response at the appropriate level required to match the 
immune challenge of the infection. 
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TLRs are a category of transmembrane Pathogen Recognition Receptors (PRRs) 
which can bind to Pathogen Associated Molecular Patterns (PAMPS) and then 
activate the cells. This activates intracellular signalling pathways e.g. the nuclear 
factor kappa-light-chain-enhancer of activated B cells pathway (NF-kB) 
(Medzhitov, 2001). Activated NF-kB can regulate DNA transcription and cell 
survival, and the synthesis and secretion of cytokines and other immune mediators 
which can activate other innate immune pathways and assist the signalling 
between immune cells to optimize their response (Beutler et al., 2006).  
To maintain virulence, pathogens have evolved various tactics during infection to 
subvert the host anti-microbial mechanisms. Genetic mutation of their antigenic 
structures e.g. in influenza virus can ensure their survival, replication, and 
persistence during infection (Coburn et al., 2007). This is countered by the host 
profile of somatic line of immune system PRRs which recognize various microbial 
molecular patterns to elicit an appropriate and fast innate immune response to 
resist infection. This ongoing ‘arms-race’ interaction between the pathogen 
virulence factors and innate immune responses of host largely determines the 
outcome of the majority of infections (Zhang et al., 2015). 
1.3.1 TLRs signalling pathways 
There are 5 steps associated with TLRs signalling:  
1. Pathogen PAMPs interact with the LRR motif of TLRs to create complexes then 
induce TLRs dimerization.  
2. Through the Toll/interleukin-1 receptor (TIR) domain of TLRs, the intracellular 
signalling adaptor molecules, e.g. MYD88 and the TIR homology domain (TRIF) 
recruit and transmit the activation signal.  
3. Binding induces the production of protein kinases, e.g. Protein Kinases C (PKC).  
4. These protein kinases recruit transcription factors which are reciprocally 
activated by phosphorylation and dephosphorylation.  
5. The activated transcription factors translocate to the cell nucleus and bind to 
specific complementary gene sequences (response elements) which lead to 
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expressions of pro-inflammatory cytokines, chemokines and cell surface molecules 
(Medzhitov, 2001). 
TLR signals can be divided into two main pathways depending on the participation 
of the adaptor molecule MyD88. The pathways can be either MyD88 dependent or 
independent. These MyD88 signalling pathways are essential in almost all 
examples of TLR and IL-1R signal transduction except TLR3. 
The MyD88-dependent pathway is initiated by recruiting the adaptor molecule 
MyD88 following TLR binding to its specific ligands. Stimulation of MyD88 is 
followed by combination of the TIR domains with both MyD88 and IL-1R-associated 
kinase (IRAK-4) to create an immune complex termed as the “MyDdosome”. IRAK-
4 then phosphorylates IRAK-1 which recruits the TNF receptor-associated factor 6 
(TRAF-6) which activates either TAB or TGF-β activated kinase (TAK-1) complex. 
Formation of TAK-1/TAB complex increases the activity of the IκB kinase (IKK) 
complex which degrades Iκβ33 and causes nuclear translocation of the 
transcription factor NF-κB. The NF-κB can induce the production of 
proinflammatory cytokines, such as IL-6, IL-12, TNF-α and other mediators (Wang 
et al., 2001). 
The MyD88-independent pathway (also called the TIR domain containing adaptor 
inducing IFN-β (TRIF)-dependent pathway) is only used by intracellular TLR3or 
internalized TLR4 (Jiang and Chen, 2012). The activation starts with the 
stimulation signal of TLRs, which recruits TRIF and activates the transcription 
factor IRF-3. This transcription factor can translocate into the nucleus and restrict 
activation of NF-κB pathways. The MyD88-independent pathway can produce type 
I IFNs, then activate STAT1 and induce expression of IFN-inducible genes 
(Toshchakov et al., 2002). Therefore, this pathway is essential for the innate 
response to viruses and intracellular infections by the production of type I IFNs.  
As discussed above, TLRs provide a rapid innate response to pathogens. TLR 
activation can contribute to the host response to antigens and can provide a bridge 
linking the innate and adaptive immune response (Rolls et al., 2007). For example, 
during salmonella infection, TLR activation by bacterial LPS can initiate the host 
inflammatory cell response by activating and recruiting macrophages and 
neutrophils to the site of infection, and then producing cytokines. These cytokines 
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include Interleukin (IL)-1β, IL-6, interferon-gamma (IFN)-γ and tumor necrosis 
factor (TNF)-α (Mittrucker et al., 2002). An important cytokine produced during 
salmonella infection is IFN-γ because this cytokine can by regulates the activation 
status of macrophage which can clear the infection (Percival et al., 2012). IL-18- 
also plays a central role in assisting IFN-γ expression as well as early resistance_ 
of immune system towards infection of S. Typhimurium. This protective response 
can become pathogenic, for example, during an invasive salmonella infection and 
an aberrantly activated pro-inflammatory immune response may cause excessive 
inflammation, tissue damage, intravascular coagulation and potential death 
(Hanna et al., 2012).  
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Figure 1.10 Mammalian TLRs signalling pathway 
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1.3.2 TLRs and salmonella  
Salmonella spp. are highly infectious, clinically important and can range from self-
limited gastrointestinal infections to toxic systemic infections (Li et al., 2012). 
Salmonella enterica Typhimurium is a Gram-negative bacterial pathogen that can 
infect a wide range of hosts, including humans and mice. S. Typhimurium has 
several PAMPs e.g. lipopolysaccharide (LPS), bacterial lipoproteins, flagellin, and 
CpG DNA and these are recognized by four TLR ligands TLR4, TLR2, TLR5 and TLR9 
respectively (Zhang et al., 2015).  
The efficiency of detecting surface structures of S. Typhimurium can be enhanced 
by the variety and homo- and heterodimerization of TLRs (Takeuchi et al., 1999). 
These include TLR2/6, TLR4, TLR5 and TLR9 (Rolls et al., 2007). Each TLR 
recognizes a specific characteristic of the pathogen. For example, TLR4 is an 
essential receptor for pathogen-associated lipopolysaccharide (Fabrega and Vila, 
2013) and activation of TLR4 is essential for the early innate immune detection of 
Gram-negative infections. This rapid detection by TLR4 has the potential as an 
immunotherapeutic strategy for detecting and eliminating specific bacterial 
infection (Leveque et al., 2003). Another example of a S. Typhimurium PAMP is 
the protein flagellin which is specifically recognized by TLR5, and this is important 
for recognizing flagellated microorganisms. Flagellin binding to TLR5 recruits NF-
kB pathway and induces synthesis of Type I cytokines, IFN-γ and IL-12, and a Th1 
immune response (Tükel et al., 2005). 
Previous cohort studies have demonstrated that TLR4 is the main receptor for the 
bacterial lipopolysaccharide (LPS) (Liew et al., 2005). LPS is a virulence factor in 
Gram-negative bacteria. Therefore, this TLR4 detection of LPS is important for 
controlling infection by pathogenic Gram-negative bacteria. LPS binding to TLR4 
can induce the secretion of pro-inflammatory cytokines, nitric oxide, and other 
immune factors which can limit and resolve the infection (Leveque et al., 2003).  
The TLR5 ligands in S. Typhimurium include the salmonella-related flagella 
protein flagellin. This ligand is a specific component for TLR5 recognition of all 
flagellated bacteria (Hayashi et al., 2001). TLR5 uses the NF-kB signalling pathway 
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to enhance the production of pro-inflammatory Type I cytokines, such as IFN-γ 
and IL-12, and can activate a Th1 adaptive response (Zhang et al., 2014).  
The Th1 response can contribute to curing the infection, an aberrant Th1 response 
can contribute to excessive inflammation and can cause tissue injury (Moss et al., 
2004). Thus, the TLR and Th1 responses have to be controlled and balanced 
carefully. This can be done by the production of other cytokines which can down-
regulate the activation process. These anti-inflammatory cytokines e.g. IL-1Ra, 
IL-10, TGFβ, are produced later in the gene expression and are involved in the 
resolution of inflammation after the infection recedes, and then in the repair 
process of immune-mediated tissue damage and restoration of homeostasis 
(Gewirtz et al., 2001). 
Generic anti-microbial responses following TLR signalling include activation of the 
transcription factor NF-κB and the production of reactive oxygen species (ROS). 
These factors in turn stimulate the expression of pro-inflammatory cytokines, 
enhance costimulatory molecules, and induce the expression of antimicrobial 
peptides including the inducible nitric oxide synthase (iNOs) and other defence 
molecules (Gowda, 2007).  
Examples of the specific signalling pathways and functions of other TLRs include 
e.g. TLR2 activation which increases the permeability of epithelial tight junctions 
in the host intestine during microbial infection (Jung et al., 2012).  
The mechanisms behind this difference are poorly understood. Therefore, it is 
essential to understand the mechanism behind. As a core innate immune cell type, 
macrophage is a good model to investigate the response in infection disease. there 
is a growing literature describing new knowledge of phenotype, identity and 
function of macrophages differentiated in infected tissue from infiltrating 
inflammatory monocytes (Corliss et al., 2016). We propose therefore to study the 
interaction of Salmonella and macrophages. 
In this project we use macrophage as the basic cell type to analysis the function 
of IL-37 in Salmonella infection. There are some explanations about why we use 
macrophage as a research tool in infections. 1) Macrophages are parts of the initial 
defence towards pathogen infection, and are essential cell type in innate 
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immunity. Therefore, it provides unique possibilities to understand the 
contribution of this extremely dynamic cell subset in the reaction to infections 
(Torraca et al., 2014). 2). During the infection, macrophage destroys bacteria by 
engulfing them in intracellular compartments, which they then acidify to kill or 
neutralize the bacteria. By counting alive bacteria in cell lysate, the invade 
bacteria number can be analysed. 3). Macrophages, especially murine RAW cell 
line, are widely used in many immune models, we also have human macrophage 
cell line THP-1 cell to compare the different gene expression and protein 
production under Salmonella infection. 
1.4 Salmonella introduction 
1.4.1 The characteristic of Salmonella spp. 
Salmonella is a Gram-negative bacterium which belongs to the Enterobacteriaceae 
family. They have similar characteristics to the other family members of the 
Enterobacteriaceae; they are bacillus-shaped, non-spore-forming and 
facultatively anaerobic (Fabrega and Vila, 2013). Salmonella spp. is an enteral 
bacterium which can invade and attack the gastrointestinal tract of its host. 
Normally, they have a regular size of about 0.8–1.5 mm wide and 2-5 mm in length. 
Most strains of salmonella have peritrichous flagella which helps in the 
identification of Salmonella spp. (Fabrega and Vila, 2013). This assists their 
movement and motility, and can enhance their infectivity. There are more than 
2000 serovars of Salmonella spp. reported up to 2011 (CDC, 2011) making this 
genus one of the most prevalent environmental pathogens. These pathogens can 
be categorized into two species: Salmonella enterica and Salmonella bongori. 
Salmonella enterica consists of approximately 2500 serovars which can be 
subdivided into 6 Salmonella subspecies. In S. enterica subsp. enterica (subspecies 
I), several members are associated with typhoid and paratyphoid infection-related 
disease. Due to the diversity of Salmonella serovars, they can infect a wide range 
of species, including humans and farm livestock (Percival et al, 2012). 
Serovars of S. enterica can be classified according to the different disease they 
cause. Salmonella enterica serovar Typhi and Salmonella enterica serovar 
Paratyphi are the main pathogens which cause typhoid fever in human, which is 
also called S. enterica serovar Typhi or S. Typhi (Sabbagh et al., 2010). However, 
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unlike the typical features of infection with other Gram-negative bacteria, the 
typhoidal Salmonella not only causes septic or neutrophilic shock but may lead to 
intestinal perforation and the potential to cause acute toxic encephalopathy 
(Tsolis et al., 2008). In contrast, infection with other Salmonella serotypes e.g. S. 
Typhimurium is not associated with high mortality typhoid fever but can cause 
self-limiting diarrhoea, with approximately 10% of those infected developing a 
secondary bacteremia. These salmonella serovars are called non-typhoidal 
Salmonella (NTS). According to Sabbagh et al. (2010), these two groups of 
salmonella share approximately 90% structural homology and the 10% of structure 
variation contributes to virulence factors. Specific virulence factors can control 
their pathogenic potential e.g. LPS. 
Of relevance to understanding these clinical difference, Salmonella typhi can 
infect human but not mice (Mittrücker et al., 2000), thereby limiting laboratory 
research models, and the mechanism for this difference is not clear.  
1.4.2 Molecular mechanism and immune response 
The host immune response during S. Typhimurium infection consists of both B and 
T cell-mediated immunity and their associated mechanisms that regulate the 
protection reaction against infection (Mittrucker, 2002). Based on the research of 
Percival and Williams (2014), salmonella infection begins when sufficient numbers 
of pathogenic bacteria are ingested. Initially, these microbes form a site of 
infection and replication by adhering to the epithelia of the intestinal lumen. Once 
established, the salmonella can penetrate through the enteral epithelium. During 
this process, the invasive bacteria interfere with the function of the epithelial cell 
apical microvilli and damage the brush border to finish the penetration process. 
This process contributes to intestinal inflammation and diarrhoea. After 
penetration, the salmonella bacilli can enter the membrane-bound vacuole 
organelles in the cell cytoplasm where they can survive and proliferate (Hanna et 
al., 2012). In this protective niche the bacilli produce toxic virulence factors which 
cause cell lysis allowing release of the pathogens from the intercellular 
environment and their dissemination. In addition, salmonella can breach the 
integrity of cell tight-junctions which can enhance the cytotoxic effects towards 
the host epithelial cells (Mittrucker, 2002). This pathogenic process decreases the 
host’s ability to manage the normal dietary processes absorbing food and water. 
60 
 
In summary, salmonella can attach to and alter the permeability of the intestinal 
epithelial cell membrane resulting in cell lysis and diarrhoea (Percival and 
Williams, 2004).  
The immune response to salmonella infection may attenuate the symptoms and 
eliminate the pathogens. Typically, an intact immune system can identify the 
salmonella antigens and initiate a protective immune response by activating Th1 
lymphocytes. Several immune cytokines and anti-bacterial substances are 
generated by activated Th1 cell, such as IFN-γ and nitric oxide in order to assist 
the killing and removal of the salmonella (Moss et al., 2004). When this is 
compromised, e.g. in patients with immunodeficiency or with an immature 
immune system, the immune response may be insufficient; for example, there 
may be insufficient production of the main therapeutic cytokine IFN-γ and may 
fail to recruit other parts of immune response allowing a much wider distribution 
of salmonella and clinical deterioration of the patient which can be life-
threatening (Lee et al., 2015). An additional hazard of salmonella infection 
includes septic shock due to the abundance of bacterial LPS and this is associated 
with increased mortality (Fierer and Guiney, 2001).  
The Th1 immune response can usually eliminate this bacterial infection, however, 
when it becomes aberrantly over-activated it can contribute to sustained 
inflammation damaging host cells and cause pathology. Therefore, the 
appropriate degree of Th1 response should be governed carefully (Moss et al., 
2004). There are mechanisms which help to control an excessive inflammation. 
Anti-inflammatory cytokines such as IL-10 and TGF-β are released by Th2 cells, 
Treg cells, B cells, macrophages and DCs in order to decrease the immune-
mediated damage to host cells, and to maintain a balanced response (Gewirtz et 
al., 2001). 
It has been reported that human and mouse also react differently in their immune 
response, especially in nitric oxide induction in S. Typhimurium infection 
(Vazquez‐Torres et al., 2008). From in vitro result, human macrophages are less 
sensitive than murine in the infectious immune response, and have comparably 
lower cytokine production and anti-bacterial factor production than mice, e.g. 
nitric oxide (ibid). Due to the features of S. Typhimurium, the invaded bacteria 
can lead to a conserved fimbrial gene cluster in mice, which is a main macrophage 
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stimulating factor. However, similar situation cannot be observed in human 
sample. Moreover, the reason why human have significantly lower nitric oxide 
production than mice is not clear. This evidence indicates that the inflammation 
responses may have variations in different species (Tükel et al., 2005). 
 
1.4.3 Salmonellosis 
Salmonellosis is the term for a disease caused by Salmonella infection. Infection 
leads to many manifestations of disease: enteric fever (typhoid fever), 
enterocolitis and systemic illness (Trebichavský and Šplíchalová, 2010). Among 
these diseases, typhoid fever and enterocolitis represent a severe social health 
concern worldwide, especially in developing countries such as Lebanon and India 
(Malaeb et al., 2016). Without efficient clinical treatment, salmonellosis leads to 
high morbidity and mortality. This can also be the case in developed countries 
that have well-established and organized healthcare systems. For example, in 
America, approximately 10% of foodborne diseases are caused by nontyphoidal 
Salmonella spp. (Scallan et al., 2011), and these diseases are a considerable 
individual, social, clinical and economic burden. In 2011, gastrointestinal 
infections caused by salmonella resulted in more than 1 million cases, resulting in 
thousands of hospitalizations and nearly 600 deaths in America (Scallan et al., 
2011). The associated costs were approximately 16 billion dollars annually for 
treating foodborne disease; predominantly associated with salmonella infection. 
Furthermore, several serotypes may cause similar symptoms in human and animals 
which contribute to the prevalence of salmonella infection. Therefore, Salmonella 
spp. is one of the most severe and prevalent pathogens during the last century. 
According to Coburn et al. (2007), the annual morbidity of Salmonellosis in humans 
was approximately 1.3 billion worldwide. Moreover, the global mortality 
associated with non-typhoid Salmonella serovars is estimated at approximately 3 
million per year. Young adults (20-39 years of age) were the most susceptible to 
Salmonella infection (25% of cases). Children and teenagers were less susceptible 
and the elderly and newborns were the least susceptible to Salmonella infection 
(Malaeb et al., 2016). Among these groups those with a compromised immune 
system are most susceptible. More than 60% of salmonellosis occurs during the 
summer months. Therefore, an increased rate of Salmonella infection is 
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associated with environmental and public health situations; one main cause is 
contamination during food processing, storage and transportation (Bajpai et al, 
2012). 
When individuals come into contact with foodstuff that is contaminated with 
Salmonella, they will become potential hosts of the bacteria (Malaeb et al., 2016). 
The pathogen can adhere to the intestinal mucosa to initiate site of infection (de 
Jong et al., 2012). Typical symptoms include fever, diarrhoea and abdominal 
cramps. For diagnosis, a positive foecal culture result is be required to confirm an 
infection. Usually these symptoms are self-limiting and recovery after 2-5 days. In 
some case the infection can develop from mild to severe, with the potential to 
become life-threating (Percival et al., 2012). Those patients infected with 
salmonella who develop bacteremia and systemic infection have a much greater 
morbidity, mortality and treatment failure. 
1.4.4 Treatment 
The most common treatment for salmonella infection is antibiotic therapy. There 
is clear evidence of antibiotics in treating S. Typhi infection, with a successful 
result in managing the process of typhoid fever (Onwuezobe et al., 2012). 
However, some nontyphoidal Salmonella spp. do not respond to antibiotics well. 
The misuse of antibiotics may cause clinical burden to the patients.  
The general overuse of antibiotics worldwide has resulted in the emergence of 
Salmonella strains that are resistant to many of antibiotics, and this is of 
considerable clinical concern worldwide (Hanna et al., 2012). Moreover, the 
increasing rate of foodborne infections also contributes to the environmental 
spread of resistant Salmonella species. These resistant bacteria can survive 
extreme environments and strong antibiotics. Based on the research by CDC 
(2011), 70% of foodborne disease pathogens are resistant to at least one antibiotic. 
According to Cosby et al. (2015), there are two mechanisms to explain the 
increasing resistance rate: 1. enzymatic inactivation of the antibiotic by 
chloramphenicol O-acetyl-transferase, and 2. removal of the antibiotic by an 
efflux pump. Therefore, it is crucial to find additional strategies or treatments 
which can control infections by Salmonella, especially nontyphoidal salmonella 
spp.  
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1.5 Project aim and hypothesis 
 
Till date, IL-37 relate studies are mainly focused on IL-37b isoform and 
demonstrate that IL-37b is an important immunosuppressive cytokine in TLR 
response in inflammatory diseases. However, the function and importance of 
other isoforms, especially the isoform a which own a unique exon 3, is still 
unknown. As IL-37a carries the same receptor-binding domain as IL-37b, the two 
isoforms may share the same receptor and signalling via similar pathway in the 
regulation of TLR function. However, the unique N-terminal domains may confer 
IL-37a additional function in nuclear translocation and gene regulation. Therefore, 
it is important to compare the functional difference between these two isoforms 
and find out the mechanism behind. My hypothesis are: 1)Based on its unique 
structure, IL-37a may be a novel immune suppressive cytokine and a nuclear 
factor, thereby IL-37a may be more effective than the well-studied IL-37 isoform-
IL-37b. 2)Given its immunosuppressive function, IL- 37a may promote Salmonella 
infection in macrophages in vitro by inhibiting immune response in vivo. 3) IL-37 
may also reduce Salmonella- mediated pathology by inhibiting pro- inflammatory 
cytokine productions in vivo. 
In this thesis, I aim to produce IL-37a and IL-37b recombinant proteins and 
transgenic mice as a research tool for comparing the functional difference 
between these two isoforms. Moreover, I will investigate the regulatory effect of 
IL-37a on TLR response in vitro and in the infectious disease model, using 
salmonella. Furthermore, I also explore the underlying molecular mechanism by 
which IL-37a and IL-37b differently affect TLR4 response in immune cells using 
transcriptomic analysis. All these results are focused on addressing the main issue: 
What is the difference between IL-37a and b in TLR stimulations and by what 
mechanism. 
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Chapter 2 
Materials and methods 
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2. Material and method 
2.1 Mice 
All mice (wildtype/transgenic mice) were housed in the Biological Services 
facility, University of Glasgow, following the United Kingdom Home Office 
regulation. All the animal procedures were undertaken at the Central Research 
Facility (CRF) of the University of Glasgow under project license NO. PD13F11FC 
and 60/4405; the researcher also hold a personal license (NO. IFB9F1C16). CRF 
stuff have specialized facilities for animal housing and expertise for animal 
handling and experiment. Mice for experiment were typically 6-8 weeks old. Mice 
strains are summarized in Table 2.1. All transgenic mice were randomly 
distributed into several groups in similar number and identified by genotyping. 
All mice had clean food and water without limitation; and for the purpose of 
environmental enrichment their cages were supplied with bedding and other 
support materials when necessary. For individual assessment, all mice were ear 
marked. The maximum capacity of each cage was five (marked as no earmarked, 
left earmarked, right earmarked, double earmarked and two left earmarked).  
 
 
 
Table 2.1 Mice strain used in this project 
 
 
 
 
 
  
strain genetic modification source
Balb/C wild-type Charles River lab
C67BL/6 wild-type Charles River lab
C67BL/6 IL-37a transgenic  (TgIL-37a) Bred at University of Glasgow 
C67BL/6 SIGIRR gene knockout  (SIGIRR KO) Bred at University of Glasgow 
C67BL/6 IL-37a transgenic with receptor knockout (TKIL-37a) Bred at University of Glasgow 
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2.2 Cell stimulators 
Cell stimulators, working concentrations and suppliers are summarised in Table 
2.2. 
 
Table 2.2 Stimulators used in experiments 
 
2.3 Antibodies 
Antibodies used for ELISA and western blot used are summarized in Table 2-3. 
 
 
 
 
Table 2.3 Antibodies used in ELISA and western blot 
  
cell stimuli Supplier working concentrations
PAM3 Thermo Fisher 10ng/ml
FlAst Thermo Fisher 10ng/ml
TPA/PMA Sigma-Aldrich 50ng/well (24 well plate)
Lipofectamine™ RNAiMAX Thermo Fisher 25ul/ well (96 well plate)
IMQ  InvivoGen 5ug/ml
CpG  InvivoGen 3ug/ml
LPS Thermo Fisher 100 ng/ml, 10ug/ml
rhIL-37a House made 50 ng/ ml
rhIL-37a (mutant monomer) House made 50 ng/ ml
rhIL-37b House made 50 ng/ ml
rhIL-37b (mutant monomer) House made 50 ng/ ml
Antibody Produced in Stock concentration Dilution Company
Anti-6 His tag Mouse   0.1 mg 1 :1000 Abcam
horseradish peroxidase (HRP) Rabbit 1.0 mg 1:10000 Abcam
Biotinylated anti-human IgG Mouse 0.5 mg/ml 1：500 BD pharmingen
Biotinylated anti-mouse IgG human 0.5 mg/ml 1：500 BD pharmingen
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2.4 Chemicals and reagents 
Chemicals and buffers used are listed in Tables 2-4 and 2-5. 
 
Table 2.4 Chemicals used throughout the project 
 
 
 
 
 
 
 
 
 
 
 
 
Chemicals Supplier Usage
10% Ammonium persulfate (APS) Sigma-Aldrich Protein purification
10% SDS Sigma-Aldrich Protein purification
1M /1N Acedic acid Sigma-Aldrich ELISA
1M /1N hydrochloric acid Sigma-Aldrich ELISA
3,3',5,5'-Tetramethylbenzidine (TMB) eBioscience ELISA
30% Acrylamide Sigma-Aldrich Protein purification
Agarose Sigma-Aldrich Genotyping
Ampicillin Sigma-Aldrich Protein purification
DNAseI Sigma-Aldrich Protein purification
EDTA-free complete protease inhibitor cocktail Sigma-Aldrich Protein purification
Ethidium Bromide Invitrogen Genotyping
Imidazole Sigma-Aldrich Protein purification
Isopropyl β‐D‐1‐thiogalactopyranoside (IPTG) Sigma-Aldrich Protein purification
Kanamycin Sigma-Aldrich Protein purification
Lysozyme Sigma-Aldrich Protein purification
N,N,N′,N′‐tetramethylethylene‐diamine  (TEMED) Sigma-Aldrich Protein purification
Protease Inhibitor Cocktail Sigma-Aldrich Protein extraction
Tris Acetate-EDTA (TAE) Sigma-Aldrich Genotyping
Tween® 20 Sigma-Aldrich ELISA
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Table 2.5 Various buffers and their composition used throughout the project 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemicals Supplier Usage
10% Ammonium persulfate (APS) Sigma-Aldrich Protein purification
10% SDS Sigma-Aldrich Protein purification
1M /1N Acedic acid Sigma-Aldrich ELISA
1M /1N hydrochloric acid Sigma-Aldrich ELISA
3,3',5,5'-Tetramethylbenzidine (TMB) eBioscience ELISA
30% Acrylamide Sigma-Aldrich Protein purification
Agarose Sigma-Aldrich Genotyping
Ampicillin Sigma-Aldrich Protein purification
DNAseI Sigma-Aldrich Protein purification
EDTA-free complete protease inhibitor cocktail Sigma-Aldrich Protein purification
Ethidium Bromide Invitrogen Genotyping
Imidazole Sigma-Aldrich Protein purification
Isopropyl β‐D‐1‐thiogalactopyranoside (IPTG) Sigma-Aldrich Protein purification
Kanamycin Sigma-Aldrich Protein purification
Lysozyme Sigma-Aldrich Protein purification
N,N,N′,N′‐tetramethylethylene‐diamine  (TEMED) Sigma-Aldrich Protein purification
Protease Inhibitor Cocktail Sigma-Aldrich Protein extraction
Tris Acetate-EDTA (TAE) Sigma-Aldrich Genotyping
Tween® 20 Sigma-Aldrich ELISA
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2.5 Tissue cell and cell-line culture 
Primary cells and cell lines were cultured in complete medium (RPMI 1640 or 
DMEM, 10% heat-inactivated FBS, 100U/ml Penicillin, 100μg/ml Streptomycin, 2 
mM L-glutamine; Thermo fisher, UK), unless otherwise specified. Cell cultures 
were maintained in a humidified chamber (Heraeus Instruments, Germany) 
supplemented with 5% CO2 at 37.0°C. Viability of the cells was evaluated by 
trypan-blue staining [0.1% (w/v) Trypan Blue (Sigma-Aldrich, USA)] and counted 
using Neubauer haemocytometers (Weber Scientific International Ltd, UK) on a 
Nikon Labphot microscope. 
2.5.1 Primary culture of murine splenocytes 
Mice were sacrificed by exposing to CO2. The animals were then placed on a clean 
dissection board and rinsed with 70% reagent alcohol. The spleens were harvested 
by incision of the abdominal cavity then put in ice-cold complete RPMI 1640 
(Roswell Park Memorial Institute – 1640, Gibco®) culture medium for short storage. 
The splenocytes were isolated using 100um sterile EASYstrainerTm (Greiner bio-
one, UK) which place on cell culture petri dish (SIGMA). Cells were gently 
separated from the tissue by 2ml syringe smashing. All cells were collected in 50ml 
falcon tube with RPMI media, and then washed with PBS 1X. Red blood cells were 
lysed with appropriate lysis buffer (SIGMA) following manufacturer’s instructions. 
Upon to times washing with RPMI, the cells were placed and cultured in complete 
RPMI media in appropriate concentration.  
 
2.5.2 Peritoneal macrophage preparation 
To prepare peritoneal macrophages, WT and IL-37a transgenic mice were 
separated into two groups (a least 3 mice per group) before injection. 50ml 5mM 
sodium m-periodate (Sigma-Aldrich) buffer was prepared for the following 
macrophage stimulation and kept on ice. 1ml of the buffer was drawn into the 
right part of peritoneal cavity of each mouse by intraperitoneal injection. Mice 
were kept in the original cages for another 4 days till cell harvest. After culled in 
a CO2 chamber following the ethics statements, mice peritoneal cavity was 
washed by 5ml of ice-cold PBS buffer and the peritoneal macrophages were 
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collected with PBS buffer using a syringe. The peritoneal macrophages were 
incubated in complete RPMI culture medium till further experiment. They cells 
became adhere in 6 hours after collection. 
2.5.3 Human peripheral blood mononuclear cell (PBMC) isolation and culture 
Human peripheral blood mononuclear cells (PBMCs) were separated from buffy 
coat of healthy donors by density gradient centrifugation using Ficoll. In more 
details, whole blood was diluted with PBS 1:1, and slowly added on the top of 3ml 
Ficoll-1077 (SIGMA) previously added in a 15ml falcon tube. The sample was 
centrifuged at 400g at room temperature for 30 minutes. The whole blood was 
separated into different layers by ficoll-1077 after centrifugation. Serum in the 
upper layer and the PBMC cell ring in the mid layer were collected by plastic 
pipette. Then the PBMCs were washed twice by sterile PBS and cultured in 
complete RPMI for further use.  
2.5.4 THP-1 cell culture 
2.5.4.1 THP-1 monocyte culture 
Human monocyte THP-1 cells were cultured in complete RPMI 1640 medium in a 
humidified incubator (Heraeus Instruments, Germany) at 37°C and 5% CO2.  
2.5.4.2 THP-1 Cell Differentiation 
THP-1 monocytes were collected with culture media and centrifuged at 1200rpm 
for 5 minutes. After discarded the supernatant, monocytes were then resuspended 
in 4ml fresh complete RPMI for cell counting. Suspension monocytes were counted 
with 0.1% (w/v) Trypan Blue (Sigma-Aldrich) stain in Neubauer haemocytometer 
and check under a Nikon Labophot microscope (x10 magnification). Monocytes 
were then placed at a density of 1.2x105 cells/ml per well into 24-well cell culture 
plate and incubated for 24 hours under 37°C, 5% CO2 culture condition. After 24 
hours’ incubation, cell density was calculated again with same method with 
additional 50ng of Tetradecanoyl phorbol acetate/ phorbol 12-myristate 13-
acetate (TPA/PMA) (Sigma-Aldrich) to each well for 48 hours to differentiate into 
adherent macrophage-like cells. Before infection process, the morphology and 
adhesion condition of THP-1 cells was observed in order to confirm the efficiency 
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of macrophage differentiation. The differentiation efficiency was around 95% for 
all the samples. Moreover, the cells were washed twice with RPMI 1640 media with 
3% FCS and 2mM L-glutamine. Fresh culture medium was applied after the old 
medium was discarded in order to remove the undifferentiated monocytes and 
supply a better experiment condition for salmonella infection. 
2.5.5 Murine macrophage (RAW 264.7) cell culture 
RAW 264.7 cells (murine macrophages) were also used in this project for 
comparing the infection result between human and murine macrophages. Raw 
cells (generation 7) were cultured in DMEM (Dulbecco's Modified Eagle Medium, 
Gibco®) media with 10% FCS, 2mM L-glutamine and 1% penicillin–streptomycin. 
Owing to the density of THP-1 cells, 2.8x10^5 RAW cells were placed in 24-well 
cell culture plates and media was replaced by complete RPMI1640 media 24h 
before infection. Therefore, cell density of THP-1 macrophage and RAW cells for 
infection would be similar. After that, old cell culture media was discarded and 
replaced by RPMI 1640 media with 10% heat inactivated FBS in addition to 2mM L-
glutamine in 24h. The purpose of this step is to make the RAW cell more sensitive 
to the infection as well as maintain in similar culture condition as human 
macrophage. Same as THP-1 cell, the cell was washed twice with RPMI 1640 media 
with 3% FCS and 2mM L-glutamine just prior to the bacterial infection. 
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Figure 2.1 Comparison of THP-1 monocytes and macrophage (Magnification: 
x10) 
 
 
 
 
Figure 2.2 Murine RAW macrophage (Magnification: x10) 
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2.6 Recombinant IL-37a and b protein production 
2.6.1 Recombinant IL-37 a and b protein expression 
2.6.1.1 Production of competent cells and transformation of Escherichia coli 
(E. coli) 
E. coli host strain BL21 (DE3) was first incubated in 10ml LB broth in a shaker at 
37°C overnight. After incubation, the wild strain was then cultured on LB agarose 
plate with chloramphenicol antibiotic to avoid contamination. The stock can be 
stored for further process at -80°C. 
In order to prepare competent E. coli, 500μl of host cells after overnight culture 
were added in a conical flask with 50ml LB broth. Then the culture flask was 
placed in a shaking incubator at 37°C, culture for 3-4 hours. After cell culture, 
cells were able to reach the optimal optical density (OD). Required OD of the 
bacteria culture is around 0.3-0.4 under 600nm wavelength measurement. Cells 
were then centrifuged at 3000rpm for 10 minutes. After discarding the 
supernatant, cell pellets were re-suspended in ice cold calcium chloride (CaCl2) 
buffer (0.1M). Because the cell become weak after centrifuge, 1ml of CaCl2 buffer 
was added and mixed gently; then volume was made up to 25 ml (half the original 
volume of LB media). As the CaCl2 in the room temperature is toxic for the cells, 
cells were incubated on ice for at least 1 hour. Moreover, cells were centrifuged 
again at 2500rpm for 5 minutes. After adding another 2ml of 0.1M CaCl2, cells 
became competent and ready to be used as a host bacterium for transformation.  
For transformation, 200μl of competent bacteria were separated in two groups in 
1.5ml sterile Eppendorf tubes labelled as test and control samples. 1ng of plasmid 
constructs which contains specific gene encoding protein (IL-37a and IL-37b) was 
added to the tubes of the test group. Tubes of both groups were place on ice and 
incubated for 45 minutes, then placed in water bath (42°C) for 90 seconds to open 
the cell membrane and assist plasmid insertion into the cell. After heat shock, 
tubes were immediately placed on ice again. Additional 800μl of LB broth was 
added into each tube and bacteria were incubated at 37°C for 30 min, the tubes 
were gently inverted every 5 minutes to avoid cells destruction. 
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2.6.1.2 Plasmid DNA extraction 
Plasmid DNA was extracted from E. coli strain DH5α using the QIAprep®Spin 
Miniprep Kit (Qiagen) according to the manufacturer’s instructions.  
2.6.1.3 Storage and bacterial growth conditions 
All bacteria stains were stored in 50% glycerol stocks at -80ºC condition. To recover 
the frozen bacteria, the stock was thawed in a 37 ºC water bath and placed on a 
LB agar plate for forming colony. Single colony was then transferred into 1ml LB 
broth culture media with 10% glycerol. After transformation, E. coli strains were 
routinely grown in typical LB agar or broth in the stable 37ºC incubator. The 
selective culture media contained antibiotics which related to the transferred 
plasmid. We used Ampicillin or Kanamycin (100µl/ml) for IL-37a and b 
respectively. 
2.6.1.4 Expression of recombinant IL-37a and IL-37b 
The recombinant IL-37 proteins (IL-37a and b) were produced in E. coli BL21 (DE3). 
Transformed DNA can be specially expressed with IPTG induction. To optimize the 
expression condition, the researcher tested variant induction conditions and the 
successfully expressed recombinant IL-37a and b in large scale.  
2.6.1.5 Recombinant IL-37a and b test expression 
E. coli BL21 (DE3) used as a template to express the IL-37 protein by transformed 
with the pET-28a vector for IL-37 (IL-37a and IL-37b). The transformation step had 
done for both pET-28a vector for IL-37a and IL-37b respectively. After the 
transformation, the successfully transformed E. coli were selected by specific 
antibiotic bacteria culture LB agarose plate and a single colony was picked up by 
tips and growth in Luria Bertani (LB) medium supplemented with 100μg/ml 
Ampicillin/ kanamycin at 37°C overnight. Moreover, the bacteria culture mixture 
was diluted in fresh LB medium (1:50 dilution) which containing kanamycin and 
grown at 37°C under continuous shaking (180rpm, 37°C), until the absorbance (OD 
level) at 600nm reached 0.6. IL-37 expression was induced by adding 1 mM IPTG 
(SIGMA, UK) to the successfully transformed E. coli BL21 (DE3), and the bacteria 
were incubated at 37°C for several time points (1, 2, 3, 4, 5, 6, and 24 h), the 
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culture mixture were collected at each time point respectively and stored in -
20°C. The expression level was evaluated by 15% Sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS–PAGE). In order to test at which time 
points the IL-37 protein has the best expression level and give a proof to optimize 
the culture conditions. 
 
 
 
Figure 2.3 the construction of IL-37  
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2.6.1.6 Large scale expression of recombinant IL-37a and b in E. coli 
One single colony of E. coli which had been successfully transformed with IL-37a 
or b DNA (pET-28a/IL-37b or pET21 a/IL-37a) was picked up from selected plate 
and grown at 37°C in Luria Bertani (LB) medium supplemented with 100μg/ml 
Ampicillin/ kanamycin overnight. The mixture of E. coli culture was diluted 100 
times in fresh LB medium 6.25 ml for a 625ml culture) which containing Ampicillin/ 
kanamycin (100ug/ml) and grown at 37°C in a shaking (180rpm, 37°C) incubator, 
until the OD at 600 nm reached 0.6. After that, IL-37 expression was induced by 
adding 1 mM IPTG to the successfully transformed E. coli BL21 (DE3), and the 
bacteria were incubated at 37°C for 4 hours. After the culture medium was cooled 
enough, the bacteria were harvested by 4°C centrifugation at 5000 rpm for 15 
minutes using the Avanti J-26PI centrifuge with a JA-25.50 fixed angle rotor 
(Beckman Coulter, Inc.). Furthermore, the culture Supernatants were decanted, 
and the pellet was stored at −80°C overnight.  
2.6.2 recombinant IL-37a and IL-37b protein purification 
The recombinant IL-37a and b with 6His-tag can be purified using immobilized 
metal affinity chromatography (IMAC) method by Ni-NTA column. Dialysis and gel 
filtration, the purity of recombinant protein was further checked by SDS-PAGE gel 
and confirmed by western blot in Dr Xu’s lab. Protein concentrations were 
measured by Coomassie Blue assay with endotoxin removal. The recombinant 
proteins are ready for cell assay after purification. 
2.6.2.1 Bacteria cell lysate Preparation  
The next day, the transformed bacteria pellet was collected from -80°C and 
resuspended in 35 ml of bacteria lysis buffer then vortexed till the pellet was 
completely dissolved. Furthermore, the lysate was sonicated on ice for further 
disruption (15 second sonication on, 45 seconds off for 10 cycles) until the solution 
was no longer viscous. After sonication, an 18000rpm centrifuge was performed 
for removing the insoluble substances at 4°C for 30 min. The supernatant was 
collected and kept on ice for protein purification.  
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2.6.2.2 Purification of recombinant IL-37a and IL-37b in Ni-NTA column 
The Ni-NTA column (GH Healthcare) was used for IL-37a and IL-37b protein 
purification. The column was equilibrating with binding buffer (500 mM NaCl, 20 
mM tris base, 10 mM imidazole, PH= 7.5 filtered by Büchner funnel) and elusion 
buffer (500 mM NaCl, 20 mM tris base, 10 mM imidazole, PH=7.5 filtered by 
Büchner funnel). The bacteria supernatant was loaded into the column after 
centrifuge and the whole process was controlled by the column machine and 
monitored by the Ni-NTA column system (Primeview). In the column, the proteins 
of loading mixture were binding to the column then eluted with the elution buffer. 
After checking the protein peak of the Ni-NTA column system on the screen, 
several tubes were selected, and samples were picked from them to prepare for 
SDS–PAGE analysis process. 
2.6.2.3 Sodium dodecyl Sulphate-Polyacrylamide gel electrophoresis (SDS-
PAGE) 
Purified IL-37 proteins (IL-37a/b) were treated with sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS–PAGE) gel. A resolving gel and stacking 
gel were prepared before the experiment using the constituents in the Table 2.6a 
and b. The recombinant bacteria extract or the purified proteins were 
resuspended in SDS–PAGE loading buffer with 95°C heating on a dry heat block for 
5-10 minutes. Then the samples were centrifuged at 12000rpm for 2 minutes and 
10µl samples were loaded per well on a 15% SDS–PAGE for 120volt, 40 minutes’ 
electrophoresis in the electrophorese tank (Sigma, UK). After electrophoresis, the 
denatured proteins were stained with 0.1% Coomassie Brilliant Blue R-250 solution 
for 1 hour to become visible and de-stained by gel de-stain buffer overnight.  
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Constituents of resolving gel for SDS-PAGE 
Reagent Amount 
 Distilled water (D.H2O) 4.4 ml 
1.5M Tris PH=8.8 5.2 ml  
30% acrylamide mixture 10 ml 
10% sodium dodecyl sulphate 
(SDS) 
200 µl  
10% ammonium per sulphate 
(APS) 
200 µl  
tetramethyl ethylenediamine 
(TEMED) 
8 µl  
Total amount (for 4 gels) 10 ml  
 
Table 2.6a Constituents of resolving gel for SDS-PAGE 
 
 
Constituents of stacking gel for SDS-PAGE 
Reagent Amount 
 Distilled water (D.H2O) 5.5 ml 
1M Tris PH=6.8 1 ml  
30% acrylamide mixture 1.3 ml 
10% SDS 80 µl  
10% APS 80 µl  
TEMED 8 µl  
Total amount (for 4 gels) 8 ml  
 
Table 2.6b Constituents of resolving gel for SDS-PAGE 
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2.6.2.4 Dialysis condition 
IL-37 proteins were collected following the result of SDS-PAGE gel and dialyzed in 
dialysis buffer for further purification with gel filtration using S75 column. 5 litres 
of plastic breakers were used for protein dialysis, the proteins (IL-37a and IL-37b) 
after NI-NTA column purification were put into a dialysis tubing cellulose 
membrane (Sigma) in the dialysis buffer with a magnetic stirrer at 4°C overnight. 
The dialyzed sample can be used for further purification such as gel filtration after 
centrifuge to remove the possible denatured protein precipitation. After the gel 
filtration, proteins were dialyzed again in PBS buffer. The dialyzed proteins kept 
at -20°C for protein bioassay.  
2.6.2.5 Gel filtration 
Gel filtration was further used to separate the protein of interest by their size. 
After purification with NI-NTA column and checking protein purity by Western 
Blot, the IL-37 protein was further purified by gel filtration chromatography. 
HiLoad Superdex 200 PG column (30 × 10 mm, Pharmacia GE Health Sciences) was 
used to purify the protein mixture after Ni-NTA column was confirmed by SDS-
PAGE gel. Before the mixture loading, the column was equilibrated for 5 hours 
with 50 mM acetate buffer which contained 100mM KCl (pH =5). The mixture was 
loaded with the assist of 10ml syringe, all the liquid was applied on the column 
and then elute with the elution buffer (200mM NaCl and 50mM Tris) at a flow rate 
of 0.33ml/min. Fraction was automatically collected after draining 80% of the void 
volume by the Fraction Collector Frac-920 obtained from Pharmacia GE Health 
Sciences. Each collection tube contained 2ml of eluted protein with elution 
buffer. Different protein can be separated in this step with the different peak 
which analysis by system. The concentration of the protein fractions was detected 
by photometer at 280nm OD level. 
2.6.2.6 Western blot  
Western blotting technique was used for testing the protein conformation and 
specificity of IL-37 (IL-37a and IL-37b). The purified protein was collected and 
separated by 20% SDS–PAGE gel. Then samples were transferred into a 
polyvinylidene difluoride (PVDF) membrane (Millipore), followed by blocking for 
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unspecific antibody binding with 5% defatted milk. The membrane was washed 
with PBS buffer with additional 0.05% Tween20 3 times and incubated with the 
diluted primary antibodies (human anti-His6 tag monoclonal antibody, ABD) in 
1:500 dilution at 4°C overnight. Furthermore, the HRP-conjugated rabbit anti-
mouse (Abcam) was used as a secondary antibody, incubated with the samples at 
room temperature for 2 hours. After buffer and antibody preparation, the western 
papers were soaking in cold buffer with sponges. The transfer process under 100V, 
constant 350mA for 1 hour using the same electrophorese tank as for SDS-PAGE 
gel (Sigma, UK). The result of Western blot was detected by luminal system 
(Thermo Fisher scientific). 
2.6.2.7 Protein concentration measurement 
IL-37 protein concentration was measured with Coomassie Blue Protein Assay Kit 
(Thermo Scientific). Briefly, 2-fold diluted protein standard has been prepared 
(Bovine serum albumin standards; Thermo Scientific, USA), Add 50µl of sample 
and standard into Eppendorf tubes with additional 1.25ml of Coomassie reagent 
into each tube; use PBS as a blank. Mix the sample and standard well and incubate 
at room temperature for 10 minutes. Mix well then transfer 150µl of samples and 
standards into each microplate wells; Measure the absorbance of supernatants at 
465nm. The standard curve of Coomassie Blue essay was developed based on 
absorbance and concentration (g/ml) of the protein standards. Protein 
concentration of the IL-37 was calculated by reference to the standard curve. 
2.6.2.8 Endotoxin removal 
Endotoxin which contained in the purified recombinant IL-37a and IL-37b protein 
products was removed by the Package Insert EndoTrap endotoxin removal column 
(EndoTrap HD). The purification was following the manufacturer`s manual. To be 
more specific, the column was placed on a shelf then loose the cap on the top and 
remove the cap at bottom of the column. The liquid in the column can drain from 
the column with gravity. After all the liquid run out from column, the column was 
then activated with 3ml regeneration buffer and wash the column twice. After 
that, fill the column with the recombinant IL-37 sample after NI-NTA column 
purification. The flow through of the column was collect directly and store on ice. 
The column can be reuse for several experiment with the regeneration buffer. 
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2.6.2.9 Endotoxin detection 
The endotoxin level in the recombinant IL-37 was measured by Limulus Amebocyte 
Lysate (LAL) Chromogenic Endotoxin Quantitation kit (Thermo Fisher Scientific, 
USA). The test process was performed following the manufacturer`s instructions: 
Firstly, IL-37 protein PH level was adjusted to 6-8 using endotoxin-free 0.1M NaOH 
or HCL solution. The microplate was heated before experiment on a heating block 
(Thermo Fisher Scientific, USA) at 37°C for 10 minutes. Dispense 50µl of standard 
dilutions and samples replicate to appropriate wells carefully in order to keep an 
adding manner and add same amount of LAL reagent water into empty wells as 
blank. Moreover, additional 50µl of LAL reagent was added into each well by 
pipette, keep the same order as the sample added in. Shaking the plate gently on 
a plate orbital shaker (AROS) for 10 seconds to mix the sample with reagent and 
incubate at 37°C for another 10 minutes. Add 100µl substrate solution into the 
whole plate and cover the plate by a plate sealer, incubate at 37°C for 6 minutes. 
Stop the reaction by adding 50µl of stop solution in the same manner as adding 
samples. Read the plate with the 96 wells plate reader (Dynex technologies) at 
506-410nm wavelength. Measure the endotoxin level by optical density (OD) of 
standards and samples which based on the Endotoxin standard curve.  
 
2.6.2.10 native gel preparation 
The native and mutant IL-37 proteins (monomer and dimer IL-37a and b) were 
confirmed by native gel in un-denature condition. A resolving gel and stacking gel 
were prepared before the experiment which using the constituents in the Table 
2.7a and b. The recombinant bacteria extract or the purified proteins were 
resuspended in native loading buffer 1:10. Then the samples were centrifuged at 
12000rpm for 2 minutes and loaded at 10µl samples per well on a 15% native gel 
for 120V, 40 minutes’ electrophoresis in the electrophorese tank (Sigma, UK) on 
ice with native gel running buffer. After electrophoresis, all the proteins were 
stained with 0.1% Coomassie Brilliant Blue R-250 solution for 1 hour to become 
visible and de-stained by gel de-stain buffer overnight.  
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Constituents of resolving gel for native gel 
Reagent Amount 
 Distilled water (D.H2O) 4.4 ml 
1.5M Tris PH=8.8 5.2 ml  
30% acrylamide mixture 10 ml 
10% ammonium per sulphate 
(APS) 
200 µl  
tetramethyl ethylenediamine 
(TEMED) 
8 µl  
Total amount (for 4 gels) 10 ml  
Table 2.7a Constituents of resolving gel for native gel 
 
Constituents of stacking gel for native gel 
Reagent Amount 
 Distilled water (D.H2O) 5.5 ml 
1M Tris PH=6.8 1 ml  
30% acrylamide mixture 1.3 ml 
10% APS 80 µl  
TEMED 8 µl  
Total amount (for 4 gels) 8 ml  
Table 2.7b Constituents of resolving gel for native gel 
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2.6.3 Protein stability test, Protein Sequencing and Identification 
The stability of recombinant IL-37 proteins were measured by Circular dichroism 
(CD) in the University of Glasgow by my colleague Najwa Hammed. CD machines 
obtained from Aviv Biomedical Ltd. (USA) for collecting data from 700 to 175nm 
wavelength. To check the protein composition, recombinant protein is unfolded 
in 6M Guanidine-HCl or 3% NaOH. The Number of amino acids. Theoretical pI and 
molecular weight can be automatically measured by the machine. Mass 
Spectrometry was also used to identify the recombinant protein and the protein 
sequencing analysis. The measurement and instrument management were assisted 
by the University of Glasgow. 
2.6.4 Protein bioactivity test 
To determine the bioactivity of the recombinant IL-37 a and b proteins the 
following procedure was followed: Murine macrophage (RAW 264.7) was seeded in 
24-well cell culture plates at 1x 106 per ml in DMEM media supplemented with 10% 
heat-inactivated fetal bovine serum, 100U/ml penicillin, and 100µg/ml 
streptomycin. Culture temperature is 37°C under 5% CO2 culture condition in the 
cell culture incubator overnight. The cells were pre-incubated with different 
doses of IL-37a and IL-37b (50ng/ml and 100 ng/ml) and then added into plates 
and cultured at 37°C under 5% CO2 condition for 2 hours. Furthermore, 200ng 
lipopolysaccharides (LPS, TLR4, Invivogen) was added to each well then incubated 
for 15 hours. The concentration of IL-6 in the cell culture supernatant was 
measured by an enzyme-linked immunosorbent assay (ELISA) kit (R&D system), 
The concentration of IL-6, the major cytokine induced by LPS the expression of 
which has been reported to be suppressed by IL-37 (Li et al., 2015) was detected 
by ELISA. The relative bioactivity of the recombinant IL-37 a and b were detected 
relative to the ELISA commercial standard. 
After endotoxin detection, the cleanness of recombinant IL-37a and b proteins 
were further checked by heat-inactivating the proteins. The test sample was 
boiled by 100°C water bath for 30 mins. 1x10^6 murine macrophage RAW cells 
were seeded in 24 wells cell culture plate; culture temperature is 37°C under 5% 
CO2 culture condition in the cell culture incubator overnight.  Furthermore, 50ng 
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of pure/ boiled recombinant IL-37a and b proteins were given to appropriate 
group. After incubating for 2h, 200ng LPS were given to all the test groups, then 
incubated for 15 hours. The gene expression of IL-6 in mRNA was measured by 
qPCR (Figure 2.4). The heat inactivated protein shows similar IL-6 level as only 
LPS group, indicates no contaminating PAMPS from the bacterial prep. 
 
 
Figure 2.4 Contaminating PAMPS checking by qPCR 
 
Murine macrophage RAW cells (1x10^6 cells/ml) were pre-treated with or without 
pure/ heat inactivated (100°C for 30 mins) recombinant monomer IL-37a and b 
stimulated with LPS, (200ng/ml) for 15 h. The gene expression levels of IL-6 in 
mRNA were measured by qPCR. Using student T-Test. Data are means ± SD, and 
are representative of three independent experiments. *P<0.05 and ***P<0.001 
compared to controls. 
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2.7 Gene expression assay 
2.7.1 Quantitative-PCR analysis 
2.7.1.1 RNA extraction 
2.7.1.1.1 Isolation of total RNA from cells 
RNA of infected THP-1 and RAW cells was isolated by the Purelink RNA mini kit 
(Life technologies). After the cell lysis, test samples were vortexed in small 
Eppendorf tubes and homogenized by 21-gauge syringe for 10 times. After that, 
the purification process was performed following manufacturer’s instructions. 
RNA concentration was measured in a Nanodrop 2000 (Thermo scientific). RNA 
samples were stored in -80°C for downstream process.  
2.7.1.1.2 Isolation of total RNA from tissues  
To isolate tissue RNA, TRIzol Reagent (Invitrogen, UK) was used for extract total 
RNA. Murine tissues were preserved in RNAlater reagent for longer storage. Cut 
tissues into small fragments (10-100mg) then wash with 1ml cold PBS. After 
washing, dry tissue pieces, add 1ml TRIzol reagent per sample. Leave sample on 
ice for around 5 minutes then homogenize tissue sample at 19,000rpm by electric 
homogenizer (Thermo Fisher Scientific Inc., US). Incubate the sample at room 
temperature after homogenization then take the liquid face out, add same amount 
of ethanol to homogenized mixture contained RNA and mix well. Then centrifuge 
the mixture at 12,000rpm by mini centrifuge for 2 minutes. After that, the 
purification process was proceeding which follow the protocol from the kit. The 
impurities were extracted in Wash buffer (Life technologies) under 12,000rpm 
centrifuge condition, 4°C, then the sample RNA dissolved in DNase free water and 
collected in Eppendorf tubes. The concentrations of these RNA were measured by 
Nanodrop 2000 (Thermo scientific) within 260/ 280 ratio absorbance (1.8~2.1 was 
considered optimum). RNA extractions were kept on ice then put in -80°C for 
other in-depth process.  
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2.7.1.1.3 RNA reverse-transcription to cDNA (RT-PCR) 
After purification, the RNA concentration (unit: ng/µl) and the purity of RNA were 
confirmed by Nanodrop 2000 (Thermo Fisher Scientific). Additionally, the purified 
RNA was normalized into 10ng/µl, 100ng of total normalized RNA were used for 
the reverse reaction. The RNA was reversed transcribed into cDNA by the High-
Capacity cDNA Reverse Transcription Kit (Life technologies). Prepare 10µl of 
reverse transcription master mix, each 10µl contains 10x RT PCR Buffer, 10x RT 
Random primers, 25x dNTP and 1µl of Reverse Transcription enzyme. Filling the 
rest with distilled water; mix the sample with master mix well by vortex. Reaction 
tubes were loaded into the thermocycler (96 wells thermocycler, Applied 
Biosystems) and run following the instructions from manufacturer. Keep the cDNA 
production in -20°C for further storage. 
2.7.1.1.4 Quantitative Real-Time PCR (qPCR) 
The cDNA was measured and quantified by Quantitative Real-Time PCR (qPCR). 
Transcripts of cytokines-of-interest which expression was measured and 
calculated included IL-37 isoforms (a-e), iNOs and other related cytokines. 
Human/murine Gapdh was utilized as the housekeeping gene. The sequence of 
Forward and reverse primers (Integrated DNA Technologies, USA) are shown in the 
Table 2.8 and 2.9. 
1 µl of cDNA which was obtained from the obtained from reverse transcription 
product was used as the template for Quantitative Real-Time PCR. 9µl of Fast 
SYBR green master mix reaction mixture (Thermo Fisher Scientific) was added into 
the reaction wells to make the total reaction volume 20µl. The reaction mixture 
contained 5µl Fast SYBR green master mix, 0.5µl Forward primer sequence (10 
µM), 0.5µl Reverse primer sequence (10µM), 3µl Nuclease-free H2O and 1µl of 
cDNA template. The Quantitative Real-Time PCR was run in a 96 well (0.1ml) 
reaction plate for 40 cycles (Applied Biosystems Step One Plus Real-Time PCR 
system). Fold changes were calculated using the 2-
ΔΔ
Ct method. The samples were 
run in triplicates. Pro-incubation was performed at 95°C for 20s, amplification at 
95°C for 15s and 60°C for 20s (40 cycles); and the annealing for 60s at 60°C. 
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Figure 2.5 qPCR process in this experiment 
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Table 2.8. Sequences of primers for the amplification of human genes by 
Quantitative Real-Time PCR (qPCR). 
 
Table 2.9 Sequences of primers for the amplification of murine genes by 
Quantitative Real-Time PCR (qPCR) 
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2.7.2 Genotyping 
2.7.2.1 DNA extraction 
Genotyping of UGLA0004 IL37a transgenic mice (strain C57BL/6) was performed 
by PCR. Mouse tail-tip biopsies (2mm) or ear pierced samples (2mm) were taken 
from the wild type mouse and transgenic mice then kept in -20°C for extraction. 
DNA was extracted from murine tail sample using 75µl Alkaline Lysis Buffer 
(containing 25mM NaOH, 40mM Tris-HCl and 0.2mM EDTA, PH=12). Cut sample into 
small pieces then mix the sample with Lysis Buffer in PCR Eppendorf tubes, heat 
the mixture on a heating block (Thermo Fisher Scientific, USA) at 95°C for 1 hour. 
During the lysis process, the Neutralizing Buffer (40mM Tris-HCl, PH=5) was 
prepared. Adding same volume of Neutralizing Buffer to each tube then measure 
the DNA concentration by Nanodrop 2000 (Thermo Fisher Scientific). Neutralizing 
Buffer was used as the blank for DNA measurement. 
2.7.2.2 PCR for genotyping 
PCR was used for genotyping to distinguish the wild-type (WT) from IL-37a 
transgenic mouse by observing the specific bind of PCR products. Two different 
primer pairs were used (Taconic, Germany) (Table 2.10). Normalize the DNA level 
after measuring the DNA concentration. Add 5µl of normalized DNA template 
(80ng/µl) into PCR Eppendorf tubes. GoTaq Master Mix (Promega, UK) was used 
for the PCR process; Centrifuge the sample and master mix with MiniStar Micro 
centrifuge (VWR) till no liquid attach to the surface; perform the PCR reaction in 
the thermocycler (96 wells thermocycler, Applied Biosystems) as the progress 
below: heat the sample mixture at 94°C for 5 minutes, then 94°C 15 seconds, 
55°C 30 seconds, 72°C 40 seconds, repeat 35 cycles; 72°C 10 minutes for final 
elongation. After the PCR process, put samples in -20°C for storage. 
Mix the PCR products with 10x Bromophenol Blue Loading Buffer (Invitrogen, UK). 
Add 20µl of mixture into separate wells of 1.5% Agrose in 1x TAE gels with 
additional ethidium bromide 0.03 µl/ml. DNA ladder (Invitrogen, UK) was used for 
checking the molecular weight expected fragments. Both WT and Tg samples, 
negative control (without DNA template) and ladder were loaded in 1x TAE buffer 
in an electrophoresis (Sigma) tank using Basic Power Supply Instruction (Bio Rad, 
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UK) at 100mV for 40-50 minutes. Image was determined by Gel Logic 200 Imaging 
System (Kodak, USA) under UV light, explore time is 2 seconds. The typical binds 
for WT and IL-37aTg mouse present in Figure 3.4. 
 
Test gene primer name primer sequence (5`-3`) 
Expected 
Fragments 
SOP 13021 2970_5 caggs3:  ATC CAC TTT GCC TTT CTC TCC  379dp 
 13021_1: ATG GAT GAC TTT GTC CTT TAT CC   
SOP 13022 13022_3 GCA ATT GTA ATG AGC CTG TTG G 401dp 
 6166_41 hGH pA 3´4: CCT TAA TTA AGT CGA CGG ATC G   
control 1260_1 GAG ACT CTG GCT ACT CAT CC  585dp 
  1260_2  CCT TCA GCA AGA GCT GGG GAC   
Table 2.10 IL-37aTg mouse PCR primer pair sequences 
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2.8 Bacteria culture and infection 
2.8.1 SL1344 culture 
Salmonella strain SL1344 was utilized as the infection microorganism in this 
project. The SL1344 colonies were cultured in a LB broth (Luria Bertani broth 
medium: 0.5% yeast extract, 1% tryptone, 1% NaCl) agar (with 1% agarose) plate 
before experiments. One single colony was collected and cultured in a 5ml LB 
broth culture universal in an incubate shaker under 180rpm, 37°C. Then the 
bacteria mixture was diluted 1:10 in LB broth and incubate in a stationary 37oC 
incubator over night before infection. OD level of SL1344 dilution was measured 
by photometer, appropriate absorbance level should be between 0.5-0.6. After 
OD measurement, the bacteria culture was diluted again in 1:6 in culture media 
RPMI1640 with 3% FBS for cell infection. 
2.8.2 BRD509 culture  
An attenuated strain of Salmonella (BRD509) was used in the in vivo test of 
toxicity during optimization of the experimental condition. Similar as SL1344 
strain culture, the signal colony of SL BRD509 was transferred into 5ml of the LB 
broth with a sterile stick and incubated in a shaker under 180rpm, 37°C for 4 
hours. Then 50ul of bacteria culture were added into 500ml of pre-auto-cleaved 
LB broth and stable incubate in 37°C incubator for at least 6 hours. After 6 hours` 
incubation, the OD level of BRD509 dilution was measured by a photometer 
(absorbance level should be between 0.5-0.6). With the standard curve of BRD 509 
CFU versus OD reading, appropriate volume of bacteria culture was collected for 
different purpose of experiment. Bacteria were centrifuged under 5000xg for 5 
minutes, and after the supernatant was discarded, bacteria pellets were 
resuspended in PBS for in vivo oral infection. 
2.8.3 Human and murine macrophage S. Typhimurium infection 
At the beginning of Salmonella infection, 200µl of SL1344 dilution (1:6) was 
pipetted into a 24 wells tissue culture plate. In comparison, 200µl of RPMI 1640 
media with 3% heat inactivated FBS and 2mM L-glutamine also added into the 
culture plate as a negative control. Then the plate was placed put in 37°C, 5% CO2 
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incubator to wait for the infection to be established. After 1h, all the supernatant 
was removed and replaced with 400µl fresh RPMI 1640 media with 3% heat 
inactivated FBS and 2mM L-glutamine as well as additional 50µg/ml antibiotic 
(Gentamycin). The purpose of additional Gentamycin was to eliminate 
extracellular SL1344 which have not invaded the macrophages. The plate was 
keeping in the bacterial incubator during the infection progress for several time 
points at 37°C, 5% CO2 condition.  
Once the time-points had elapsed, the supernatant was collected then stored in -
20°C freezer immediately in order to kill any residual salmonella which may not 
have been killed by antibiotic. Supernatant was used to test the production of 
Nitric Oxide (NO) by the Griess diazotization reaction, and to detect and quantify 
the concentration of pro-inflammatory protein level (human/mouse IL-6) by 
Enzyme-Linked Immunosorbent Assay (ELISA). The adherent cells which contain 
live bacteria were harvested using 2% Trition-X100 then prepared for bacteria CFU 
counting. Furthermore, the 1:6 SL13344 dilution was also used for other in-depth 
experiments and RNA extraction under same culture condition. At the end point 
of infection, the macrophages which attach to the bottom of each well were 
harvest by cell lysis buffer then put on ice to direct purify RNA or further 
processing. 
2.8.4 Dilution plate for bacteria counting 
Infected cells were harvested with 2% Triton-X100 in PBS and lysed using a sonic 
water bath (DAWE instrument, UK) to release the intracellular salmonella which 
contained in the macrophage for spot plate analysis. Cell lysate of SL1344 was 
diluted 1:10, 8 times in a 96 wells cell culture plate. 10µl of each dilution was 
dropped in triplicates on LB agar plate and incubated at 37°C for 24 hours. Colony 
forming units (CFU) were counted and calculated with dilute equations, in order 
to find out the relative number of SL1344 which infected THP-1 and RAW 
macrophages. 
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Figure 2.6 Bacteria spot plates of salmonella strain 1344 and BRD509 
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2.8.5 Nitric oxide (NO) production test 
Griess Reagents kit (Progema) was used for the detection of Nitric oxide (NO) 
expression. Reagent I and II were put in room temperature for 30 minutes before 
detection. NaNO2 (1M) was utilised as the test standard and dilute with cell culture 
media. Test samples come from the supernatants of cultured cells and put in 96-
well ELISA plate 50µl per well in Triplicate. In addition, 50µl of Reagent I and II 
were added into each well, separately. Optical densities (OD) of standards and 
experimental samples were read at 550nm wavelength using a 96 wells plate 
reader (Dynex technologies). NO concentrations were plotted against a standard 
curve set up which compare with the standard curve of the Griess kit in order to 
account for calculation errors when reading. Then the concentration of each 
experimental sample can be calculated from the standard curve. 
2.8.6 Tool-like receptor (TLR) stimulations 
RAW 264.7 macrophages were cultured at 1.2x105 cells in 24 wells cell culture 
plate, the cells were seeded overnight period of the stimulation. THP-1 cell 
differentiates into macrophage-like cells. They were seeded at 1.2x105 cells in 24 
wells in 4 days before stimulation with PMA then the culture media was replaced 
by the fresh culture media 48 hours before stimulation in order to remove the 
effect of PMA. Different doses of TLRs: lipopolysaccharide (LPS, TLR4, Invivogen), 
synthetic triacylated lipopeptide (PAM3cSK2, TLR1/2, Invivogen) and Flagellin 
from S. Typhimurium (FLA-ST, TLR5, Invivogen) were added in both cell lines and 
incubated with different time points. Cell lysate and supernatant were harvested 
then collected at appropriate time according to experiment requirement. The 
supernatant was used for NO detection and ELISA test, and RNA was purified form 
the cell lysate as a template for qPCR and further analysis. 
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2.9 Enzyme-Linked Immunosorbent Assay (ELISA) 
The supernatants of cultured cells were analysed for the levels of IL-6 using the 
Human IL-6 Quantikine ELISA Kit (R&D systems) and Mouse IL-6 Quantikine ELISA 
Kit (R&D systems) following the manufacturers. The wells were coated with a 
polyclonal antibody specific for human IL-6 with an ELISA cover sealer and 
incubated in room temperature overnight. After overnight incubation, the coating 
buffer was discarded and washed with washing buffer 3 times, 100µl of assay 
diluent (4 times) and standard were added in appropriate wells for 2 hours of 
incubation in room temperature. Moreover, after another 4 times washing steps 
to remove unbound composites, 100µl of detection antibody solution was added 
into both IL-6 standard and test samples then incubate for another 2 hours. After 
this incubation, washing the plate again to remove excess polyclonal antibody that 
has not bound before additional Conjugate (HRP conjugated) and cover with a new 
plate sealer for 2 hours` incubation. After the final washing steps, 100µl Substrate 
Solution (TMB, 3, 3’, 5, 5’-tetramethylbenzidine) was added to test peroxidase 
activity. ELISA plate was cultured in dark protected from light for 20 minutes in 
this step to avoid the photolysis of the reagents. Then adding 50 µL of Stop Solution 
(0.2M sulfuric acid) to each well to stop the reaction. The ELISA plate was reading 
by a 96 wells plate reader (Dynex technologies) at 450nm wavelength. Optical 
densities (OD) of experimental samples were then plotted against human/ mouse 
IL-6 standard values for creating the IL-6 standard curve. IL-6 concentration 
(pg/ml) was calculated by the standard curve in order to know the extracellular 
protein (human/mouse IL-6) level in each sample. 
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2.10 siRNA 
Small interfering RNA (siRNA) molecules against human IL-37 and its isoform IL-
37a were designed and used to knockdown the expression of the proteins-of-
interest proteins (IL-37a mRNA GeneBank accession mumber: NM_173205.1). 
Custom siRNA oligos were synthesized and obtained from Invitrogen Life 
Technologies (UK). siRNA sequences of IL-37 and IL-37a are shown in Table 2.11 
The RNA interference (RNAi) negative control is Silencer® select negative 
control#1 siRNA obtained from Thermo Fisher Scientific as a nontargeting siRNA 
control, 5nM with Nuclease-free water. For the siRNA transfection experiment, 
human THP-1 cells were seeded in 24-well cell culture plate at 1.2x105 cells/ ml 
per well then stimulated with additional 50ng of TPA/PMA (Sigma-Aldrich) and 
incubated for 48 hours before transfection. After incubation, suspension cells 
were removed by washing with complete RPMI twice. SiRNA sequence for IL-37 IL-
37a and negative control was mixed by Lipofectamine® RNAiMAX Reagent (Cat: 
13778-100, Thermo Fisher Scientific). RPMI medium was used with additional 10% 
FCS (fetal calf serum) and 2mM L-glutamine to avoid the infection of antibiotics. 
After incubation for 48 hours, cells were stimulated by extra 100ng LPS after 
washing and changing into new complete culture medium. Cells were collected at 
6, 12, 18 hours later by lysis buffer and the efficiency of IL-37 and IL-37a SiRNA 
was confirmed by qPCR analysis. 
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Target gene primer position primer sequence (5`-3`) 
IL-37 Target all isoforms UCA AGG AUG AGG CUA AUG CUU 
  
CAA UGU GUU UCC UGU UCU CUU 
UUA CAA UUG CAG GAG GUG CUU 
  UUA UCC UUG UCA CAG UAG AUU 
IL-37a 5#（target 16-38）: 
GAG GGA AAC AGA AAC CAA AUU  
UUU GGU UUC UGU UUC CCU CUU 
  21#（target 35-57）: 
GGA AAG AAC AGC UUU AAG AUU 
UCU UAA AGC UGU UCU UUC CUU 
 
Table 2.11 siRNA primer sequence 
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2.11 Transcriptome analysis  
Transcriptome analysis was performed on transgenic IL-37a and b mice (transgenic 
mice with CMV promoter) splenocytes. Splenocytes of WT C57BL6/J and IL-
37a/bTg mice were seeded in 24 wells cell culture plate in the density of 
1x106/ml. These cells were stimulated with 500ng/ml LPS for 4 hours. Total RNA 
from each sample was isolated and purified. Construction of cDNA libraries and 
next-generation sequencing was performed. 
Raw data from RNA-seq were analysed for each group (WT, IL-37aTg mice and IL-
37bTg mice, n=3). The average RPKM (Reads Per Kilobase Million) per group was 
estimated. Moreover, the p-value and fold-changes were analysed for comparisons 
between: IL-37a vs. WT and IL-37b vs. WT. Using a cut off values (p value< 0.05, 
fold-change ≥1.5), we detected the differential expressed genes compared IL-
37a and bTg vs. WT. 
Bioinformatics analysis: Area-proportional Euler diagrams were generated using 
the BioVenn© tool (http://www.biovenn.nl/). The genes in IL-37a/bTg mice vs. 
WT specific and common area of the Venn diagram were analysed for the 
detection of TLR-related signalling pathways which affect by IL-37a or b 
specifically or commonly by String DB software, Gene ontology (GO) and KEGG 
pathways database. 
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2.12 Animal work 
The experimental group size was determined by disease incidence and from the 
expected difference among experimental groups from preliminary experiments 
or from literature search wherever possible, also taking into account resources 
available and ethical animal use. A power of 0.8 was used to calculate the  
experiment group sizes (Festing and Altman, 2002, Charan and Kantharia, 2013). 
 
2.12.1 Lipopolysaccharide (LPS) challenge 
Mice are grouped and injected intraperitoneally with a sub-lethal dose of LPS 
(Sigma-Aldrich, UK) in 200 µL PBS by a 26-gauge needle. Final LPS dose is based 
on the weight of each mice in LPS treat group at 1µg/g body weight (around 
150ug/mice) and the control group were given same volume of PBS. Mice are kept 
in appropriate condition for 18 hours after injection and was killed by CO2 under 
ethical protocol. A 500µl blood sample is taken from heart were collected for 
serum isolation and spleens were harvest and kept in complete RPMI media on ice. 
Blood samples are analysed for the expression level of IL-37 by ELISA, RNAs were 
isolate from spleen for qPCR measurement. 
2.12.2 S. Typhimurium (BRD509) infection model 
S. Typhimurium (BRD509) were cultured overnight with shaking at 200 RPM before 
the infection model set up. These bacteria were further diluted in PBS in 1x10^8 
CFU/ml. Mice are grouped and given 5% Sodium carbonate (Sigma-Aldrich, UK) in 
100ul/mice by a bulb-tipped 22G gavage needle and a 1 mL syringe to neutralize 
stomach acid. Then mice were challenged by oral infection with 200 ul of 1x108 
CFU/ml BRD509, same amount of Sodium carbonate and PBS were given to the 
control mice orally.  
we use a 0-4 scoring system to rate the severity of diarrhea based on the gross 
appearance of the colon at necropsy. A normal feces was given a score as 0. If the 
cecum was shrunken and white it was scored as 1. We gave 4 score to a mouse 
that had a shrunken cecum and a distal colon that was fluid-filled with little or no 
formed stool. The whole process was checked by the stuff of CRF (Table 2.12). 
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The mice were kept for 6 and 8 days and killed by CO2 under ethical protocol. A 
500µl blood sample is taken from heart were collected for serum isolation, liver 
and drain lymph nodes were collect in PBS for bacteria counting, and spleens were 
harvest and kept in complete RPMI media on ice. Serum samples are analysed for 
the NO level, bacteria from liver and LN were counted by spot plate, and RNAs 
were isolate from spleen for qPCR measurement. 
 
Table 2.12 Scoring system for grading diarrhea 
 
2.13 Statistical analysis 
The statistical evaluation of the experimental data was performed using GraphPad 
Prism v5.0a (GraphPad Software Inc.). Depending on the normal or skewed 
distribution of the data, either a T-test or a Mann-Whitney test was used 
respectively when comparing two sets of data. For comparison of more than two 
groups, a one-way ANOVA (or non-parametric equivalent) method was utilized. 
Any p-value of <0.05 was considered statistically significant. The two-tailed value 
of significance was set at p ≤ 0.05 (*), 0.01 (**) or 0.001 (***) for describing group 
differences. Data were expressed as means with ± standard error of mean (SEM), 
unless otherwise indicated. 
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Chapter 3 
Generation of recombinant IL-37 
proteins and IL-37 transgenic mice 
 3. Generation of recombinant IL-37 proteins and IL-
37 transgenic mice 
3.1 Introduction 
In order to understand the biological function of IL-37a and the functional 
difference between IL-37a and b, we sought firstly to produce recombinant IL-37a 
and b proteins. Furthermore, to study the function of human IL-37a in vivo in 
diseases, we generated human IL-37a transgenic mice in our lab. Moreover, to 
reveal if IL-37a and b signal via the same or different receptor, we also obtained 
and breed the IL-37 receptor IL-1R8 deficient mice (Garlanda et al., 2004). 
 Bacterial protein expression system is widely employed to produce recombinant 
protein for the purpose of research and drug development (Joseph et al., 2015). 
The His-tagged recombinant human IL-37b proteins have been sucessfully 
produced in E. coli (Gu et al., 2015). IL-37b proteins expressed in E. coli can be 
soluble located in the cytoplasm or insoluble in inclusion bodies (Yang et al., 2011; 
Singh et al., 2015). The soluble proteins can be directly purified to produce the 
natural bioactive IL-37 (Gu et al., 2015). The insoluble proteins in the inclusion 
bodies have to be made soluble first by denaturing the proteins with detergent 
and then purifing them. The purified denatured proteins then need to be 
renatured by the removeal of the detergent from the protein in order to regain 
their bioactivity (Yang et al., 2015). After expressed in E. coli, the His-tagged IL-
37b proteins can be initially purified by metal-affinity chromatography, for 
instance, Nickel affinity chromatography (Gu et al., 2015). The His-tag of proteins 
can bind to the Ni-NTA agarose resin in the low dose of imidazole and can be 
eluted by increasing the imidazole concentration. Resins, such as Ni-NTA 
Superflow Agarose provide greater capacity for His-tagged protein purification, 
can bind up to 80mg of His-tagged protein per ml of agarose beads (Stuehr et al., 
1991; Kaur and Reinhardt, 2012). However, the Nickel purified proteins from E. 
coli can only be 80-85% pure and will be still contaminated with bacterial proteins 
and lipopolysaccharide (LPS). The proteins need to be further purified by different 
approaches of chromatography, including gel filtration and ion-exchange. The LPS 
can be removed effectively from purified proteins from E. coli, including IL-37b 
by EndoTrap® affinity chromatography (Guillou et al., 2015. Gu et al., 2015). 
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While the recombinant IL-37b has been produced successfully, there is no report 
on IL-37a purificaiton, and no commercial IL-37a is avilable at the moment. 
Recently, it has been reported that natural IL-37b proteins can form homodimer 
(Ellisdon et al., 2017). The study of IL-37b crystal structure identified that the 
number 85 amino acid, tyrosine (Y85) in IL-37b protein sequence is responsible for 
the dimerisation of IL-37b (Ellisdon et al., 2017). The replacement of the tyrosine 
(Y) with alanine (A) by point mutation in IL-37b cDNA has effctively prevented IL-
37b dimerization (Ellisdon et al., 2017, Eisenmesser et al., 2019). As with the 
natural IL-37b, the mutant His tagged-IL-37b has been produced in E. coli and 
purified by the Ni-affinity chromatography and gel filtration. The mutant IL-37b 
proteins are existed in the monomer form. More importantly, the IL-37b monomer, 
rather than homodimer, has bioactivity (Eisenmesser et al., 2019). However, it is 
unknown whether the natural IL-37a can also form homodimer and if this affects 
its function.  
While IL-37 gene was lost in mice during evolution, the IL-37 receptors, both IL-
1R8 and IL-18Ra chain, reamin intact and functional (Nold-Petry et al., 2015). As 
with most cytokins, human IL-37b is also functional in mice (Nold-Petry et al., 
2015, Nold et al., 2010). Thus, mouse has provided a unique model to study human 
IL-37 function in vivo. Human IL-37b transgenic mice have been generated that 
are critical in the understanding of the importance of human IL-37b in homostasis 
and disease (Nold et al., 2010, McNamee et al., 2011, Teng et al., 2014, Lunding 
et al., 2015). 
The IL-1R8-deficient (IL-1R8KO) mice have been generated by several research 
laboratories (Wald et al., 2003, Garlanda et al., 2004). Using this strain of mice, 
IL-1R8 had been defined as a signaling receptor in IL-37b receptor complex (Nold-
Petry et al., 2015). It will be intriguing to know if IL-37a signal via the same 
receptor as IL-37b. 
As the first step toward the understanding of the biological function of IL-37a and 
what is the difference between IL-37a and b in immunity and disease, in this 
chapter, I sought first to determine the dimerisation of IL-37a and then to produce 
both natural and mutant IL-37a and b proteins in E. coli system. Furthermore, the 
human IL-37a transgenic mice were also generated to study IL-37a in vivo. In order 
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to identify IL-37a receptor, we also obtained the IL-37 receptor (IL-1R8) knockout 
mice. The aims of the chapter were: 
1. Determination the dimerisation of IL-37a. 
2. Expression and purification of natural and mutant IL-37a and b proteins in E.coli. 
3. Generation and breeding of IL-37a transgenic and IL-37a receptor (IL-1R8) 
knockout mice.  
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3.2 Results 
3.2.1 Comparison of IL-37a and IL-37b in the amino acid level and 
biochemical parameters 
In order to understand the biochemical variations between these two IL-37 
isoforms, the differences between IL-37a and b in amino acid level were compared 
using analysis platform Protparam (Boraschi et al., 2011). Analysis results were 
showed in table 3.1. 
The IL-37a has 9 positively charged arginine and 22 lysine residues; the isoform b 
has 5 positively charged arginine and 20 lysine, which comprise 16.2% and 11.5% 
of total proteins in the two isoforms, respectively. The percentages of negative 
charged amino acids (aspartate and glutamate) in the two isoforms are similar, 
11.5% in IL-37a and 12.9% in IL-37b. There was no dramatic difference in the 
percentage of aliphatic amino acids between these two isoforms. In general, the 
differences in amino acid have led to a clear difference in isoelectric point (pI) 
between IL-37a and b (9.23 vs 6.09, respectively). These variations may make 
them different in protein charge, solubility and stability which may influence 
protein purification and their bioactivity. 
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Table 3.1 Differences between IL-37a and IL-37b in the amino acid level 
(data from https://web.expasy.org/protparam). 
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Table 3.2 Comparison of biochemical parameters between IL-37a and IL37b 
proteins (data from http://web.expasy.org/compute_pi). 
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3.2.2 Production of recombinant IL-37a and b protein 
In order to investigate the biological function and difference between IL-37a and 
b in vitro and in vivo, large quantities of recombinant protein are needed. 
Therefore, the full-length IL-37a and IL-37b recombinant proteins were produced 
in E. coli system and purified with several purification methods. The working flow 
chart of recombinant human IL-37a and b protein production process is shown as 
Figure 3.2. 
3.2.2.1 Plasmid construction for the expression of IL-37a and b in E. coli 
system 
The plasmid encoding His-tagged full-length recombinant human IL-37a and IL-37b 
were constructed by Dr Jiangning Liu in Dr Xu’s lab (unpublished results). Briefly, 
human IL-37a and b cDNAs were cloned between Sal I and Xba I sites of pET- 21 
(+) and pET- 28 (+) vector, respectively, and fused with hexahistidine cDNA. The 
His-tagged recombinant IL-37a and b were expressed in the plasmids with the T7 
promoter (Figure 3.3). The recombinant plasmids were transformed into E. coli 
strain BL21(λDE3) and the successful transformed bacteria were selected by LB 
agarose plates containing appropriate antibiotic (Ampicillin and Kanamycin for IL-
37a and b, respectively).  
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Figure 3.1 Flow chart of IL-37a and b recombinant protein expression and 
purification 
 
The plasmid vectors for the expression of hexahistidine His-tagged recombinant 
IL-37a or b protein were transformed into host E. coli BL21 (DE3). The protein 
expression was inducible by adding Beta-galactosidase expression inducer — IPTG. 
The recombinant His-tag proteins are purified initially by Ni-NTA column followed 
by gel filtration system. The purity and specificity of the protein were 
subsequently confirmed by SDS-PAGE gel and western blotting after endotoxin 
removal by Endotrap® column.  
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Figure 3.2 Schematic representation of IL-37a/b construct 
 
The PET-21a (+) and PET-28a (+) vectors were used to express recombinant IL-37a 
and IL-37b, respectively. These two vectors can express His-tag fusion proteins 
with T7 promoter. In these two vectors, Ori means the origin of replication; dark 
grey areas are the antibiotic resistant gene coding sequence (Ampicillin resistant 
gene in PET-21a, Kanamycin resistant gene for PET-28a); light grey areas are T7 
promoters; the red areas are the coding sequences of 6His-tag, IL-37a and b cDNAs 
were inserted into the two plasmids between the Nde I(158) and Xho I(238) sites. 
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3.2.2.2 Test expression of IL-37a and b  
We firstly tested the expression of recombinant human IL-37a and b proteins in E. 
coli strain BL21 (λDE3). Briefly, the host E. coli strains carrying the plasmid vectors 
expressing IL-37a and b, respectively, were cultured in LB medium in the existence 
of ampicillin or kanamycin for recombinant IL-37a and b expressions, respectively. 
IPTG was added into the cultures as the protein expression inducer in the Log 
phase of bacterial growth. We firstly determined the kinetics of expression of 
recombinant IL-37a and b in E. coli with or without IPTG induction. The protein 
expression levels of IL-37a and b in the transformed bacteria were determined by 
SDS-PAGE. The SDS-PAGE result in Figure3.3 showed that the optimized induction 
time for both IL-37a and b recombinant protein expression was between 4-5 hours, 
with higher specific protein (around 25kD) expressions but relatively lower 
unspecific protein expression in E. coli. However, after 5 hours induction, the 
expression rate of our recombinant proteins was decreased. 
Since recombinant protein produced in E. coli system can be soluble or insoluble 
(Sørensen and Mortensen, 2005). I firstly checked the solubility of the expressed 
IL-37a and b proteins by E. coli. The E. coli expressing recombinant IL-37 proteins 
were cultured in shaking incubator with IPTG induction for 5 hours. After 
induction, the bacterial pellets containing recombinant IL-37a and b were 
collected by centrifugation and then re-suspended in lysis buffers containing 
protease inhibitors and lysate by sonication. The soluble and insoluble parts of 
protein produced by the E. coli were separated simply by centrifugation. The IL-
37 protein location in the supernatant (soluble) and cell pellet (insoluble) were 
checked by SDS-PAGE. Most of the recombinant IL-37 proteins were detected in 
the liquid phase of cell lysate (result not shown). Thus, the majority of the IL-37a 
and b recombinant proteins in our expression system were soluble. 
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Figure 3.3 Test expression of recombinant IL-37a and b in E. Coli 
 
The kinetic expressions of IL-37a and b proteins in E. coli (BL21) were induced by 
1mM IPTG at 37°C up to 20 hours. After induction, total bacteria were lysed to 
get the soluble proteins. The proteins were separated by 15% SDS-PAGE and 
stained with Coomassie blue. a) The test expression of IL-37a recombinant 
protein. b) The test expression of IL-37b recombinant protein. The line 1 and 10 
of these two gels are the protein kDa markers. Line 2,4,6,8,11,13,15 are the 
protein expressions of BL21 without IPTG induction in different time points (as 
control group). Line 3,5,7,9,12,14,16 are the protein expressions of test group 
with IPTG induction. The result is representative of at least three experiments.  
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3.2.2.3 Purification of recombinant IL-37a by Ni-NTA chromatography 
The recombinant His-tagged IL-37a proteins expressed in the E. coli host were 
initially purified by Ni-NTA affinity purification. As the six-histidine tag of the 
recombinant IL-37a and IL-37b protein can bind to Ni2+ in the Ni-NTA column 
(Stuehr et al., 1991; Kaur and Reinhardt, 2012). The soluble proteins that contain 
the IL-37 proteins in the bacterial lysis were loaded onto the Ni-NTA column 
(Figure 3.4a). The unbound proteins were eluted from the column and the non-
specifically bound proteins were washed away from the column using Elution 
buffer (containing imidazole, the flow rate was 2ml/min) until no protein could 
be detected in the flowed-out fraction (Figure 3.4a). The His-tagged IL-37a 
proteins were eluted from the column, shown as a sharp protein peak, at 74% of 
the elution buffer level within 120-190 min after loading the sample (Figure 3.4a).  
The fractions from T7-T14 within the protein peak were collected as recombinant 
IL-37a protein fractions. To evaluate the success of the affinity purification of His-
IL-37a protein by Ni-NTA column, the levels of His-IL-37a protein in each of the 
samples from the loading samples were unbound and washed out and elution 
fractions in the purification procession were further checked by SDS-PAGE. As 
showed in Figure 3.4b, the IL-37 protein bands (about 22kDa) could be seen in 
both the soluble (loading sample) and insoluble fraction of bacterial lysis (lines 2 
and 3), respectively. The proteins could also be detected in the flow though 
(unbound) fractions (lines 4 and 5); this could be due to the overloading of the 
samples beyond the binding ability of the Ni-NTA column. Importantly, most IL-37 
proteins eluted from the column were in the fractions T7-T14 within the protein 
elution peak (Figure 3.4a). The IL-37a proteins were markedly purified compared 
with the loading sample (line 2) and unbound samples (line 4 and 5) using only the 
Ni-NTA column. Therefore, the Ni-NTA affinity purification is effective and 
successful in the initial purification of His-IL-37a proteins from E. coli.  
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Figure 3.4 Nickel affinity chromatography for IL-37a purification 
 
His-IL-37a protein was purified by 5ml His-Trap column using the AKTA protein 
purification system. a) The chromatography of recombinant IL-37a with Ni-NTA 
column. 35ml of soluble protein from total bacteria lysate were loaded onto the 
column, followed by washing with the elution buffer to wash away the unbound 
proteins (the flow rate was 2ml/min). The protein concentration was monitored 
using spectrophotometer at absorbance UV 280 nm. The peak of predicted IL-37a 
expression is highlighted by black brackets. b) SDS-PAGE result. Line 1: the 100kDa 
protein marker; Line 2: the soluble fraction of bacteria lysis. Line 3: insoluble 
fraction of bacterial lysis. Line 4: the flow through (unbound proteins); Lines 5 
and 6: the elution fractions of weak band proteins (T5-T6). Lines 7-14: the elution 
fractions of IL-37a proteins (T7-14). The samples were mixed with SDS-PAGE 
loading buffer, 95ºC heating for 10 minutes. The protein samples were separated 
by 15% SDS-PAGE and stained with Coomassie Blue buffer for 40 minutes then de-
stained. The result is representative of three experiments. 
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3.2.2.4 Purification of IL-37b by Ni-NTA chromatography 
I next purified the 6His-tagged IL-37b protein. Since the kinetic of IL-37b induction 
in E. coli is similar to IL-37a (Figure 3.3) and the proteins were also soluble 
expressed in E. coli, I used the same method and purifying strategy for IL-37b 
production. The soluble proteins from total bacteria lysate which contains IL-37b 
were loaded onto the Ni-NTA column, followed by washing the column with elution 
buffer to wash away the unbound proteins (the flow rate was 2ml/min). The 
protein concentration in the flow through fractions was monitored using 
spectrophotometer. As showed in Figure 3.5a, unbound proteins were effectively 
removal by the washing and the expected IL-37b proteins were eluted from the 
column at 63% of the elution buffer level 100-180min after adding the elution 
buffer (Figure 3.5a). The fractions within the protein peak from T5-T12 were 
collected as potential recombinant IL-37b protein fractions.  
SDS-PAGE was used to further check the purity and efficiency of IL-37b protein 
purified by the Ni-NTA column. The existence of IL-37b protein in the protein 
samples was identified by a protein band, size about 25kDa in 15% SDS gel (Figure 
3.5b). As shown in Figure 3.5b, both the insoluble and soluble fraction (line 2 and 
3) of bacterial lysis contain the 25kDa bands, suggesting that the recombinant IL-
37b could also be soluble in the E. coli host. The washed-out fractions (lines 4 and 
5) contained less IL37b compared with the loading samples (line 3). The 8 
collected samples (T6-T12) within the eluted protein peak in the Figure 3.5a 
showed clear IL-37b protein band with higher purity compared with the loading 
sample (line 3) and the washed fractions (lines 4 and 5). Thus, the recombinant 
IL-37b purification by Ni-NTA column was effective and successful.  
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Figure 3.5 Nickel affinity chromatography for IL-37b purification 
 
The His-IL-37b protein was purified by 5ml His-Trap column using the AKTA protein 
purification system. a) The chromatography of recombinant IL-37b using Ni-NTA 
column. 35ml of soluble protein from total bacteria lysate were loaded onto the 
column, followed by adding the elution buffer into the column to wash away the 
unbound proteins (the flow rate was 2ml/min). The protein concentration was 
monitored using spectrophotometer at absorbance UV 280nm. b) SDS-PAGE result. 
Line 1: the 100kDa protein marker; Line 2: insoluble fraction of bacterial lysis. 
Line 3: the soluble fraction of bacteria lysis. Line 4 and 5: the flow through 
(unbound proteins); Lines 6-12: the elution fractions of IL-37b proteins (T5-12). 
The samples collected from Ni-NTA elution were mixed with SDS-PAGE loading 
buffer, 95ºC heated for 10 minutes. The protein samples were then separated by 
15% SDS-PAGE and gel stained with Coomassie Blue for 40 minutes then de-stained. 
The result is representative of three experiments.  
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3.2.2.5 Confirmation of the His-tagged IL-37a and b by western blot 
 
Although the SDS-PAGE results suggest that the proteins purified from the 
bacterial lysis were the IL-37a and b protein based on the molecular weight of the 
protein bands in the samples, it is essential to further confirm the recombinant 
proteins by western blot. Since there is no commercial anti-IL-37 antibody 
available for western blot so far, I used anti-6His-tag monoclonal antibody for the 
identification of the His-IL-37 recombinant protein. Briefly, the different protein 
samples in Figures 3.4 and 3.5 were collected before and after the Ni-NTA affinity 
purification. The protein samples were separated by SDS-PAGE and transferred 
onto Nylon membrane. The His-IL-37 proteins were identified with the conjugated 
anti- 6His-tag monoclonal antibody by western blot.  
From Figure 3.6a, it was clearly observed that a single band about 20kDa existed 
in the bacterial lysate and eluted fractions but not in the washed-out fractions. 
The similar result was also obtained in IL-37b samples (Figure 3.6b). A single band 
around 25kDa was observed in all the samples by western blot. These results are 
consistent with the result in Figures 3.4 and 3.5 and confirmed that the 20 and 25 
kDa protein bands in the samples are the His-IL-37a and His-IL-37b, respectively.  
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Figure 3.6 The identification of His-tagged IL-37a and b proteins by western 
blot 
 
The recombinant His-IL-37 proteins were detected by western blot before and 
after protein purification. a) Western blot result of recombinant IL-37a. The first 
line was the protein marker (kDa); Line 1 was the soluble fraction of bacterial 
lysis, the loading sample; Lines 2-4 represent the washed-out proteins from the 
column. Lines 4-7 were the 4 eluted samples from Ni-NTA column. b) Western blot 
result of recombinant IL-37b. The first line was the protein marker (kDa); Line 1 
was the soluble fraction of bacterial lysis, the loading sample; Lines 2,3 represent 
the washed-out proteins from the column. Lines 4,5 were the eluted samples from 
Ni-NTA column. The result is representative of three experiments. 
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3.2.2.6 Purification of IL-37a and b proteins by gel filtration 
Although the Ni-NTA affinity chromatography was effective in the separation of 
His-IL-37 proteins from the whole bacteria proteins, several contaminated 
bacteria proteins could not be removed from IL-37 protein by this method. 
Therefore, the IL-37 proteins purified by Ni-NTA column needed to be further 
purified by size exclusion chromatography (SEC). This system separates proteins 
based on their difference in molecular weight (Figure 3.7a). 
The recombinant IL-37a protein samples were loaded into the Superdex-75 SEC 
column equilibrated with DPBS buffer; the native condition maintains the protein 
bioactivity proteins. The proteins were separated with 1.5ml/min flow rate in cool 
room. Fractions (A11-B14) from the predicted protein peak which appeared 
120min after sample loading were collected (Figure 3.7a). The purity of the IL-
37a sample was checked by SDS-PAGE. Nearly all proteins in the sample were 
recombinant IL-37a, about 22kDa in size (Figure 3.7b).  
Using the same method, the recombinant IL-37b protein was also further purified 
by gel filtration under the same purification condition. 115min after loading, a 
clear protein peak of recombinant IL-37b was observed (Figure 3.8a). All samples 
(A12-B8) from this peak were collected and the protein purity and size checked 
by SDS-PAGE gel (Figure 3.8b). On the SDS gel, sample B13 and B10 showed that 
the majority of protein bands were recombinant IL-37b, about 25kDa in size. 
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Figure 3.7 Gel filtration purification of recombinant IL-37a proteins  
 
After Ni-NTA column purification, the recombinant IL-37a proteins were further 
purified by AKAT Pure gel filtration system. 
 a) Chromatograph of recombinant IL-37a with the Superdex-75 column of AKAT 
Pure system; the buffer flow rate was 1.5 ml/minute. The peak of interest protein 
was highlighted by black bracket. 
 b) The purity of the collected fraction after gel filtration was further checked by 
15% SDS-PAGE gel with Coomassie blue staining and de-stained. Line 1 is the 
protein marker, line 2 is fraction A14 collected from gel filtration.  
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Figure 3.8 Gel filtration purification of recombinant IL-37b protein  
 
 The recombinant IL-37b protein from Ni-NTA purification was further purified by 
AKAT Pure gel filtration system.  
a) Recombinant IL-37b sample was further purified using Superdex-75 column of 
AKAT Pure system; the filtration buffer flow rate was 1.5ml/minute. The peak of 
protein interested is highlighted by black bracket. 
 b) The fractions from gel filtration were further checked for purity by 15% SDS-
PAGE gel with Coomassie blue staining and de-stained. Line 1 is the protein 
marker; line 2 and 3 were the protein fractions B13 and B10 collected from gel 
filtration.  
 
  
122 
 
 
3.2.2.7 Dialysis of purified IL-37a and b proteins 
Dialysis is a commonly used method in protein purification. This method is mainly 
used as one of the purification steps to replace the protein solution with a suitable 
buffer which is better for protein stability and also for the next step of protein 
purification procedure (Macedo and Cordeiro, 2017). For instance, the imidazole 
in the elution buffer of Ni-NTA purification can be toxic to the cells in the 
subsequent bioassay of purified recombinant IL-37, therefore it must be removed 
by dialysis. Since the defined size of holes in the dialysis tube membrane allows 
only smaller molecules to pass and keeps the large molecules inside (Bollag and 
Edelstein, 1991) dialysis also allows to remove the contaminated small proteins.  
An important issue in the dialysis is to ensure the protein stability and solubility 
during the buffer replacement via dialysis. Several physical and chemical factors 
may affect protein stability, such as protein nature, concentration, temperature, 
buffer pH, ionic strength and composition (Pesarrodona et al., 2015). Among these 
factors, the buffer composition is the most important factor. Several buffers are 
commonly used for protein storage as well as dialysis, for instance, Tris–HCl, PBS, 
sodium phosphate and sodium citrate (Pesarrodona et al., 2015) In this project, 
based on the published results and the protein features of IL-37 isoforms, I tested 
four dialysis buffers: Tris buffer, two different concentrations of NaCl with Tris 
and PBS in IL-37 protein purification process (Table 3.3). Both IL-37a and b 
proteins were stable, no precipitations had been seen in the buffer 1 which 
contained low concentration of NaCl (250mM) and Tris. IL-37a proteins were 
insoluble and precipitated in the other 3 buffers during the dialysis, while IL-37b 
proteins were also soluble in the buffer 2. The dialysis in buffer 1 had also the 
highest recovery, 86% for IL-37a and 90% for IL-37b, respectively. Thus, the buffer 
1 was selected for the dialysis of both IL-37 protein isoforms.  
123 
 
 
Table 3.3 Different buffers for IL-37a and b protein dialysis and stability 
  
before dialysis after dialysis
1
250 mM NaCl+ Tris 50 
mM (PH=7.5)
1.62mg/ml 1.39mg/ml 86% —
2
 500 mM   NaCl+ Tris 
50mM (PH=7.5)
1.62mg/ml 1.32mg/ml 82% +
3
PBS (137 mM NaCl; 2.7 
mM KCl; 8 mM 
Na2HPO4; 2 mM 
KH2PO4, pH=7.5)
1.62mg/ml 1.28mg/ml 79% +
4 Tris buffer (PH=7.5) 1.62mg/ml 1.24mg/ml 76.50% +
before dialysis after dialysis
1
250 mM NaCl+ Tris 50 
mM (PH=7.5)
2.21mg/ml 1.99mg/ml 90% —
2
 500 mM   NaCl+ Tris 
50mM (PH=7.5)
2.21mg/ml 1.87mg/ml 85% —
3
PBS (137 mM NaCl; 2.7 
mM KCl; 8 mM 
Na2HPO4; 2 mM 
KH2PO4, pH=7.5)
2.21mg/ml 1.83mg/ml 83% +
4 Tris buffer (PH=7.5) 2.21mg/ml 1.24mg/ml 77.00% +
Precipitation
IL-37b concentration dialysis 
efficiency
PrecipitationDialysis conditions
Dialysis conditions
IL-37a concentration dialysis 
efficiency
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3.2.2.8 Endotoxin removal of recombinant IL-37a and b proteins 
I sought next to remove the endotoxin from IL-37 proteins produced in E. coli by 
polymyxin B columns. The Polymyxin B Sepharose gel column can bind micrograms 
of endotoxin so that it is an effective method to remove LPS from the recombinant 
IL-37 proteins produced in E. coli. The endotoxin levels in the recombinant 
proteins were measured by Limulus Amebocyte lysate (LAL) QCL-1000 pyrogen test 
kit (Mølvig and Back, 1987), before and after endotoxin removal. The endotoxin 
levels in IL-37a and b recombinant proteins were 0.0235 EU/µg and 0.0357EU/µg, 
respectively, before the polymyxine B purification. After endotoxin removal, the 
endotoxin levels in recombinant IL-37a and b were less than 0.01EU/µg 
(0.00483EU/µg and 0.00957EU/µg, respectively), which is an acceptable level of 
endotoxin for cell culture and animal experiment.  
 
 
Figure 3.9 Comparison of the endotoxin level in IL-37a and IL-37b protein 
products before and after endotoxin removal 
 
Endotoxin in the recombinant IL-37a and b was removed by polymyxin B affinity 
purification according to the instruction of manufacturer. The endotoxin levels in 
the two samples were detected by endotoxin detection kit (ETR= endotoxin 
removal). The endotoxin levels of IL-37a/b after ETR are compared with the level 
before ETR. Using student T-test, data are means ± SD and are representative of 
three independent measurements. ***P<0.001 compared to control. 
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3.2.3 Production of IL-37a and b monomer proteins 
Following the recent report that the dimerization of IL-37b proteins can dampen 
their bioactivity and immune suppress function (Ellisdon et al., 2017), it is 
important to produce the monomeric IL-37b protein for research. Furthermore, it 
is currently unknown if IL-37a can also form homodimer and whether this can also 
affect its function. In this part of the project, I firstly determine the dimerization 
possibility of IL-37a protein by electronic remodelling, then design the mutant IL-
37a and b gene for the expression and production of monomeric IL-37a and b 
proteins in E. coli, respectively.  
3.2.3.1 Determine the dimerization possibility of IL-37a  
Based on IL-37b protein structure, the IL-37a protein structure can be predicted 
with SWISS-MODEL using the comparative modelling engine (Waterhouse et al., 
2018). As with the previously published result that IL-37b proteins can form head 
to head homodimers via their Try85 (Ellisdon et al., 2017, Figure 3.10b), I found 
that IL-37a can also form homodimer in the similar way, but via Try59 (Figure 
3.10a). Intriguingly, IL-37a and b may also form heterodimer via their Try within 
each of the two isoform proteins (Figure 3.10c). 
 
3.2.3.2 Plasmid construction for the expression of IL-37a and b protein 
monomer in E. coli 
After identifying the amino acid (tyrosine) responsible for the dimer formation of 
IL-37a and b, I next replaced the tyrosine (Y) with alanine (A) by point mutation 
in IL-37a and b cDNA. This has successfully prevented IL-37b dimerization (Ellisdon 
et al., 2017). Briefly, the DNA sequence TAC175 (encoding Y59) in IL-37a cDNA and 
TAC294 (encoding Y85) in IL-37b cDNA were changed into GCC (encoding Alanine) 
for monomeric IL-37a and b production, respectively in E. coli. The cDNA 
sequences for encoding mutant IL-37a and b proteins were synthesised and 
inserted into the expression vectors PET-21a and PET-28a (Figure 3.11) and 
transformed into host E. coli. The sequence confirmed plasmids for the expression 
of mutant IL-37a (Y59A) and IL-37b (Y85A) were used for the monomeric protein 
production as above.  
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Figure 3.10 The difference in monomer and dimer formation between IL-37a 
and IL-37b proteins 
 
The electronic modelling was performed by the software SWISS-MODEL and 
Phyre2. The dimer forming site marked by red point. 
a) The modelling of monomer and homodimer structure of IL-37a protein (Green).  
b) The modelling result for monomer and homodimer structure of IL-37b protein 
(Purple). 
c) Superimposing of monomer and heterodimer IL-37a and b protein. 
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Figure 3.11 Schematic representation of plasmid DNA for the expression of 
mutant IL-37a and b monomeric protein in E. coli (changing the cDNAs to IL-37a 
(Y59A) and IL-37b (Y85A), also changing the antibiotic resistant genes). 
The PET-21a and PET-28a vectors were used to express mutant IL-37a (Y59A) and 
IL-37b (Y85A) proteins. The mutant IL-37a and b cDNA sequences were synthesised 
and inserted between the Xho I and Nde I sites in the two plasmids, respectively. 
Ori means the origin of replication; Lacl is the LacI coding sequence; dark grey 
areas are the antibiotic resistant gene coding sequence (Ampicillin resistant gene 
for PET-21a, Kanamycin one for PET-28a); light grey areas are T7 promoters; the 
red areas are the coding sequences of 6His Tag. 
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3.2.3.3 Nickel affinity chromatography for mutant IL-37a and b purification 
The mutated IL-37a and b proteins were purified using the same strategy and 
method as the natural form IL-37 proteins. His-tagged IL-37 mutants bound to the 
Ni-NTA column and eluted by the increasing dose of imidazole. Figure 3.12a 
showed the Nickel affinity purification of IL-37a Y59A mutant proteins from E. coli 
lysate. Figure 3.13a shows the result of IL-37b Y85A mutant purification by Nickel 
chromatography. The presence and purity of IL-37a and b mutants after Nickel 
purification were confirmed by SDS-PAGE (Figure 3.12b and Figure 3.13b). The 
results demonstrated that the mutant IL-37a and b proteins could also be purified 
by the same method as the native ones. 
3.2.3.4 Purification of mutant monomeric IL-37a by gel filtration 
Since the mutant IL-37 proteins purified by Nickel affinity chromatography N were 
still contaminated with bacterial proteins, it was necessary to further purify the 
proteins by size exclusion chromatography (SEC). The mutant IL-37a proteins 
collected from Nickel purification were further separated in Superdex-75 column 
of AKTA pure system. Three protein fractions eluted in the predict protein peak 
were collected (Figure 3.14a). The existence and purity of the IL-37a proteins 
were confirmed by SDS-PAGE gel (Figure 3.14b). Thus, the mutant IL-37a proteins 
were successfully produced and purified. 
The mutant IL-37b proteins were also produced and purified in the same way 
successfully (Ellisdon et al., 2017, data not shown). 
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Figure 3.12 Nickel affinity chromatography for mutant IL-37a purification 
 
The mutant 6His-IL-37a proteins were purified by His-Trap column using the AKTA 
protein purification system. a) The chromatography of IL-37a mutant with Ni-NTA 
column, flow rate was 2ml/min; the peak of predicted IL-37a mutant proteins is 
highlighted by black brackets and protein fractions were collected. b) SDS-PAGE 
result. 5 fractions collected from Nickel chromatography were separated by 15% 
SDS- gel. Line 1: the 100kDa protein marker; Lines 2 and 3: the soluble loading 
protein and insoluble bacteria lysate. Line 4-6: the unbound flow-through 
proteins; Lines numbered 7-11: were the eluted fractions of mutant IL-37a by 
different concentration of imidazole. 
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Figure 3.13 Nickel affinity chromatography for monomer IL-37b purification 
 
Mutant His-IL-37b protein was purified by His-Trap column using the AKTA protein 
purification system. a) The chromatography of mutant IL-37b with Ni-NTA column, 
flow rate was 2ml/min; the protein peak of predicated IL-37b elution was 
highlighted by black brackets. b) SDS-PAGE result.  
5 fractions collected from Nickel chromatography were separated by 15% SDS-
PAGE gel. Line 1: the 100kDa protein marker; Lines 2 and 3: the loading soluble 
loading protein and insoluble bacteria lysate. Line 4-6: the unbound flow through 
proteins; Lines 7-10: the eluted fractions of mutant IL-37b by increasing 
concentration of imidazole.  
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Figure 3.14 Purification of mutant IL-37a proteins by gel filtration 
 
The recombinant IL-37a mutant proteins from Ni-NTA column were further 
purified by gel filtration. a) Recombinant IL-37a monomer (orange line) 
information in Superdex-75 column of AKAT Pure system; with filtration buffer 
flow rate of 1.5ml/minute. The peak of interest protein highlighted by black 
bracket. b) Collected protein fractions from gel filtration were further checked 
by 15% SDS-PAGE gel with Coomassie blue staining and de-stained. Line 1: 100kDa 
protein ladder; lines 2-7: 6 fractions collected from gel filtration. 
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3.2.3.5 Identification of the monomer and dimer protein of recombinant IL-
37a and b by native PAGE 
We next determined whether the mutant IL-37a and b proteins that we produced 
are in monomeric form. Whereas the SDS-PAGE is useful to estimate the molecular 
weight of protein, it cannot be used to identify the IL-37 dimers. This is because 
the mobility of a protein in a PAGE is determined by both charge and size and SDS 
can disrupt the protein structure to produce a linear polypeptide chain coated 
with negatively charged SDS molecules. Therefore, the protein mobility in SDS 
PAGE depends mainly on its molecular weight. In contrast, in the native PAGE, 
proteins are prepared and run without detergent, which maintains both the 
proteins’ secondary structure and native charge density, thus, the protein 
movement during the electrophoresis will mainly depend on their primary amino 
acid sequence which can reflect the real protein molecular weight (Arndt et al., 
2012). Therefore, the native polyacrylamide gel electrophoresis can be used to 
distinguish protein monomer and dimer, such as the native and mutant IL-37a and 
b proteins. 
Three samples each of the natural and mutant (monomers) of IL-37a and b 
proteins, respectively were separated on the 15% native PAGE gel. The 
electrophoresis system was run in ice-cold condition to maintain the protein 
structure. It was expected that the monomer for IL-37a and b should be around 
22 and 25kDa, respectively and the dimer over 40 and 50kDa, respectively. As 
shown in the Figure 3.15a, the natural IL-37a proteins (sample 4-6) consisted of 
both the monomer and dimers. In contrast, the mutant IL-37a proteins (samples 
1-3) were only presented in the monomeric state. It was noted that there were 
also some bands with sizes in between the monomer and dimer IL-37, the nature 
of the proteins is unknown. 
The similar result was also obtained with the natural and mutant IL-37b proteins 
(Figure 3.15b). 
Thus, the result demonstrated that mutagenesis of IL-37a (Y59A) can prevent the 
dimerization of IL-37a. Our results also confirmed that mutation of IL-37b (Y85A) 
is sufficient to avoid IL-37b dimerization, as reported (Ellisdon et al., 2017).  
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In summary, I have successfully produced both natural and mutant IL-37a and b 
proteins. As summarised in the Table 3.4, from 5 litres of bacterial culture, 9.4 
mg of natural and 8.1mg of mutant IL-37a protein and 5.4mg of natural and 10mg 
of mutant IL-37b proteins have been produced. The recombinant proteins were 
highly purified by both Nickel affinity chromatography and gel filtration. The 
endotoxin levels in the purified protein samples were less than 0.01EU/µg in most 
of the protein preparations. 
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Figure 3.15 Identification of IL-37a and b monomers and dimers by native 
PAGE 
 
The monomer and dimer state of both recombinant IL-37a and b proteins was 
confirmed using 15% native PAGE gel. a) Native PAGE result of natural and mutant 
IL-37a proteins. Line 1-3: 3 samples from mutant IL-37a (recognized as monomer) 
purified by gel filtration; Line 4-6: 3 samples from natural IL-37a purified by gel 
filtration. Predicted monomer size is about 22kDa, dimer size is >40kDa. b) Native 
PAGE of natural and mutant IL-37b proteins. Line 1-3 were the 3 samples of 
purified mutant IL-37b (recognized as monomer). Line 4-6 were the samples from 
natural purified IL-37b. Predicted monomer size is about 25kDa, dimer size is 
>50kDa. 
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 Table 3.4 Summary of the production and purification of wild type and mutant 
IL-37a and IL-37b proteins in E. coli 
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3.2.4 Generation of human IL-37a transgenic and receptor knockout mice 
To investigate the role of human IL-37a in disease in vivo, we generated human 
IL-37a-transgenic (IL-37aTg) mice via a company (Taconic Biosciences GmbH). The 
IL-37 receptor IL-1R8/IL-1R8 knockout mice (IL-1R8KO) were kindly obtained from 
Professor Alberto Mantovani (Garlanda et al., 2004).  
All mice were housed in specific–pathogen-free conditions at the Biological 
Service, University of Glasgow. 6-10 week-old mice were used in the experiments 
under licence and in accordance with the UK Home Office guidelines. 
3.2.4.1 Generation and identification of IL-37a transgenic mice 
The transgenic mice were generated using the standard method (Xiang et al., 
2010). Briefly, full-length human IL37a cDNA (NM_173205.1) was inserted 
downstream of the CAG promoter in the vector pIRES (Figure 3.16a). The cloning 
plasmids were linearized by endonuclease digestion and the gel-purified DNA 
fragments were injected into the pronucleus of fertilized zygotes harvested from 
C57BL/6 mice, using conventional microinjection methods for the generation of 
transgenic mice (Nold et al., 2010).  
Two pairs of PCR primers were designed to identify the transgenic line (Figures 
3.16b and c). The primer pair A was designed for the amplification of a 379bp 
fragment between CAG promoter and the 5’-end of IL-37a cDNA with oligo1 and 2 
(Figure 3.16b); the primer pair B was designed for the 401bp fragment amplified 
with oligo3 and 4 between the 3’-end of IL-37a cDNA and hGHpa site on the 
plasmid (Figure 3.16c). If the transgenic mouse genome carries both the 379bp 
and the 401bp fragment detected by PCR, the mouse can be identified as IL-37a 
transgenic mice. If the mouse genome carries only one of the fragments, this 
suggest that the mouse carries a truncated IL-37a transgenic construct. Thus, with 
the two primer pairs, IL-37a transgenic line (IL-37aTg) can be successfully 
detected by PCR.  
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Figure 3.16 The transgene construct and the identification of human IL-37 
transgenic mice by PCR  
  
a) Schematic representation of Transgenic IL-37 construct. 
b) The PCR primer pair A for the identification of 3’ –terminal of IL-37a transgene 
construct. 
c) The location of PCR primer pair B for the identification of 5’ of IL-37 transgene 
construct.  
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Figure 3.17 Transgenic mice crossbreeding process flow chart 
 
The founder IL-37aTg mice (G0) were mated with WT mice for 3 generations. The 
transgenic mice were identified by genotyping with PCR using specific primers. 
The expression level of IL-37 mRNA and protein in each generation were measured 
by qPCR and ELISA. The stable transgenic mice were kept for further breeding and 
animal experiments. 
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3.2.4.2 The breeding and identification of IL-37aTg mice  
Since the transgenic IL-37a mouse lines that we received were the F0 founder 
animals, the lines have to be further bred for at least three generations in order 
to identify the stable transgenic mice for experiment and breeding. This is 
because the transgenic construct is randomly inserted into the host genome so 
that its stability and the level of transgene expression can vary in different 
founder mice. Thus, it is important to screen the transgenic lines in that the 
transgene is stably inherited and has appropriate expression level of transgene. 
Since the IL37aTg mice are in C57BL/6 background the same background WT mice 
were used to cross with the Tg mice. The strategy for the breeding of IL37aTg 
mice was illustrated in Figure 3.17. The stability and expression level of IL-37a 
transgene in each generation of the IL37aTg mice were determined and compared. 
All the breeding was carried out in VRF (Veterinary Research Facility), University 
of Glasgow. The confirmed F3 IL-37aTg mice were kept for further breeding and 
experiments.  
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Figure 3.18 Genotyping identification of IL-37a transgenic mice by PCR  
 
Mice ears were lysate and extract DNA from them, followed by two specific primer 
pairs PCR reaction. The PCR result were checked by 1.5% agarose gel.  
a) IL-37aTg mice detected by primer pair A. line 1: 100bp DNA marker; Line 3-11: 
test sample from 9 transgenic mice litters; Line 2,12: negative control. Predict 
IL37aTg band at 379bp. 
 b) IL-37aTg mice detected by primer pair B. line 1: 100bp DNA marker; Line 3-11: 
test sample from 9 transgenic mice litters; Line 2, 12: no DNA template control. 
Predict IL37atg band about 401bp. 
The result was the representative of 80 genotyping results. 
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3.2.4.3 Genotype and stability of IL-37aTg mice 
After weaning of each new litter of IL-37aTg mice, ear samples were collected by 
ear puncher (Project licence ID: PD13F11FC) and genomic DNA extracted for 
genotyping by PCR using both Primer pairs A and B as described before (Figure 
3.16c). The Figure 3.18 is a representative of many genotyping results. 9 DNA 
samples from one litter of 9 mice produced by the IL37aTg and WT parents were 
extracted, and PCR performed for IL-37aTg construct. The specific IL-37aTg 
fragment (379bp) amplified by the primer pair A was detected in 4 of 9 samples 
(Figure 3.18a). The presence of specific IL-37aTg band (401bp) amplified by primer 
pair B was also observed in 5 of 9 samples (Figure 3.18b). Based on the criterion 
that only the Tg mouse whose DNA contains specific IL-37Tg bands amplified by 
both primer pairs A and B were considered to be the successful IL-37aTg mouse, 
the mouse number 4, 6 and 7 were the IL-37aTg mice in this experiment. The 
mouse DNA samples (number 5, 8 and 10) only produced one band either by primer 
pair A or B, and therefore were not successful transgene, this may be due to a 
partial insertion of the IL37a transgenic construct.  
The genotyping method is also useful to determine the stability of transgene in 
mice. According to the principle of heredity, around 40% of the offspring from the 
transgenic and WT parents should carry the transgene successfully. In my 
genotyping results of IL-37aTg mice, the majority of the breeders had around 50% 
transgene rate for at least three generations (Table 3.5 and data not shown). 
Therefore, this strain of IL37aTg mice were breeding successfully and the 
transgene is stably inherited. 
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Table 3.5 Stability of IL-37aTg mice 
  
 ID male female 
male 
genotype
female 
genotype
mice 
number
positive 
mice
positive 
rate
1 2096947 x VRF10136 Tg WT 20 12 60.00%
2 VRF10137 x 2097165 WT Tg 27 15 55.56%
3 VRF10137 x 2096964 WT Tg 16 6 37.50%
4 VRF10137 x VRF9960  #5 WT Tg 16 8 50.00%
5 VRF10137 x VRF9960 #7 WT Tg 15 8 53.33%
6 VRF10137 x VRF10101 #15 WT Tg 14 8 57.14%
7 VRF11001 B #22 x VRF 13679 C57 Tg WT 20 13 65.00%
8 VRF11006 A #37 x VRF 13679 C57 Tg WT 22 15 68.18%
9 VRF10113 A #27 x VRF 13679 C57 Tg WT 15 7 46.67%
10 VRF12124 A #91 x VRF 13679 C57 Tg WT 11 7 63.64%
11 VRF12124 A #91 x VRF 13679 C57 Tg WT 12 7 58.33%
12 VRF13679 C57 x VRF12125 C #104 WT Tg 13 7 53.85%
13 VRF10137 x VRF12947 B #172 WT Tg 18 11 61.11%
14 VRF15164 #1 x VRF12947 B #173 WT Tg 14 6 42.86%
15 VRF15164 #2 x VRF12947 C #174 WT Tg 14 8 57.14%
16 VRF11001 B #22 x VRF12948 B #181 Tg Tg 12 7 58.33%
17 VRF15164 #3 x VRF12948 B #180 WT Tg 17 10 58.82%
18 VRF15164 #4 x VRF12947 C#175 WT Tg 15 8 53.33%
19 VRF15164 #1 x VRF16916 B #275 WT Tg 18 8 44.44%
20 VRF15164 #2 x VRF16918 c # 286 WT Tg 21 10 47.62%
21 VRF18287 A #292 x CRF19714 #1 Tg WT 17 9 52.94%
22 VRF18287 A #292 x CRF19714 #2 Tg WT 16 9 56.25%
23 VRF18287 A #292 x CRF19714 #3 Tg WT 16 8 50.00%
24 VRF18287 A #292 x CRF21575 C57 Tg WT 10 6 60.00%
25 VRF22157 A #357 x CRF21575 C57 Tg WT 13 7 53.85%
26 VRF22157 A #358 x CRF22650 C57 Tg WT 6 3 50.00%
27 VRF22157 A #361 x CRF22650 C57 Tg WT 12 7 58.33%
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3.2.4.4 The organ expression level of IL-37a in IL37aTg mice 
I next determined the tissue expression of IL-37a transgene in mice. Several 
important immune organs were collected from WT and IL-37aTg mice (3 each), 
including heart, liver, lung, gut, kidney, skin, brain and spleen. Total RNA was 
extracted and the expression levels of the IL37a in each organ were determined 
by qPCR and compared. As showed in Figure 3.19, no IL-37 expression was 
detected in the WT mice. All the organs from IL37atg mice had significantly high 
IL-37 expression compared to each of the WT control organs. Lung was the organ 
with highest IL-37 expression, followed by heart, gut, skin, liver, kidney, spleen 
and brain.  
To further determine if the expression and production levels of IL-37a are 
inducible in the IL-37aTg mice, I collected serum and spleen samples from the 4 
generations of IL37aTg mice (G0-G3) with or without LPS injection and compared 
their IL-37a mRNA and protein levels by qPCR and ELISA, respectively. As showed 
in Figure 3.20a, the expression of IL-37a in the transgenic mice was inducible by 
LPS injection. Furthermore, the expression levels of IL-37a in the 4 generation of 
IL37atg mice were comparable. The result suggests that the IL37a transgene is 
stable, at least in spleen. To further confirm the IL-37a transgene stability and 
the protein level of IL-37a in the transgenic mice, the IL-37a protein productions 
in the serum of the 4 generations of IL-37aTg mice were measured by ELISA kit. In 
consistent with the RNA levels, the IL-37a protein productions were also induced 
by LPS in the transgenic mice (Figure 3.20b). Different from the mRNA level, the 
serum IL-37a protein levels were slightly increased from GO to G4 of the mice.  
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Figure 3.19 IL-37 tissue distribution in IL-37aTg mice 
 
The organs from WT and IL-37aTg mice were collected and RNA extracted. The 
levels of IL-37a expression in each organ were measured by qPCR. The gene 
expression form all tissues of IL-37aTg are compared with WT as a control by 
student T-test. Data are means ± SD, and are representative of at least 3 
mice/group. ***P<0.001 compared to control.  
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Figure 3.20 Comparing RNA and protein levels of IL-37a in the 4 generations 
of IL37aTg mice 
 
Four generations (G0-G3) of IL-37aTg mice (around 4 mice/group) were injected 
or not injected with LPS (150ug/mice). a). The spleen samples were collected 
from the mice and the IL-37a mRNA level was measured by qPCR. Using T-test, 
data are means ± SD and are representative of at least 4 mice. ***P<0.001 
compared to control. b). Serum samples were collected from the mice before and 
after LPS stimulation. The IL-37 protein level in serum samples was measured by 
IL-37 ELISA kit. Using T test, data are means ± SD and are representative of at 
least 4 mice. ***P<0.001 compared to control. 
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3.2.4.5 Generation and identification of IL-37a receptor (IL-1R8) knockout 
mice 
The IL-1R8-deficient (IL-1R8KO) mice were generated by homologous 
recombination (Garlanda et al., 2004). An internal ribosome entry site (IRES)–LacZ 
cassette followed by the PGK-neomycin resistance gene was inserted into the 
downstream of the first ATG of IL-1R8 gene to abolish the gene expression (Figure 
3.21a). The homo and heterozygous IL-1R8KO mice can be identified by genotyping 
using PCR (Figure 3.21b). The IL-1R8KO homozygous mice should display a 402bp 
band by PCR, the WT mice should have a 126bp band and the IL-1R8KO 
heterozygous should have both bands (Figure 3.21b). The IL-1R8KO mice can also 
be further identified in RNA levels by RT-qPCR (Figure 3.21c). The WT and IL-
37aTg, but not the IL-1R8KO mice expressed IL-1R8 in splenocytes (Figure 3.21). 
We amplified the strain of mice by interbreeding with the homozygous male and 
female IL-1R8KO mice to produce homozygous mice for experiments. 
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Figure 3.21 The generation and genotyping of IL-1R8 deficient mice 
 
a) Schematic representation of IL-1R8 knockout mice construct. This construct 
built on Lambda FIX II vector, with an (IRES)-LacZ cassette to replace the IL-1R8 
site. PGK-neomycin resistant site is the antibiotic resistant gene coding sequence.  
b) Genotype detection of IL-1R8 knockout mice by PCR. Predicted IL-1R8KO band 
at 402bp, WT band at 126dp. line 1: 100bp DNA marker; Line 3-10: IL-1R8KO 
homozygous (-/-); Line 2: negative control; Line 9: IL-1R8KO heterozygous mice 
(+/-); Line 10: WT mice.  
c) The splenocytes from wild type, IL-1R8KO and IL-37aTg mice were collected. 
The IL-1R8 mRNA level was measured by RT-qPCR. Using student T-test for 
analysis, data are means ± SD and are representative of at least 5 experiments. 
***P<0.001 compared to control. 
  
148 
 
 
3.3 Discussion 
In summary, we found for the first time that the dimerization of human IL-37a 
protein and the key amino acid are involved in the IL-37a protein. I also 
established the method for the successful production and purification of natural 
and mutant human IL-37a and b recombinant protein in E. coli. Finally, we 
generated IL-37aTg mice and obtained IL-1R8 deficient mice in order to study IL-
37a function and receptor in vivo. These are invaluable tools and widely used in 
our laboratory and beyond for the study of IL-37a biology and function. 
We demonstrated the dimerization of human IL-37a by native PAGE, molecular 
modelling and gene mutagenesis. Using the native PAGE, we found that natural 
IL-37a proteins existed in both the monomer and dimer forms, with majority of 
the proteins was dimer. We further identified amino acid Y59 in IL-37a protein as 
the key amino acid in the IL-37a dimerization by molecular modelling. Finally, we 
confirm that mutagenesis of IL-37a Y59A effectively prevents the dimerization of 
IL-37a. Thus, like IL-37b, IL-37a can also form homodimers. It is important to know 
whether this affects IL-37a function.  
Intriguingly, IL-37a and b may also form heterodimers via their Try within each 
isoform, as suggested by molecular modelling. However, since the two isoforms 
are different in N-terminal sequence and in molecular size it is still unclear how 
stable the heterodimer can be. This needs to be further confirmed empirically.  
We designed the constructs for the expression of both natural and mutant IL-37a 
and b protein produced in E. coli. We also established the protocol for the 
purification of these IL-37 proteins from E. coli. With the results presented in this 
chapter, I have successfully produced milligram level of highly purified both 
natural and mutant IL-37a and b proteins.  
Despite the successful expression of IL-37 proteins, I found that the production of 
IL-37a was more problematic than IL-37b. This was mainly because IL-37a was less 
soluble than IL-37b in several commonly used buffers and can precipitate from the 
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solution during the dialysis. Therefore, several dialysis conditions have been 
tested and optimised. 
The chemical analysis of the two IL-37 isoforms suggests that the lesser solubility 
of IL-37a than IL-37b may relate to its higher isoelectric point, 9.2 for IL-37a 
comparing with 6.1 for IL-37b. Thus, in order to make IL-37a soluble in a dialysis 
buffer with PH 7.5, the salts concentration has to be relatively lower. For 
instance, IL-37a was insoluble in buffer 1 (PH7.5) with 500 mM of NaCl, and it 
became soluble when we reduced the concentration of NaCl to 250mM. This 
suggests again that IL-37a is different from IL-37b in protein features.  
The human IL-37a transgenic mice showed no obvious difference compared with 
C57BL/6 wild-type mice in birth-rates, sex ratios and body weights. No obvious 
changes were identified in the anatomic and histological analysis of major organs: 
heart, liver, spleen, kidney, intestine and brain of the mice at 10 weeks of age 
(data not shown). Moreover, there is no differences in the IL37aTg mice at 6-10 
weeks of age compare with WT mice which are normally used in our experiments. 
This suggests that transgenic production IL-37a is safe with no observed influence 
on mice homeostasis. 
Differing from the reported IL-37b transgenic mice that express IL-37b from CMV 
promoter, our IL-37aTg mice express IL-37a from the CAG promoter. The reason 
for using CAG promoter was because CAG is more effective than CMV in initiation 
of gene expression in mammalian cells (Koyama et al., 2000). This is mainly due 
to the CAG promoter containing both CMV immediate early enhancer and an 
enhancer element from the intron of the chicken beta actin gene, which is highly 
conserved among vertebrates (Tardieu et al., 2014). Indeed, previous report 
shows the serum level of IL-37a in the IL-37aTg mice is much higher than the 
reported level of serum IL-37b in the IL37bTg mice (Nold et al., 2010). The CAG 
promoter seemed to work well in all tested cell populations from the Tg mice, 
including T, B cells and macrophages (data not shown). This should be valuable 
for studying the function of IL-37a in each of the immune and tissue cells. 
As with IL-37bTg mice, the transgene IL-37a expression in mice was inducible by 
TLR signal, including LPS, and its expression was initiated with a constitutive (non-
inducible) CAG promoter. This may be due to the IL-37 mRNA containing an 
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instability element which can be stabilised by inflammatory signal, including TLR 
signals (Dinarello et al., 2016). 
Altogether, I have successfully produced a sufficient amount of highly purified 
natural and mutant IL-37a and b recombinant proteins. We have also generated 
and bred IL-37aTg and receptor deficient mice. While it was very time consuming, 
I have learnt a great deal from this part of the work. I believe these techniques 
are very useful, not only for the next part of my work involved in the functional 
study of IL-37a and b, but also for the ongoing research projects in our lab.  
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Chapter 4 
IL-37 regulates TLR response 
 in vitro and in vivo 
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4. IL-37 regulate TLR response in vitro and in vivo 
4.1 Introduction 
Although the biology and function of IL-37b have been studied, the biology and 
effect of other IL-37 isoforms, especially IL-37a, are still poorly studied. By analyzing 
IL-37a structure and key protein domains, we believe IL-37a should have bioactivity 
which is similar but different from IL-37b. Both IL-37a and b share C’-terminal IL-1-
like domain that is important for receptor binding and signaling (Nold-Petry et al., 
2015). Thus, as IL-37b, IL-37a may also bind to the receptor complex consisting of 
IL-1R8 and IL-18Ra chains for signaling, and thereafter has similar bioactivity. 
However, the different N-terminals may make them different in biology and activity. 
The unique N-terminal of IL-37a contains a putative nuclear localization sequence 
(NLS) and elastase cleavage site. Research in this group has found that the NLS is 
functional and can translocate FLIL-37a from cytoplasm into cell nucleus 
(unpublished result), thus, IL-37a is largely a nuclear protein. Different from other 
IL-37 isoforms that carry a caspase I cleavage site, IL-37a contains a putative elastase 
cleavage site. Caspase I can cleave FLIL-37a into mature IL-37a (Nold-Petry et al., 
2015). However, the maturation process of FLIL-37b seems to be not required for IL-
37b secretion and function since both FL and mature IL-37b can be released from 
cells and both forms of IL-37b are bioactive (Gu et al., 2015). The maturation of IL-
37a and the importance of maturation in IL-37a function and secretion are unknown. 
Furthermore, both IL-37b and a can form homodimer in higher concentration 
(Ellisdon et al., 2017 and Chapter 4). The IL-37b monomer is better than dimer in 
bioactivity (Eisenmesser et al., 2019). However, the bioactivity of dimer and 
monomer of IL-37a is also unknown. 
Intriguingly, IL-37 is selectively expressed in human but not mice (Nold et al., 2010). 
Thus, study of human specific IL-37 function may help to understand not only its 
function in human, but also the difference between human and mice in immunity 
and disease. 
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While mice lost IL-37 in evolution, the receptors IL-1R8 and IL-18Ra remain and can 
respond to human IL-37 (Nold-Petry et al., 2015). Therefore, mice are an optimal 
choice to study the function of human IL-37 in vitro and in disease in vivo. The 
function of IL-37b in diseases has been investigated in IL-37b transgenic mice 
(McNamee et al., 2011; Liu et al., 2018). The function of IL-37a in diseases has not 
been explored. 
Salmonellosis is a food-born disease caused by salmonella infection. salmonella 
leads to many manifestations of disease: enteric fever (typhoid fever), enterocolitis 
and systemic illness (Trebichavský and Šplíchalová, 2010). TLRs play a critical role 
in salmonella infection (Mittrucker et al., 2002). Several TLR agonists from 
salmonella, including lipopolysaccharide (LPS, for TLR4), lipoprotein (TLR2) and 
flagella (TLR5) have been identified (ibid). After salmonella infection, host innate 
immune cells, including DC and macrophages recognize the salmonella-derived TLR 
ligands via their TLRs and trigger a protective Th1 immune response, producing IL-
12 and IFN-γ to kill intracellular salmonellas (Trebichavský and Šplíchalová, 2010). 
several anti-bacteria substances are generated by this process, for instance nitric 
oxide, in order to assist in the removal of intracellular salmonella (Moss et al., 2004). 
Thus, factors that regulate NO production are likely important in salmonella 
infection. TLR2,4 and 5 play a critical role in the early immune response by 
identifying the invaded pathogens, then activate host innate immune response (Roll 
et al., 2007). While an appropriate level of TLR response is beneficial, dysregulation 
of TLR function may lead to inflammatory response, pathogenesis and death 
(Mittrucker et al., 2002). Thus, TLR response in salmonella infection must be 
carefully controlled. 
It has been noted that Salmonella infection is different in human and mouse, also in 
nitric oxide induction (Vazquez‐Torres et al., 2008). Salmonella typhi can only 
infect human but not mice (Crump et al., 2004). The reason behind this is still less 
understood. 
In Chapter 3, I have produced the monomer and dimer rIL-37a and b proteins. I also 
generated the IL-37aTg mice and introduced IL-IR8KO mice, with all these reagents 
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and mice strains, I studied here the function of IL-37a in vitro and in salmonella 
infection in vivo.  
 The main aims of this chapter were: 
To investigate the induction and regulation of IL-37 isoforms under different TLR 
stimulations in human macrophages.  
Determine the function of endogenous and exogenous IL-37a in the regulation of TLR 
response in vitro. 
Investigate the function of IL-37a in Salmonella infection in vitro and in vivo. 
We demonstrated here that IL-37a is highly induced among the IL-37 isoforms in TLR-
stimulated macrophages. Both endogenous and exogenous IL-37a are bioactive and 
immunosuppressive in TLR-induced inflammatory response. The monomer IL-37a is 
more immunosuppressive than the dimer. Moreover, the IL-37a-mediated immune 
regulatory effect is IL-1R8 dependent. 
While inhibiting inflammatory response, IL-37a also promotes salmonella infection 
in human and murine macrophages and in mice in vivo. This may be due to its 
regulatory effect on protective immunity and NO production. Thus, IL-37a is a 
previously unrecognized immunoregulatory cytokine which plays a regulatory role in 
TLR response and in infection. 
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4.2 Result 
4.2.1 The induction of IL-37 isoform and receptor expression in macrophages 
by TLRs 
The optimal induction and regulation of IL-37 isoform and receptor expression in 
macrophages is unknown. To investigate whether the IL-37 isoform and receptors 
are equally or differently regulated by TLR signals in macrophage, the human THP-
1 monocytes were differentiated into macrophage first adding PMA, then stimulated 
by 4 different TLRs (LPS, PAM3, FLA-st and IMQ) for 12h and the IL-37 isoform and 
receptor expressions were determined by qPCR. As shown in Figure 1, in LPS and IMQ 
stimulated macrophages, the IL-37a, b and c were markedly induced, compared to 
IL-37d and e. However, in PAM-activated macrophages, both IL-37a and e were highly 
induced, IL-37c and d were less induced, while the IL-37b was not induced. In the 
case of FLA-st stimulated cells, all isoforms, except IL-37d, were significantly 
induced. These results suggested that IL-37 isoform expressions were selectively 
induced by different TLR signals and that among the IL-37 isoforms, IL-37a was highly 
induced and IL-37d was less induced in all the tested TLR stimulatory conditions.  
the dynamics of IL-37 receptors (SIGIRR and IL-18Rα) expression in murine and 
human macrophages were also analysed by qPCR. Compared to the unstimulated 
control human macrophages, the IMQ, PAM3 and FLA-st, but not LPS significantly 
down-regulated IL-1R8 mRNA expression (Figure 4.2). PAM3, but not the other three 
TLR agonists enhanced the expression of IL-18Ra chain expression in human 
macrophages. In murine macrophage, PAM3 but not the other three tested TLR 
ligands also enhanced the expression of IL-1R8 (Figure 4.2), whereas all 4 TLR 
agonists, in particularly LPS, markedly elevated IL-18Ra expression. Thus, compared 
to murine macrophages, IL-1R8 expression in human macrophages was largely down-
regulated by most tested TLR ligands. 
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Figure 4.1 The regulation of IL-37 protein isoform expression in human 
macrophages stimulated by TLR agonists 
 
Human macrophage THP-1 cells (1x10^6 cells/ml) were cultured and stimulated with 
LPS, IMQ, FLA-st and PAM3cSK2 (100ng/ml). The expression levels of IL-37 isoforms 
were measured by qPCR 12 hours after stimulation. All samples compared with 
negative control (Fold change = 1). Using ANOVA test, data are means ± SD, and are 
representative of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001 
compared to untreated cell controls. 
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Figure 4.2 The expression of IL-37 receptors in murine/ human macrophages 
stimulated by TLR ligands 
 
Human macrophage THP-1 cells and murine macrophage RAW cells (1x10^6 cells/ml) 
were stimulated with LPS, IMQ, FLA-st and PAM3cSK2 (100ng/ml) for 12 h. The levels 
of IL-37 receptors (IL1R8/IL-18Ra) were measured by qPCR. All samples compared 
with negative control (Fold change = 1). Using ANOVA test, data are means ± SD, and 
are representative of three independent experiments. *P<0.05 and ***P<0.001 
compared to controls. 
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4.2.2. Knockdown IL-37a mRNA enhances inflammation cytokine production in 
human macrophages 
Since IL-37a is highly inducible among the IL-37 isoforms by all tested TLR signals I 
sought next to study the function of IL-37a. To understand the function and 
importance of the endogenous IL-37a in the regulation of TLR response in human 
THP-1 macrophages, we knockdown the RNA of total IL-37 or IL-37a only in 
macrophages with specific siRNA. The siRNA for knockdown all IL-37 isoforms was 
designed to target the common exon 5 used by all IL-37 isoforms (siTotal IL-37) and 
siRNA for IL-37a (siIL-37a) targets its unique exon 3. The human THP-1 monocytes 
were differentiated into macrophage by adding PMA, then transduced with the 
control or specific siRNAs, respectively, for 48 hours. A scrambled siRNA was used as 
siRNA control. After that, the macrophages were stimulated with LPS for different 
times (6, 18 and 24 hours). The IL-37 isoform RNA and protein levels were measured 
by qPCR and ELISA. As shown in Figure 3, The knockdown of total IL-37 effectively 
dampened the expression of all IL-37 isoforms 18 hours after stimulation. IL-37a 
siRNA predominantly decreased the expression of IL-37a but, to a lesser extent, the 
IL-37e expression as well (Figure 4.3). Compared to the protein level of IL-37 in 
control siRNA group, siRNA knockdown either total IL-37 or IL-37a alone markedly 
reduced the production of IL-37 in culture supernatant, while the effect was more 
dramatic in the group of knockdown of total IL-37 (Figure 4.4). The result suggests 
that whereas the siRNA for total IL-37 isoforms was effective, the siRNA for IL-37a 
was less specific and also affected IL-37e. the reason is currently unclear. Since IL-
37e only possesses part of the IL-1-like domain which is required for the receptor 
binding and signalling it is highly possible that IL-37e lacks suppressive activity 
(Boraschi et al., 2011). We next compared the inhibitory effect between the total 
IL-37 and IL-37a knockdown groups on LPS-induced inflammatory cytokine expression 
in macrophages.  
Compared with the control group, siIL-37a group significantly elevated the level of 
LPS-induced pro-inflammatory cytokines, IL-1α and IL-6 RNA expression and protein 
production (Figure 4.5a and b). The levels of inflammatory cytokines were further 
increased by the knockdown of total IL-37 (Figure 4.5a and b). At 36 hours culture, 
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no difference found between the two specific knockdown groups in the IL-6 protein 
enhancement (Figure 4.5b). Thus, these results suggest that endogenous IL-37a is 
bioactive and immunosuppressive. Our result also suggests that it is possible that IL-
37-derived inhibitory effect on inflammatory cytokine production is largely mediated 
by IL-37a isoform.  
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Figure 4.3 The effect of Knockdown of total IL-37 and IL-37a by specific siRNA 
on the expression of IL-37 isoforms 
 
The total IL-37 and IL-37a RNA in human macrophages were knocked down by 
liposome-mediated siRNA transduction for 48 hours SiRNA sequence for IL-37, IL-37a 
and negative control (5pmol for each sample) mixed by Lipofectamine® RNAiMAX 
Reagent (1.5µl). After siRNA transduction, 1x10^6 cells were stimulated with LPS 
(100ng/ml) for 6, 18 and 36 hours. The RNA at each time point was isolated and the 
expression of five IL-37 isoforms were determined by qPCR. All samples compared 
with negative control (Fold change = 1). Using ANOVA test, data are means ± SD, and 
are representative of two independent experiments. *P<0.05 and ***P<0.001 
compared to siRNA control. 
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Figure 4.4. siRNA for total IL-37 and IL-37a decrease the protein production of 
IL-37 in LPS-stimulated macrophages 
 
We also measured the production of IL-37 by ELISA. The total IL-37 or IL-37a RNA in 
macrophages were knocked down by specific siRNA transduction. 48 hours later, 
1x10^6 macrophages were stimulated with LPS (100ng/ml) for 6, 18 and 36 hours. 
The production of IL-37 protein after siTotal IL-37 and siIL-37a treatments was 
determined by qPCR. In no LPS groups, all samples compared with negative control, 
in LPS groups, all samples compared with each other. Using ANOVA test, data are 
means ± SD, and are representative of two independent experiments. *P<0.05, 
**P<0.01 and ***P<0.001 compared to siRNA control. 
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Figure 4.5 Knockdown of IL-37a and total IL-37 by specific siRNA increases LPS 
induced pro-inflammatory cytokines production in macrophages 
 
Initially, total IL-37 and IL-37a RNA in THP1 cells were knocked down by specific 
siRNA as above. 48 hours after siRNA transduction, the cells were stimulated with 
100ng LPS for 6,18 and 36 hours. a) Pro-inflammatory cytokine mRNA levels were 
determined by qPCR. b) Human IL-6 protein production was measured by ELISA. In 
no LPS groups, all samples compared with negative control, in LPS groups, all 
samples compared with each other. Using ANOVA test, data are means ± SD, and are 
representative of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001 
compared to controls.  
(a) 
(b) 
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4.2.3. Recombinant IL-37a protein is immunosuppressive 
I next investigated whether the exogenous IL-37 is bioactive and whether IL-37a and 
IL-37b are the same or different in bioactivity. We answered the questions by using 
recombinant IL-37a and b (rIL-37) proteins that I had produced before (Chapter 1). 
Firstly, I compared their capability in the inhibition of LPS-induced IL-6 production 
in murine macrophage RAW 264.7 cells (Figure 4.6). Macrophages were activated 
with or without LPS stimulation and treated with or without increased doses of IL-
37a or IL-37b for 12 hours, the IL-6 production was measured by ELISA. As shown in 
Figure 4.6a, rIL-37a was immunosuppressive, which suppress LPS-induced IL-6 
production in a dose-dependent manner. This is consistent with the function of 
endogenous IL-37a. Furthermore, rIL-37a was more effective than rIL-37b in the 
suppression of IL-6 production in macrophages. The best concentration for their 
inhibitory effect was 50 ng/ml. I further compared the dose and time-effect of rIL-
37a and b in the context (Figure 4.6b). Macrophages were stimulated with LPS as 
above and treated with rIL-37a and b (10, 50 and 100 ng/ml) for 6, 12 and 24 hours 
as indicated. The bioactivity of IL-37a and b in suppressing LPS-mediated IL-6 
production was measured and compared. The best time point for both IL-37 and b 
to suppress LPS-induced IL-6 secretion started from 12 hours. Again, the best dose 
for both cytokines to inhibit IL-6 production was the 50 ng/ml and IL-37a was more 
suppressive than IL-37b (Figure 4.6b).  
According to the study of Ellisdon et al. (2017), the only form of IL-37 in human 
serum is monomer instead of dimer. Moreover, the natural IL-37 protein exists in a 
monomeric form and only the monomer but not the homodimer is bioactive and 
current recombinant IL-37 proteins are largely homodimer (Eisenmesser et al., 2019). 
Therefore, I use mutant-monomer IL-37 in our experiment to mimic the condition of 
IL-37 in human serum and seek for better bio-activity. 
 4.2.4. IL-37a monomer is more effective than dimer in immunosuppression  
Since it has been reported that the monomer form of IL-37b is more active than the 
dimers, I next investigated if this was also the case for IL-37a using the natural 
(dimer) and mutant (dimer) rIL-37a and b. I also compared the bioactivity of 
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monomer and dimer of rIL-37a and b in the same system of LPS-induced IL-6 
production in macrophages as above. We found that monomer form of IL-37a was 
more suppressive compared to the dimer in LPS-induced IL-6 expression (Figure 4.7a) 
and protein production in macrophages in dose-dependent manner (Figure 4.7b), 
this was also the case for dimer and monomer IL-37b as reported (Figure 4.7a and 
b). In addition, similar to the bioactivity of natural IL-37a and b, the monomer form 
of IL-37a was also better than the monomer IL-37b in the inhibition of IL-6 production 
in this experimental context. Thus, monomer form of rIL-37a and b were utilised for 
the subsequent in vitro and in vivo experiments. 
4.2.5. IL-37a also signals via IL-1R8 
In order to define whether IL-37a also signals via the same receptor (IL-1R8) as IL-
37b, I determined the bioactivity of IL-37a in splenocytes from IL-1R8 deficient (IL-
1R8KO) mice. Briefly, the splenocytes from WT and IL-1R8KO mice were stimulated 
with or without LPS or IMQ and treated or not treated with IL-37a and b, 
respectively. Their effect on the inflammatory cytokines—IL-1α, IL-12 and IFN-γ 
expressions were quantified by qPCR. As shown in Figure 4.8, both IL-37a and b 
inhibited all three cytokine expressions in LPS or IMQ-stimulated WT splenocytes, 
compared with the controls. In contrast, both IL-37a and b lost their suppressive 
activity in the cells from IL-1R8KO mice. The result confirmed that the same as IL-
37b, IL-37a also signals via IL-1R8.  
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 Figure 4.6 rIL-37a is bioactive and more effective than IL-37b in the inhibition 
of LPS-induced IL-6 production in vitro 
 
RAW cells (1x10^6/ml) were stimulated with 100ng/ml of LPS in the presence or 
absence of rIL-37a or b. The IL-6 levels in culture supernatant were measured by 
ELISA kit. a) The dose-dependent effect of IL-37a and b on the suppression of IL-6 
production in LPS stimulated RAW cell. b) The time-effect of recombinant IL-37a 
and b proteins in IL-6 production. Using ANOVA test, data are means ± SD, and are 
representative of three independent experiments. **P<0.01 and ***P<0.001 
compared to controls.   
(b) 
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Figure 4.7 IL-37a and b dimers are more suppressive than the dimers in LPS-
induced pro-inflammatory cytokine production 
 
Murine macrophages (RAW cells, 1x10^6/ml) were cultured in the presence or 
absence of 100ng/ml of LPS and treated with or without different doses of natural 
(dimer) or mutant (dimer) of IL-37a or IL-37b for 12 hours. a) The mRNA level of IL-
6 in activated macrophages treated with mutant and natural IL-37a and b was 
determined by qPCR. b) IL-6 protein level in cell culture supernatants measured by 
ELISA. Using ANOVA test, data are means ± SD, and are representative of three 
independent experiments. *P<0.05, **P<0.01 and ***P<0.001 compared to controls.   
(a) 
(b) 
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Figure 4.8 IL-37a signals via IL-1R8 
 
Splenocytes from WT and IL-1R8KO mice (1x10^6/ml) were cultured in the presence 
or absence of 100ng/ml of LPS or IMQ and natural or mutant IL-37a and b (50ng/ml) 
for 12 hours. Total RNAs were extracted from total cell lysate and the expression 
levels of pro-inflammatory cytokines (IL-1α, IL-6, IL-12 and IFN-γ) were measured by 
qPCR. Using ANOVA test, data are means ± SD, and are representative of three 
independent experiments. *P<0.05, **P<0.01 and ***P<0.001 compared to controls.   
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4.2.6. IL-37aTg cells suppress TLR-induced inflammatory response in vitro 
To further determine the regulatory role of human IL-37a in TLRs response in primary 
immune cells in vitro and in disease in vivo, we generated human IL-37a transgenic 
mice as described in Chapter 3. Initially, we tested the function of splenocytes from 
IL-37aTg mice in the regulation of TLR-induced IL-37a, receptor IL-1R8 and 
inflammatory mediator production in vitro. The splenocytes of IL-37aTg and WT 
mice were collected and cultured with or without LPS or IMQ stimulation for 12 and 
24 hours. RNA was extracted from cultured cells for IL-37a, IL-1R8 and inflammatory 
cytokine detection by qPCR. As shown in Figure 4.9, we can only detect IL-37a in IL-
37aTg mice not in WT, while the cells from both the WT and Tg mice expressed 
similar levels of IL-1R8 at 12 hours after culture with or without TLR stimulation. At 
24 hours after IMQ stimulation, the IL-37a expression of Tg mice is reduced compared 
with 12 hours; there is no significant change of IL-37a expression in LPS stimulate 
group. Moreover, LPS but not IMQ cause the increase IL-1R8 gene expression in WT 
cells. However, this increase cannot be observed in Tg group. Furthermore, IMQ may 
leads to a decrease of IL-1R8 gene expression (Figure 4.9). 
More importantly, the IL-37aTg cells dramatically reduced the expression of all 
tested inflammatory cytokines, IL-1α, IL-6, TNF-α, IL-12 and IFN-γ induced by either 
LPS or IMQ, compared to the WT control cells, in time-dependent fashion (Figure 
4.10). Altogether, IL-37aTg mice are functional and immunosuppressive as the 
recombinant IL-37a. 
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Figure 4.9 Determining the expression levels of IL-37a and receptor in human 
IL-37a transgenic mice 
 
The splenocytes from IL-37aTg and WT mice (1x10^6/ml) were stimulated with 100 
ng/ml of LPS or IMQ for 12 or 24 hours. The mRNA level of IL-37a and IL-1R8 in the 
cultured cells were quantified by qPCR. Using ANOVA test, data are means ± SD, and 
are representative of three independent experiments. *P<0.05, **P<0.01 and 
***P<0.001 compared to controls.  
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Figure 4.10 IL-37aTg cells suppress the expression of pro-inflammatory 
cytokines induced by TLRs 
 
The splenocytes from IL-37aTg and WT mice (1x10^6/ml) were stimulated with 100 
ng/ml of LPS or IMQ for 12 or 24 hours. The mRNA level of pro-inflammatory 
cytokines IL-1α, IL-6, TNF-α, IL-12 and IFN-γ in the cultured cells were quantified by 
qPCR. Using ANOVA test, data are means ± SD, and are representative of three 
independent experiments. *P<0.05, **P<0.01 and ***P<0.001 compared to controls.  
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4.2.7. IL-37a is highly induced by salmonella infection in human macrophage  
Since we found that IL-37a has the capability to suppress TLR ligand-induced 
inflammatory response, including the salmonella-derived TLR ligands, TLR4 ligand 
LPS, TLR2 ligand lipoprotein and TLR5 ligand flagellin, as a part of our research 
project, I sought next to study its role in salmonella infection in vitro and in vivo. 
In order to understand the involvement of IL-37 in salmonella infection, I primarily 
determined the induction of IL-37 isoform in salmonella infected macrophages.  
Human THP-1 monocytes were differentiated into macrophages by PMA and culture 
in complete RPMI medium overnight before infection. The cells were infected with 
Salmonella Typhimurium bacteria (strain 1344) for different times and IL-37 isoform 
expression analysed by real-time PCR. As showed in Figure 4.11, all 5 of IL-37 
isoforms were induced from 6 h after salmonella infection in macrophages. Among 
the isoforms, IL-37a was the most induced isoform, followed by IL-37c, b, e and d at 
12 h. 24 h after infection, IL-37c was the dominant and IL-37d still was the lowest. 
In general, IL-37 expression is induced by salmonella infection in human 
macrophages and IL-37a was one of the highly induced IL-37 isoform, therefore, our 
subsequent experiments focused on IL-37a in salmonella infection.  
4.2.8. Salmonella infection is different between murine and human 
macrophages 
The next question we asked was: what is the difference between human that express 
IL-37 and murine macrophages which do not, in salmonella infection? 
Both human and murine macrophage cell line were cultured in the same way, in the 
same medium. Same number of murine and human macrophages (1x10^6/ml) were 
infected with 10^8 of salmonella in the same time for up to 24 h. After infection, 
the bacterial numbers in the macrophages were counted under microscope and 
displayed as clone formation unit (CFU) count, as shown in Figure 4.12a and b. One 
hour after salmonella infection, murine macrophages contained more bacteria than 
human cells. However, the bacterial number was markedly reduced in murine cells 
6 h after infection, while the bacterial number in human cells was increased. At 12h 
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and 24 h, no bacteria were found in infected murine macrophages, in contrast, the 
bacteria were still observed in human cells (Figure 4.12a and b). The result suggests 
that while salmonella infects murine macrophages more easily than human cells, 
they survive longer in human macrophage than in murine macrophage.  
Nitric oxide (NO) is one of the main bactericidal factors in intracellular salmonella 
infection. NO is generated from arginine in the presence of the inducible NO 
synthase (iNOs). iNOs is largely induced by inflammatory signals, including TLR, 
inflammatory cytokines, IFN-γ, IL-1 and IL-6 in macrophages (Jin et al., 2016). I 
investigated next whether the difference in salmonella infection between human 
and murine macrophages was due to their difference in NO production. In the same 
experiment, the levels of iNOs expression and related NO production in the infected 
murine and human macrophages were measured and compared. in the comparison 
with uninfected cell control group, salmonella infection enhanced iNOs expression 
in both murine and human macrophage and with same kinetics; peaked at 12 hours 
and declined after that (Figure 4.13a). However, the quantity of NOs induction 
varied between human and murine macrophages. The iNOs expression was 3-4 folds 
higher in murine macrophages than in human cells (Figure 4.13a). this was further 
confirmed by the NO measurement in the culture supernatants (Figure 4.13b); 
Infected murine macrophages that expressed higher iNOs, also produced more NO 
than human cells. Intragluteally, the NO levels were negatively correlated with the 
bacteria count in Figure 4.12. 
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4.2.9. Salmonella infection induces less inflammatory-related cytokines in 
human than murine macrophages 
As iNOs expression can be upregulated by proinflammatory cytokines, IL-1, IL-6 and 
downregulated by anti-inflammatory cytokines, including IL-10, we determined and 
compared the key cytokine expression profiles between human and murine 
macrophages in the same infection experimental context. The transcription of 7 pro-
inflammatory cytokines and one anti-inflammatory cytokine, IL-10, were determined 
by qPCR. As shown in Figure 4.14, in infected murine macrophages, all the tested 
cytokines were induced from 6 h after infection, but with different kinetics. The 
most induced cytokines were IL-6 followed by IL-1α and IL-1b. However, in human 
THP-1 cells, the most induced cytokine was the anti-inflammatory cytokine IL-10. 
The inflammation-related cytokines IL-6, IL-12 and IFN-γ were only marginally 
induced and IL-1α, IL-1β, IL-33 and TNF-a were largely uninducible in the infected 
human macrophages, compared to those in murine cells (Figure 4.14). In summary, 
salmonella infection in human macrophages lead to dominant IL-10 expression and 
reduced inflammatory cytokines and NO production, thereby prolonging infection, 
compared to that in murine cells.  
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Figure 4.11 IL-37a is the dominate IL-37 isoforms induced by salmonella 
infection in macrophages 
 
Human THP-1 monocytes were differentiated into macrophages by PMA and cultured 
in complete RPMI medium overnight before infection. Macrophages(1x10^6/ml) were 
infected with salmonella (SL1344 strain, 1x10^8/ml). The kinetic expression of IL-
37 isoforms in macrophages was determined by qPCR 1,6,12 and 24 hours after 
infection. All samples compared with negative control (fold change = 1). Using 
ANOVA test, data are means ± SD, and are representative of three independent 
experiments. *P<0.05, **P<0.01 and ***P<0.001 compared to controls.  
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Figure 4.12 Salmonella Typhimurium survive longer in human macrophages 
compared to murine cells 
THP-1 macrophages and RAW cells (1x10^6/ml) were infected with SL1344 
bacteria(1x10^8/ml). The cells were collected 1, 6, 12 and 24 hours after infection. 
The cells were harvested in lysis buffer and sonicated to release the intracellular 
bacteria. The cell lysis was diluted eight times and incubated on LB agar plate 37℃ 
for 24 hours. The bacterial numbers in each of the samples were counted using spot 
plate and displayed as Colony-forming unit (CFU). a) The bacterial counts in infected 
THP-1 and RAW cells at different time points. Using ANOVA test, data are means ± 
SD, and are representative of three independent experiments. *P<0.05, **P<0.01 and 
***P<0.001 compared to controls. b) Pictures of serial dilutions of bacterial colony in 
spot plate of salmonella infected human and murine macrophages (24h picture result 
is different from the CFU).  
(a) 
(b) 
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Figure 4.13 Human macrophages reduce iNOs expression and NO production 
compare with murine cell after Salmonella infection 
 
Human THP-1 macrophage and murine RAW macrophage cells were cultured in 
1x10^6 cell/ml and infected with SL1344 infection (1x10^8/ml) for 1,6,12 and 24 
hours. Cells and culture supernatants were collected from each time point. The iNOs 
mRNA level were measured by qPCR and NO production in cell culture supernatant 
was measured by Griss Reagent kit. a) Comparison of iNOs expression in THP-1 and 
RAW cells. b) Comparison of NO production in THP-1 and RAW cells. Using ANOVA 
test, data are means ± SD, and are representative of three independent experiments. 
*P<0.05, **P<0.01 and ***P<0.001 compared to controls.   
(a) 
(b) 
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Figure 4.14 Differential induction and expression of anti- and pro-inflammatory 
cytokines in salmonella infected human and murine macrophages 
 
Human THP-1 and murine RAW macrophage cells were cultured in 1x10^6 cell/ml 
and infected with Salmonella (1x10^8/ml) for 1,6,12 and 24 hours. Cells were 
collected and RNA isolated. The mRNA levels of inflammation-related cytokines (IL-
1α, IL-1β, IL-6, IL-10, IL-12, IL-33, IFN-γ and TNF-α) were measured by qPCR. All 
samples are compared with negative control (fold change = 1). Using ANOVA test, 
data are means ± SD, and are representative of three independent experiments. 
*P<0.05, **P<0.01 and ***P<0.001 compared to controls.   
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4.2.10 Recombinant IL-37a and IL-37b promote salmonella infection in murine 
macrophages 
In order to understand if IL-37 is responsible for the difference of salmonella 
infection in human and murine macrophages, we next pre-treated the murine 
macrophages with rIL-37 before the salmonella infection, to see whether IL-37 is 
able to influence the course of salmonella infection. The RAW cells were cultured 
as before and treated with or without rIL-37a and b for 2 hours before the salmonella 
infection. Cell samples and culture supernatants were collected 6, 12 and 24 hours 
after infection. The bacteria CFU number, inflammatory gene level and NO 
production in each group were measured as before. 
As seen in Figure 4.15b, the treatment of IL-37a, to a lesser extent IL-37b, 
significantly enhanced salmonella numbers in the infected murine macrophages 6 h 
after infection. At 12 hours, only IL-37a, not IL-37b, still enhanced bacteria numbers; 
at 24 h, no difference had been found in bacterial number between the IL-37a 
treated and untreated cells, while IL-37b significantly reduced the salmonella 
number. In general, the bacterial number in each group was reversely associated 
with the levels of iNOs and NO; as such, the untreated cells that carried less bacteria 
produced more NO (Figure 4.16a and b). in contrast, the IL-37 treated cells that 
contained more bacteria produced less NO. this phenomenon was even clear in the 
IL-37a treated cells (Figure 4.16a and b).  
Furthermore, the inflammatory cytokines, IL-1α, IL-12 and IFN-γ levels in each of 
the experimental groups were also negatively associated with bacterial number, but 
positively associated with NO levels in most of the cases (Figure 4.17). This 
phenomenon was mimicked the salmonella infection in human cells. Thus, IL-37, 
particularly IL-37a, helps salmonella survival during its early infection in host 
macrophages.  
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Figure 4.15 Recombinant IL-37a and b proteins assist the survival of 
intracellular bacteria in murine macrophages 
 
Murine macrophage RAW cells (1x10^6 cell/ml) were pre-treated with 50ng/ml of 
mutant IL-37a and b proteins for 1 hour, then infected with SL1344 (1x10^8/ml) for 
6, 12 and 24 hours. The cells were harvested and lysed for bacteria count on spot 
plates as before. a) Experimental and treatment processes. b) Bacteria counting 
result. Using ANOVA test, data are means ± SD, and are representative of three 
independent experiments. *P<0.05, **P<0.01 and ***P<0.001 compared to controls.  
 
 
 
 
(b) 
(a) 
181 
 
 
 
 
Figure 4.16 Recombinant IL-37a and b proteins decrease the expression of iNOs 
and the production of NO in murine macrophage infected with Salmonella 
 
Murine macrophage RAW cells were pre-treated with 50ng mutant IL-37a and b 
proteins, then infected with SL1344 for 6, 12 and 24 hours. The cells were harvested 
and lysed for RNA extraction and cell culture supernatants were collected for NO 
detection. a) The kinetic of iNOs expression in infected RAW cells pre-treated with 
or without rIL-37a and b. b) NO production was measured by Greiss method. Using 
ANOVA test, data are means ± SD, and are representative of three independent 
experiments. *P<0.05, ***P<0.001 compared to controls.  
(a) 
(b) 
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Figure 4.17 Recombinant IL-37a and b proteins decrease the gene expression of 
pro-inflammatory cytokines in murine macrophage infected with Salmonella 
 
Murine macrophage RAW cells were pre-treated with 50ng each of mutant IL-37a or 
b proteins, then infected with SL1344 for 6, 12 and 24 hours. The cells were 
harvested for RNA isolation. The mRNA expression levels of four main pro-
inflammatory cytokines (IL-1α, IL-6, IL-12 and IFN-γ) were measured by qPCR. Using 
ANOVA test, data are means ± SD, and are representative of three independent 
experiments. *P<0.05, **P<0.01 and ***P<0.001 compared to controls.  
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4.2.12. Macrophages from IL-37aTg mice also susceptible to salmonella 
infection 
After identifying the potential pathogenic role of IL-37 in salmonella infection in 
macrophage cell lines, we sought to confirm this finding in primary macrophages. 
peritoneal macrophages were collected from WT and IL-37aTg mice. These 
macrophages were infected with salmonella and the CFU were counted as before 6, 
12 and 24 h after infection. the cells were also harvested for iNOs and inflammatory 
cytokine production by PCR and the cell supernatant for NO detection.  
Consistent with the observations using macrophage cell lines and treated with 
recombinant IL-37, the peritoneal macrophages from IL-37atg mice also contained 
more intracellular bacteria than the WT cells at 6 and 12 hours after infection 
(Figure 4.18b). There was no significant difference in bacteria number between WT 
and Tg cells 24 hours after infection.  
In agreement with our previous results in macrophage cell line, the enhanced 
bacterial number in cells from IL-37aTg mice was also accompanied by a significantly 
reduced levels of iNOs transcription and NO production in the cultures, compared to 
the WT cells (Figure 4.19a and b). This was also the case in the inflammatory 
cytokine expression levels (Figure 4.20). 
This finding in primary macrophages further suggests that IL-37, particularly IL-37a 
helps early salmonella infection in macrophages, probably by inhibiting 
inflammatory cytokine and NO production.  
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Figure 4.18 The peritoneal macrophages from IL-37aTg mice had higher 
survival rate of intracellular bacteria compared with WT mice during 
Salmonella infection 
 
WT and IL-37aTg mice were injected peritoneally with sodium m-periodate. 4 days 
later, the peritoneal macrophages were isolated from mice and cells (1x10^6/ml) 
were infected with salmonella (1x10^8/ml) as before and collected 6, 12 and 24 
hours after infection. The cells were harvested and lysed for bacteria count on spot 
plates. a) Experimental and treatment processes. b) Bacteria counting result. Using 
ANOVA test, data are means ± SD, and are representative of three independent 
experiments. *P<0.05 and ***P<0.001 compared to controls.  
 
 
  
 
 
(a) 
(b) 
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Figure 4.19 The peritoneal macrophage from IL-37aTg mice reduce iNOs gene 
expression and NO production, compared with WT mice during salmonella 
infection 
 
Murine peritoneal macrophages were isolated from WT and IL-37atg mice injected 
with sodium m-periodate for 4 days. Cells (1x10^6 cell/ml) were washed and 
infected with salmonella (1x10^8/ml) for 6, 12 and 24 hours. The cells were 
harvested and lysed for RNA extraction and cell culture supernatants were collected 
for NO detection. a) The kinetics of iNOs gene expression in peritoneal macrophage 
of IL-37aTg and WT mice. b) NO production cells from WT and IL-37aTg mice. Using 
ANOVA test, data are means ± SD, and are representative of three independent 
experiments. *P<0.05, ***P<0.001 compared to controls.  
(a) 
(b) 
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Figure 4.20 The peritoneal macrophages from IL-37aTg mice express lower pro-
inflammatory cytokine genes compared with cells from WT mice after 
salmonella infection 
 
Murine peritoneal macrophages were isolated from mice given sodium m-periodate 
stimulation for 4 days. Cells were washed and cultured in 1x10^6 cell/ml with 
salmonella (1x10^8/ml) for 6, 12 and 24 hours. The RNAs were extracted from total 
cell lysate and pro-inflammatory cytokine mRNA levels (IL-1β, IL-6, IL-12 and IFN-γ) 
were measured by qPCR. Using ANOVA test, data are means ± SD, and are 
representative of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001 
compared to controls.   
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4.2.13 IL-37aTg mice are susceptible to salmonella infection in vivo 
Based on our results from the study of IL-37 in salmonella infection in macrophages 
in vitro, we thought it clinically important to further investigate the potential 
pathogenic role of IL-37 in salmonellosis in mice in vivo.  
 An attenuated salmonella strain BRD509 were used to infect the WT and IL-37atg 
mice orally by using our established method (Trieu et al., 2009). Groups of WT and 
IL-37aTg mice were feed with 1x10^10 BRD509 orally. Their wellbeing and severity 
of diarrhoea in each group of mice were checked daily and recorded. Some mice 
from each group were culled at day 6 and day 8 after infection and splenocytes were 
collected for qPCR measurement, serum for NO detection and liver and drain lymph 
node for bacteria count. Firstly, the diarrhoea in IL-37a mice was much severe than 
WT at both 6 and 8 days after infection (Figure 4.21b). The IL-37aTg mice also had 
higher bacterial loading in both liver and LN at day 6 of infection, compared to the 
WT control mice (Figure 4.22). The difference was more pronounced at day 8.  
Salmonella infection also enhanced the iNOs expression in spleen and serum NO 
production in both IL-37aTg and WT controls (Figure 4.23). However, the iNOs and 
NO levels in IL-37aTg mice were significantly lower compared to the WT control at 
both day 6 and 10 after infection. 
Finally, the transcription levels of key inflammatory cytokines IL-1α, IL-6, IL-12 and 
IFN-γ in the infected and uninfected WT and Tg mice were also quantified by qPCR. 
The expression of all tested inflammatory cytokines in the BRD509 infected IL-37ATg 
mice were dramatically decreased in comparison with the WT mice at day 6 and day 
8. This is consistent with the in vitro results using rIL-37 protein in salmonella 
infected macrophages. Therefore, the results demonstrated that IL-37a plays a 
critical pathogenic role in salmonella infection, that may facilitate intracellular 
survival in macrophages via downregulating protective inflammatory cytokine and 
bactericide NO production.   
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Figure 4.21 Experimental process and diarrhoea severity of IL-37aTg mice and 
WT mice orally infected with salmonella 
 
IL-37aTg and WT mice were infected with salmonella strain BRD509 (1x10^10/mice) 
orally. a) Experimental and treatment processes. b) The diarrhoea severity of each 
mouse was observed at day 6 and 8 and recorded. Using ANOVA test, data are means 
± SD, and are representative of three independent experiments. *P<0.05, **P<0.01 
and ***P<0.001 compared to controls.  
  
(a) 
(b) 
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Figure 4.22 Bacterial loading in organs of IL-37aTg mice and WT mice after 
BRD509 infection 
 
IL-37aTg and WT mice were infected with salmonella strain BRD509 (1x10^10/mice) 
orally. liver, and lymph nodes were collected on day 6 and 8 and bacteria number 
in the organs determined by spot plates. Using ANOVA test, data are means ± SD, 
and are representative of three independent experiments. *P<0.05, **P<0.01 and 
***P<0.001 compared to controls.  
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Figure 4.23 Salmonella infected IL-37aTg mice have lower iNOs expression and 
NO production compared with WT mice 
 
IL-37aTg and WT mice were infected with salmonella strain BRD509 (1x10^10/mice) 
orally. Serum and spleens were collected from the infected mice. a) RNAs were 
extracted from total solenocytes for iNOs expression by qPCR; b) NO concentration 
in serum was detected by Griss kit. Using ANOVA test, data are means ± SD, and are 
representative of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001 
compared to controls.  
 
 
(a) 
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Figure 4.24 IL-37aTg mice develop impaired pro-inflammatory cytokine mRNA 
levels after salmonella infection 
 
IL-37aTg and WT mice were infected with Salmonella strain BRD509 (1x10^10/mice) 
orally. RNAs were extracted from total splenocyte lysate, the mRNA level of pro-
inflammatory cytokines (IL-1α, IL-6, IL-12 and IFN-γ) were measured by qPCR. Using 
ANOVA test, data are means ± SD, and are representative of three independent 
experiments. *P<0.05, **P<0.01 and ***P<0.001 compared to controls.   
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4.3 Discussion 
In summary, I demonstrated in this part of the work for the first time that: 
A) IL-37a is highly induced by TLR signals in human macrophages among the IL-37 
isoforms. B) both endogenous and exogenous IL-37a are bioactive and can suppress 
TLR-induced inflammatory gene expressions. C) monomer form of IL-37a is better 
than the dimer in immunosuppression. D) IL-37a is more effective than IL-37b in the 
suppression of TLR response in vitro. E) IL-37a signals via receptor IL-1R8. F) human 
macrophages are more susceptible than murine cells and this may be due to their 
difference in IL-37 expression. G) IL-37a suppresses bactericide mechanism and 
facilitates salmonella infection in human macrophages in vitro and in mice 
salmonellosis. These findings suggest that IL-37a is a new immunoregulatory cytokine 
that suppresses TLR-induced inflammatory response, but, on the other hand, may 
also promote bacterial infection if dysregulated. 
It is still unclear if IL-37 isoforms are equally or differently induced in a given 
immune context. To answer this question, we performed the experiment of time 
and dose-dependent induction of IL-37 isoform expression in TLR-stimulated human 
macrophages. The results demonstrated that IL-37 isoforms are differently regulated 
by different TLR signals and IL-37a is the most inducible one among the 5 isoforms 
in all tested TLR contexts. However, it is worthwhile to further investigate the 
expression pattern of IL-37a in other immune contexts, particularly in diseases. 
While the precise mechanism by which TLRs regulate IL-37 isoform expression is still 
largely unknown, it has been suggested that IL-37 gene exon 5 encodes an instability 
element which can be stabilised by inflammatory signals (Boraschi et al., 2011). 
Thus, TLR-inducing IL-37 expression may be, at least in part, via enhanced IL-37 
mRNA stability. However, it is unknown why IL-37 isoforms are differentially 
regulated and why IL-37a is dominantly induced. 
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Until now, it is still unknown whether IL-37a is bioactive. Using several approaches, 
including siRNA, recombinant protein and transgene, we demonstrated that IL-37a 
is bioactive and can suppress TLR-induced inflammatory response. In identifying IL-
37a transgenic mice, we used both ELISA and qPCR. Because ELISA can only measure 
secreted IL37 and doesn’t account for any IL37 in the nucleus. Although we detected 
the IL-37a level in transgenic mice serum by ELISA already, there is still necessary 
to check the mRNA expression by qPCR. We (me and others in the group) found that 
IL-37a is able to inhibit the function of all known TLRs located on cell surface or 
intracellular (this chapter and unpublished results). Thus, IL-37a is likely to be an 
important regulatory factor for TLR response. The regulatory effect of IL-37a that 
we found so far is exclusively immunosuppressive.  
Intriguingly, we found that rFLIL-37a is more suppressive than rFLIL-37b in TLR 
response. Given that IL-37a is the most induced among the 5 isoforms in all tested 
TLR contexts, also the knockdown total IL-37 and IL-37a had similar degree of 
enhancement of TLR response in macrophages, together, these results suggest that 
IL-37a may be a dominant isoform and responsible for most IL-37-mediated 
immunoregulatory effects, at least, TLR-induced inflammatory responses. However, 
it is essential to further study the induction and function of IL-37a in other immune 
contexts, particularly in diseases, for instance, autoimmunity, cancer and allergy.  
Using IL-1R8KO mice, we defined that IL-1R8 is an IL-37a receptor. This suggests that 
IL-1R8 is a receptor for both IL-37a and b. The IL-37 receptor complex consists of IL-
1R8 and IL-18a and both chains are required for IL-37 signalling (Nold-Petry et al., 
2015). IL-18Ra is involved in the initial interaction with IL-37 protein, that then 
subsequently recruits IL-1R8 for signalling. While we have not determined the 
association of IL-18Ra in IL-37a signalling, it is most likely that it will be involved in 
IL-37a signalling. We found that IL-18Ra is highly induced compared to IL-18R by IL-
37a in macrophage. The importance of IL-18Ra in IL-37a signalling will be 
investigated by siRNA knockdown or blocking antibody. 
It is still unknown why rFLIL-37a is superior to rFLIL-37b in activity. Since we found 
that mature IL-37a has comparable bioactivity with mature IL-37b (data not shown), 
it is possible that their difference in bioactivity may be attributed to their difference 
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in N-terminal sequence. Since both isoforms bind to the same receptor, the different 
N-terminal sequence may differently influence their receptor binding affinity and 
signalling. Testing their relative binding affinity with receptor may answer the 
question. Nevertheless, this further suggests that IL-37a is a major cytokine in all IL-
37 isoforms.  
We found that same as IL-37b, IL-37a monomer is also more effective in suppressive 
function than its dimer. While the reason is still less understood, it is possible that 
the dimer may interfere its interaction with IL-37 receptor and signalling. The 
monomer form IL-37a may be more useful in research and potential clinical 
application in the future. Interestingly, the high dose of IL-37 dimers not only fails 
to suppress TLR response but enhances the response. Again, the reason behind is 
unclear and deserves more investigations. 
TLR, in particular TLR2, 4 and 5 signals play a critical role in salmonella infection. 
After identifying the regulatory effect of IL-37a on TLR, including the salmonella 
related TLRs, TLR2, 4 and 5, we explored the potential importance of IL-37a in 
salmonella infection by developing several in vitro and in vivo experiments and 
found that IL-37a downregulates host protective immunity and bactericidal 
mechanism, and thereby promotes salmonella infection.  
Firstly, we found that salmonella infection primarily enhanced IL-37a expression in 
human macrophages. These consistent results shown that IL-37a is also highly 
induced among the IL-37 isoforms by TLRs, particularly TLR4 in macrophages. In 
order to understand the physiological and pathological meaning of the selective 
expression of IL-37 in human but not in mice in infection, we systemically compared 
the ability of murine with human macrophages in clearance of salmonella infection. 
Our results suggest that human macrophages are less effective in the clearance of 
salmonella bacteria compared to that in murine cells. To understand if IL-37 is 
responsible for the deficiency of salmonella infection in human, we further 
determined the role of IL-37a in salmonella infection in mice in vitro and in vivo 
using recombinant and transgenic IL-37a. These results clearly demonstrated the IL-
37a is able to promote salmonella infection in the early stage. 
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While the detailed mechanism underlying IL-37a promoting salmonella infection is 
still not yet fully understood, our preliminary results from salmonella infected 
macrophages or organs in vitro and in vivo suggest that IL-37a may do so by 
suppressing the key bactericidal mechanism-NO production in macrophages; we 
demonstrated that after salmonella infection, human macrophages which express 
IL37 produce lower levels of NO than murine cells that do not express IL-37. Since 
IL-37a also suppresses iNOs expression it is possible that the reduced NO production 
in infected macrophages was attributed from the reduced iNOs transcription.  
However, the IL-37a-reduced NO in salmonella infection is also accompanied by 
reduced inflammatory cytokine production. It is well known that iNOs can be induced 
by inflammatory cytokines, including IL-1, IL-6 and IFN-γ (Jin et al., 2016). Thus, 
the reduced iNOs/NO may also be the consequence of IL-37a inhibited inflammatory 
cytokine production in the salmonella infected macrophages. Further studies are 
needed to define the direct or indirect effect of IL-37a in iNOs/NO production and 
also the physiology or pathology of IL-37a in salmonella infection. 
Th1 cells play a protective role against salmonella infection (Pashine et al., 1999). 
Since this study was focused on the role of IL-37a in the regulation of innate immune 
response in early salmonella infection in macrophages the potential importance for 
IL-37a in the modulation of Th1 function in salmonella infection has not been 
explored. However, we found that IL-37a is able to suppress the Th1 cytokines 
production in macrophages in vitro and in splenocytes in vivo, thus, it may be 
expected that IL-37a may be also capable of inhibiting Th1 cell development and 
function in salmonella infection. 
Based on current knowledge and our findings, we would like to propose a possible 
role and mechanism of IL-37a in salmonella infection: During salmonella infection, 
the bacteria will be phagocyted, internalised and amplified in the phagosomes of 
macrophages. The salmonella related TLR agonists, LPS, BLP and flagellins will be 
reorganised by the TLRs on the macrophages and induce inflammatory cytokine and 
NO production to kill the intracellular bacteria. In the meantime, salmonella related 
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TLR agonist will also induce IL-37, in particularly IL-37a expression that has feedback 
effect to inhibit TLR-induced inflammatory cytokine and NO-mediated inflammation 
and bactericidal, thereby facilitating salmonella infection by inhibiting innate 
immune response.  
There are still some shortages which need to be developed in the future 
experiments: 
In this chapter, we illustrate that the existence of IL-37, especially IL-37a may be 
an explanation why murine and human macrophages act differently in salmonella 
infection and TLR stimulations. However, the differences between human and mice 
are not only in IL-37 expression. There are other factors which may affect their 
sensitivity in inflammation and infection disease:1) In humans, the type I IFN, IFN-α 
which secreted macrophages, acts on T cells to induce Th1 development. This 
process is dependent upon STAT4 activation. In mice, however, IFN-α fails to induce 
Th1 cells and does not activate STAT4 (Farrar et al., 2000). 2). The expression of 
iNOS in mouse macrophages has been clearly demonstrated and iNOS mRNA can be 
highly induced by LPS. However, these same inflammatory mediators have failed to 
show consistent effects on human macrophages. Instead, other mediators, such as 
IFN-a/b and various chemokines work more efficient in inducing iNOS in human 
macrophages (Bogdan, 2001). This phenomenon may also explain why human 
macrophage has lower iNOS expression in TLR stimulation condition. 
Moreover, in this experiment, we use murine macrophage cell line RAW 264.7 cell 
compare with human macrophage cell line THP-1 in TLR stimulation and salmonella 
infection in vitro. The Raw cell are SV40 transformed peritoneal macrophage from 
a male BALB/c mouse. They are more sensitive than primary macrophage in 
stimulation and bacteria infection. In this case, the pro-inflammatory cytokine 
expression level would be higher than normal condition. To address this, we used 
murine peritoneal macrophage to test the infection condition in vitro. However, we 
did not use human primary macrophage as a control here to compare the difference 
between human and mice in salmonella infection, which need to be done in the early 
future.  
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Furthermore, the experiment condition can be further optimized. In my experiment, 
I test the mice condition on day6 and day8 in WT and IL-37aTg mice after infection. 
However, whether the bacteria number in IL-37aTg mice will continually increase or 
not remains a question. In the recovery stage, what is the function of IL-37a and 
how IL-37 be regulated is still unknown. Therefore, the experiment condition can be 
optimized by extend the infection time, in order to check in which time point IL-37 
start their function and in the later stage of infection whether IL-37aTg mice have 
higher mortality than WT.  
Although the pathophysiological meaning of the selective expression of IL-37 in 
human but not mice in salmonella infection is still unclear, our result is in agreement 
with the report that mice have higher rates of production of reactive oxygen species 
and suffer higher rates of oxidative damage than do humans (Kalghatgi et al., 2013). 
Thus, IL-37a promoted salmonella infection may be accidently rather than 
deliberately. Furthermore, this finding may also provide explanations, at least in 
part, for why mice are more resistant to foodborne infections. 
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5. Transcriptomic analysis of LPS-induced genes 
modulated by transgenic IL-37 in murine cells 
 
 
5.1 Introduction 
In Chapter 4, I have demonstrated that IL-37a is bioactive and able to suppress 
inflammatory cytokine expression induced by all tested TLR ligands in splenocytes, 
monocytes and macrophages. In addition, IL-37a and IL-37b display similarity and 
difference in biology and function. However, the molecular mechanism underlying 
their common and different in bioactivity is still not yet understood. In this chapter, 
using LPS/TLR4-induced inflammatory response in splenocyte as a model, I 
performed transcriptomic experiments to reveal the common and unique gene and 
signalling pathways regulated by IL-37a and/or IL-37b in LPS response. This part of 
work was also aimed to provide some molecular explanations for the regulatory role 
of IL-37a and b in the LPS/TLR4 signalling-mediated effect on macrophages and in 
salmonella infection in Chapter 4. 
TLR4 signalling in innate immune cells, including macrophages, has been well 
studied and is described in Chapter 1. Briefly, TLR4 signals via a MyD88-dependent 
and TRIF-dependent pathway. The former is triggered by an agonist binds to the cell 
surface TLR4 complex, and the recruitment of MyD88 and adaptor TIRAP (MAL) and 
the activation of signalling cascades nuclear factor-kB (NF-kB) and mitogen-
activated protein (MAP) kinases, resulting in inflammatory gene expression. The 
latter is elicited when the TLR4 is internalised into cell plasma and the recruitment 
of adaptor TRIF and TRAM, leading to the activation of interferon (IFN) response 
factors (IRFs) and subsequent type I IFN expression (Medzhitov, 2001; Wang et al., 
2001). 
While the IL-37a signalling pathway is unknown, the IL-37b signal in LPS response 
has been studied (Nold-Petry et al., 2015 and Chapter 1). In brief, the splenocyte 
RNA was isolated from wild-type and IL-37tg mice 3 hours after intraperitoneal 
injection of LPS, and the immune gene profiles were analysed by RNA-sequencing 
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along with the Innate Immune Database (Innate DB). The results indicate that 1) IL-
37b not only suppresses but also enhanced gene expressions compared to the WT 
control, with the suppression effect dominant. 2) IL-37b primarily inhibited genes 
that are largely associated with inflammatory response, including inflammatory 
cytokines, chemokines, metabolism and signalling molecules. 3) IL-37b induced some 
genes with immunoregulatory property. (Nold-Petry et al., 2015). This work has 
established IL-37b signalling and function in gene regulation. While how IL-37a signal 
regulates inflammatory genes is still largely unknown, the research in IL-37b 
signalling is helpful for the understanding of IL-37a signalling and the difference 
between the two isoforms. Based on all the results from our own and from other lab, 
I propose that: the functional similarity and difference between IL-37a and IL-37b 
be attributed to their similarity and difference in protein sequence and signalling 
transduction. Using their sheared C-terminal protein sequence containing IL-1-like 
domain for receptor binding and signalling, IL-37a and IL-37b may regulate common 
signalling pathways and genes. However, given their difference in N-terminal 
sequence, they may regulate different pathways and genes. The overall aim in this 
chapter was to test this hypothesis using LPS/TLR4 activated murine splenocytes 
from IL-37a and b transgenic mice as a cellular model to understand how IL-37a and 
IL-37b regulate TLR signalling transduction and what are the common and difference 
between the two IL-37 isoforms in gene regulation. 
The aims of the project were to: 
1. Identify the global different expressed genes regulated by IL-37a and IL-37b with 
RNA-sequencing and bioinformatics assay. 
2. Assess the immune genes/signalling pathways which are commonly regulated by 
both IL-37a and IL-37b. 
3. Identify the immune gene/pathways specifically regulated by IL-37a or IL-37b. 
4. Explore the possible molecular mechanism by which IL-37a and IL-37b regulate 
LPS/TLR4-mediated inflammatory response.  
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5.2 Results 
5.2.1 Identifying the early LPS-induced genes differentially regulated by IL-37a 
and IL-37b transgenic cells 
To explore the common and specific regulatory effect of IL-37a and b on TLR-
stimulated gene expression, I systematically identified and compared genes in 
splenocytes of IL-37a and b transgenic and WT mice using transcriptome analysis. To 
be more specific, splenocytes from IL-37a and b transgenic and WT control mice 
were seeded in 24 wells cell culture plate in the density of 1x10^6/ml. These cells 
were stimulated with 500 ng/ml LPS for 5 hours. Total RNA from each sample was 
isolated, cDNA libraries were constructed, and the next-generation sequencing 
performed using RNA-sequencing. The results were analysed by bioinformatics which 
mentioned in Chapter 2. 
To understand the differentially expressed genes regulated by IL-37 a and b, the 
global differentially expressed genes (DEG) between LPS- stimulated splenocytes 
from WT and IL-37a and b transgenic mice were initially identified. Raw data from 
RNA-seq were analysed for each group (WT, IL-37a and IL-37b transgenic mice, n=3). 
The average RPKM (Reads Per Kilobase Million) per group was estimated. All results 
from IL-37a and IL-37b groups were compared with the WT control. Upregulated 
genes and pathways mean compare with control group, the same gene expression 
enhanced by the existence of IL-37a or b and the pathway they belong to. 
Downregulated genes and pathways mean compare with control group, the same 
gene expression decreased by the existence of IL-37a or b and their pathways. The 
cut off p value (< 0.05) and fold-change (≥1.5) were used to detect the differential 
expressed genes between IL-37a or b transgenic and WT cells. 
Firstly, the global DEG between LPS-stimulated cells between IL-37aTg and WT mice 
were identified, including the upregulated and downregulated genes using bio Venn 
programme and visualised by the area-proportional and overlapping Euler (Figure 
5.1). As shown in the Euler diagrams, compared with WT control (2147 genes), 1511 
from the total analysed genes were significantly downregulated by IL-37a (Figure 
5.1a). 1068 genes also upregulated by IL-37a compared with the WT control (Figure 
5.1b).  
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With the same analysis strategy, the global DEG between IL-37b and the WT control 
were also identified (Figure 5.2). In comparison with the WT control, there were 
1849 genes downregulated by IL-37b (Figure 5.2a). Furthermore, 1321 genes were 
identified which were upregulated by IL-37b (Figure 5.2b).  
Next, the commonly and specifically regulated genes by IL-37a and b were further 
identified by comparing the DEG of IL-37a and b gene pools. As shown in Figure 5.3, 
the downregulated DEG between IL-37a and b groups were compared and illustrated 
by Venn diagram. Among all these genes, 738 DEG were the common genes 
downregulated by both IL-37a and b (about 28% of common/total genes); 773 genes 
were detected to be specifically downregulated by IL-37a and 1111 genes were 
specifically downregulated by IL-37b (Figure 5.3a).  
Furthermore, by comparing the upregulated DEG of IL-37a and IL-37b groups, 336 
genes were found to be commonly upregulated by these two IL-37 isoforms (the rate 
of common gene is 16%, (common/total genes); 732 genes were detected to be 
specifically downregulated by IL-37a and 985 genes were specifically downregulate 
by IL-37b (Figure 5.3b).  
Thus, IL-37a and b not only suppressed but also enhanced the expression of some 
LPS-induced genes. Our result also suggests that IL-37b may regulate more genes 
compared with IL-37a in this context, 1.17 folds more downregulated genes and 1.23 
folds more upregulated genes.  
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Figure 5.1. Identification of the differentially expressed genes regulated by IL-
37a in LPS stimulated transgenic mice splenocytes compared with WT 
 
Splenocytes from IL-37aTg mice were compared with WT after 500ng/ml LPS 
stimulation for 5 hours; total RNAs from each group were isolated for microarray. 
The differential expressed genes identified using bio Venn programme and visualised 
by the area-proportional and overlapping (relationship) Euler. a) shows differentially 
expressed genes (DEGs) that are specifically downregulated by IL-37a (blue area) 
compared with WT control; the rest of yellow area are genes not affected by IL-37a. 
b) The blue area is DEGs that are specifically upregulated by IL-37a; the overlap area 
are the common genes both up regulated in IL-37a and WT; while the rest of yellow 
area are genes not influenced by IL-37a. 
  
(a) 
(b) 
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Figure 5.2. Identification of the differentially expressed genes regulated by IL-
37b in LPS stimulated transgenic mice splenocytes compared with WT 
 
Splenocytes from IL-37bTg mice were compared with WT after 500ng/ml LPS 
stimulation for 5 hours; total RNAs from each group were isolated for microarray. 
The differential expressed genes identified using bio Venn programme and visualised 
by the area-proportional and overlapping (relationship) Euler. a). Differentially 
expressed genes (DEGs) that are specifically downregulated by IL-37b (red area) 
compared with WT control; the rest of yellow area are genes not affected by IL-37b. 
b). The red area is DEGs that are specifically upregulated by IL-37b; the overlap area 
are the common genes both up regulate in IL-37b and WT; while the rest of yellow 
area are genes not influenced by IL-37b. 
  
(a) (b) 
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Figure 5.3 Identification of common and specific genes differentially regulated 
by IL-37a and b in LPS stimulated transgenic mice splenocytes 
Splenocytes from IL-37a and IL-37bTg mice were compared with each other after 
500ng/ml LPS stimulation for 5 hours; total RNAs from each group were isolated for 
microarray. The differential expressed genes identified using bio Venn programme 
and visualised by the area-proportional and overlapping (relationship) Euler. a) 
represents the genes that are downregulated by IL-37a and b; the red area shows 
genes downregulated by IL-37a only; the overlap area shows the genes that are 
downregulated by both IL-37a and b; while the blue area represents the genes that 
are downregulated by IL-37b only. b) shows the set of genes that are upregulated by 
IL-37a and b; specific genes upregulated by IL-37a shown in red area; the overlap 
area are common genes, which are upregulated by both IL-37a and b; the blue area 
are genes that are upregulated specifically by IL-37b. 
(a) 
(b) 
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5.2.2 Revealing the common signalling pathways/genes regulated by both IL-
37a and IL-37b 
To explore the molecular mechanism by which IL-37a and b regulate LPS/TLR4 
response in TLR stimulated immune cells in vitro and salmonella infection in vivo, I 
further identified the nature of the common and specific genes regulated by IL-37a 
and b and related signalling pathways. The Innate Immune Database (Innate DB) was 
used as a general immune gene research database in our research, which was 
generated from several major databases and focused on, but not limited to the 
innate immunity by curating with experimentally-validated human and mouse 
interactions from the biomedical literature (Lynn et al., 2010). It provides a 
manually curated knowledgebase of the genes, proteins, and particularly, the 
interactions and signalling pathways involved in mammalian immune response, 
including TLR-mediated response (Lynn et al., 2010; Breuer et al., 2012). Based on 
our research direction and the research results in Chapter 4, the TLR signalling and 
Salmonella infection relate pathways are particularly focused on and studied in more 
details.  
Firstly, gene ontology of these common genes, 738 downregulated and 336 
upregulated (Figure 5.3) by both IL-37a and IL-37b were identified using Innate DB 
and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. From these 
analyses, 40 signalling pathways were significantly downregulated by both IL-37a 
and b (data not shown), 7 of 40 pathways which related to our research aims were 
selected and shown in Figure 5.4a, including T cell receptor signalling and TLR 
signalling pathways. These key pathways and their relate genes are listed in Table 
5.1. Within these 7 pathways, TLR signalling pathway was with false discovery rate 
of 0.0114 and 9 genes were found to be involved in this pathway (Table 5.1).  
In line with my results in Chapter 4, showing IL-37a and IL-37b inhibited TLR-induced 
inflammatory cytokine production in innate and adaptive immune cells, here both 
the IL-37 cytokines also suppressed several signalling components in the TLR 
pathway (Table 5.1 and Figure 5.4a). These included TLR3 that recognise viral 
double-stranded RNA via MyD88-independent pathway and, interestingly, irf5 
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involved in the MyD88-independent signalling for type I interferon production was 
also inhibited; the upstream signalling molecules TAB1 and RelA that enhance the 
IκB kinase (IKK) complex activity and nuclear translocation of the transcription 
factor NF-κB (Beutler et al., 2006); Mapk11 and 12 that encode p38α mitogen-
activated protein kinases (MAPK), NF-kB elements and Pik3cd (Table 5.1a); the Nos2 
encodes nitric oxide synthase 2 which induces nitric oxide (NO) production. NO 
mediates bactericidal actions and is also involved in inflammation, enhances the 
synthesis of proinflammatory mediators such as IL-6 and IL-8 (Vlahopoulos et al., 
1999). This is consistent with my results in Chapter 4 showing that IL-37 suppresses 
Nos2 expression and NO production in vitro and in vivo. Furthermore, some 
molecules in T cell receptor (TCR) signalling pathway, including the cd3d and cd3g 
in TCR complex and TCR co-receptor genes cd4 and cd8b also inhibited. This suggests 
that both isoforms have profound regulatory effect on T cell-mediated response. 
IL-37a and b suppressed genes were further analysed in triplicate and compared with 
WT control by heatmap (Figure 5.5a), to further confirm the gene downregulation 
and the repetitive of the assay.  
The upregulated genes by both IL-37a and b were associated with 4 pathways (Figure 
5.4b). These key pathways and their relate genes are listed in Table 5.2. 9 IL-37a 
and b inhibited genes and 6 enhanced genes were further analysed and compared by 
heatmap (Figure 5.5b).  
Both isoforms also enhanced the expression of some signalling molecules expression 
in NF-kappa B pathway in T and B cell activation, including Lck and Zap70 involved 
in early T/B cell activation (Arulraj and Barik, 2018; Lo et al., 2018) and the T cell 
growth cytokine/receptors il7 and il2rb, while the impact is still unknown. Some co-
signalling molecules and molecules involved in apoptosis were also enhanced by both 
IL-37 isoforms, including icam1, fit3 and Bcl22b, Bcl2a, Gadd45b and Wt1, suggesting 
that both isoforms may be also associated with the regulation of co-stimulation and 
cell death. However, the biological meaning is still unclear. 
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Together with the result from Chapter 4, these results further reveal that IL-37a and 
b share similar functional ability in suppression of several signalling pathways and 
components induced by LPS in splenocytes.  
 
 
Figure 5.4 The signalling pathways regulated by both IL-37a and b in LPS 
stimulated transgenic mice splenocytes  
The signalling pathways of the common genes regulated by both IL-37a and IL-37b 
in LPS-stimulated transgenic mice identified by the enrichment analysis on KEGG. 
The x-axis is the name of KEGG pathways; the left y-axis is associated p-value 
presented by (-log10^ p value) and the right y-axis is the count percentage of 
regulated genes in this analysis of the whole gene in each pathway; orange line is 
the count percentage value for each pathway. The cut-off value in this experiment 
is p value <0.05. a). Represents common pathways downregulated by IL-37a and b; 
b). The common pathways upregulated by IL-37a and b. 
(a) 
Down regulation 
(b) 
Up regulation 
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Table 5.1 Common pathways and related genes downregulated by both IL-37a 
and b 
The key pathways selected from the Pathways analysis presented in Figure 5.4a; 
these pathways are presented here in detail. Background gene count is the total 
number of genes in this pathway; the name and number of the genes that are 
downregulated by IL-37a and b and involved pathway with false discovery rate (p 
value).  
  
Term description
Observed 
gene count
Background 
gene count
False 
discovery 
rate
Matching proteins in your network (labels)
T cell receptor signaling pathway 10 100 8.42E-05
Cd3d,Cd3g,Cd4,Cd8b1,Csf2,Map2k7,Mapk11,
Mapk12,Nfatc2,Rela
Cell cycle 15 122 0.00032
Bub1b,Ccna2,Ccnb1,Cdc25c,Cdc45,Cdk1,Cdk
n2d,Chek2,Dbf4,Fzr1,Mcm6,Mcm7,Rb1,Tfdp
2,Ttk
cGMP-PKG signaling pathway 16 164 0.0014
Adcy6,Adcy9,Adra2a,Atp2a3,Gna12,Gucy1a3,
Gucy1b3,Insr,Mrvi1,Myl9,Mylk,Pde3a,Pde5a
,Ppif,Prkg1,Trpc6
HIF-1 signaling pathway 11 102 0.0072
Angpt1,Egln3,Eif4ebp1,Eno1,Insr,Mknk1,Mk
nk2,Nos2,Pfkl,Pik3cb,Prkca
Regulation of lipolysis in adipocytes 7 55 0.0298 Adcy6,Adcy9,Insr,Pik3cb,Prkg1,Ptger3,Ptgs1
Toll-like receptor signaling pathway 9 98 0.0114
Cd80,Il12b,Irf5,Map2k7,Mapk11,Mapk12,Rel
a,Tab1,Tlr3
TNF signaling pathway 9 108 0.0188
Ccl2,Creb3l4,Csf2,Icam1,Map2k7,Mapk11,Ma
pk12,Rela,Tab1
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Table 5.2. Common pathways and related genes upregulated by both IL-37a and 
b 
The key pathways selected from the Pathways analysis presented in Figure 5.4b, 
these pathways are presented here in detail. Background gene count is the total 
number of genes in this pathway; the name and number of the genes that are 
downregulated by IL-37a and b and involved pathway with false discovery rate (p 
value).  
  
Term description
Observed 
gene count
Background 
gene count
False 
discovery 
rate
Matching proteins in your network (labels)
Hematopoietic cell lineage 9 90 0.00014
Flt3,H2-Aa,H2-Ab1,H2-DMb1,H2-DMb2,H2-
Oa,Il7
Primary immunodeficiency 4 34 0.00066 Cd79a,Lck,Tap1,Zap70
NF-kappa B signaling pathway 6 93 0.0084 Bcl2a1c,Card11,Gadd45b,Lck,Ltb, Zap70
Transcriptional misregulation in cancer 11 167 0.0138
Bcl11b,Bcl2a1c,Cdkn1a,Flt3,Gadd45b,Il2rb,It
gb7,Ngfr,Uty,Wt1
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Figure 5.5 Heat maps presentation of the common genes regulated by IL-37a 
and b compared to WT control 
 
The representative common regulated genes by IL-37a and b selected from tables 
5.1 and 5.2 displayed in heat maps. The genes were analysed by microarray assay in 
triplicate. a) The representative genes that are downregulated by IL-37a and b; b) 
the representative genes that are upregulated by IL-37a and b compared with WT 
controls.  
  
(a) 
(b) 
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5.2.3 Identifying the signalling pathways/genes specifically regulated by IL-37a  
The IL-37a specifically regulated genes identified in Figure 5.3 were further analysed 
for their association with signalling pathways as above. While IL-37a specifically 
inhibited 773 but enhanced 732 genes compared with IL-37b (Figures 5.3a and b), it 
downregulates more signalling pathways than it enhanced (Figures 5.6a and b). As 
shown in Figure 5.6a, IL-37a significantly downregulated genes in 5 signalling 
pathways and upregulated genes in 4 pathways. The downregulated pathways closely 
related to this study included TLR signalling, MAPK, IL-17 signalling pathways, 
salmonella infection and chemokine (Figure 5.6a and Table 5.3).  
The results suggest that IL-37a may specifically suppress TLR response and signalling 
in several aspects: downregulated TLR4 and TLR8 expressions in MyD88-dependent 
TLR pathway together with IL-37a can also inhibit TLR3 expression (Figure 5.4a), 
these suggest that IL-37a can suppress both MyD88-dependent and independent TLR 
pathways; IL-37a also inhibited LPS-response by downregulate the expression of LPS-
binding protein (LBP) which binds to the lipid A moiety of LPS, serves as an affinity 
enhancer for CD14, facilitating its association with LPS and signalling via TLR4 (Weiss 
and Barker, 2018); it also suppressed the expression of downstream TLR signalling 
elements Tab1 and 3 Map kinases, Mapk3, 13 and 14; IL-37a also specifically inhibited 
IL-17 signalling pathway, mainly by suppressing the Map kinases and the expression 
of pro-inflammatory cytokines/chemokines and receptors; S100a8 and S100a9 
Binding to TLR4 and AGER activates the MAP-kinase and NF-kappa-B signalling 
pathways resulting in the amplification of the pro-inflammatory cascade; Igf1r- 
Receptor tyrosine kinase for the actions of insulin-like growth factor 1 (IGF1). The 
activated IGF1R is involved in cell growth and survival control (Elmadan et al., 2019); 
Il12a (IL-12 a chain) is involved in Th1 polarisation and IFN-γ induction. 4 chemokine 
receptors Ccr1, 2, 3 and Cxcr2 are associated with the migration of a wide range of 
immune cells (Hölscher, 2004). IL-37a also affected drug metabolism pathway, 
however, its contribution to IL-37a-mediated regulatory effect in immunoregulation 
is currently unknown. 
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The genes/pathways specifically enhanced by IL-37a were also identified (Figure 
5.6b, Table 5.4 and Figure 5.7 b). Two of the upregulated pathways by IL-37a were 
the cortisol synthesis and secretion and intestinal immune network for IgA 
production (Figure 5.6b and Table 5.4). IL-37a markedly increased expression of 
several genes in the two pathways, however, the biological function of the genes 
and pathways in IL-37a-mediated effect is currently unknown. 
IL-37a specifically up and downregulated genes were further confirmed in triplicate 
and compared with WT control in heatmap (Figure 5.5a and b). 
  
214 
 
 
 
 
Figure 5.6 The signalling pathways selectively regulated by IL-37a in LPS 
stimulated transgenic mice splenocytes  
The signalling pathways of the common genes regulated by IL-37a in LPS-stimulated 
transgenic splenocytes identified by the enrichment analysis on KEGG. The x-axis is 
the name of KEGG pathways; the left y-axis is associated p-value presented by (-
log10^ p value) and the right y-axis is the count percentage of regulated genes in this 
analysis of the whole gene in each pathway; orange line is the count percentage 
value for each pathway. The cut-off value in this experiment is p-value <0.05. a) 
Represents pathways downregulated by IL-37a. b) are the pathways upregulated by 
IL-37a. 
(a) 
(b) 
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Table 5.3 KEGG pathways and related genes down regulated by IL-37a  
The key pathways selected from the Pathways analysis presented in Figure 5.6a 
these pathways are presented here in detail. Background gene count is the total 
number of genes in this pathway; the name and number of the genes that are 
downregulated by IL-37a and involved pathway with false discovery rate (p value).  
 
Table 5.4 KEGG pathways and related genes up regulated by IL-37a  
The key pathways selected from the Pathways analysis presented in Figure 5.6b; 
these pathways are presented here in detail. Background gene count is the total 
number of genes in this pathway; the name and number of the genes that are 
downregulated by IL-37a and involved pathway with false discovery rate (p value).  
Term description
Observed 
gene count
Background 
gene count
False 
discovery 
rate
Matching proteins in your network (labels)
Chemokine signaling pathway 16 179 0.0052
Adcy5,Arrb1,Braf,Ccl9,Ccr1,Ccr2,Ccr3,Cxcl3,C
xcr2,Gnb5,Mapk3,Plcb1,Plcb2,Prkacb,Shc3,Ti
am1
Salmonella infection 9 78 0.0125
Cxcl3,Dync1li2,Flna,Lbp,Mapk13,Mapk14,Ma
pk3,Tlr4,Wasf2
IL-17 signaling pathway 9 91 0.019
Cxcl3,Lcn2,Mapk13,Mapk14,Mapk3,Mmp9,S1
00a8,S100a9,Srsf1
MAPK signaling pathway 18 292 0.0259
Arrb1,Braf,Cacnb2,Dusp6,Flna,Hgf,Igf1r,Map
k13,Mapk14,Mapk3,Pdgfd,Prkacb,Ptpn7,Ras
grp4,Rps6ka1,Rps6ka5,Tab1,Zak
Toll-like receptor signaling pathway 9 98 0.0259
Il12a,Lbp,Mapk13,Mapk14,Mapk3,Spp1,Tab1
,Tlr4,Tlr8
Term description
Observed 
gene count
Background 
gene count
False 
discovery 
rate
Matching proteins in your network (labels)
Transcriptional misregulation in cancer 10 167 0.0035
Bcl2a1a,Bcl2a1b,Bcl2a1d,Cd86,Cdk9,Igfbp3,
Myc,Plat,Rel,Tspan7
Complement and coagulation cascades 6 88 0.0276 C1ra,C1s1,Plat,Procr,Serping1,Thbd
Cortisol synthesis and secretion 5 66 0.0415 Cacna1c,Ldlr,Nr5a1,Prkacb,Star
Intestinal immune network for IgA 
production
4 40 0.0429 Ccr10,Cd86,Cxcl12,Tnfrsf17
216 
 
 
 
 
Figure 5.7 Heat maps presentation of the genes regulated by IL-37a compared 
to WT control 
 
The representative common regulated genes by IL-37a selected from tables 5.3 and 
5.4 displayed in heat maps. The genes were analysed by microarray assay in 
triplicates. a) the representative genes (table 5.3) that are downregulated by IL-
37a; b) the representative genes (table 5.4) that are upregulated by IL-37a compared 
with WT controls. 
(b) 
(a) 
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5.2.4 Identifying the signalling pathways/genes specifically regulated by IL-37b  
Using the same strategies, the IL-37b specifically regulated genes identified by RNA-
seq analysis in Figure 5.3 were further analysed for their association with signalling 
pathways as above. As shown in Figure 5.8, IL-37b significantly downregulated genes 
in 4 KEGG pathways and enhanced in 3 pathways. The most significantly inhibited 
pathway was metabolic pathway (Figure 5.8a and Table 5.5).  
The metabolism pathways include anabolism and catabolism pathways. Anabolism 
uses energy to construct the components of cells, for example proteins, while 
catabolism involves the breakdown of organic matter and stores energy as ATP. Host 
metabolism plays a critical role in the homeostasis and disease (Abbas et al., 2011). 
The metabolic pathways can be influenced and regulated by many biological, 
physiological or chemical factors, including the immune mediators, temperature and 
the chemical environment, such as the pH level. Dysregulation of metabolism will 
lead to inflammation and disease (Zhao et al., 2019). 
As shown in Figures 5.8a, 5.9a and Table 5.5b, 85 genes in the metabolic pathways 
were significantly downregulated by IL-37b. We further analysed the 85 genes in the 
pathways and found that 83 of the genes are involved in the metabolic process and 
77 involved in the cellular metabolic process (Figure 5.8c and Table 5.5b). This is 
different from IL-37a but is in consistent with the report that IL-37b may regulate 
cellular function by affecting cell metabolic pathways (Nold-Petry et al., 2015). 
The forkhead box O (FOXO) signalling pathway was the second key pathway 
regulated by IL-37b. FOXO family controls the expression of genes involved in cell 
apoptosis, cell-cycle, glucose metabolism and oxidative stress resistance. FOXOs can 
promote inflammatory response (Luo et al., 2019). FOXO function can be activated 
by JNK and AMPK and inhibited by Akt/PKB), downstream of phosphatidylinositol 3-
kinase (PI3K) (Léger et al., 2006). However, the significance of regulation of FOXO 
pathway in IL-37b function is still less understood. 
The most upregulated pathway was Fluid shear stress and atherosclerosis pathway 
(Fig, 5.8b). Shear stress caused by abnormal blood flow at the endothelial surface 
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of the blood vessel wall may trigger inflammatory response, the activation of pro-
atherogenic pathways, NF-kB, AP1 and inflammatory cytokine/mediators and results 
in the development of atherosclerosis (Pan, 2017). This stress response is normally 
controlled by the host anti-atherogenic mechanisms, including upregulating the 
expressions of key anti-atherosclerosis factors, Kruppel-like factor 2 (KLF2), nuclear 
factor erythroid 2-like 2 (Nrf2) and eNOS in endothelial cell, that protective against 
atherosclerosis (Ota et al., 2010). Consistent with the reports that IL-37b plays a 
protective role in the pathogenesis of atherosclerosis by anti-inflammation (Wang et 
al., 2019), we also find that IL-37b could suppress AP1, NF-kB pathways and 
inflammatory cytokine production. Here IL-37b was able to enhance the expression 
of key anti-atherosclerosis factor KLF2. Thus, the protective effect of IL-37b in 
atherosclerosis could be via both the enhance anti-inflammatory and reduced pro-
atherosclerosis mechanisms. However, the functions of other molecules enhanced 
by IL-37b in the pathway are unknown and need to be evaluated. 
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 Figure 5.8 The signalling pathways selectively regulated by IL-37b in LPS 
stimulated transgenic mice splenocytes  
Up regulation 
(c) 
(b) 
(a) 
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The signalling pathways of the common genes regulated by IL-37b in LPS-stimulated 
transgenic mice splenocytes identified by the enrichment analysis on KEGG. The x-
axis is the name of KEGG pathways; the left y-axis is associated p-value presented 
by (-log10^ p value) and the right y-axis is the count percentage of regulated genes in 
this analysis of the whole gene in each pathway; orange line is the count percentage 
value for each pathway. The cut-off value in this experiment is p-value <0.05.  
a) represents pathways downregulated by IL-37b. 
b) the detailed metabolic pathways downregulated by IL-37b 
c) the pathways upregulated by IL-37b. 
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Table 5.5a KEGG pathways and related genes down regulated by IL-37b  
The key pathways selected from the Pathways analysis presented in Figure 5.8a; 
these pathways are presented here in detail. Background gene count is the total 
number of genes in this pathway; the name and number of the genes that are 
downregulated by IL-37b and involved pathway with false discovery rate (p value).  
  
Term description
Observed 
gene count
Background 
gene count
False 
discovery 
rate
Matching proteins in your network (labels)
Metabolic pathways 85 1296 0.003
Acaa2,Acer2,Acmsd,Acox1,Acss1,Agpat3,Ak1
,Alad,Aldh1a1,Aldh1a7,Aldh9a1,Atp5g1,Atp
5g2,B3gat3,Blvrb,Btd,Cox7b,Cox8a,Dnmt3a,
Dpm3,Extl3,Fahd1,Galk1,Galnt10,Gch1,Gclc,
Gcnt1,Gm21987,Gpaa1,Hexa,Hk1,Hmgcl,Hmg
cr,Hyal1,Hyal3,Idh3g,Itpkb,Lpin1,Mboat2,Mp
i,Mpst,Mri1,Mthfr,Mtmr3,Nat2,Ndst3,Ndufa
2,Ndufa6,Ndufb11,Ndufs7,Nt5c3,P4ha1,Pcyt
1a,Pcyt1b,Pfkm,Pgp,Pi4k2b,Pigp,Pigq,Pigyl,
Pla2g12a,Pla2g16,Plcb3,Plcg2,Pmm1,Pold1,P
olr2c,Polr2d,Polr2e,Ppox,Prim2,Ptgs2,Pycr2,
Rfk,Rrm2,Shmt2,Smpd1,St3gal1,St3gal3,Suo
x,Tusc3,Uqcr11,Uqcrq,Urod,Uros
FoxO signaling pathway 16 132 0.0143
Ccnb2,Cdkn1b,Fasl,Foxo4,Gabarapl1,Gabara
pl2,Gadd45a,Irs2,Mapk12,Nlk,Plk1,Prkab1,Pr
kab2,Prkag1,Tgfb1,Tnfsf10
Cell cycle 15 122 0.0143
Anapc11,Ccnb2,Ccne1,Ccne2,Cdc25b,Cdc6,C
dc7,Cdkn1b,Cdkn2c,Gadd45a,Plk1,Prkdc,Pttg
1,Tgfb1,Ywhah
Measles 16 132 0.0143
Ccne1,Ccne2,Cd209b,Cdkn1b,Eif2ak1,Fasl,G
nb2l1,Hspa1a,Hspa1b,Il1b,Irf7,Mavs,Oas1a,
Oas3,Prkcq,Tnfsf10
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Table 5.5b metabolic pathways downregulated by IL-37b  
The key metabolic pathways selected from the pathway analysis presented in Figure 
5.8b; these pathways are presented here in detail. Background gene count is the 
total number of genes in this pathway; the name and number of the genes that are 
downregulated by IL-37b and involved pathway with false discovery rate (p value).  
Term description
Observed 
gene 
count
Background 
gene count
False 
discovery 
rate
Matching proteins in your network (labels)
Small molecule metabolic process 47 1489 2.55E-29
Acaa2,Acer2,Acmsd,Acox1,Acss1,Agpat3,Ak1,Aldh
1a1,Aldh1a7,Atp5g1,Atp5g2,B3gat3,Btd,Cox8a,Galk
1,Gch1,Gclc,Hk1,Hmgcl,Hmgcr,Hyal1,Hyal3,Idh3g,L
pin1,Mpi,Mpst,Mri1,Mthfr,Ndst3,Nt5c3,P4ha1,Pfk
m,Pgp,Pla2g16,Plcb3,Plcg2,Pmm1,Ptgs2,Pycr2,Rfk,
Rrm2,Shmt2,St3gal1,Suox,Uqcrq,Urod,Uros
Cellular metabolic process 77 7348 1.84E-25
Acaa2,Acer2,Acmsd,Acox1,Acss1,Agpat3,Ak1,Alad,
Aldh1a1,Aldh1a7,Aldh9a1,Atp5g1,Atp5g2,B3gat3,B
lvrb,Btd,Cox7b,Cox8a,Dnmt3a,Dpm3,Extl3,Galk1,G
alnt10,Gch1,Gclc,Gcnt1,Gpaa1,Hexa,Hk1,Hmgcl,Hm
gcr,Hyal1,Hyal3,Idh3g,Lpin1,Mboat2,Mpi,Mpst,Mri
1,Mthfr,Mtmr3,Ndst3,Nt5c3,P4ha1,Pcyt1a,Pcyt1b,P
fkm,Pgp,Pi4k2b,Pigp,Pigq,Pigyl,Pla2g12a,Pla2g16,
Plcb3,Plcg2,Pmm1,Pold1,Polr2c,Polr2d,Polr2e,Ppo
x,Prim2,Ptgs2,Pycr2,Rfk,Rrm2,Shmt2,Smpd1,St3gal
1,St3gal3,Suox,Tusc3,Uqcr11,Uqcrq,Urod,Uros
Carbohydrate derivative metabolic process 33 882 1.17E-21
Acaa2,Acss1,Ak1,Atp5g1,Atp5g2,B3gat3,Cox8a,Dp
m3,Extl3,Galk1,Galnt10,Gcnt1,Gpaa1,Hexa,Hk1,Hm
gcl,Hmgcr,Hyal1,Hyal3,Mpi,Ndst3,Nt5c3,Pfkm,Pigp
,Pigq,Pigyl,Pmm1,Rfk,Rrm2,St3gal1,St3gal3,Tusc3,
Uqcrq
Lipid metabolic process 27 961 1.74E-14
Acaa2,Acer2,Acox1,Acss1,Agpat3,Aldh1a1,Dpm3,G
paa1,Hexa,Hmgcl,Hmgcr,Lpin1,Mboat2,Mtmr3,Pcyt
1a,Pcyt1b,Pgp,Pi4k2b,Pigp,Pigq,Pigyl,Pla2g12a,Pla
2g16,Plcb3,Plcg2,Ptgs2,Smpd1
Phospholipid metabolic process 17 263 3.60E-14
Agpat3,Dpm3,Gpaa1,Mboat2,Mtmr3,Pcyt1a,Pcyt1b
,Pgp,Pi4k2b,Pigp,Pigq,Pigyl,Pla2g12a,Pla2g16,Plcb
3,Plcg2,Smpd1
Primary metabolic process 64 7426 3.90E-13
Acaa2,Acer2,Acox1,Acss1,Agpat3,Ak1,Aldh1a1,Atp
5g1,Atp5g2,B3gat3,Cox8a,Dnmt3a,Dpm3,Extl3,Galk
1,Galnt10,Gclc,Gcnt1,Gpaa1,Hexa,Hk1,Hmgcl,Hmgc
r,Hyal1,Hyal3,Idh3g,Lpin1,Mboat2,Mpi,Mpst,Mri1,
Mthfr,Mtmr3,Ndst3,Nt5c3,P4ha1,Pcyt1a,Pcyt1b,Pf
km,Pgp,Pi4k2b,Pigp,Pigq,Pigyl,Pla2g12a,Pla2g16,Pl
cb3,Plcg2,Pmm1,Pold1,Polr2c,Polr2d,Polr2e,Prim2
,Ptgs2,Pycr2,Rfk,Rrm2,Shmt2,Smpd1,St3gal1,St3gal
3,Tusc3,Uqcrq
Nucleotide metabolic process 18 488 3.60E-11
Acaa2,Acss1,Agpat3,Ak1,Atp5g1,Atp5g2,Cox8a,Gal
k1,Hk1,Hmgcl,Hmgcr,Idh3g,Mpi,Nt5c3,Pfkm,Rfk,Rr
m2,Uqcrq
Carbohydrate metabolic process 14 381 1.38E-08
B3gat3,Galk1,Gclc,Hexa,Hk1,Hyal1,Hyal3,Mpi,Ndst
3,Pfkm,Pgp,Pmm1,St3gal1,St3gal3
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Table 5.6 KEGG pathways and related genes up regulated by IL-37b  
The key pathways selected from the Pathways analysis presented in Figure 5.8c; 
these pathways are presented here in detail. Background gene count is the total 
number of genes in this pathway; the name and number of the genes that are 
downregulated by IL-37b and involved pathway with false discovery rate (p value).  
  
Term description
Observed 
gene count
Background 
gene count
False 
discovery 
rate
Matching proteins in your network (labels)
Fluid shear stress and atherosclerosis 23 140 1.50E-05
Acvr1,Bcl2,Bmpr1a,Bmpr2,Ccl12,Cdh5,Dusp1
,Edn1,Gpc1,Gstm1,Gstm4,Hmox1,Klf2,Mgst1
,Mgst2,Mmp9,Ncf2,Sdc1,Sdc4,Tnfrsf1a,Txn1
Staphylococcus aureus infection 9 50 0.0326 C2,C3ar1,Cfb,Cfh,Fcgr3,Fcgr4,Fpr1,Fpr2,Fpr3
Tuberculosis 15 172 0.0455
Bcl2,Camk2d,Camp,Clec4e,Coro1a,Cycs,Eea1
,Fcer1g,Fcgr3,Fcgr4,Hspa9,Ksr1,Ppp3ca,Tnfrs
f1a,Traf6
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Figure 5.9 Heat maps presentation of the genes regulated by IL-37b compared 
to WT control 
 
The representative common regulated genes by IL-37a selected from tables 5 and 6 
displayed in heat maps. The genes were analysed by microarray assay in triplicate. 
a) The representative genes (table 5.5) that are downregulated by IL-37b; b) the 
representative genes (table 5.6) that are upregulated by IL-37b compared with WT 
controls.  
(a) 
(b) 
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5.2.5 Identifying the later LPS-induced genes differentially regulated by IL-37a 
and IL-37b in macrophage  
Since many IL-37-related experimental results in Chapter 4 were generated from 
murine macrophage line RAW cells I sought next to further investigate the 
transcriptome of LPS-induced genes regulated by IL-37 isoforms using this cell line. 
Furthermore, considerable amount of my results in this context were obtained from 
macrophages about 18 h after TLR ligand stimulation, therefore, this transcriptome 
study was to focus on the later LPS stimulated gene profiles regulated by IL-37a and 
b in macrophages. RAW cells were transduced with plasmid expressing IL-37a, b or 
empty plasmid as a control, respectively. The cells were cultured in 24 wells plate 
and stimulated with 500ng/ml LPS for 18 hours. The total RNAs were isolated and 
transcriptome performed and analysed as before. 
 In order to identify the common and differential expressed genes between IL-37a 
and b, firstly, the differential expressed genes (DEG) between the WT and transgenic 
cells expression IL-37a or b, respectively, were identified using bio Venn programme 
and visualised by the area-proportional and overlapping Euler as before (data not 
shown). The DEG of IL-37a and b were used to further identify the common and 
specific genes regulated by the two isoforms using the same strategy. These results 
are shown in Figure 5.10.  
Consistent with the transcriptome result from splenocytes (Figure 5.3), both 
cytokines were largely different in the regulation of LPS-induced genes, as shown in 
the specific regulated genes, further confirming that they vary in functions (Figure 
5.10). 426 genes were downregulated by IL-37a and 1318 by IL-37b (Figure 5.10a). 
249 genes were also upregulated by IL-37a and 1269 by IL-37b (Figure 5.10b). While 
both IL-37a and b dominantly inhibited LPS-induced gene expressions (Figures 5.10a 
and b). Furthermore, 371 genes were downregulated and 186 upregulated by both 
cytokines, further suggesting that they also share functional similarity in gene 
regulation.  
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Figure 5.10 Identification of common and specific genes differentially regulated 
by IL-37a and b in LPS stimulated transgenic RAW cells 
RAW cells with IL-37a and IL-37b transgene were compared with WT RAW cells after 
500ng/ml LPS stimulation for 18 hours; total RNAs from each group were isolated for 
RNA-seq. The differential expressed genes identified using bio Venn programme and 
visualised by the area-proportional and overlapping (relationship) Euler. a) 
represents the genes that are downregulated by IL-37a and b; the red area shows 
genes downregulated by IL-37a only; the overlap area shows the genes that are 
downregulated by both IL-37a and b; while the blue area represents the genes that 
are downregulated by IL-37b only. b) shows the set of genes that are upregulated by 
IL-37a and b; specific genes upregulated by IL-37a shown in red area; the overlap 
area are common genes, which are upregulated by both IL-37a and b; the blue area 
are genes that are upregulated specifically by IL-37b. 
(b) 
(a) 
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5.2.6 Identifying the LPS-induced genes and signalling pathways commonly 
regulated by both IL-37a and b  
The IL-37a and b regulated genes identified in Figure 5.10 were further analysed for 
their association with signalling pathways as above. Due to the time limitation, only 
the gene/pathways regulated by both IL-37a and b were analysed in detail here. The 
specifically gene/pathways regulated by either IL-37a or b in LPS-stimulated 
macrophages have not been but will be analysed soon.  
Consistently, both cytokines downregulated more signalling pathways than they 
enhanced (Figure 5.11a and b). As shown in Figure 5.11a, IL-37a and b significantly 
downregulated genes in 10 signalling pathways and only upregulated genes in 5 
pathways in macrophages. The top two significantly inhibited pathways were the 
TNF and chemokine signalling pathways (Figure 5.11a and Table 5.7). This is 
consistent with the regulatory role of IL-37 in cytokine/chemokine expression and 
function in diseases (Nold-Petry et al., 2015; Petry et al., 2015; Nold et al., 2010).  
Also, in agreement with our results in Chapter 4, IL-37a and b inhibited 17 genes in 
TNF pathway, including Tnfrsf1b (encoding TNF-α receptor 1), signalling molecules 
Fos, Mapk13 and ptgs2 and several chemokines/cytokines (Figure 5.11a and Table 
5.7). In line with this, both isoforms significantly suppress the chemokine signalling 
pathway and downregulation of 16 chemokines/receptors, many of the 
chemokine/receptors are involved in inflammatory response (Inohara and Nuñez, 
2001). 
A number of inflammatory cytokine/receptor genes, including Il1b, Il4r, Il6, Il7r, Il18 
were significantly inhibited by both isoforms (Table 5.7). Furthermore, IL-37a 
impaired the expression of key genes in Jak-STAT signal pathway, including stat3 
which is important in cytokine induction. IL-10, TGF-β, Socs1 and 3 are important 
cytokine regulators, but also suppressed by IL-37 a and b, suggesting that IL-37 
suppressing cytokines may not via these classic immunoregulators. 
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 Also agreeing with my previous results in Chapter 4, showing IL-37a and IL-37b 
inhibited TLR response in macrophages, here both the cytokines also suppressed 
several signalling components in the TLR pathway (Table 5.7 and Figures 5.11a, 12a). 
These included the most important TLR adaptor MyD88 that plays initial role in TLR 
signalling (Medzhitov, 2001), the downstream signalling molecules Mapk13 that 
encode p38α mitogen-activated protein kinases (MAPK) and Irf7 (Table 5.7 and 
Figure 12a).  
The expression of 18 genes in NOD-like receptor (NLR) signalling pathway were also 
inhibited by IL-37b in the LPS-stimulated cells. NLR is required for the inflammasome 
formation and IL-1β and IL-18 maturation and secretion (Kavathas et al., 2013; 
Moreira and Zamboni, 2012). its impact on LPS/TLR4 signalling need to be evaluated. 
Both the isoforms also significantly upregulated genes in 5 pathways (Figures 5.11b 
and 5.12). The top enhanced pathway was the biosynthesis of amino acids. However, 
the biological and immunological significance of these remain unknown.  
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Figure 5.11 The signalling pathways regulated by both IL-37a and b in LPS 
stimulated transgenic RAW cells 
The signalling pathways of the common genes regulated by both IL-37a and IL-37b 
in LPS-stimulated RAW cells identified by the enrichment analysis on KEGG. The x-
axis is the name of KEGG pathways; the left y-axis is associated p-value presented 
by (-log10^ p value) and the right y-axis is the count percentage of regulated genes 
in this analysis of the whole gene in each pathway; orange line is the count 
percentage value for each pathway. The cut-off value in this experiment is p-value 
<0.05. a) Represents common pathways downregulated by IL-37a and b. b) are the 
common pathways upregulated by IL-37a and b. 
(b) 
(a) 
Down regulation 
up regulation 
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Table 5.7 Common pathways and related genes downregulated by both IL-37a 
and b 
The key pathways selected from the Pathways analysis presented in Figure 5.11a; 
these pathways are presented here in detail. Background gene count is the total 
number of genes in this pathway; the name and number of the genes that are 
downregulated by IL-37a and b and involved pathway with false discovery rate (p 
value).  
 
 
 
 
Term description
Observed 
gene count
Background 
gene count
False 
discovery 
rate
Matching proteins in your network (labels)
TNF signaling pathway 17 108 3.45E-07
Bcl3,Ccl12,Ccl2,Ccl5,Creb5,Csf1,Cxcl10,Cxcl2,
Cxcl3,Fos,Il1b,Il6,Lif,Mapk13,Ptgs2,Socs3,Tnf
rsf1b
Chemokine signaling pathway 19 179 3.38E-06
Ccl12,Ccl2,Ccl22,Ccl3,Ccl4,Ccl5,Ccl6,Ccl7,Ccl9
,Ccr1,Ccr7,Cxcl10,Cxcl2,Cxcl3,Cxcr3,Cxcr5,Gn
g7,Src,Stat3
NOD-like receptor signaling pathway 18 164 4.11E-06
AI607873,Antxr2,Ccl12,Ccl2,Ccl5,Cxcl2,Cxcl3,
Gbp3,Gbp7,Il18,Il1b,Il6,Irf7,Mapk13,Nlrc4,O
as2,Oas3,Trpm2
Salmonella infection 13 78 1.56E-05
Ccl3,Ccl4,Cxcl2,Cxcl3,Fos,Il18,Il1a,Il1b,Il6,Ma
pk13,Nlrc4,iNOs,MyD88
Toll-like receptor signaling pathway 12 98 0.0016
Ccl3,Ccl4,Ccl5,Cd80,Cxcl10,Fos,Il1b,Il6,Irf7,M
apk13,MyD88,Tbk1
Jak-STAT signaling pathway 13 161 0.0016
Aox2,Cdkn1a,Csf3,Il10,Il11,Il4ra,Il6,Il7r,Lif,O
sm,Socs1,Socs3,Stat3
HIF-1 signaling pathway 10 102 0.0019
Camk2a,Cdkn1a,Eno2,Eno3,Hmox1,Il6,iNOs,
Pfkfb3,Serpine1,Stat3
PI3K-Akt signaling pathway 20 349 0.0023
Cdkn1a,Creb5,Csf1,Csf3,Epha2,Gng7,Il4ra,Il6
,Il7r,Itgav,Itgb4,Itgb7,Lpar1,Mdm2,Nr4a1,Os
m,Pik3ap1,Syk,Thbs1,Thbs3
FoxO signaling pathway 9 132 0.0235
Cdkn1a,Homer3,Il10,Il6,Il7r,Mapk13,Mdm2,S
tat3,Tgfb3
MAPK signaling pathway 14 292 0.0423
Csf1,Dusp1,Dusp2,Dusp5,Epha2,Fos,Hspa1b,
Il1a,Il1b,Mapk13,Nr4a1,Ptpn5,Tgfb3,Zak
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Table 5.8 Common pathways and related genes upregulated by both IL-37a and 
b 
The key pathways selected from the Pathways analysis presented in Figure 5.11b; 
these pathways are presented here in detail. Background gene count is the total 
number of gene in this pathway; the name and number of the genes that are 
upregulated by IL-37a and b and involved pathway with false discovery rate (p 
value).  
  
Term description
Observed 
gene count
Background 
gene count
False 
discovery 
rate
Matching proteins in your network (labels)
Biosynthesis of amino acids 7 75 0.00072 Aldh18a1,Ass1,Cth,Gpt2,Psph,Pycr1,Shmt2
One carbon pool by folate 3 19 0.0482 Aldh1l2,Mthfd2,Shmt2
Cell cycle 6 122 0.0482 Bub1b,Ccna2,Cdc20,Cdc25c,Cdkn2c,Plk1
Progesterone-mediated oocyte 
maturation
5 90 0.0482 Ccna2,Cdc25c,Igf1,Kif22,Plk1
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Figure 5.12 Heat maps presentation of the common genes regulated by IL-37a 
and b compared to WT control 
 
(a) 
(b) 
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The representative common regulated genes by IL-37a and b selected from tables 
5.1 and 5.2 displayed in heat maps. The genes were analysed by microarray assay in 
triplicate. a) The representative genes (table 5.1) that are downregulated by IL-37a 
and b; b) the representative genes (table 5.2) that are upregulated by IL-37a and b 
compared with WT controls.  
 
5.2.7 Validation of the differential expression genes induced by LPS and 
regulated by IL-37a in splenocytes in vitro 
Some of the differentially expressed genes identified by RNA-seq between the WT 
and IL-37a groups were further validated in LPS-stimulated primary splenocytes from 
IL-37aTg mice by QPCR (Figure 5.13). The genes were randomly selected. We 
confirmed that, the same as the results in RNA-seq, IL-37a also downregulated CD80, 
Cxcl10, TBK1, MAPK13, STAT3 and Fos in time-dependent manner. There are 3 of 
the upregulated genes by IL-37a in RNA-seq also confirmed including Aldh18a1, psph 
and Cth (Figure 5.14). These results suggested that the RNA-seq results are reliable. 
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Figure 5.13 IL-37a up regulated gene validation in murine splenocytes in vitro 
 
To validate the gene experiment and confirm the time dependent trend of IL-37a 
down regulated genes. Splenocytes from WT and IL-37aTg (1x10^6/ml) were 
cultured in the presence or absence of 500ng/ml of LPS for 5, 12 and 18 hours. Total 
RNAs were extracted from total cell lysate and the expression levels of interest 
genes from IL-37a downregulation group (CD80, Cxcl10, TBK1, MAPK13, STAT3 and 
Fos) were measured by qPCR. Using ANOVA, data are means ± SD, and are 
representative of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001 
compared to controls.  
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Figure 5.14 IL-37a upregulated gene validation in murine splenocytes in vitro 
 
To validate the gene experiment and confirm the time dependent trend of IL-37a 
upregulated genes. Splenocytes from WT and IL-37aTg (1x10^6/ml) were cultured in 
the presence or absence of 500ng/ml of LPS for 5, 12 and 18 hours. Total RNAs were 
extracted from total cell lysate and the expression levels of interest genes from IL-
37a upregulation group (Aldh18a1, psph and Cth) were measured by qPCR. Using 
ANOVA, data are means ± SD, and are representative of three independent 
experiments. *P<0.05, **P<0.01 and ***P<0.001 compared to controls. 
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5.3 Discussion 
In summary, the transcriptomic results demonstrated for the first time: 
1. Compared to the WT control, IL-37a significantly downregulated 2151 genes and 
upregulated 1068 genes in the LPS-stimulated cells, indicating that IL-37a has a 
broad regulatory effect on global gene expression, not only suppressing but 
enhancing gene expressions.  
2. Compared to the IL-37b, IL-37a specifically inhibited 773 and also enhanced 732 
genes, suggesting that IL-37a differs from IL-37b in gene regulation. 
3. Compared with IL-37b, the common regulated genes between the two IL-37 
isoforms were also identified, explaining the functional similarity between the two 
isoforms.  
4. the common and unique signalling pathways between the two isoforms were also 
revealed using innate DB gene bank and KEGG enrichment analysis. These have 
provided molecular explanations, at least in part, for the IL-37-mediated regulatory 
effect in the previous experimental observations in Chapter 4.  
The RNA-seq experiment has been established in our Chinese collaborator’s lab (by 
R.Wei). The spleen cells are harvested from WT C57BL6 mice and C57BL6 mice with 
IL-37a and IL-37b transgene (CMV promotor). We extracted RNA from these 
splenocytes and generated transcriptomic analysis. The IL-37a and IL-37b gene 
expression from these mice are similar in mRNA level and protein level. The protein 
level is around 15ng/ml in serum and the mRNA level of IL-37 is stable in these two 
lines. Therefore, the gene expression can be controlled and to maintain in similar 
level, their RNA-seq result is comparable.  
We use primary cell instead of RAW macrophage cell line here for RNA-sequencing. 
One of the most important reason for that is RAW cells are transformed and are not 
functional for certain signalling pathways like Ah receptor signalling. Moreover, the 
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transformed macrophage cell lines are more sensitive to the stimulation compare 
with primary cells, which may not reflect the real condition and gene expression. 
Therefore, except RAW cells, we also use splenocytes from WT and IL-37a/b 
transgenic mice to seek for the regulation mechanism of IL-37a and b in TLR 
stimulation. 
The transcriptomic analysis further demonstrated that IL-37a is a previously 
unrecognised immunoregulatory cytokine and play critical role in the regulation of 
TLR-signalling and beyond. In addition, IL-37a differs from IL-37b in gene regulation 
and signalling and may be a potential therapeutic intervention for inflammatory 
diseases. 
Consistent with our results that show IL-37a and IL-37b share functional similarity in 
the regulation of immune cell function (Chapter 4), considerable number of genes 
in LPS-stimulated cells were regulated by both IL-37a and IL-37b in the 
transcriptomics analysis. While the detailed mechanism still need to be elucidated, 
because the two isoforms share the IL-1-like cytokine domain for receptor binding 
and signal via the same receptor, it is mostly likely that the common genes are 
regulated via the common IL-37 receptor-dependent pathway.  
Intriguingly, apart from the common regulated genes/pathways, many of the 
genes/pathways were specifically regulated by either IL-37a or IL-37b, respectively. 
For instance, the most downregulated genes/pathways by IL-37b were the metabolic 
pathways, while IL-37a mainly affects the immune response, including chemokine 
and TLR response. The result further demonstrates that IL-37a and IL-37b differ from 
each other, not only in biology but also in gene regulation and signalling. However, 
at the moment, it is poorly understood how the two IL-37 isoforms regulate gene 
profile differently. I believe that this is largely due to their difference in N-terminal 
sequence of the two IL-37 isoforms, which may cause their difference in nuclear 
translocation and bioactivity. 
It has been shown that matured, but not the full-length IL-37b is able to translocate 
into cell nucleus via smad3 (Luo et al., 2017). Using the IL-37b transgenic mice 
lacking the IL-1R8, it was further demonstrated that nuclear located mature IL-37b 
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can regulate some LPS-induced cytokines in an IL-1R8-independent manner in vitro 
and in vivo (Nold et al., 2010; Moretti et al., 2014). However, the subsequent report 
from the same research group showed that receptor-independent regulatory 
pathway of IL-37b was not important in vivo in LPS-induced shock (Nold-Petry et al., 
2015). Therefore, the regulatory effect of the mature IL-37b in cell nucleus may not 
be important, at least in LPS shock.  
Because the unique N-terminal of the full-lengthy IL-37a (FL-IL-37a) contains a 
putative NLS (Nold-Petry et al., 2015), we investigated the ability of the NLS in IL-
37a translocation. Our preliminary results indicated that indeed, the majority FLIL-
37a proteins were translocated into cell nucleus via their NLS (R. Wei, unpublished 
result). This is different from FLIL-37b. Thus, we speculate that the genes 
specifically regulated by IL-37a may be predominantly attributed to the nuclear FLIL-
37a in a receptor-independent manner. Further experiments are needed to define 
the hypothesis by using the mice strain that expresses FLIL-37a but not the IL-1R8. 
While the molecular targets and mechanism of action of NIL-37a in the nucleus are 
still unknown and currently under investigation in our lab using Chip-sequence, it is 
known that the NLS containing N-terminal of IL-1α is sufficient to regulate cell 
function by translocation to the nucleus and binding to transcription activators and 
chromatin (Werman et al., 2004b).  
Since the putative elastase-matured IL-37a protein (R22-D192) shares 98% homology 
with the caspase-1 matured IL-37b (V46-D218), it is possible that after processing, 
matured IL-37a may also be translocated to the cell nucleus through the same 
Smad3-mediated mechanism as mature IL-37b. However, our preliminary result 
suggests that, different from the FLIL-37a, majority of mature IL-37a proteins are 
located in the cell plasma, not cell nucleus (R.Wei, unpublished result). The reason 
is still unknown, but it is likely that FL but not mature IL-37a is primarily responsible 
for the gene regulation in the cell nucleus. 
 Nevertheless, our results suggest that FLIL-37a is a dual functional regulatory 
molecule which regulates genes and cell function by two mechanisms: different from 
FlIL-37b; FLIL-37a can serve as a nuclear regulatory factor when translocated into 
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the cell nucleus; similar to IL-37b, FL and mature IL-37a can also act as a cytokine 
when released from producing cells and trigger signalling via IL-37 receptor.  
Since many of my results in Chapter 4 studied the regulatory effect of IL-37a and b 
on LPS response I therefore studied their role in the regulation of TLR4 signalling 
here in more detail. Our transcriptomic analysis revealed that IL-37a and IL-37b 
control LPS/TLR4 signalling transduction by targeting multiple signalling cascades in 
the pathway and via common and specific mechanisms (Figure 5.15).  
Both isoforms inhibited the expression of TLR4 co-receptor CD14 and the key adaptor 
protein MyD88. All these will prevent the initiation of LPS/TLR4 signalling. Both 
isoforms can further suppress the downstream TLR signalling, from the upstream 
signalling molecules in MyD88-dependent pathways including IRAK, TAB, MAPK, NF-
kB and JAK-STAT pathways to the downstream JAK-STAT and proinflammatory 
cytokine and mediators productions.  
Apart from the shared capacity in gene regulation, both isoforms can also act 
independently in gene modulation and control TLR signalling by different 
mechanisms. Furthermore, IL-37a appeared to be more effecting on the regulation 
of the MyD88-dependent pathway, and IL-37b on the TRIF-dependent pathway 
(Figure 5.15). As such, IL-37a, but not IL-37b, specifically inhibited the expression 
of TLR4 and also the LPS-binding protein (BLP), and this will affect LPS binding to 
TLR4 and signalling. Thus, IL-37a may prevent the initiation of TLR4 signalling from 
the very early stage. IL-37a also inhibited IRF5 and IKK expression. 
In the regulation of TRIF-dependent pathways (Figure 5.15), IL-37b might play more 
role than IL-37a in this. IL-37b specifically suppressed TRIF, the key adaptor 
molecule in the pathway. On the other hand, IL-37b also inhibited the key signalling 
molecules Irf3 and AKT. Both isoforms further inhibited TBK1, together; this may 
lead to the downregulation of type I IFN production.  
Altogether, these IL-37a and b-mediated effects will impair the LPS-induced 
production of inflammatory cytokines, chemokines and mediators and also 
ameliorate inflamed leucocyte migration, and immune reactions, and thereafter 
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decrease inflammatory response. Hence, the selective induction of IL-37, in 
particular IL-37a, may represent a novel strategy for improving immunotolerance 
against dysregulated inflammatory response. In addition, this analysis also provides 
a possible molecular explanation for the IL-37a-mediated regulatory effect on 
salmonella infection and NO production in Chapter 4. 
At least 3 surface molecules of salmonella can be recognised by different TLRs, the 
LPS, lipoproteins and flagella (Zhan et al., 2015). LPS/TLR4 and flagellin/TLR5 
signals and perhaps the most important in salmonella-mediated immune response 
and pathogenesis (Li et al., 2012). Our previous results showed that IL-37a and b can 
promote salmonella survival, probably by inhibiting TLR-induced proinflammatory 
cytokine and bactericidal NO production (Chapter 4). However, the molecular 
mechanism is still unknown. We therefore assessed the gene profile regulated by IL-
37 isoforms on salmonella infection signalling pathway. As illustrated in Figure 5.16, 
the transcriptomic results agreed with the biological result in Chapter 4 and 
suggested that IL-37a and IL-37b also negatively regulate the key inflammatory 
genes, alone or together, in salmonella infection signalling pathways in splenocytes 
and macrophages. TLR4 signal in salmonella infection is mainly through the MyD88-
dependent pathways, leading to the activation of AP1, P38 and NF-κB and 
inflammatory gene expression (Medzhitov, 2001; Toshchakov et al., 2002). Both the 
IL-37a and IL-37b suppressed MyD88 and signalling molecules P38 and AP1. IL-37 
isoforms also directly or indirectly suppressed the key pro-inflammatory cytokines 
and iNOs productions. Interestingly, we found that IL-37a also specifically inhibits 
the transcription of LBP, TLR4 and ERK1/2 in the pathway. The result may help to 
explain the results in Chapter 4 and suggests that the advanced regulatory effect of 
IL-37a in salmonella infection may be due to its capability of targeting more genes 
in the pathway than IL-37b (Figure 5.16).  
While IL-37 promotes bacterial survival in this salmonella context, its ultimate effect 
on salmonella infection is still not fully understood. Inflammation induced by 
salmonella can be pathogenic and lethal. The anti-inflammatory effect performed 
by IL-37 in salmonella infection may be also beneficial to reduce the tissue damage 
and septic shock. It is worthwhile to further test the hypothesis by looking at the 
dual effect of IL-37 in lethal salmonella infection model.  
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I realised that the transcriptomic experiment has some limitations and could be 
improved. Whereas we have looked at the transcriptomic changes early (4 hours) 
and later (18 hours) after LPS stimulation, it will be ideal to have more LPS 
stimulation time points in splenocytes in order to see the kinetic changes in gene 
expressions. The important differentially expressed genes need to be further 
validated in protein levels by western blot, FACS or ELISA. Their function in IL-37-
mediated effect also needs to be evaluated by siRNA knockdown or overexpression 
in immune cells. The transcriptomics study also shows that IL-37a and b may have 
global regulatory effect on other diseases beyond LPS-induced inflammation. 
Furthermore, the gene/pathways enhanced by IL-37a and/or b are less understood 
and could be potentially important in the understanding of the ultimate effect of 
the IL-37 isoforms in immunity and in disease. This will be discussed in the General 
discussion chapter and addressed in further studies.  
Although the quality of our RNA-seq result is good and fits our hypothesis. We also 
have some shortages in these experiments which can be developed in later 
experiments: 1). The sample size of each group was not big enough. We only have 
three sample per group, which is the minimum number to do statistical analysis. For 
an ideal experiment. It will be better to enlarge the group size and test results from 
more time points for a clear change of the TLR stimulation related immune 
pathways. 2). The transgene expression (number of copies) can be furthered 
controlled by normalizing RNA level of these sample. The difference in transgene 
expression may largely affect our result trends. 3). To use a better control, we can 
use the primary macrophage from mice spleen instead of the RAW macrophage cell 
line, which can reflect the real condition in human.  
In order to establish an ideal RNA-seq experiment based on our project. There are 
some strategies I would like to do for my future experiments: 1). Using primary 
macrophage instead of macrophage cell line, sorting macrophage from WT and Tg 
mice after Salmonella infection/ TLR stimulation by Facs then do sequencing. Since 
IL-37a is the dominate IL-37 isoform which expresses in the early stage, I would like 
to check the gene expression within 6 hours after infection.  2). Considering the 
limited experiment condition, we only did one TLR ligand stimulation (LPS). 
However, based on our previous results, other TLR ligands (such as IMQ and Fla-st) 
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also affect the gene expression of IL-37 and other cytokines production in human 
cells. Therefore, it is necessary to test whether IL-37a affect TLR relate pathways 
under other TLR ligands stimulation, and by which mechanism. 
 
 
 
 
 
 
 
Figure 5.15 Proposed molecular mechanism by which IL-37a and IL-37b 
regulated TLR4 signalling 
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The genes related to TLR signalling pathway were analysed and generated in a 
proposed molecular pathway based on the Kyoto Encyclopedia of Genes and 
Genomes database (https://www.genome.jp/kegg/). Light blue represents the 
genes specific downregulated by IL-37a and light red represents the genes 
downregulated by IL-37b; blue/red represent genes regulated both by IL-37a and b. 
All the genes on this pathway are downregulated by IL-37a/b, there is no 
upregulation gene detected.  
 
 
Figure 5.16 Proposed molecular mechanism by which IL-37a and IL-37b regulated 
salmonella infection 
The genes related to salmonella infection were analysed and generated in a 
proposed molecular pathway based on the Kyoto Encyclopedia of Genes and 
Genomes database (https://www.genome.jp/kegg/). Light blue represents the 
genes specifically downregulated by IL-37a and light red represents the genes 
downregulated by IL-37b; blue/red represents gene regulate both by IL-37a and b. 
All the genes on this pathway are downregulated by IL-37a/b, there is no 
upregulation gene detected. (IPAF=NLRC4, Dynein=Dync)  
245 
 
 
 
 
Chapter 6 
General discussion 
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6. General discussion 
6.1 IL-37 isoforms: do we need 5 isoforms? 
Interleukin-37 is a newly discovered member of the IL-1 superfamily, consisting of 5 
isoforms (IL-37a-e) due to different RNA splicing. Current studies are only focused 
on IL-37b and show that IL-37b is an important immunosuppressive cytokine in 
inflammatory and autoimmune diseases. However, the biology and function of the 
other isoforms are still not clear. From the evolutionary perspective, the existence 
of a specific gene always has a necessary reason behind it; if a gene is no longer 
needed, it will be deleted or become a pseudo-gene. Therefore, it is important to 
understand the function of other IL-37 isoforms. Based on the previous studies 
mentioned in the general introduction of IL-37 and its isoforms (Chapter 1) and some 
result from our lab and our collaborators, in this chapter, I will mainly discuss the 
difference of IL-37 isoforms in their sequence, protein structure, induction, 
regulation, tissue distribution and potential function. In this case, we may have an 
answer for some questions of IL-37, at least, for the reason why we need all five 
isoforms. 
6.1.1 IL-37 isoforms are different in gene organisation and protein levels 
There are 6 exons of IL-37 gene which encode five isoforms of it with alternative 
mRNA splicing (Boraschi D et al., 2011). To be specific, pro-IL-37a is a protein 
encoded by exon 3 to 6, which contains 192 amino acids. The pro-protein of IL-37a 
has a unique putative nuclear localization sequence (NLS) on the site of its N-
terminal. NLS is a short sequence for importing of several nuclear proteins from 
cytoplasm into the cell nucleus by nuclear transport (Kalderon et al., 1984). The 
pro-IL-37a also has a unique elastase cleavage which can be digested by elastase to 
become mature protein, while the rest of the IL-37 isoforms carry a caspase I 
cleavage site for protein maturation (Nold-Petry et al., 2015).  
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The biggest isoform of the IL-37 family is IL-37b protein which contains 218 amino 
acids, this longest IL-37 isoform encoded by 5 of 6 total IL-37 exons, excepting exon3. 
The pro-IL-37b can be cleaved by caspase-1 to form mature IL-37b. The IL-37d 
protein is encoded by exon 1 and exons 4 to 6 to create a 197 amino acid long pro-
protein and can also be processed by caspase I. Pro-IL-37c protein is 178 amino acid 
long which encoded by exons 1, 2, 5 and 6 and pro-IL-37e protein is 157 amino acid 
long which encoded by exons 1,5 and 6 (both of them lack exon 4). The most unique 
IL-37 isoform is IL-37a, which pro-protein is 192 amino acid long, encoded by exon 3 
and exon 4 to 6; although IL-37a does not have exon 1 and 2, its exon3 encode a 
unique N-terminus to endow it with unique structure and function.  
In these five isoforms, some of them contain an IL-1-like -trefoil structure encoded 
by the exons 4-6, which is essential for receptor binding and signalling. According to 
the feature whether these isoforms carry the IL-1-like domain or not, the IL-37 
isoforms can be further divided into two functional groups: 1) Isoform which has the 
IL-1-like domain, the IL-1-like -trefoil structure encoded by the complete exon 4-
6. The IL-37a, b and d have the complete domain which may be expected to bind to 
the same receptor, then trigger similar signal in immune response. And therefore, 
may have similar biological effects. 2) Isoform which lacks the IL-1-like domain. IL-
37c and e do not have the exon 4 for their protein encoding, which may not have a 
partial IL-1-like -trefoil structure. These isoforms may have different biological 
function from the former group whose function is still not clear. This evidence of 
isoform protein structure suggests that the isoforms of IL-37 may vary in their 
induction and function. 
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6.1.2 IL-37 isoforms differ in induction and expression 
There is one possibility for the reason why we need all these five isoforms. These IL-
37 isoforms may be selectively expressed in different organs or differently induced 
in different cell types or tissues in disease by various stimuli.  
In fact, the IL-37 isoforms do have a tissue specific expression which has been 
studied (Taylor et al., 2002). They also express in several common organs, like 
spleen and lymph nodes. To be specific, IL-37a is the only isoform which have 
expression in the brain; IL-37b is the only isoform which present in kidney; IL37c is 
specifically expressed in heart and IL-37d and e only have expression in bone marrow 
and testis, not in the other tissues. Therefore, IL-37 isoforms have a different tissue 
distribution and may have different function in variable cells and organs. 
Current study also suggests that IL-37 gene expression is highly regulated under 
stimulation condition, e.g. LPS. There is an instability element (A-rich homology box) 
in exon 5 of IL-37 gene, which makes the IL-37 mRNA unstable (Bufler et al., 2004). 
However, the function of this instability element of IL-37 gene can be overcome by 
the inflammatory signalling to ensure this gene can only be increased and expressed 
in inflammatory condition instead of in the homeostasis conditions. Moreover, 
resting cells can only produce IL-37b proteins in low level and this expression can be 
upregulated by several inflammatory stimuli and cytokines (TLR agonists, IL-1α, IL-
18, TNF-α and IFN-γ) (Nold et al., 2010). Therefore, it is important to explore the 
mechanism of how the other IL-37 isoforms are regulated and whether the regulation 
is acts in the same or different ways in immunity and disease. Since the information 
of this area is still very rare, mainly due to the potential importance of other IL-37 
isoforms which has not been well studied.  
There is only one report about other IL-37 isoforms except IL-37b determined the 
expression of all IL-37 isoforms in human PBMCs (Rudloff et al., 2016). According to 
this result, the expression of IL-37 isoforms is differently regulated by several TLR 
agonists in PBMCs within 8 hours culture. The TLR agonist, LPS, can upregulate the 
expression of IL-37b and c in this experimental condition. Moreover, the expression 
of IL-37c is predominantly induced by Pam3, a TLR2 ligand. However, in this 
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experiment, the TLR7/8 ligands (IMQ) cannot influence the induction of IL-37 isoform 
expression. Furthermore, this report also revealed that the expression of IL- e 
cannot be induced by these stimulations at 8 hours.  
This report was the first and only research on the regulation of IL-37 isoform 
expression in cell level to show a new insight for the different induction ways of IL-
37 isoforms. However, there are some clear gaps in this research, for instance, this 
research only focuses on the gene express at 8 hours, which may not be long enough 
for gene expression, and the induction of IL-37 isoform expression beyond this time 
point has not been mentioned. Additionally, the detail sequence of qPCR primers for 
each IL-37 isoform was not provided in this study, which makes a bit difficult to 
interpret and repeat the real mRNA expression level of this result. Therefore, we 
designed specific primers for qPCR mainly based on their intron/exon bindery and 
further studied dose and time effect of TLR agonists on the expression of IL-37 
isoforms. Our result indicates that the induction of IL-37 isoforms was both dose and 
time dependent (Chapter 4). Moreover, the result also shows that the IL-37a is one 
of the highly inducible IL-37 isoforms under TLR ligands stimulation in human 
macrophage cell lines (THP-1 cells) and primary cells (B cells, Najwa H, unpublished 
result). 
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6.1.3 Functional differences of IL-37 isoforms  
Although the gene of IL-37 (IL1F7) has been identified for 19 years, its main 
biological function has only been confirmed recently. Moreover, only the biological 
function of isoform IL-37b and d has been studied. The function of the other isoforms 
is still unknown. 
Current studies illustrate that the isoform IL-37b is a new cytokine belonging to the 
classical anti-inflammatory cytokine family which contains IL-10 and TGF-β (Conti 
et al., 2016). However, unlike multifunctional immunoregulatory cytokines, such as 
IL-10 and TGF-β, the suppress function of IL-37 may only exist in the inflammatory 
response. This cytokine is inducible by the inflammatory signal and feedback to 
suppress the ongoing inflammatory response in vitro and in vivo. 
IL-37b is thought to be a dual functional cytokine which can suppress inflammatory 
response via its receptor dependent and independent mechanisms (Dinarello et al., 
2016). In the receptor-dependent manner, the secreted IL-37b (mature or full-length) 
binds to receptor complex IL-18Ra/IL-1R8 (SIGIRR) then elitists anti-inflammatory 
signalling (Nold-Petry et al., 2015). In the receptor-independent fashion, the mature 
but not the full-length IL-37b protein can interact with Smad3, a nuclear factor, 
which can translocate into cell nucleus and facilitate the cytokine-suppressing 
function in a Smad3-dependent mechanism. The importance and detail mechanism 
underlying the receptor-independent regulatory effect of IL-37b is still under 
investigation; while the protective effect of IL-37b against endotoxic shock induced 
LPS is receptor-dependent and needs the receptor complex IL-18Ra/IL-1R8 (SIGIRR) 
(Jia and Han, 2018). 
Another IL-37 isoform, IL-37d, has been confirmed to be a bioactive cytokine 
recently (Zhao et al., 2018). Similar to IL-37b, IL-37d can also bind to Smad3 and 
suppress inflammatory response via Smad3-dependent mechanism. However, 
different from IL-37b, the IL-37d cannot induce signal via the IL-37 co-receptor 
system. Since both IL-37b and d share the common C’- terminal sequence and the 
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IL-1 like domain, it is hard to understand why isoform IL-37d fails to signal via IL-37 
co-receptors. 
Since the function of isoform IL-37a had not been confirmed and its unique structure, 
this isoform is the current focus in our lab. Till now, we have found that the pro-
protein of IL-37a works as a dual functional protein which can both act as a regulator 
in cell nuclear and also has cytokine function when secreted out by its producing 
cells (B cells and macrophages, Xu, unpublished result). Different from other 
isoforms of IL-37, the pro-IL-37a carries a unique putative NLS domain which may 
allow it to translocate into cell nucleus through this site.  
Moreover, our result also confirms its nuclear location and further demonstrated 
that nuclear IL-37a can regulate other IL-37 isoform gene expression (Xu, 
unpublished result). Furthermore, our group also found that IL-37a possesses a C’-
terminal structure which is similar to IL-37b and can also bind to the same receptor 
(IL-18Ra/IL-1R8) then trigger the similar signal and have similar biological effects. 
However, we expect that the unique structure of IL-37a may endow it a super 
regulatory function in immunity and disease in comparison with IL-37b and d. This 
hypothesis is currently under investigation in our lab and some preliminary results 
can support it. 
There is no recent research about the function of the other two IL-37 c and e, which 
lack the exon4 and lose the full IL-1-like domain. Due to the existence of the 12 -
trefoils in the IL-1-like domain is essential for the receptor binding and signalling in 
IL-1 family; both IL-37c and e lack the first three -strands of this structure, the IL-
37c and IL-37e may not be able to bind to the co-receptor and therefore may lose 
the activity as cytokines (Nold et al., 2010; Ellisdon et al., 2017). However, these 
two IL-37 isoforms may work as a regulator to mediate the function of other IL-37 
isoforms by competing or interfering with their mRNA splicing.  
Because all the pro-IL-37 isoforms, apart from pro-IL-37a, contain a caspase I 
cleavage site and can be cleaved into mature protein by the same enzyme, IL-37c 
and IL-37e may also influence the maturation of other isoforms and their biological 
function by competing with the enzyme in the microenvironment in vivo. There is 
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an evidence to support this hypothesis: all cytokines in IL-1 family are self-regulated, 
for instance, IL-1α and β can be regulated by their antagonist; IL-18 regulates via its 
binding protein (IL-18BP) and IL-33 regulates by the soluble IL-33 receptor 
(Hayakawa et al., 2007; Dinarello et al., 2013). On the other hand, although IL-37c 
and IL-37e fail to induce the receptor-dependent effect, they may also regulate gene 
expression via Smad3 to translocate into cell nuclear like IL-37b and Il-37d.  
6.1.4 Conclusion and future directions 
In summary, the five IL-37 isoforms are different in their protein structure, induction 
and function. There are three IL-37 isoforms (IL-37a, b and d) with the full-length 
IL-1-like domain and these have been demonstrated to play an essential 
immunoregulatory role in immunity and disease. These IL-37 isoforms may be 
therapeutically important in the treatment of many chronic disorders, especially in 
inflammatory and autoimmune diseases. Apart from these, many questions of IL-37 
isoforms remain unknown: 1. Whether these isoforms have same or different 
function in regulating inflammations. 2. The precise mechanisms by which IL-37 
isoforms suppress inflammatory response needs answer. 3. The variant participation 
and interaction of IL-37 isoforms in certain disease conditions are still not clear. 
4.Although the first group of IL-37 isoforms which has the full-length IL-1-like domain 
is likely bioactive, the effect of IL-37c and IL-37e needs to be determined. 5. The 
importance and relationship of IL-37 with other immunoregulatory cytokines, such 
as IL-10 and TGF-b in immunotolerance need to be studied in the future.  
Moreover, these IL-37 isoforms may synergise, back up or balance the function of 
each other in the regulation of inflammation. Therefore, the self-regulation of IL-37 
ensures that the ongoing inflammatory response can be carefully and properly 
controlled.  
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6.2 IL-37: an immune inhibitor or regulator? 
Il-37b has been initially identified as a fundamental inhibitor of innate immune 
response (Nold et al., 2010). Following studies confirmed this hypothesis on innate 
immune cells and further revealed that IL-37 (IL-37b) can not only inhibits innate 
immune cells but also T-cells (Nold-Petry et al., 2015). Thus, IL-37 may inhibit both 
innate and adaptive immunity. Moreover, all the current reports suggest that IL-37 
is an inhibitor of immune system and can suppress immune cell functions via both 
direct and indirect mechanisms. However, current results from us and others suggest 
that IL-37 may also enhance immune cell function, such as enhance antibody 
production in B cells (Xu, unpublished result). Therefore, all evidence has raised an 
essential question: whether IL-37 is an immune inhibitor or a regulator. In the 
following part of my general discussion, I sought to answer the question by collecting 
and analysing existing results which support both proposals. 
6.2.1 Evidence supporting IL-37 as an immune inhibitor 
Much evidence supports IL-37 working as an immune inhibitor and confirmed that IL-
37 can inhibit the function of both innate and adaptive immune cells. The IL-37 
protein can be expressed in a broad range of immune cells, such as monocyte, 
macrophages, mast cells and T cells. Moreover, the expressed IL-37 protein plays an 
inhibitory role in these immune cell functions.  
It has been demonstrated that monocytes express the highest level of IL-37 proteins 
compared with other immune cells in human (Rudloff et al., 2016). Thus, human 
monocytes may be a main source of IL-37 protein production in immune response. It 
has also been reported that both mRNA and protein level of IL-37 are inducible in 
monocytes by mycobacterial tuberculosis in TB patients. Moreover, this expression 
is negatively correlated with the expression of several inflammatory cytokines, such 
as IL-1β, IL-6 and TNF-α (Zhang et al., 2016). Although the detailed function of IL-
37 on monocytes has not been studied, its function on macrophages has been studied 
in many research centres, including our lab. IL-37 can effectively suppress 
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inflammatory cytokine production induced by TLR signalling (Nold-Petry et al., 2015; 
Huang et al., 2016). Furthermore, IL-37b can effectively suppress the production of 
TNF-α, IFN-γ and NO in human macrophage under oxygenated low-density 
lipoprotein (ox-LDL)-activation condition (Huang et al., 2016).  
Mast cell acts as a pathogenic cell in many disease conditions, such as allergy, 
asthma and psoriasis (Conti, 2017). Some studies demonstrate that IL-37b protein 
can suppress mast cell migration and its function in murine disease model of psoriasis 
(Teng et al., 2014) and asthma (Conti et al., 2016).  
Moreover, the effect of IL-37b on adaptive immune cells has been assessed and only 
the influence of T cells has been confirmed till now. The report illustrate that the 
IL-37 protein can be expressed by CD3+ and CD4+ T cells which can further inhibit 
the function of Th 17 cells in human (Ye et al., 2014). In the situation of Th17 cell 
polarisation, the expression of IL-37 can significantly inhibit IL-17 expression and the 
proliferation of Th17 cells but cannot affect their differentiation from naive human 
CD4+ T cells (ibid). 
Unlike the well-studied isoform IL-37b, we are in the initial stage to explore the 
regulatory effect of IL-37a and IL-37d. The only report illustrates that IL-37d is 
expressed in human peripheral blood mononuclear cells (PBMCs), umbilical cord-
derived mesenchymal stem cells (UCMSCs) and epithelia. The overexpression of IL-
37d inhibits inflammatory cytokine IL-6 production which is induced by IL-1b in 
macrophages and epithelia cell line (Zhao et al., 2018). However, the regulation 
function of IL-37d in the other immune cells has not been studied to date. 
Furthermore, our results confirmed that isoform IL-37a is another bioactive IL-37 
isoform like IL-37b, which can suppress the inflammatory cytokine production (IL-6. 
IL-1 and TNF) induced by LPS stimulation in human and murine macrophage and 
monocytes (Chapter 4; Xu, unpublished results). Its effect on other innate and 
adaptive immune cell function is currently under investigation. Although the exact 
mechanisms of how IL-37 inhibits these cells are still poorly understood, current 
evidence shows that IL-37 can suppress innate and adaptive immune cell function in 
a direct or indirect way. 
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6.2.1.1 The direct inhibitory effect of IL-37 on immune cell activity  
The direct inhibitory effect of IL-37 protein is performed in autocrine or paracrine 
manner. Through the autocrine pathway, IL-37 will be initially produced by an 
immune cell, followed by cytokine secretion, then have the regulatory function via 
receptor dependent or independent pathways. As discussed in the first part of 
general discussion, IL-37a, b and d can translocate into cell nuclear then work as a 
nuclear factor to have their regulatory function without the assistance of the 
receptors. However, the mechanism of how nucleus IL-37 isoforms regulate pro-
inflammatory cytokine gene function remains unknown. Nevertheless, the receptor-
dependent regulatory effects of IL-37 isoforms are comparatively better studied; IL-
37a and b protein, apart from IL-37d, can bind to their common co-receptors and 
have their regulatory function by receptor-mediated signalling (Nold-Petry et al., 
2015; Zhao et al., 2018). This phenomenon was confirmed in murine model by the 
lost inhibitory function of endogenous or recombinant IL-37 (IL-37b) in IL-37 receptor 
knockout (IL-1R8KO) mice or mice treated with anti-IL-37 receptor antibody (Nold-
Petry et al., 2015). 
Through the paracrine pathway, the IL-37 will be initially produced by some types 
of immune cells, for instance, monocytes from human donor can suppress the 
function of other immune cells which is mainly possess by IL-37 receptor (IL1R8) 
(Zhao et al., 2018). Therefore, it allows the enlargement of IL-37-regulated function 
in immune response in tissue and organ.  
6.2.1.2 The indirect inhibitory effect of IL-37 on immune cell activity  
Additionally, IL-37 may further regulatory immune activation in an indirect way by 
suppressing Antigen-presenting cell (APC) function and/or by inducing Regulatory T 
cells (Treg) and tolerogenic dendritic cells (tDC) (Nold-Petry et al., 2015). Therefore, 
this could cause a systemic influence of IL-37 on the ongoing inflammatory response.  
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IL-37 effect on APC function: DC is an essential APC in tissues which act as a crucial 
factor in the initiation of immune response. Results show that the IL-37 protein can 
prevent the maturation and antigen presentation of DCs. For instance, the 
maturation and activation of DCs are induced by LPS, which shows a significant 
reduction in IL-37bTg mice compared with WT (Luo et al., 2014). The similar result 
can be observed in IL-37 treated DCs, which show a decreased expression of MHC II 
and the costimulatory molecule CD40 then reduced production of inflammatory 
cytokines, such as IL-1β, IL-6, and IL-12 (Luo et al., 2014). Moreover, IL-37b-treated 
DC cannot effectively activate naive T cells (Chang et al., 2017). Therefore, the 
regulatory function of IL-37b may influence the development of antigen-specific 
immune response. Furthermore, the potential effect of other IL-37 isoforms in the 
regulation of APC, Treg and tDC is still unknown. The influence of IL-37 on tDC and 
Treg development and their function will be discussed as below. 
6.2.1.3 IL-37 can enhance function of immune cell sets 
The inhibitory function of IL-37 in immunity and disease has been well studied, the 
immune enhancement effect of IL-37 has been largely neglected. According to the 
existing review and analysis of the results from our and other labs, some evidence 
supports that IL-37 can also efficiently promote functions of some immune cells.  
Treg cells, especially the Forkhead box proteins-3 (FOXP3+) Treg, are fundamental 
cell types in the regulation of development of inflammatory and autoimmune disease 
(Long and Buckner, 2011). It has been reported that IL-37 can also be expressed by 
T cells which in turn differently regulate the function of CD4+ T cell subsets. The 
treatment of recombinant IL-37 protein can selectively decrease Th1 and Th17 cell 
development but enhance Treg cell function and polarisation (Ji et al., 2017). 
Moreover, IL-37 also expresses in CD4+ Treg which promotes the expression of Treg 
transcript factor FOXP3; it also enhances the expression of suppressive cytokines 
such as IL-10 and TGF-β in Treg (Shuai et al., 2015). Furthermore, silencing the IL-
37 gene in human Treg impairs the suppressive function of Treg (Shuai et al., 2015). 
 
257 
 
IL-37 may also regulate inflammatory response through the induction of tolerogenic 
DC (tDC). The tDC is a DC subset which acts as a regulatory cell in immune tolerance. 
Different from other DC, tDC is characterised by its ability of immune suppression 
and the polarisation of Treg (Chang et al., 2017). It has been reported that the DCs 
isolated from IL-37bTg mice express IL-10 in high level and reduced their function in 
the antigen-specific T cells activation, which suggests that these DCs are the tDCs. 
Moreover, the tDC can polarise Treg cells and decrease the CD8+ cytotoxic function 
in vitro and in contact hypersensitivity of mice (Luo et al., 2014). Thus, by inhibiting 
APC and promoting development and functions of Treg and tDC, IL-37 can maximise 
its systemic regulatory function in order to control inflammatory response more 
effectively. However, these studies only focus on IL-37b, the potential effect of 
other IL-37 isoforms in the regulation of immune cells is still unknown. 
IL-37 also plays a role in regulating macrophage functions. Macrophages (M0) can be 
further polarised into M1 or M2 subtypes (Martinez and Gordon, 2014). The M1 
macrophages are essential in infection and inflammation. These cells are 
characterised by the expression of iNOs and NO production, and expression of several 
pro-inflammatory cytokines, including IL-1b and IL-12 (Castleberry et al., 2008). The 
M2 macrophages, on the other hand, play an important role in immunoregulation 
and tissue repair by producing suppressive cytokines IL-10, TGF-β, arginase 1 (ARG1) 
and suppressing NO production. It has been demonstrated that IL-37 can enhance 
the development of M2 macrophages in mycobacterium tuberculous infection by 
elevating the expression of ARG1, IL-10, TGF-β and reducing NO production in the 
macrophages (Huang et al., 2015). Furthermore, IL-37b also effectively suppresses 
the ox-LDL-induced M1 macrophage development, which in turn polarise these cells 
into M2 cells (Huang et al., 2016). These evidences demonstrate that IL-37 can 
selectively polarise macrophages into M2 cells. Therefore, IL-37 may acts as IL-10 
and TGF-B which participate in tissue repair and homeostasis. 
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6.2.2 Transcriptomic evidence supports that IL-37 can enhance immune 
response 
The transcriptomic (RNA sequencing) results from our own and other labs also 
demonstrated the enhancement function of IL-37 in the transcriptome in immune 
cells. One report illustrates that IL-37b can predominantly upregulate the expression 
of many genes, while it can also downregulate many gene expressions in the LPS-
stimulated splenocytes from IL-37b transgenic mice (Nold-Petry et al., 2015). This 
result suggests that IL-37b may work in both aspects, which can either to enhance 
or suppress gene expressions in the LPS-stimulated cells. Unfortunately, the value 
and related signal pathways of these enhanced genes have not been provided in this 
article. Instead, the authors focused on the 139 genes which associate with innate 
immune response and showed that 46% of them were enhanced by IL-37b in the 
context. With further analysis of these genes which upregulate by IL-37b, they found 
that these genes belong to two groups: 1. Some of these genes encoded inhibitors 
of inflammation. 2. Others are closely associated with inflammatory response, for 
instance, the TRAIP (a TLR adaptor), Plcd3, TNF-α, S100a (a TLR4 agonist) and 
Pycard gene (Nold-Petry et al., 2015). 
 However, the immunological significance of these upregulated inflammatory genes 
in IL-37-mediated effect in the immune context has not been well studied. 
Nevertheless, these results demonstrated that IL-37b not only inhibits but also 
enhances some gene expression in immune cells. 
6.3 Role of IL-37 in infectious diseases, friend or foe? 
Accumulating reports suggest that IL-37 plays a critical, but controversial role in 
infectious disorders, depending on pathogen (Wang et al., 2018; Allama et al., 2019). 
Thus, it is important to be fully aware of the dual effects of IL-37 on the 
development and pathogenesis of infectious diseases. Here I will give a general view 
of each type of infectious disease first, including virus, bacterial, helminth and fungi 
infection, and then focus on the critically studied IL-37-regulated diseases in this 
category to assess the impact of IL-37 on this type of disease. I hope the review will 
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help to understand the potential beneficial and detrimental effect of IL-37 on 
infectious disease, including salmonellosis for better clinical application. 
The implication of IL-37 in infectious disorders is poorly understood, particularly in 
the parasite infection, and likely to be complicated, depending on the pathogen. IL-
37b exhibits a profound effect on the development and perpetuation of a wide range 
of infectious diseases, including virus, bacterial, parasite and fungi infection. 
However, the effect of IL-37 on diseases is varying, and can be beneficial or 
detrimental. 
In virus diseases tested, IL-37b is generally protective in Influenza and coxsackie 
virus B3 (CVB3) infection. The IL-37-mediated beneficial effect was largely 
attributed to its role in the downregulation of virus-induced inflammatory response. 
Intriguingly, IL-37 can also directly suppress the replication of influenza virus in 
epithelia cells. Thus, IL-37b may be potentially therapeutic in the treatment of virus 
infections.  
The role of IL-37 in mycobacterium tuberculosis (Mtb) and Streptococcus pneumonia 
infection is controversial, depending on the bacterial and immune context, and 
could be beneficial or detrimental. This certainly is the case in Mtb infection in mice 
and in human. More studies are needed to clarify the issue. 
In Streptococcus pneumonia (SP) infections, IL-37 appears to be pathogenic by 
harnessing the protective inflammatory response and promoting bacterial growth. 
Thus, IL-37 is a potential therapeutic target molecule. 
Similar to SP infection, IL-37 also promotes candida infection, enhanced fungal 
growth in the organ and mortality. IL-37b does so also by downregulating the 
protective inflammatory cytokine produces and the recruitment of neutrophils to 
the site of infection. In contrast, IL-37-reduced inflammatory response and 
increased IL-10 production in lung tissue during aspergillosis is protective against 
aspergillus infection. Thus, it is clinically important to understand the contradictory 
role of IL-37-medidated anti-inflammatory effect in the outcome to bacterial 
infection. 
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Finally, the impact of IL-37 on parasite infection is less studied and largely unknown. 
Given the clinical importance of parasite infection in human health, more attention 
should be paid to this ignored area.  
Thus, IL-37 may have impact on the treatment and prognostic of infectious diseases, 
dependent on type of pathogen. Future studies should focus on the systemic effect 
of IL-37 on homeostasis and immunity in infectious disorders. While the basic 
research from animal models has greatly enhanced our knowledge of the potential 
application of IL-37 in clinical diseases, its importance in human disease is less 
understood. The function and relation of other IL-37 isoforms, including IL-37a in 
human diseases is still largely unknown. Since IL-37 is selectively expressed in human 
but not mice it will be interesting to see whether this can influence host 
resistance/susceptibility to infection in mice and human. 
 
6.4 What is the impact of IL-37a on immunoregulation of 
inflammation? 
The immune response is tightly controlled by multiple mechanisms including 
regulatory cytokines (Murphy and Weaver, 2016). Dysregulation of any step of the 
initiation, propagation and resolution of the immune response will increase the risk 
of developing an inflammatory disorder.  
An inflammatory response can be initiated by antigen-dependent or independent 
mechanisms. In the former, an inflammatory response can be initiated by a 
dysregulated antigen-presenting cell (APC) and/or dysregulated adaptive immune 
cell function. In the latter, physical (e.g. injury or heat), chemical or biological 
factors (e.g. toxins, PAMPs) can damage host tissue. This damage will initiate the 
release of alarmins and DAMPs, for example, inflammatory cytokines IL-1 and IL-33 
in innate immune cells located in the damaged tissue (Abbes et al., 2011). The 
released DAMPs and PAMPs will then activate more innate immune cells that 
expressing the appropriate receptors, for example, macrophages, neutrophil and 
mast cells, and will induce these cells to produce more inflammatory cytokines 
which will amplify the  acute inflammatory response (Tang et al., 2012). In both 
contexts, if the innate and adaptive immune response is intense and/or persistent, 
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it may cause tissue damage and death, for example, LPS-induced shock in infectious 
diseases and autoimmune disorders respectively. 
While the detailed mechanism by which IL-37a regulates the inflammatory response 
is still largely unknown, our early results suggest that IL-37a may play an important 
role in the regulation of key steps of innate and adaptive inflammatory response. 
This new knowledge has improved our understanding of the immunoregulation of 
inflammation in several aspects as follows:  
 
6.4.1 IL-37a governs ongoing innate and adaptive inflammatory responses in a 
negative immunoregulatory feedback-loop 
Until now the relative induction and expression of different IL-37 isoforms in immune 
cells were unknown. We demonstrated that IL-37a is the predominant induced 
isoform in TLR-stimulated human PBMCs. We also found that IL-37a is widely 
expressed by most innate immune cells, including macrophages, monocytes, and DCs 
(Xu, data not shown). Following LPS stimulation, we demonstrated that monocytes 
express highest levels of IL-37 mRNA, including IL-37a among the immune cells, 
therefore monocytes may represent the main source of IL-37 in humans.  Tissue cells, 
fibroblasts and epithelial cells also express IL-37a mRNA, suggesting that local IL-
37a may contribute to regulation of the inflammatory response in stromal tissue. 
Furthermore, resting immune cells express constitutively low levels of IL-37a and 
this expression can be markedly enhanced by inflammatory mediators, for example, 
by TLR ligands and inflammatory cytokines IL-1 and TNFα. This is partly because the 
IL-37 mRNA contains an instability element which can be stabilised by inflammatory 
signals (Bufler et al., 2004).  
The impact of IL-37a on the adaptive immune response is less well understood and 
is currently under investigation. Our early results indicate that T and B cells express 
IL-37a, and that importantly, IL-37a and IL-37b can regulate DC, T and B cell 
functions. It has been shown that IL-37b plays an important role in the regulation of 
adaptive immune responses by interfering DC antigen presentation and Th1 and Th17 
cell polarisation and function in inflammatory and autoimmune diseases (Nold-Petry 
et al., 2015; Boraschi et al., 2011). Since IL-37a and IL-37b signal via the same 
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receptor it is anticipated that IL-37a might have same effects as IL-37b. It is already 
known that the IL-37 receptor complex, IL-18R and IL-1R8 is expressed by almost all 
innate and adaptive immune cells (Lech et al., 2007). However, the selective 
expression and location of IL-37 isoforms in human tissues is largely unknown, mainly 
due to the lack of specific antibodies for tissue staining by immunohistochemistry.  
Thus, IL-37a can directly and indirectly affect innate and adaptive immune cell 
function in autocrine and paracrine fashions.  
Since IL-37a is induced by inflammatory factors and hinders ongoing inflammatory 
responses, IL-37a may have evolved to restrain aberrant hyper-reactivity, but not to 
interfere with normal immune activation. Therefore, IL-37a may be an early 
checkpoint of the inflammatory response.   
 
6.4.2 IL-37a can regulate the inflammatory response by IL-1R8-dependent and 
independent mechanisms 
We demonstrated that recombinant IL-37a inhibits the in vitro production of 
inflammatory cytokines IL-1 and TNFα by LPS-stimulated splenocytes from WT but 
not IL-1R8-/- mice. This suggested that IL-37a and IL-37b shared the same functional 
receptor because both isoforms contain the IL-1-like domain for receptor binding 
and signalling. Further experiments are needed to study in detail how IL-37a signals 
via IL-1R8 and whether the co-receptor IL-18R is required for signalling.  
A striking feature of IL-37a is its nuclear localisation via its NLS; no other IL-37 
isoforms has the capability. I have not studied the nuclear function of IL-37a as part 
of my thesis, others in my research team have found that nuclear IL-37a can interact 
with several nuclear proteins and can regulate inflammatory response by receptor-
independent mechanism, for example, the N-terminal IL-37a in the nuclear can 
suppress MAPK13 and TNFα (Xu, D et al, unpublished result). Thus, IL-37a is a dual 
functional immunoregulatory factor that can control inflammatory responses via 
receptor dependent and independent pathways. 
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6.4.3 IL-37a can help identify different human and mouse immunoregulation 
systems 
Since IL-37 is expressed in humans but not in mice, a comparative study of IL-37 
function will help to understand different mechanisms by which mice and humans 
regulate inflammatory disease. This is an important issue because the mouse has 
been widely used as an exploratory model for many human immune responses and 
diseases. Whereas the immunological meaning of the differential requirement of IL-
37 in the human and mouse remains unclear, experimental results from our and 
other group (Nold-petry et al., 2015) suggest that the selective expression of IL-37 
makes the human immune system more manageable than the mouse. This may 
contribute to better regulation of inflammatory diseases in humans. However, we 
found evidence for more subtle complexity in the role of IL-37. In a salmonella 
infection model we founds that transgenic expression of IL-37a in mice renders them 
less resistant to salmonella infection. We also found that this was in part due to IL-
37 inhibition of microbicidal nitric oxide and inflammatory cytokine production. This 
suggests that the selective expression of IL-37a may make human more susceptible 
and mouse resistant to infection, and that evolutionary loss of IL-37 in the wild may 
help survival.  The relative function of IL-37 in humans and mice may need to be 
considered in the limitation of mouse model in the study of mechanisms of infection 
and perhaps other human immune-mediated disease that involves IL-37. 
6.4.4 IL-37 isoforms act as a composite regulatory system in which IL-37a has a 
dominant role. 
Among the five IL-37 isoforms (IL-37a-e), the three isoforms (IL-37a, b and d) with 
an intact IL-1-like domain are found to have immunosuppressive function. Therefore, 
these isoforms may represent a novel immunoregulatory checkpoint to ensure the 
inflammatory response is under control.  
It is intriguing to better understand the functional differences between the isoforms, 
and their relative importance in immunoregulation. During my thesis I found that IL-
37a and b are the most responsive to induction by TLR ligands in human PBMCs, and 
that IL-37a is more immunosuppressive than IL-37b in TLR response in vitro and in 
vivo. This is mainly attributed to the additional regulatory effect of nuclear IL-37a. 
Given that among the isoforms, IL-37b and d share greatest similarity in protein 
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sequence and function, it is likely IL-37a may be the dominant isoform in IL-37-
mediated effects. Future investigations, in particularly in diseases will confirm this 
hypothesis. 
The difference and interaction between IL-37 and other known regulatory cytokines, 
including IL-10 and TGFβ has not been fully investigated. Current evidence suggests 
that IL-10 and TGFβ are pleotropic cytokines that can inhibit or enhance certain type 
of immune responses. In contrast, IL-37 seems to be predominantly 
immunosuppressive. Furthermore, IL-37-mediated immunosuppression is 
independent of IL-10 and TGFβ, and IL-37 can inhibit IL-10 and TGFβ function, for 
example in psoriasis and fibrosis, respectively (Teng et al., 2014; Kim et al., 2019). 
More studies are needed to understand their inter-relationship in immunoregulation. 
 
6.5 Future directions for study 
The study of IL-37a is in its infancy; there are many more questions than answers.  
For my future research, I will undertake the following projects:  
1. Difference between human and mice in Salmonella infection - role of IL-
37a 
I have discussed with my supervisor Dr Xu and the following experiments to complete 
the current project and produce a publication. 
- Human study: Collect blood samples from healthy donors and patients with 
salmonella infection and determine their difference in IL-37 isoforms, 
inflammatory cytokines and iNOS expression in PBMC by qPCR and mediator 
concentrations in serum by ELISA. I would predict here that the Salmonella 
infected patients may have higher IL-37 gene expression and protein expression, 
which may lead to the downregulation of pro-inflammatory cytokine expression. 
However, the IL-37 level may also regulate by some unknow mechanism which 
protect patients from bacteria burden. 
 
Confirm the difference between human and mouse in salmonella infection in 
primary macrophages in vitro. 
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In vivo study: We sought to using WT Salmonella typhimurium strain to further 
confirm the IL-37 effect in attenuate salmonella infection. This is a real infection 
model and allows to observe the protective effect of IL-37 on salmonella-induced 
mortality.  
 
In order to reveal receptor-dependency of the IL-37a mediated effect on 
salmonella infection, the experiment can also be done in an IL-37aTg/IL-1R8-/- 
mouse strain which is now available. 
 
Immune mechanism study: the regulatory role of IL-37a on adaptive immune 
response is less well understood. Since a Th1 response is required for the 
resolution of salmonella infection, the potential role of IL-37a in DC function, 
Th1 development, migration and function will be studied. 
 
Molecular mechanism: how IL-37a inhibits NO expression is unknown and will be 
studied in detail. If IL-37a affects Th1 development and/or function, the 
molecular mechanism will also be revealed.  
Together, these experiments and the findings in my thesis will provide a fuller 
picture on how IL-37a regulates salmonella infection in human and in transgenic 
mice. 
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2. Potential therapeutic effect of IL-37a in inflammatory disorders: 
We and others have demonstrated in vitro and in vivo the immunosuppressive effects 
of IL-37a and b, respectively, on inflammatory response development by using 
transgenic mice, virus vector and recombinant protein. While the preventive effect 
is important, there is no convincing evidence that IL-37 has a therapeutic effect in 
disease models in vivo using current approaches. This is mainly because the natural 
IL-37 protein exists in a monomeric form and only the monomer but not the 
homodimer is bioactive and current recombinant IL-37 proteins are largely 
homodimer. By using point mutation of the amino acid involved in the dimerization, 
we have successfully produced recombinant IL-37a monomers that are substantially 
more suppressive than the dimer in in vitro assay (Chapter 3). The recombinant IL-
37a monomer proteins will be used to test its therapeutic potential in a variety of 
infectious and autoimmune disease models, including salmonella infection, collagen 
induced arthritis and psoriasis in mice. If IL-37a is therapeutic and safe, its 
application in human diseases might be considered. 
  
  
267 
 
References 
 
1. Abbas, A., Lichtman, A. and Pillai, S. (2012). Cellular and molecular 
immunology. Philadelphia: Elsevier, 
2. Aderem, A. and Underhill, D. (1999). Mechanisms of Phagocytosis In 
Macrophages. Annual Review of Immunology, 17(1), pp.593-623.  
3. Akira, S., Uematsu, S., Takeuchi, O. (2006). Pathogen recognition and 
innate immunity.Cell, 124(4), PP. 783–801 
4. Alber, A., Howie, S., Wallace, W. and Hirani, N. (2012). The role of 
macrophages in healing the wounded lung. International Journal of 
Experimental Pathology, 93(4), pp.243-251. 
5. Allam, G., Gaber, A.M., Othman, S.I. and Abdel-Moneim, A., 2019. The 
potential role of interleukin-37 in infectious diseases. International 
reviews of immunology, pp.1-8. 
6. An, B., Liu, X., Li, G. and Yuan, H., 2017. Interleukin-37 ameliorates 
coxsackievirus B3-induced viral myocarditis by modulating the 
Th17/regulatory T cell immune response. Journal of cardiovascular 
pharmacology, 69(5), pp.305-313. 
7. Anuradha, R., Munisankar, S., Bhootra, Y., Dolla, C., Kumaran, P., 
Nutman, T.B. and Babu, S., 2017. Modulation of CD4+ and CD8+ T cell 
function and cytokine responses in Strongyloides stercoralis infection by 
interleukin-27 (IL-27) and IL-37. Infection and immunity, 85(11), 
pp.e00500-17. 
 
268 
 
8. Aoki-Kinoshita, K.F. and Kanehisa, M., 2007. Gene annotation and 
pathway mapping in KEGG. In Comparative Genomics (pp. 71-91). Humana 
Press. 
9. Arndt, C., Koristka, S., Bartsch, H. and Bachmann, M., 2012. Native 
polyacrylamide gels. In Protein electrophoresis (pp. 49-53). Humana 
Press, Totowa, NJ. 
10. Arulraj, T. and Barik, D., 2018. Mathematical modeling identifies Lck as a 
potential mediator for PD-1 induced inhibition of early TCR signaling. PloS 
one, 13(10), p.e0206232. 
11. Bajpai, V., Baek, K. and Kang, S. (2012). Control of Salmonella in foods by 
using essential oils: A review. Food Research International, 45(2), pp.722-
734. 
12. Ballak, D.B., Van Diepen, J.A., Moschen, A.R., Jansen, H.J., Hijmans, A., 
Groenhof, G.J., Leenders, F., Bufler, P., Boekschoten, M.V., Müller, M. 
and Kersten, S., 2014. IL-37 protects against obesity-induced inflammation 
and insulin resistance. Nature communications, 5, p.4711. 
13. Berry, M.P.R., Blankley, S., Graham, C.M., Bloom, C.I. and O’Garra, A., 
2013. Systems approaches to studying the immune response in 
tuberculosis. Current opinion in immunology, 25(5), pp.579-587. 
14. Beutler, B., Jiang, Z., Georgel, P., Crozat, K., Croker, B., Rutschmann, S., 
Du, X. and Hoebe, K., 2006. Genetic analysis of host resistance: Toll-like 
receptor signaling and immunity at large. Annu. Rev. Immunol., 24, 
pp.353-389. 
15. Bollag, D.M. and Edelstein, S.J., 1991. Protein methods. Wildy-Liss. Inc., 
New York, NY. 
269 
 
16. Boraschi, D., Lucchesi, D., Hainzl, S., Leitner, M., Maier, E., 
Mangelberger, D., Oostingh, G.J., Pfaller, T., Pixner, C., Posselt, G. and 
Italiani, P., 2011. IL-37: a new anti-inflammatory cytokine of the IL-1 
family. European cytokine network, 22(3), pp.127-147. 
17. Bouali, E., Kaabachi, W., Hamzaoui, A. and Hamzaoui, K., 2015. 
Interleukin-37 expression is decreased in Behçet's disease and is 
associated with inflammation. Immunology letters, 167(2), pp.87-94. 
18. Breuer, K., Foroushani, A., Laird, M., Chen, C., Sribnaia, A., Lo, R., 
Winsor, G., Hancock, R., Brinkman, F. and Lynn, D. (2012). InnateDB: 
systems biology of innate immunity and beyond—recent updates and 
continuing curation. Nucleic Acids Research, 41(D1), pp.D1228-D1233. 
19. Bufler, P., Gamboni-Robertson, F., Tania, A.Z.A.M., Soo-Hyun, K.I.M. and 
Dinarello, C.A., 2004. Interleukin-1 homologues IL-1F7b and IL-18 contain 
functional mRNA instability elements within the coding region responsive 
to lipopolysaccharide. Biochemical Journal, 381(2), pp.503-510. 
20. Bulau, A.M., Nold, M.F., Li, S., Nold-Petry, C.A., Fink, M., Mansell, A., 
Schwerd, T., Hong, J., Rubartelli, A., Dinarello, C.A. and Bufler, P., 2014. 
Role of caspase-1 in nuclear translocation of IL-37, release of the 
cytokine, and IL-37 inhibition of innate immune responses. Proceedings of 
the National Academy of Sciences, 111(7), pp.2650-2655. 
21. Busfield, S.J., Comrack, C.A., Yu, G., Chickering, T.W., Smutko, J.S., 
Zhou, H., Leiby, K.R., Holmgren, L.M., Gearing, D.P. and Pan, Y., 2000. 
Identification and gene organization of three novel members of the IL-1 
family on human chromosome 2. Genomics, 66(2), pp.213-216. 
22. Carruth, L.M., Demczuk, S. and Mizel, S.B., 1991. Involvement of a 
calpain-like protease in the processing of the murine interleukin 1 alpha 
precursor. Journal of Biological Chemistry, 266(19), pp.12162-12167. 
270 
 
23. Carson, M., Johnson, D.H., McDonald, H., Brouillette, C. and DeLucas, 
L.J., 2007. His-tag impact on structure. Acta Crystallographica Section D: 
Biological Crystallography, 63(3), pp.295-301. 
24. Casals, C., Barrachina, M., Serra, M., Lloberas, J. and Celada, A. (2007). 
Lipopolysaccharide Up-Regulates MHC Class II Expression on Dendritic Cells 
through an AP-1 Enhancer without Affecting the Levels of CIITA. The 
Journal of Immunology, 178(10), pp.6307-6315. 
25. Castleberry, J., Scott, A., Alusta, P., Soderberg, L. and Tarasenko, O. 
(2008). P7. Nitric oxide involved in macrophage activation and 
neutralization of Bacillus anthracis toxins during glycoconjugate 
treatment. Nitric Oxide, 19, p.1. 
26. CDC. FoodNet 2011 Surveillance Report. 
27. Chang, K., Song, J.Y. and Lim, D.S., 2017. Tolerogenic dendritic cell-
based immunotherapy. Oncotarget, 8(53), p.90630. 
28. Charrad, R., Berraïes, A., Hamdi, B., Ammar, J., Hamzaoui, K. and 
Hamzaoui, A. (2016). Anti-inflammatory activity of IL-37 in asthmatic 
children: Correlation with inflammatory cytokines TNF-α, IL-β, IL-6 and IL-
17A. Immunobiology, 221(2), pp.182-187. 
29. Chen, W., 2011. Tregs in immunotherapy: opportunities and 
challenges. Immunotherapy, 3(8), pp.911-914. 
30. Crotty, S., 2014. T follicular helper cell differentiation, function, and 
roles in disease. Immunity, 41(4), pp.529-542. 
31. Coburn, B., Grassl, G.A. and Finlay, B.B., 2007. Salmonella, the host and 
disease: a brief review. Immunology and cell biology, 85(2), pp.112-118. 
271 
 
32. Conesa, A., Madrigal, P., Tarazona, S., Gomez-Cabrero, D., Cervera, A., 
McPherson, A., Szcześniak, M.W., Gaffney, D.J., Elo, L.L., Zhang, X. and 
Mortazavi, A., 2016. A survey of best practices for RNA-seq data 
analysis. Genome biology, 17(1), p.13. 
33. Conti, P. (2017). Possible role of mast cells and IL-37 in the pathogenesis 
of psoriasis. Clinical Dermatology, 5(1), p.30. 
34. Conti, P., Ronconi, G., Caraffa, A., Lessiani, G. and Duraisamy, K. (2016). 
IL-37 a New IL-1 Family Member Emerges as a Key Suppressor of Asthma 
Mediated by Mast Cells. Immunological Investigations, 46(3), pp.239-250. 
35. Corliss, B.A., Azimi, M.S., Munson, J.M., Peirce, S.M. and Murfee, W.L., 
2016. Macrophages: an inflammatory link between angiogenesis and 
lymphangiogenesis. Microcirculation, 23(2), pp.95-121. 
36. Crump, J.A., Luby, S.P. and Mintz, E.D., 2004. The global burden of 
typhoid fever. Bulletin of the World Health Organization, 82, pp.346-353. 
37. de Sousa, J.R., Prudente, R.L., Junior, L.B.D., Carneiro, F.R.O., Sotto, 
M.N. and Quaresma, J.A.S., 2018. IL-37 and leprosy: A novel cytokine 
involved in the host response to Mycobacterium leprae 
infection. Cytokine, 106, pp.89-94. 
38. Delves, P. and Roitt, I. (2011). Roitt's essential immunology. Chichester, 
West Sussex: Wiley-Blackwell. 
39. Demain, A.L. and Vaishnav, P., 2009. Production of recombinant proteins 
by microbes and higher organisms. Biotechnology advances, 27(3), pp.297-
306. 
40. Di Stefano, A., Caramori, G., Barczyk, A., Vicari, C., Brun, P., Zanini, A., 
Cappello, F., Garofano, E., Padovani, A., Contoli, M. and Casolari, P., 
272 
 
2014. Innate immunity but not NLRP3 inflammasome activation correlates 
with severity of stable COPD. Thorax, 69(6), pp.516-524. 
41. Dinarello, C., Arend, W., Sims, J., Smith, D., Blumberg, H., O'Neill, L., 
Goldbach-Mansky, R., Pizarro, T., Hoffman, H., Bufler, P. and Nold, M., 
2010. IL-1 family nomenclature. Nature immunology, 11(11), p.973. 
42. Dinarello, C., Nold-Petry, C., Nold, M., Fujita, M., Li, S., Kim, S. and 
Bufler, P. (2016). Suppression of innate inflammation and immunity by 
interleukin-37. European Journal of Immunology, 46(5), pp.1067-1081. 
43. Dinarello, C.A., 2009. Immunological and inflammatory functions of the 
interleukin-1 family. Annual review of immunology, 27, pp.519-550. 
44. Dinarello, C.A., Nold‐Petry, C., Nold, M., Fujita, M., Li, S., Kim, S. and 
Bufler, P., 2016. Suppression of innate inflammation and immunity by 
interleukin‐37. European journal of immunology, 46(5), pp.1067-1081. 
45. Ding, C., Chen, X., Dascani, P., Hu, X., Bolli, R., Zhang, H., Mcleish, K. 
andYan, J. (2016). STAT3 Signaling in B Cells Is Critical for Germinal 
Center Maintenance and Contributes to the Pathogenesis of Murine Models 
of Lupus. The Journal of Immunology, 196(11), pp.4477-4486. 
46. Ding, V.A., Zhu, Z., Xiao, H., Wakefield, M.R., Bai, Q. and Fang, Y., 2016. 
The role of IL-37 in cancer. Medical oncology, 33(7), p.68. 
47. Dullah, E.C. and Ongkudon, C.M., 2017. Current trends in endotoxin 
detection and analysis of endotoxin–protein interactions. Critical reviews 
in biotechnology, 37(2), pp.251-261. 
48. Eisenmesser, E.Z., Gottschlich, A., Redzic, J.S., Paukovich, N., Nix, J.C., 
Azam, T., Zhang, L., Zhao, R., Kieft, J.S., Meng, X. and Dinarello, C.A., 
2019. Interleukin-37 monomer is the active form for reducing innate 
273 
 
immunity. Proceedings of the National Academy of Sciences, 116(12), 
pp.5514-5522. 
49. Ellisdon, A.M., Nold-Petry, C.A., D’Andrea, L., Cho, S.X., Lao, J.C., 
Rudloff, I., Ngo, D., Lo, C.Y., da Costa, T.P.S., Perugini, M.A. and Conroy, 
P.J., 2017. Homodimerization attenuates the anti-inflammatory activity of 
interleukin-37. Science immunology, 2(8), p.eaaj1548. 
50. Elmadani M, Khan S, Tenhunen O, Magga J, Aittokallio T, Wennerberg K, 
Kerkelä R. Novel Screening Method Identifies PI 3Kα, mTOR, and IGF 1R as 
Key Kinases Regulating Cardiomyocyte Survival. Journal of the American 
Heart Association. 2019 Nov 5;8(21):e013018. 
51. Elmadani, M., Khan, S., Tenhunen, O., Magga, J., Aittokallio, T., 
Wennerberg, K. and Kerkelä, R., 2019. Novel Screening Method Identifies 
PI 3Kα, mTOR, and IGF 1R as Key Kinases Regulating Cardiomyocyte 
Survival. Journal of the American Heart Association, 8(21), p.e013018. 
52. Fàbrega, A. and Vila, J., 2013. Salmonella enterica serovar Typhimurium 
skills to succeed in the host: virulence and regulation. Clinical 
microbiology reviews, 26(2), pp.308-341. 
53. Fairweather, D., Frisancho‐Kiss, S. and Rose, N.R., 2005. Viruses as 
adjuvants for autoimmunity: evidence from Coxsackievirus‐induced 
myocarditis. Reviews in medical virology, 15(1), pp.17-27. 
54. Fierer, J. and Guiney, D.G., 2001. Diverse virulence traits underlying 
different clinical outcomes of Salmonella infection. The Journal of clinical 
investigation, 107(7), pp.775-780. 
55. Fonseca-Camarillo, G., Furuzawa-Carballeda, J. and Yamamoto-Furusho, 
J.K., 2015. Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral 
274 
 
expression by T and B regulatory cells in patients with Inflammatory Bowel 
Disease. Cytokine, 75(2), pp.389-402. 
56. Garlanda, C., Anders, H. and Mantovani, A. (2009). TIR8/SIGIRR: an IL-
1R/TLR family member with regulatory functions in inflammation and T 
cell polarization. Trends in Immunology, 30(9), pp.439-446. 
57. Garlanda, C., Dinarello, C. and Mantovani, A. (2013). The Interleukin-1 
Family: Back to the Future. Immunity, 39(6), pp.1003-1018. 
58. Garlanda, C., Riva, F., Polentarutti, N., Buracchi, C., Sironi, M., De 
Bortoli, M., Muzio, M., Bergottini, R., Scanziani, E., Vecchi, A. and Hirsch, 
E., 2004. Intestinal inflammation in mice deficient in Tir8, an inhibitory 
member of the IL-1 receptor family. Proceedings of the National Academy 
of Sciences, 101(10), pp.3522-3526. 
59. Gewirtz, A.T., Navas, T.A., Lyons, S., Godowski, P.J. and Madara, J.L., 
2001. Cutting edge: bacterial flagellin activates basolaterally expressed 
TLR5 to induce epithelial proinflammatory gene expression. The Journal 
of Immunology, 167(4), pp.1882-1885. 
60. Godaly, G., Bergsten, G., Hang, L., Fischer, H., Frendeus, B., Lundstedt, 
A.C., Samuelsson, M., Samuelsson, P. and Svanborg, C., 2001. Neutrophil 
recruitment, chemokine receptors, and resistance to mucosal 
infection. Journal of Leukocyte Biology, 69(6), pp.899-906. 
61. Golubovskaya, V. and Wu, L., 2016. Different subsets of T cells, memory, 
effector functions, and CAR-T immunotherapy. Cancers, 8(3), p.36. 
62. Gordon, S. M. et al. The transcription factors T-bet and Eomes control key 
checkpoints of natural killer cell maturation. Immunity 36, 55–67 (2012) 
275 
 
63. Gowda, D.C., 2007. TLR-mediated cell signaling by malaria GPIs. Trends in 
parasitology, 23(12), pp.596-604. 
64. Grimsby, S., Jaensson, H., Dubrovska, A., Lomnytska, M., Hellman, U. and 
Souchelnytskyi, S. (2004). Proteomics-based identification of proteins 
interacting with Smad3: SREBP-2 forms a complex with Smad3 and inhibits 
its transcriptional activity. FEBS Letters, 577(1-2), pp.93-100. 
65. Gu, J., Gao, X., Pan, X., Peng, X., Li, Y. and Li, M., 2015. High-level 
expression and one-step purification of a soluble recombinant human 
interleukin-37b in Escherichia coli. Protein expression and 
purification, 108, pp.18-22. 
66. Guillou, C., Derambure, C., Fréret, M., Verdet, M., Avenel, G., Golinski, 
M., Sabourin, J., Loarer, F., Adriouch, S., Boyer, O., Lequerré, T. and 
Vittecoq, O. (2015). Prophylactic Injection of Recombinant Alpha-Enolase 
Reduces Arthritis Severity in the Collagen-Induced Arthritis Mice Model. 
PLOS ONE, 10(8), p.e0136359. 
67. Haabeth, O.A.W., Tveita, A.A., Fauskanger, M., Schjesvold, F., Lorvik, 
K.B., Hofgaard, P.O., Omholt, H., Munthe, L.A., Dembic, Z., Corthay, A. 
and Bogen, B., 2014. How do CD4+ T cells detect and eliminate tumor 
cells that either lack or express MHC class II molecules?. Frontiers in 
immunology, 5, p.174. 
68. Hanna, L.F., Matthews, T.D., Dinsdale, E.A., Hasty, D. and Edwards, R.A., 
2012. Characterization of the ELPhiS prophage from Salmonella enterica 
serovar Enteritidis strain LK5. Appl. Environ. Microbiol., 78(6), pp.1785-
1793. 
69. Hardy, R. and Hayakawa, K. (2001). B Cell Development Pathways. Annual 
Review of Immunology, 19(1), pp. 595-621. 
276 
 
70. Hayakawa, H., Hayakawa, M., Kume, A. and Tominaga, S. (2007). Soluble 
ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation. 
Journal of Biological Chemistry, 282(36), pp.26369-26380. 
71. Hayashi, F., Smith, K.D., Ozinsky, A., Hawn, T.R., Eugene, C.Y., Goodlett, 
D.R., Eng, J.K., Akira, S., Underhill, D.M. and Aderem, A., 2001. The 
innate immune response to bacterial flagellin is mediated by Toll-like 
receptor 5. Nature, 410(6832), p.1099. 
72. Healey, R., Lebhar, H., Hornung, S., Thordarson, P. and Marquis, C. 
(2017). An improved process for the production of highly purified 
recombinant thaumatin tagged-variants. Food Chemistry, 237, pp.825-
832. 
73. Højen, J.F., Rasmussen, T.A., Andersen, K.L.D., Winckelmann, A.A., 
Laursen, R.R., Gunst, J.D., Møller, H.J., Fujita, M., Østergaard, L., 
Søgaard, O.S. and Dinarello, C.A., 2015. Interleukin-37 expression is 
increased in chronic HIV-1-infected individuals and is associated with 
inflammation and the size of the total viral reservoir. Molecular 
Medicine, 21(1), pp.337-345. 
74. Holdsworth SR, Gan PY. Cytokines: names and numbers you should care 
about. Clinical Journal of the American Society of Nephrology. 2015 Dec 
7;10(12):2243-54. 
75. Hölscher C. The power of combinatorial immunology: IL-12 and IL-12-
related dimeric cytokines in infectious diseases. Medical microbiology and 
immunology. 2004 Feb 1;193(1):1-7. 
76. Huang, J., Hou, F., Zhang, A. and Li, Z. (2016). Protective effect of the 
polarity of macrophages regulated by IL-37 on atherosclerosis. Genetics 
and Molecular Research, 15(2). 
277 
 
77. Huang, Z., Gao, C., Chi, X., Hu, Y., Zheng, L., Zeng, T. and Wang, Q. 
(2015). IL-37 Expression is Upregulated in Patients with Tuberculosis and 
Induces Macrophages Towards an M2-like Phenotype. Scandinavian Journal 
of Immunology, 82(4), pp.370-379. 
78. Huang, Z., Gao, C., Chi, X., Hu, Y.W., Zheng, L., Zeng, T. and Wang, Q., 
2015. IL‐37 expression is upregulated in patients with tuberculosis and 
induces macrophages towards an M2‐like phenotype. Scandinavian journal 
of immunology, 82(4), pp.370-379. 
79. Imaeda, H., Takahashi, K., Fujimoto, T., Kasumi, E., Ban, H., Bamba, S., 
Sonoda, H., Shimizu, T., Fujiyama, Y. and Andoh, A. (2013). Epithelial 
expression of interleukin-37b in inflammatory bowel disease. Clinical & 
Experimental Immunology, 172(3), pp.410-416. 
80. Ji, Q., Meng, K., Yu, K., Huang, S., Huang, Y., Min, X., Zhong, Y., Wu, B., 
Liu, Y., Nie, S. and Zhang, J., 2017. Exogenous interleukin 37 ameliorates 
atherosclerosis via inducing the Treg response in ApoE-deficient 
mice. Scientific reports, 7(1), p.3310. 
81. Jia, H., Liu, J. and Han, B. (2018). Reviews of Interleukin-37: Functions, 
Receptors, and Roles in Diseases. BioMed Research International, 2018, 
pp.1-14. 
82. Jiang, X. and Chen, Z.J., 2012. The role of ubiquitylation in immune 
defence and pathogen evasion. Nature Reviews Immunology, 12(1), p.35. 
83. Jin, Y., Liu, L., Zhang, S., Tao, B., Tao, R., He, X., Qu, L., Huang, J., 
Wang, X. and Fu, Z., 2016. Chromium alters lipopolysaccharide-induced 
inflammatory responses both in vivo and in vitro. Chemosphere, 148, 
pp.436-443. 
84. Joseph, B.C., Pichaimuthu, S., Srimeenakshi, S., Murthy, M., Selvakumar, 
K., Ganesan, M. and Manjunath, S.R., 2015. An overview of the 
278 
 
parameters for recombinant protein expression in Escherichia coli. J Cell 
Sci Ther, 6(05), p.1. 
85. Jung, C., Meinzer, U., Montcuquet, N., Thachil, E., Château, D., Thiébaut, 
R., Roy, M., Alnabhani, Z., Berrebi, D., Dussaillant, M. and Pedruzzi, E., 
2012. Yersinia pseudotuberculosis disrupts intestinal barrier integrity 
through hematopoietic TLR-2 signaling. The Journal of clinical 
investigation, 122(6), pp.2239-2251. 
86. Kalderon, D., Roberts, B.L., Richardson, W.D. and Smith, A.E., 1984. A 
short amino acid sequence able to specify nuclear location. Cell, 39(3), 
pp.499-509. 
87. Kalghatgi, S., Spina, C.S., Costello, J.C., Liesa, M., Morones-Ramirez, 
J.R., Slomovic, S., Molina, A., Shirihai, O.S. and Collins, J.J., 2013. 
Bactericidal antibiotics induce mitochondrial dysfunction and oxidative 
damage in mammalian cells. Science translational medicine, 5(192), 
pp.192ra85-192ra85. 
88. Kanai, K., Satoh, Y., Yamanaka, H., Kawaguchi, A., Horie, K., Sugata, K., 
Hoshikawa, Y., Sata, T. and Sairenji, T., 2007. The vIL-10 gene of the 
Epstein-Barr virus (EBV) is conserved in a stable manner except for a few 
point mutations in various EBV isolates. Virus genes, 35(3), pp.563-569. 
89. Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. and Morishima, K., 
2016. KEGG: new perspectives on genomes, pathways, diseases and 
drugs. Nucleic acids research, 45(D1), pp.D353-D361. 
90. Kaplan, M.H., 2013. Th9 cells: differentiation and disease. Immunological 
reviews, 252(1), pp.104-115. 
279 
 
91. Kaur, J. and Reinhardt, D.P., 2012. Immobilized metal affinity 
chromatography co-purifies TGF-β1 with histidine-tagged recombinant 
extracellular proteins. PLoS One, 7(10), p.e48629. 
92. Kavathas PB, Boeras CM, Mulla MJ, Abrahams VM. Nod1, but not the ASC 
inflammasome, contributes to induction of IL-1β secretion in human 
trophoblasts after sensing of ChlaMyDia trachomatis. Mucosal immunology. 
2013 Mar;6(2):235. 
93. Keermann, M., Kõks, S., Reimann, E., Abram, K., Erm, T., Silm, H. and 
Kingo, K., 2015. Expression of IL-36 family cytokines and IL-37 but not IL-
38 is altered in psoriatic skin. Journal of dermatological science, 80(2), 
pp.150-152. 
94. Kosmidis, C. and Denning, D.W., 2015. The clinical spectrum of pulmonary 
aspergillosis. Thorax, 70(3), pp.270-277. 
95. Koyama, F., Sawada, H., Fujii, H., Hirao, T., Ueno, M., Hamada, H. and 
Nakano, H., 2000. Enzyme/prodrug gene therapy for human colon cancer 
cells using adenovirus-mediated transfer of the Escherichia coli cytosine 
deaminase gene driven by a CAG promoter associated with 5-
fluorocytosine administration. Journal of experimental & clinical cancer 
research: CR, 19(1), pp.75-80. 
96. Kumar, S., Hanning, C.R., Brigham-Burke, M.R., Rieman, D.J., Lehr, R., 
Khandekar, S., Kirkpatrick, R.B., Scott, G.F., Lee, J.C., Lynch, F.J. and 
Gao, W., 2002. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 
and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-γ 
production. Cytokine, 18(2), pp.61-71. 
97. Lassoued, K. (1993). Expression of surrogate light chain receptors is 
restricted to a late stage in pre-B cell differentiation. Cell, 73(1), pp.73-
86. 
280 
 
98. Lech, M., Garlanda, C., Mantovani, A., Kirschning, C., Schlöndorff, D. and 
Anders, H. (2007). Different roles of TiR8/Sigirr on toll-like receptor 
signaling in intrarenal antigen-presenting cells and tubular epithelial 
cells. Kidney International, 72(2), pp.182-192. 
99. Léger B, Cartoni R, Praz M, Lamon S, Dériaz O, Crettenand A, Gobelet C, 
Rohmer P, Konzelmann M, Luthi F, Russell AP. Akt signalling through GSK‐
3β, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and 
atrophy. The Journal of physiology. 2006 Nov 1;576(3):923-33. 
100. Leveque, G., Forgetta, V., Morroll, S., Smith, A.L., Bumstead, N., Barrow, 
P., Loredo-Osti, J.C., Morgan, K. and Malo, D., 2003. Allelic variation in 
TLR4 is linked to susceptibility to Salmonella enterica serovar 
Typhimurium infection in chickens. Infection and immunity, 71(3), 
pp.1116-1124. 
101. Levings, M.K. and Schrader, J.W., 1999. IL-4 inhibits the production of 
TNF-α and IL-12 by STAT6-dependent and-independent mechanisms. The 
Journal of Immunology, 162(9), pp.5224-5229. 
102. Li, D., Zhang, X. and Chen, B., 2015. SIGIRR participates in negative 
regulation of LPS response and tolerance in human bladder epithelial 
cells. BMC immunology, 16(1), p.73. 
103. Li, J., Zhai, Y., Ao, L., Hui, H., Fullerton, D., Dinarello, C. and Meng, X. 
(2017). Interleukin-37 suppresses the inflammatory response to protect 
cardiac function in old endotoxemic mice. Cytokine, 95, pp.55-63. 
104. Li, S., Neff, C.P., Barber, K., Hong, J., Luo, Y., Azam, T., Palmer, B.E., 
Fujita, M., Garlanda, C., Mantovani, A. and Kim, S., 2015. Extracellular 
forms of IL-37 inhibit innate inflammation in vitro and in vivo but require 
the IL-1 family decoy receptor IL-1R8. Proceedings of the National 
Academy of Sciences, 112(8), pp.2497-2502. 
281 
 
105. Li, Y., Wang, Z., Yu, T., Chen, B., Zhang, J., Huang, K. and Huang, Z., 
2014. Increased expression of IL-37 in patients with Graves' disease and its 
contribution to suppression of proinflammatory cytokines production in 
peripheral blood mononuclear cells. PloS one, 9(9), p.e107183. 
106. Li, Z., Zhang, C., Zhou, Z., Zhang, J., Zhang, J. and Tian, Z., 2012. Small 
intestinal intraepithelial lymphocytes expressing CD8 and T cell receptor 
γδ are involved in bacterial clearance during Salmonella enterica serovar 
Typhimurium infection. Infection and immunity, 80(2), pp.565-574. 
107. Liew, F.Y., Xu, D., Brint, E.K. and O'Neill, L.A., 2005. Negative regulation 
of toll-like receptor-mediated immune responses. Nature Reviews 
Immunology, 5(6), p.446. 
108. Liu H, Zheng R, Wang P, Yang H, He X, Ji Q, Bai W, Chen H, Chen J, Peng 
W, Liu S. IL-37 confers protection against mycobacterial infection 
involving suppressing inflammation and modulating T cell activation. PloS 
one. 2017 Jan 11;12(1):e0169922. 
109. Liu, J., Lin, J., He, S., Wu, C., Wang, B., Liu, J., Duan, Y., Liu, T., Shan, 
S., Yang, K., Dong, N., Ji, Q., Huang, K. and Li, D. (2018). Transgenic 
Overexpression of IL-37 Protects Against Atherosclerosis and Strengthens 
Plaque Stability. Cellular Physiology and Biochemistry, 45(3), pp.1034-
1050. 
110. Liu, L., Xue, Y., Zhu, Y., Xuan, D., Yang, X., Liang, M., Wang, J., Zhu, X., 
Zhang, J. and Zou, H., 2016. Interleukin 37 limits monosodium urate 
crystal-induced innate immune responses in human and murine models of 
gout. Arthritis research & therapy, 18(1), p.268. 
111. Liu, Y., Zhang, J., Lane, P., Chan, E. and Maclennan, I. (1991). Sites of 
specific B cell activation in primary and secondary responses to T cell-
282 
 
dependent and T cell-independent antigens. European Journal of 
Immunology, 21(12), pp. 2951-2962. 
112. Lo, W.L., Shah, N.H., Ahsan, N., Horkova, V., Stepanek, O., Salomon, 
A.R., Kuriyan, J. and Weiss, A., 2018. Lck promotes Zap70-dependent LAT 
phosphorylation by bridging Zap70 to LAT. Nature immunology, 19(7), 
p.733. 
113. Long, S. and Buckner, J. (2011). CD4+FOXP3+ T Regulatory Cells in Human 
Autoimmunity: More Than a Numbers Game. The Journal of Immunology, 
187(5), pp.2061-2066. 
114. Lunding, L., Webering, S., Vock, C., Schröder, A., Raedler, D., Schaub, B., 
Fehrenbach, H. and Wegmann, M., 2015. IL‐37 requires IL‐18Rα and 
SIGIRR/IL‐1R8 to diminish allergic airway inflammation in 
mice. Allergy, 70(4), pp.366-373. 
115. Luo H, Hao E, Tan D, Wei W, Xie J, Feng X, Du Z, Huang C, Bai G, Hou Y, 
Cheng C. Apoptosis effect of Aegiceras corniculatum on human colorectal 
cancer via activation of FoxO signaling pathway. Food and Chemical 
Toxicology. 2019 Oct 1:110861. 
116. Luo, Y., Cai, X., Liu, S., Wang, S., Nold-Petry, C.A., Nold, M.F., Bufler, P., 
Norris, D., Dinarello, C.A. and Fujita, M., 2014. Suppression of antigen-
specific adaptive immunity by IL-37 via induction of tolerogenic dendritic 
cells. Proceedings of the National Academy of Sciences, 111(42), 
pp.15178-15183. 
117. Lynn, D., Chan, C., Naseer, M., Yau, M., Lo, R., Sribnaia, A., Ring, G., 
Que, J., Wee, K., Winsor, G., Laird, M., Breuer, K., Foroushani, A., 
Brinkman, F. and Hancock, R. (2010). Curating the innate immunity 
interactome. BMC Systems Biology, 4(1), p.117. 
283 
 
118. Macedo, B. and Cordeiro, Y., 2017. Unraveling prion protein interactions 
with aptamers and other PrP-binding nucleic acids. International journal 
of molecular sciences, 18(5), p.1023. 
119. MALAEB, M., BIZRI, A., GHOSN, N., BERRY, A. and MUSHARRAFIEH, U. 
(2016). Salmonella burden in Lebanon. Epidemiol. Infect., pp.1-9. 
120. Marshall, G. (1992). Cytokines: Clinical Potentials for the Allergic Patient. 
Allergy and Asthma Proceedings, 13(6), pp.311-315. 
121. Martinez, F.O. and Gordon, S., 2014. The M1 and M2 paradigm of 
macrophage activation: time for reassessment. F1000prime reports, 6. 
122. McCurdy, S., Baumer, Y., Toulmin, E., Lee, B.H. and Boisvert, W.A., 2017. 
Macrophage-specific expression of IL-37 in hyperlipidemic mice attenuates 
atherosclerosis. The Journal of Immunology, 199(10), pp.3604-3613. 
123. McNamee, E., Masterson, J., Jedlicka, P., McManus, M., Grenz, A., 
Collins, C., Nold, M., Nold-Petry, C., Bufler, P., Dinarello, C. and Rivera-
Nieves, J. (2011). Interleukin 37 expression protects mice from colitis. 
Proceedings of the National Academy of Sciences, 108(40), pp.16711-
16716. 
124. McNamee, E.N., Masterson, J.C., Jedlicka, P., McManus, M., Grenz, A., 
Collins, C.B., Nold, M.F., Nold-Petry, C., Bufler, P., Dinarello, C.A. and 
Rivera-Nieves, J., 2011. Interleukin 37 expression protects mice from 
colitis. Proceedings of the National Academy of Sciences, 108(40), 
pp.16711-16716. 
125. Medzhitov R. (2001). Toll-like receptors and innate immunity. Nat Rev 
Immunol, 1(2), PP.135–145. 
284 
 
126. Meffre, E. and Wardemann, H. (2008). B-cell tolerance checkpoints in 
health and autoimmunity. Current Opinion in Immunology, 20(6), pp.632-
638. 
127. Mittrücker, H.W. and Kaufmann, S.H., 2000. Immune response to infection 
with Salmonella typhimurium in mice. Journal of leukocyte biology, 67(4), 
pp.457-463. 
128. Mittrücker, H.W., Köhler, A. and Kaufmann, S.H., 2002. Characterization 
of the murine T-lymphocyte response to Salmonella enterica serovar 
Typhimurium infection. Infection and immunity, 70(1), pp.199-203. 
129. Mølvig, J. and Baek, L., 1987. Removal of Endotoxin from Culture Media 
by a Polymyxin B Sepharose Column: The Activity of Contaminating 
Endotoxin in Culture Media Measured by the Interleukin 1 Inducing Effect 
on Human Monocyte Cultures and by the Limudus Test. Scandinavian 
journal of immunology, 26(6), pp.611-619. 
130. Moreira L, Zamboni DS. NOD1 and NOD2 signaling in infection and 
inflammation. Frontiers in immunology. 2012 Nov 8;3:328. 
131. Moretti S, Bozza S, Oikonomou V, Renga G, Casagrande A, Iannitti RG, 
Puccetti M, Garlanda C, Kim S, Li S, van de Veerdonk FL. IL-37 inhibits 
inflammasome activation and disease severity in murine aspergillosis. 
PLoS pathogens. 2014 Nov 6;10(11):e1004462. 
132. Moretti, S., Bozza, S., Oikonomou, V., Renga, G., Casagrande, A., Iannitti, 
R.G., Puccetti, M., Garlanda, C., Kim, S., Li, S. and van de Veerdonk, 
F.L., 2014. IL-37 inhibits inflammasome activation and disease severity in 
murine aspergillosis. PLoS pathogens, 10(11), p.e1004462. 
133. Moro, K., Yamada, T., Tanabe, M., Takeuchi, T., Ikawa, T., Kawamoto, 
H., Furusawa, J., Ohtani, M., Fujii, H. and Koyasu, S. (2009). Innate 
285 
 
production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ 
lymphoid cells. Nature, 463(7280), pp.540-544. 
134. Moss, R.B., Moll, T., El-Kalay, M., Kohne, C., Soo Hoo, W., Encinas, J. and 
Carlo, D.J., 2004. Th1/Th2 cells in inflammatory disease states: 
therapeutic implications. Expert opinion on biological therapy, 4(12), 
pp.1887-1896. 
135. Mungrue, I.N., Husain, M. and Stewart, D.J., 2004. The role of NOS in 
heart failure: lessons from murine genetic models. In The Role of Nitric 
Oxide in Heart Failure (pp. 113-128). Springer, Boston, MA. 
136. Murphy, K. and Weaver, C., 2016. Janeway's immunobiology. Garland 
Science. 
137. Murphy, R. and Roberts, C. (2013). Protein misfolding and aggregation 
research: Some thoughts on improving quality and utility. Biotechnology 
Progress, 29(5), pp.1109-1115. 
138. Nagalakshmi, U., Waern, K. and Snyder, M., 2010. RNA‐Seq: a method for 
comprehensive transcriptome analysis. Current protocols in molecular 
biology, 89(1), pp.4-11. 
139. Nallamsetty, S., Austin, B.P., Penrose, K.J. and Waugh, D.S., 2005. 
Gateway vectors for the production of combinatorially‐tagged His6‐MBP 
fusion proteins in the cytoplasm and periplasm of Escherichia coli. Protein 
Science, 14(12), pp.2964-2971. 
140. Namen, A., Lupton, S., Hjerrild, K., Wignall, J., Mochizuki, D., Schmierer, 
A., Mosley, B., March, C., Urdal, D., Gillis, S., Cosman, D. and Goodwin, 
R. (1988). Stimulation of B-cell progenitors by cloned murine interleukin-
7. Nature, 333(6173), pp.571-573. 
286 
 
141. Nicklin, M.J., Barton, J.L., Nguyen, M., FitzGerald, M.G., Duff, G.W. and 
Kornman, K., 2002. A sequence-based map of the nine genes of the human 
interleukin-1 cluster. Genomics, 79(5), pp.718-725. 
142. Nishimoto, N., Kubagawa, H., Ohno, T., Gartland, G., Stankovic, A. and 
Cooper, M. (1991). Normal pre-B cells express a receptor complex of mu 
heavy chains and surrogate light-chain proteins. Proceedings of the 
National Academy of Sciences, 88(14), pp.6284-6288. 
143. Nold, M., Nold-Petry, C., Zepp, J., Bufler, P. and Dinarello, C. (2009). IL-1 
family member 7 is a fundamental inhibitor of innate immunity. Cytokine, 
48(1-2), pp.68-69. 
144. Nold, M., Nold-Petry, C., Zepp, J., Palmer, B., Bufler, P. and Dinarello, C. 
(2010). IL-37 is a fundamental inhibitor of innate immunity. Nature 
Immunology, 11(11), pp.1014-1022. 
145. Nold, M.F., Nold-Petry, C.A., Lo, C., Li, S., Rudloff, I., Zepp, J.A., Azam, 
T., Bufler, P., Garlanda, C., Mantovani, A. and Dinarello, C.A., 2013. 187: 
interleukin 37 employs the IL-1 family inhibitory receptor SIGIRR and the 
alpha chain of the IL-18 receptor to suppress innate 
immunity. Cytokine, 63(3), p.287. 
146. Nold-Petry, C.A., Lo, C.Y., Rudloff, I., Elgass, K.D., Li, S., Gantier, M.P., 
Lotz-Havla, A.S., Gersting, S.W., Cho, S.X., Lao, J.C. and Ellisdon, A.M., 
2015. IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out 
its multifaceted anti-inflammatory program upon innate signal 
transduction. Nature immunology, 16(4), p.354. 
147. Onwuezobe, I.A., Oshun, P.O. and Odigwe, C.C., 2012. Antimicrobials for 
treating symptomatic non‐typhoidal Salmonella infection. Cochrane 
Database of Systematic Reviews, (11). 
287 
 
148. O'Shea, J. and Paul, W. (2010). Mechanisms Underlying Lineage 
Commitment and Plasticity of Helper CD4+ T Cells. Science, 327(5969), 
pp. 1098-1102. 
149. Pan JX. LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-
kB signaling pathway. Eur Rev Med Pharmacol Sci. 2017 Jan 1;21(2):322-8. 
150. Pan, G., Risser, P., Mao, W., Baldwin, D.T., Zhong, A.W., Filvaroff, E., 
Yansura, D., Lewis, L., Eigenbrot, C., Henzel, W.J. and Vandlen, R., 2001. 
IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-
1Rrp. Cytokine, 13(1), pp.1-7. 
151. Parisi, L., Gini, E., Baci, D., Tremolati, M., Fanuli, M., Bassani, B., 
Farronato, G., Bruno, A. and Mortara, L., 2018. Macrophage polarization 
in chronic inflammatory diseases: Killers or builders?. Journal of 
immunology research, 2018. 
152. Pashine, A., John, B., Rath, S., George, A. and Bal, V., 1999. Th1 
dominance in the immune response to live Salmonella typhimurium 
requires bacterial invasiveness but not persistence. International 
immunology, 11(4), pp.481-489. 
153. Paterson, G.K. and Orihuela, C.J., 2010. Pneumococci: immunology of the 
innate host response. Respirology, 15(7), pp.1057-1063. 
154. Patton, J.B., Bonne-Année, S., Deckman, J., Hess, J.A., Torigian, A., 
Nolan, T.J., Wang, Z., Kliewer, S.A., Durham, A.C., Lee, J.J. and 
Eberhard, M.L., 2018. Methylprednisolone acetate induces, and Δ7-
dafachronic acid suppresses, Strongyloides stercoralis hyperinfection in 
NSG mice. Proceedings of the National Academy of Sciences, 115(1), 
pp.204-209. 
155. Percival, S., Yates, M., Williams, D., Chalmers, R. and Gray, N. 
(n.d.). Microbiology of waterborne diseases.Fabrega, A. and Vila, J. 
288 
 
(2013). Salmonella enterica Serovar Typhimurium Skills To Succeed in the 
Host: Virulence and Regulation. Clinical Microbiology Reviews, 26(2), 
pp.308-341. 
156. Percival, S.L., Chalmers, R., Embrey, M., Hunter, P.R., Sellwood, J. and 
Wyn-Jones, P., 2004. Microbiology of waterborne diseases. 
157. Pesarrodona, M., Unzueta, U. and Vázquez, E., 2015. Dialysis: A 
characterization method of aggregation tendency. In Insoluble 
Proteins (pp. 321-330). Humana Press, New York, NY. 
158. Plantinga, M., Hammad, H. and Lambrecht, B. (2010). Origin and 
functional specializations of DC subsets in the lung. European Journal of 
Immunology, 40(8), pp.2112-2118. 
159. Qin, J., Qian, Y., Yao, J., Grace, C. & Li, X. (2005). SIGIRR inhibits 
interleukin-1 receptorand toll-like receptor 4-mediated signaling through 
different mechanisms. J. Biol. Chem. 280, 25233–25241.  
160. Quirk, S. and Agrawal, D. (2014). Immunobiology of IL-37: mechanism of 
action and clinical perspectives. Expert Review of Clinical Immunology, 
10(12), pp.1703-1709. 
161. Raphael, I., Nalawade, S., Eagar, T.N. and Forsthuber, T.G., 2015. T cell 
subsets and their signature cytokines in autoimmune and inflammatory 
diseases. Cytokine, 74(1), pp.5-17. 
162. Rolls, A., Shechter, R., London, A., Ziv, Y., Ronen, A., Levy, R. and 
Schwartz, M. (2007). Toll-like receptors modulate adult hippocampal 
neurogenesis. Nature Cell Biology, 9(9), pp.1081-1088. 
289 
 
163. Rosano, G.L. and Ceccarelli, E.A., 2014. Recombinant protein expression 
in Escherichia coli: advances and challenges. Frontiers in microbiology, 5, 
p.172. 
164. Roussel, L., Farias, R. and Rousseau, S., 2013. IL-33 is expressed in 
epithelia from patients with cystic fibrosis and potentiates neutrophil 
recruitment. Journal of Allergy and Clinical Immunology, 131(3), pp.913-
916. 
165. Rudloff, I., Cho, S., Lao, J., Ngo, D., McKenzie, M., Nold-Petry, C. and 
Nold, M. (2016). Monocytes and dendritic cells are the primary sources of 
interleukin 37 in human immune cells. Journal of Leukocyte Biology, 
101(4), pp.901-911. 
166. Sabbagh, S.C., Forest, C.G., Lepage, C., Leclerc, J.M. and Daigle, F., 
2010. So similar, yet so different: uncovering distinctive features in the 
genomes of Salmonella enterica serovars Typhimurium and Typhi. FEMS 
microbiology letters, 305(1), pp.1-13. 
167. Sattler, S., Smits, H., Xu, D. and Huang, F. (2013). The Evolutionary Role 
of the IL-33/ST2 System in Host Immune Defence. Archivum Immunologiae 
et Therapiae Experimentalis, 61(2), pp. 107-117. 
168. Scallan, E., Hoekstra, R., Angulo, F., Tauxe, R., Widdowson, M., Roy, S., 
Jones, J. and Griffin, P. (2011). Foodborne Illness Acquired in the United 
States—Major Pathogens. Emerg. Infect. Dis., 17(1), pp.7-15. 
169. Schauer, A.E., Klassert, T.E., von Lachner, C., Riebold, D., Schneeweiß, 
A., Stock, M., Müller, M.M., Hammerschmidt, S., Bufler, P., Seifert, U. 
and Dietert, K., 2017. IL-37 causes excessive inflammation and tissue 
damage in murine pneumococcal pneumonia. Journal of innate 
immunity, 9(4), pp.403-418. 
290 
 
170. Schlissel, M. and Baltimore, D. (1989). Activation of immunoglobulin 
kappa gene rearrangement correlates with induction of germline kappa 
gene transcription. Cell, 58(5), pp.1001-1007. 
171. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, 
Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM. IL-33, an interleukin-1-
like cytokine that signals via the IL-1 receptor-related protein ST2 and 
induces T helper type 2-associated cytokines. Immunity. 2005 Nov 
1;23(5):479-90. 
172. Sharma, S., Kulk, N., Nold, M.F., Gräf, R., Kim, S.H., Reinhardt, D., 
Dinarello, C.A. and Bufler, P., 2008. The IL-1 family member 7b 
translocates to the nucleus and down-regulates proinflammatory 
cytokines. The Journal of Immunology, 180(8), pp.5477-5482. 
173. Shuai, X., Wei-Min, L., Tong, Y.L., Dong, N., Sheng, Z.Y. and Yao, Y.M., 
2015. Expression of IL-37 contributes to the immunosuppressive property 
of human CD4+ CD25+ regulatory T cells. Scientific reports, 5, p.14478. 
174. Singh, A., Upadhyay, V., Upadhyay, A.K., Singh, S.M. and Panda, A.K., 
2015. Protein recovery from inclusion bodies of Escherichia coli using mild 
solubilization process. Microbial cell factories, 14(1), p.41. 
175. Smithrithee, R., Niyonsaba, F., Kiatsurayanon, C., Ushio, H., Ikeda, S., 
Okumura, K. and Ogawa, H., 2015. Human β-defensin-3 increases the 
expression of interleukin-37 through CCR6 in human 
keratinocytes. Journal of dermatological science, 77(1), pp.46-53. 
176. Song, L., Qiu, F., Fan, Y., Ding, F., Liu, H., Shu, Q., Liu, W. and Li, X., 
2013. Glucocorticoid regulates interleukin-37 in systemic lupus 
erythematosus. Journal of Clinical Immunology, 33(1), pp.111-117. 
291 
 
177. Sørensen, H.P. and Mortensen, K.K., 2005. Soluble expression of 
recombinant proteins in the cytoplasm of Escherichia coli. Microbial cell 
factories, 4(1), p.1. 
178. Southcombe, J.H., Redman, C.W.G., Sargent, I.L. and Granne, I., 2015. 
Interleukin‐1 family cytokines and their regulatory proteins in normal 
pregnancy and pre‐eclampsia. Clinical & Experimental 
Immunology, 181(3), pp.480-490. 
179. Spartalis, M., Tzatzaki, E., Spartalis, E., Damaskos, C., Mavrogeni, S. and 
Voudris, V., 2017. Parvovirus B19 myocarditis of fulminant 
evolution. Cardiology research, 8(4), p.172. 
180. Spears, M., McSharry, C., Donnelly, I., Jolly, L., Brannigan, M., Thomson, 
J., Lafferty, J., Chaudhuri, R., Shepherd, M., Cameron, E. and Thomson, 
N. (2011).Peripheral blood dendritic cell subtypes are significantly 
elevated in subjects with asthma. Clinical & Experimental Allergy, 41(5), 
pp.665-672. 
181. Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J., Eberl, G., 
Koyasu, S., Locksley, R., McKenzie, A., Mebius, R., Powrie, F. and Vivier, 
E. (2013). Innate lymphoid cells — a proposal for uniform nomenclature. 
Nature Reviews Immunology, 13(2), pp.145-149. 
182. Stuehr, D.J., Cho, H.J., Kwon, N.S., Weise, M.F. and Nathan, C.F., 1991. 
Purification and characterization of the cytokine-induced macrophage 
nitric oxide synthase: an FAD-and FMN-containing 
flavoprotein. Proceedings of the National Academy of Sciences, 88(17), 
pp.7773-7777. 
183. Tang, D., Kang, R., Coyne, C.B., Zeh, H.J. and Lotze, M.T., 2012. PAMP s 
and DAMP s: signal 0s that spur autophagy and immunity. Immunological 
reviews, 249(1), pp.158-175. 
292 
 
184. Takeuchi, O., Kawai, T., Sanjo, H., Copeland, N.G., Gilbert, D.J., Jenkins, 
N.A., Takeda, K. and Akira, S., 1999. TLR6: A novel member of an 
expanding toll-like receptor family. Gene, 231(1-2), pp.59-65. 
185. Tardieu, M., Zérah, M., Husson, B., de Bournonville, S., Deiva, K., 
Adamsbaum, C., Vincent, F., Hocquemiller, M., Broissand, C., Furlan, V. 
and Ballabio, A., 2014. Intracerebral administration of adeno-associated 
viral vector serotype rh. 10 carrying human SGSH and SUMF1 cDNAs in 
children with mucopolysaccharidosis type IIIA disease: results of a phase 
I/II trial. Human gene therapy, 25(6), pp.506-516. 
186. Tawfik, M.G., Nasef, S.I., Omar, H.H. and Ghaly, M.S., 2017. Serum 
Interleukin-37: a new player in Lupus Nephritis?. International journal of 
rheumatic diseases, 20(8), pp.996-1001. 
187. Taylor, S.L., Renshaw, B.R., Garka, K.E., Smith, D.E. and Sims, J.E., 2002. 
Genomic organization of the interleukin-1 locus. Genomics, 79(5), pp.726-
733. 
188. Teng, X., Hu, Z., Wei, X., Wang, Z., Guan, T., Liu, N., Liu, X., Ye, N., 
Deng, G., Luo, C. and Huang, N., 2014. IL-37 ameliorates the 
inflammatory process in psoriasis by suppressing proinflammatory cytokine 
production. The Journal of Immunology, 192(4), pp.1815-1823. 
189. Thomson, A. and Lotze, M. (2003). The cytokine handbook. Amsterdam: 
Academic Press. 
190. Toshchakov, V., Jones, B., Perera, P., Thomas, K., Cody, M., Zhang, S., 
Williams, B., Major, J., Hamilton, T., Fenton, M. and Vogel, S. (2002). 
TLR4, but not TLR2, mediates IFN-β–induced STAT1α/β-dependent gene 
expression in macrophages. Nature Immunology, 3(4), pp.392-398. 
293 
 
191. Trebichavský, I., Šplíchal, I. and Šplíchalová, A. (2010). Innate immune 
response in the gut against Salmonella — review. Folia Microbiol, 55(3), 
pp.295-300. 
192. Trieu, A., Bokil, N., Dunn, J.A., Roberts, T.L., Xu, D., Liew, F.Y., Hume, 
D.A., Stacey, K.J. and Sweet, M.J., 2009. TLR9‐independent effects of 
inhibitory oligonucleotides on macrophage responses to S. 
typhimurium. Immunology and cell biology, 87(3), pp.218-225. 
193. Tsolis, R.M., Young, G.M., Solnick, J.V. and Bäumler, A.J., 2008. From 
bench to bedside: stealth of enteroinvasive pathogens. Nature Reviews 
Microbiology, 6(12), p.883. 
194. Tükel, Ç., Raffatellu, M., Humphries, A.D., Wilson, R.P., Andrews‐
Polymenis, H.L., Gull, T., Figueiredo, J.F., Wong, M.H., Michelsen, K.S., 
Akçelik, M. and Adams, L.G., 2005. CsgA is a pathogen‐associated 
molecular pattern of Salmonella enterica serotype Typhimurium that is 
recognized by Toll‐like receptor 2. Molecular microbiology, 58(1), pp.289-
304. 
195. van de Veerdonk, F.L., Gresnigt, M.S., Oosting, M., van der Meer, J.W., 
Joosten, L.A., Netea, M.G. and Dinarello, C.A., 2015. Protective host 
defense against disseminated candidiasis is impaired in mice expressing 
human interleukin-37. Frontiers in microbiology, 5, p.762. 
196. Vazquez‐Torres, A., Stevanin, T., Jones‐Carson, J., Castor, M., Read, R. 
C., & Fang, F. C. (2008). Analysis of Nitric Oxide‐Dependent Antimicrobial 
Actions in Macrophages and Mice. Methods in enzymology, 437, 521-538. 
197. Vazquez‐Torres, A., Stevanin, T., Jones‐Carson, J., Castor, M., Read, R.C. 
and Fang, F.C., 2008. Analysis of nitric oxide‐dependent antimicrobial 
actions in macrophages and mice. In Methods in enzymology (Vol. 437, pp. 
521-538). Academic Press. 
294 
 
198. Veerdonk, F.V.D. and Netea, M., 2013. New insights in the immunobiology 
of IL-1 family members. Frontiers in immunology, 4, p.167. 
199. Vlahopoulos S, Boldogh I, Casola A, Brasier AR. Nuclear Factor-κB–
Dependent Induction of Interleukin-8 Gene Expression by Tumor Necrosis 
Factor : Evidence for an Antioxidant Sensitive Activating Pathway Distinct 
From Nuclear Translocation. Blood. 1999 Sep 15;94(6):1878-89.  
200. Wald, D., Qin, J., Zhao, Z., Qian, Y., Naramura, M., Tian, L., Towne, J., 
Sims, J.E., Stark, G.R. and Li, X., 2003. SIGIRR, a negative regulator of 
Toll-like receptor–interleukin 1 receptor signaling. Nature 
immunology, 4(9), p.920. 
201. Walker, J., Barlow, J. and McKenzie, A. (2013). Innate lymphoid cells — 
how did we miss them?. Nature Reviews Immunology, 13(2), pp.75-87. 
202. Walls, D. and Loughran, S.T., 2011. Tagging recombinant proteins to 
enhance solubility and aid purification. In Protein Chromatography (pp. 
151-175). Humana Press. 
203. Wang X, Zhan E, Lu G, Mu Q, Zhang T, Yang N. Sphingosine-1-Phosphate 
Improves the Biological Features of Mouse Bone Marrow-Derived EPCs 
Partially through PI3K/AKT/eNOS/NO Pathway. Molecules. 2019 
Jan;24(13):2404. 
204. Wang, C., Deng, L., Hong, M. (2001). TAK1 is a ubiquitin-dependent kinase 
of MKK and IKK. Nature, 412(6844), PP. 346–351. 34- Takeuchi, O., 
Takeda, K., Hoshino, K., Adachi, O., Ogawa, T. and Akira, S. (2000). 
Cellular responses to bacterial cell wall components are mediated through 
MyD88-dependent signaling cascades. International Immunology, 12(1), 
pp.113-117. 
295 
 
205. Wang, L., Quan, Y., Yue, Y., Heng, X. and Che, F., 2018. Interleukin-37: A 
crucial cytokine with multiple roles in disease and potentially clinical 
therapy. Oncology letters, 15(4), pp.4711-4719. 
206. Wang, S., An, W., Yao, Y., Chen, R., Zheng, X., Yang, W., Zhao, Y., Hu, 
X., Jiang, E., Bie, Y. and Chen, Z., 2015. Interleukin 37 expression inhibits 
STAT3 to suppress the proliferation and invasion of human cervical cancer 
cells. Journal of Cancer, 6(10), p.962. 
207. Wang, X., Xu, K., Chen, S., Li, Y. and Li, M., 2018. Role of interleukin-37 
in inflammatory and autoimmune diseases. Iranian Journal of 
Immunology, 15(3), pp.165-174. 
208. Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., 
Gumienny, R., Heer, F.T., de Beer, T.A.P., Rempfer, C., Bordoli, L. and 
Lepore, R., 2018. SWISS-MODEL: homology modelling of protein structures 
and complexes. Nucleic acids research, 46(W1), pp.W296-W303. 
209. Weaver, C., Elson, C., Fouser, L. and Kolls, J. (2013). The Th17 Pathway 
and Inflammatory Diseases of the Intestines, Lungs, and Skin. Annual 
Review of Pathology: Mechanisms of Disease, 8(1), pp.477-512. 
210. Xia, T., Zheng, X.F., Qian, B.H., Fang, H., Wang, J.J., Zhang, L.L., Pang, 
Y.F., Zhang, J., Wei, X.Q., Xia, Z.F. and Zhao, D.B., 2015. Plasma 
interleukin-37 is elevated in patients with rheumatoid arthritis: its 
correlation with disease activity and Th1/Th2/Th17-related 
cytokines. Disease markers, 2015. 
211. Yang, J., Yan, R., Roy, A., Xu, D., Poisson, J. and Zhang, Y., 2015. The I-
TASSER Suite: protein structure and function prediction. Nature 
methods, 12(1), p.7. 
212. Yang, Z., Zhang, L., Zhang, Y., Zhang, T., Feng, Y., Lu, X., Lan, W., 
Wang, J., Wu, H., Cao, C. and Wang, X., 2011. Highly efficient production 
296 
 
of soluble proteins from insoluble inclusion bodies by a two-step-
denaturing and refolding method. PloS one, 6(7), p.e22981. 
213. Ye, L., Ji, L., Wen, Z., Zhou, Y., Hu, D., Li, Y., Yu, T., Chen, B., Zhang, 
J., Ding, L. and Du, J., 2014. IL-37 inhibits the production of inflammatory 
cytokines in peripheral blood mononuclear cells of patients with systemic 
lupus erythematosus: its correlation with disease activity. Journal of 
translational medicine, 12(1), p.69. 
214. Ye, Z., Wang, C., Kijlstra, A., Zhou, X. and Yang, P., 2014. A possible role 
for interleukin 37 in the pathogenesis of Behcet's disease. Current 
molecular medicine, 14(4), pp.535-542. 
215. Yurasov, S., Wardemann, H., Hammersen, J., Tsuiji, M., Meffre, E., 
Pascual, V. and Nussenzweig, M. (2005). Defective B cell tolerance 
checkpoints in systemic lupus erythematosus. The Journal of 
Experimental Medicine, 201(5), pp.703-711. 
216. Zhan, Q. and Zeng, Q. (2017). IL-37 Suppresses MyD88-mediated 
Inflammatory Responses in Human Aortic Valve Interstitial Cells. Molecular 
Medicine, 23(1), p.1. 
217. Zhan, R., Han, Q., Zhang, C., Tian, Z. and Zhang, J., 2015. Toll-like 
receptor 2 (TLR2) and TLR9 play opposing roles in host innate immunity 
against Salmonella enterica serovar Typhimurium infection. Infection and 
immunity, 83(4), pp.1641-1649. 
218. Zhang, J., Yang, J., Xu, X., Liang, L., Sun, H., Liu, G., Zhang, L. and Su, 
Y., 2016. The influence of genetic polymorphisms in TLR4 and TIRAP, and 
their expression levels in peripheral blood, on susceptibility to 
sepsis. Experimental and therapeutic medicine, 11(1), pp.131-139. 
219. Zhang, J.A., Liu, G.B., Zheng, B.Y., Lu, Y.B., Gao, Y.C., Cai, X.Z., Dai, 
Y.C., Yu, S.Y., Jia, Y., Chen, C. and Zhuang, Z.G., 2016. Tuberculosis-
297 
 
sensitized monocytes sustain immune response of interleukin-
37. Molecular immunology, 79, pp.14-21. 
220. Zhang, L., Pan, Z., Kang, X., Yang, Y., Kang, H., Zhang, N., Rosati, J.M. 
and Jiao, X., 2015. Amino acids 89–96 of Salmonella typhimurium flagellin 
represent the major domain responsible for TLR5-independent 
adjuvanticity in the humoral immune response. Cellular & molecular 
immunology, 12(5), p.625. 
221. Zhang, Y., Lu, Y., Ma, L., Cao, X., Xiao, J., Chen, J., Jiao, S., Gao, Y., 
Liu, C., Duan, Z. and Li, D., 2014. Activation of vascular endothelial 
growth factor receptor-3 in macrophages restrains TLR4-NF-κB signaling 
and protects against endotoxin shock. Immunity, 40(4), pp.501-514. 
222. Zhao X, Kwan JY, Yip K, Liu PP, Liu FF. Targeting metabolic dysregulation 
for fibrosis therapy. Nature Reviews Drug Discovery. 2019 Sep 23:1-9. 
223. Zhao, M., Hu, Y., Shou, J., Su, S.B., Yang, J. and Yang, T., 2017. IL-37 
impairs host resistance to listeria infection by suppressing macrophage 
function. Biochemical and biophysical research communications, 485(2), 
pp.563-568. 
224. Zhao, M., Li, Y., Guo, C., Wang, L., Chu, H., Zhu, F., Li, Y., Wang, X., 
Wang, Q., Zhao, W. and Shi, Y., 2018. IL-37 isoform D downregulates pro-
inflammatory cytokines expression in a Smad3-dependent manner. Cell 
death & disease, 9(6), p.582. 
225. Zhao, M., Li, Y., Guo, C., Wang, L., Chu, H., Zhu, F., Li, Y., Wang, X., 
Wang, Q., Zhao, W., Shi, Y., Chen, W. and Zhang, L. (2018). IL-37 isoform 
D downregulates pro-inflammatory cytokines expression in a Smad3-
dependent manner. Cell Death & Disease, 9(6). 
226. Zhao, P.W., Jiang, W.G., Wang, L., Jiang, Z.Y., Shan, Y.X. and Jiang, 
Y.F., 2014. Plasma levels of IL-37 and correlation with TNF-α, IL-17A, and 
298 
 
disease activity during DMARD treatment of rheumatoid arthritis. PloS 
one, 9(5), p.e95346. 
227. Zhao, S., Zhang, B., Zhang, Y., Gordon, W., Du, S., Paradis, T., Vincent, 
M. and von Schack, D., 2016. Bioinformatics for RNA-Seq Data 
Analysis. Bioinformatics—Updated Features and Applications: InTech, 
pp.125-49. 
228. Zhou, F., Zhu, C.L., Niu, Z.L., Xu, F.X., Song, H. and Liu, X.H., 2019. 
Influenza A virus inhibits influenza virus replication by inducing IL‐
37. Journal of clinical laboratory analysis, 33(1), p.e22638. 
229. Zvonova, E.A., Ershov, A.V., Ershova, O.A., Sudomoina, M.A., Degterev, 
M.B., Poroshin, G.N., Eremeev, A.V., Karpov, A.P., Vishnevsky, A.Y., 
Goldenkova-Pavlova, I.V. and Petrov, A.V., 2017. PASylation technology 
improves recombinant interferon-β1b solubility, stability, and biological 
activity. Applied microbiology and biotechnology, 101(5), pp.1975-1987. 
 
 
 
 
 
